Document ID: EPA-HQ-OPPT-2002-0046-0003
Agency: epa
Document Type: Supporting & Related Material
Title: 
Posted Date: 2002-09-05T04:00Z

+
A
e>
P.
O.
Box
331,
Millwood,
VA
22646
(540)
837­
1602
Task
Fort
June
7,2002
Document
Control
Office
(7407)
Office
of
Pollution
Prevention
and
Toxics
Room
G­
099
Environmental
Protection
Agency
401
M
Street,
S.
W.
Washington,
D.
C.
20460
Re:
Testing
Consent
drder
for
1,1,2­
Trichloroethane;
Final
Reports
of
Subchronic
Inhalation
Toxicity
and
Pharmacokinetic
Model
Development
Studies
(Docket
No.
OPPTS­
42
198Cj
Dear
Sirs:

Pursuant
to
Table
1
of
the
Enforceable
Consent
Agreement
for
1,1,2­
Trichloroethane,
the
HAP
Task
Force
submits
the
enclosed
final
reports:
4
­
"A
90­
Day
Inhalation
Study
of
1,1,2­
Trichloroethane
(I,
1,2­
TCE)
in
Rats.
(With
Satellite
Groups
for
Pharmacokinetic
Evaluations
in
Rats
and
Mice)"
WIL
Research
Laboratories,
Inc.

"Physiologically
Based
Pharmacokinetic
Model
Development,
Simulations,
and
Sensitivity
Analysis
for
Repeated
Exposure
to
1,1,2­
Trichloroethane"
by
The
Sapphire
Group
Six
copies
of
each
report
are
enclosed.
Please
do
not
hesitate
to
let
me
kno&
there
are
any
questions.
G,
CD­
9
%
zg
~~~~~~~~~~~~
11~~~~~~
­
<;~
y&
y/,~
;
$rr
Peter
E.
Voytek,
Pi.
D.
4
;;
Manager
+

Enclosures
C.
Auer
(w/
out
enclosures)
R.
Leukroth
(w/
out
enclos&
es)
J.
Schaeffer
W.
C.
Norman,
Esq.
FINAL
REPORT
Volume
1
of
2
(Text,
Summary
and
Individual
Tables
l­
3
1)

STUDY
TITLE
A
90­
Day
Inhalation
Toxicity
Study
of
1,
1,2­
Trichloroethane
(1,
1,2­
TCE)
in
Rats
(With
Satellite
Groups
for
Pharmacokinetic
Evaluations
in
Rats
and
Mice)

STUDY
NUMBER
WIL­
4
17002
DATA
REQUIREMENT
U.
S.
EPA­
TSCA
799.9346
STUDY
DIRECTOR
Daniel
T.
Kirkpatrick,
Ph.
D.,
D.
A.
B.
T.

STUDY
INITIATION
DATE
May
15,200l
STUDY
COMPLETION
DATE
May
23,2002
PERFORMING
LABORATORY
WIL
Research
Laboratories,
Inc.
1407
George
Road
Ashland,
OH
44805­
928
1
SPONSOR
HAP
Task
Force
P.
O.
Box
331
Millwood,
VA
22646
1
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
COMPLIANCESTATEMENT
This
study,
designated
WIL­
417002,
was
conducted
in
compliance
with
the
Environmental
Protection
Agency
Toxic
Substances
Control
Act
(EPA
TSCA)
Good
Laboratory
Practice
ReguIations
(40
CFR
Part
792),
the
standard
operating
procedures
of
WIL
Research
Laboratories,
Inc.,
and
the
protocol
as
approved
by
the
sponsor.
The
protocol
was
designed
to
generally
conform
with
the
EPA
TSCA
Guideline
799.9346:

90­
Day
Inhalation
Toxicity
Study.
Analyses
of
test
article
samples
were
performed
by
the
sponsor
(presented
in
Appendix
A);
it
is
unknown
whether
the
characterization
analyses
were
conducted
according
to
Good
Laboratory
Practices
(GLP).

Study
Difector
2
of
619
­­.
WIL­
4
17002
1,
1,2­
Trichloroethane
HAP
Task
Force
TABLE
OF
CONTENTS
VOLUME
1
w
Compliance
Statement
..............................................................................
2
Table
Of
Contents
.....................................................................................
3
Index
Of
Tables
.........................................................................................
6
Index
Of
Appendices
.................................................................................
8
Summary
....................................................................................................
9
Objective
.....................................................................................................
9
Study
Design
...............................................................................................
9
Results
.......................................................................................................
10
Conclusions
...............................................................................................
11
Introduction
.............................................................................................
12
General
Study
Information
........................................................................
12
Key
Study
Dates
........................................................................................
12
Study
Design
............................................................................................
13
Experimental
Procedures
­
Materials
And
Methods
...........................
14
Test
Article
................................................................................................
14
Test
Article
Identification
.........................................................................
14
Exposure
Methods..
...................................................................................
14
Generation
Of
Exposure
Atmosphere
.......................................................
16
Characterization
Of
Exposure
Atmospheres
.............................................
16
Organization
And
Treatment
Regimen
.....................................................
16
Animal
Receipt
And
Acclimation/
Pretest
Period..
....................................
19
Animal
Housing
........................................................................................
19
Diet,
Drinking
Water
And
Maintenance
...................................................
20
Environmental
Conditions
........................................................................
20
Assignment
Of
Animals
To
Treatment
Groups
.......................................
.20
Data
Retention
...........................................................................................
21
1.

1.1.

1.2.

1.3.

1.4.

2.

2.1.

2.2.

3.

4.

4.1.

4.1.1.

4.1.2.

4.1.3.

4.1.4.

4.1.5.

4.2.

4.3.

4.4.

4.5.

4.6.

4.7.

3
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
VOLUME
1
(continued)
Page
5.

5.1.

5.2.

5.3.

5.4.

5.4.1.

5.4.2.

5.5.

5.6.

5.7.

5.7.1.

5.7.2.

5.7.3.

5.8.

6.

6.1.

6.2.

6.3.

6.4.

6.4.1.

6.4.2.

6.5.

6.6.

6.6.1.

6.6.2.

6.6.3.

7.

8.

9.
Parameters
Evaluated
.............................................................................
22
Clinical
Observations
And
Survival
(All
Groups)
...................................
­22
Body
Weights
(All
Groups)
.....................................................................
.22
Food
Consumption
(Toxicology
Groups)
................................................
.22
Clinical
Pathology
(Toxicology
Groups)
..................................................
23
Hematology
...............................................................................................
23
Serum
Chemistry
.......................................................................................
24
Plasma
Level
Determinations
(Pharmocokinetic
Groups)
........................
24
Ophthalmic
Examinations
(Toxicology
Groups)
.....................................
.25
Anatomic
Pathology
(Toxicology
Groups).
..............................................
25
Macroscopic
Examination
.........................................................................
25
Organ
Weights
...........................................................................................
27
Slide
Preparation
And
Microscopic
Examination..
..................................
.27
Statistical
Methods
....................................................................................
27
Results
And
Discussion
(Toxicology
Groups)
.......................................
29
Clinical
Observations
And
Survival
..........................................................
29
Body
Weights
............................................................................................
29
Food
Consumption
....................................................................................
30
Clinical
Pathology
.....................................................................................
30
Hematology
...............................................................................................
30
Serum
Chemistry..
.....................................................................................
3
1
Ophthalmic
Examinations..
.......................................................................
3
1
Anatomic
Pathology
..................................................................................
31
Macroscopic
Examination..
.......................................................................
3
1
Organ
Weights..
.........................................................................................
32
Microscopic
Examination
.........................................................................
32
Conclusions
..............................................................................................
37
Key
Study
Personnel
And
Report
Submission
.....................................
40
Quality
Assurance
Unit
Statement
........................................................
41
4of619
WIL­
417002
HAP
Task
Force
1,
1,2­
Trichloroethane
VOLUME
1
(continued)
&

9.1.
Phases
Inspected..
......................................................................................
41
9.2.
Approval
....................................................................................................
43
10.
References
................................................................................................
44
11.
Deviations
From
The
Protocol
...............................................................
46
5
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
INDEX
OF
TABLES
VOLUME
1
(continued)
Page
1~
Summary
Of
Survival
And
Disposition
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
48
2.
Summary
Of
Clinical
Findings:
Total
Occurrence/
No.
Of
Animals
(Detailed
Physical
Examinations/
Dispositions)
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
50
3.
Summary
Of
Clinical
Findings:
Total
Occurrence/
No.
Of
Animals
(Prior
To
Exposure)
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
54
4.
Summary
Of
Clinical
Findings:
Total
Occurrence/
No.
Of
Animals
(Following
Exposure)
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
56
5.
Summary
Of
Clinical
Findings:
Total
Occurrence/
No.
Of
Animals
(Non­
Exposure
Days)
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.5
8
6.
Summary
Of
Body
Weights
[G]
................................................................................
.60
7.
Summary
Of
Body
Weight
Changes
[G]
..................................................................
.68
7A.
Summary
Of
Cumulative
Body
Weight
Changes
[G]
..............................................
.74
8.
Summary
Of
Weekly
Food
Consumption
[G/
Animal/
Day]
......................................
80
9.
Summary
Of
Hematology
Values
..............................................................................
86
10.
Summary
Of
Leukocyte
Differential
Counts
[%]
......................................................
90
11.
Summary
Of
Leukocyte
Counts
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
92
12.
Summary
Of
Serum
Chemistry
Values
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
94
13.
Summary
Of
Ophthalmic
Examination
Findings
(Week
­
1
Pretest
Evaluation)
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
102
14.
Summary
Of
Ophthalmic
Examination
Findings
(Week
12
Evaluation)
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
103
15.
Gross
Necropsy
Observations
Incidence
Summary
(Unscheduled
Death)
.
.
.
.
.
.
.
.
.
.
...
104
16.
Gross
Necropsy
Observations
Incidence
Summary
(Primary
Necropsy).
..............
.105
17.
Organ
Weights
(Grams)
­
Summary
Of
Means
......................................................
.107
6of619
WIL­
417002
HAP
Task
Force
1,
1,2­
Trichloroethane
VOLUME
1
(continued)
&

18.
Organ
Weights
Relative
To
Final
Body
Weights
(Grams/
100
Grams)
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
112
19.
Organ
Weights
Relative
To
Brain
Weights
(Grams/
100
Grams)
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
118
20.
Individual
Survival
And
Disposition
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
123
2
1.
Individual
Body
Weights
[G]
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
127
22.
Individual
Body
Weight
Changes
[G]
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
143
23.
Individual
Food
Consumption
[G/
AnimaVDay]
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
159
24.
Individual
Hematology
Values..
..............................................................................
.175
25.
Individual
Leukocyte
Differential
Counts
["
A].
.......................................................
.183
26.
Individual
Leukocyte
Counts
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
19
1
27.
Individual
Serum
Chemistry
Values..
......................................................................
.199
28.
Individual
Ophthalmic
Examination
Findings
(Week
­1
Pretest
Evaluation).
......
..
215
29.
Individual
Ophthalmic
Examination
Findings
(Week
12
Evaluation)
...................
.2
19
30.
Individual
Macroscopic
Findings
(Unscheduled
Death).
........................................
.223
3
1.
Individual
Macroscopic
Findings
(Primary
Necropsy)
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
224
VOLUME
2
32.
Individual
Organ
Weights
And
Final
Body
Weights
[G]
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
305
33.
Individual
Organ
Wts.
Relative
To
Final
Body
Wts.
[G/
100
G]
............................
.3
17
34.
Individual
Organ
Weights
Relative
To
Brain
Weights
[G/
100
G]
.........................
.329
7
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
INDEX
OF
APPENDICES
A.

B.

C.

D.

E.

F.

G.

H.

I.

J.

K.

L.
VOLUME
2
(continued)
Paae
Analysis
of
Test
Article
Samples
(Sponsor­
Provided)
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
..
I..............
341
Purity
Assessment
(WIL
Research
Laboratories,
Inc.)
..**...................................,....
353
Test
Atmosphere
Generation
and
Environmental
Conditions
During
Exposure
(WIL
Research
Laboratories,
Inc.)
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
366
Clinical
Pathology
Parameters
For
Control
Animals
(Study
Week
8)
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
414
Pretest
Clinical
Observations.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.4
19
Serological
Screening
(BioReliance
Corporation)
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
423
Clinical
Pathology
Methods,
Procedures
and
References
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
427
Individual
Clinical
Observations
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
,
,
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.432
Dispositions
and
Body
Weights
(Pharmacokinetic
Groups)
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
493
Ophthalmic
Examination
Report
(David
A.
Wilkie,
D.
V.
M.,
M.
S.,
D.
A.
C.
V.
O.)
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
502
Histopathology
Report
(Experimental
Pathology
Laboratories,
Inc.)
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
504
Study
Protocol
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
585
8
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
1.
SUMMARY
1.1.
OBJECTIVE
The
objective
of
the
study
was
to
evaluate
potential
subchronic
toxic
effects
of
1,
1,
2­
Trichloroethane
when
administered
via
whole­
body
inhalation
to
rats
for
90
days.

In
addition,
36
female
F­
344
rats
and
36
female
B6C3Fl
mice
were
exposed
by
whole­

body
inhalation
for
28
days
and
used
for
a
pharmacokinetic
study.

1.2.
STUDY
DESIGN
Potential
subchronic
toxic
effects
of
the
test
article,
1,
1,
2­
Trichloroethane,
were
evaluated
in
this
90­
day
study
in
rats.
The
test
article
was
administered
via
whole­
body
inhalation
as
a
vapor
to
three
groups
(Groups
2­
4),
each
comprised
of
10
male
and
10
female
Fischer
344
CDF@(
F­
344)
Crl:
BR
rats,
five
days
per
week,
as
a
six­
hour
exposure,

for
13
consecutive
weeks
(minimum
of
65
exposures).
The
targeted
exposure
concentrations
were
15,
40
and
100
ppm.
The
exposure
concentrations
were
measured
by
chromatographic
methods
and
were
found
to
be
15,
40
and
100
ppm.
A
concurrent
control
group'
(Group
1)
of
identical
design
was
exposed
to
clean,
filtered
air
on
a
comparable
regimen.
Clinical
examinations
were
performed
daily
and
detailed
physical
examinations
were
conducted
weekly.
Individual
body
weights
and
food
consumption
were
recorded
weekly.
Ophthalmic
examinations
were
conducted
prior
to
exposure
initiation
and
near
exposure
termination.
Clinical
pathology
evaluations
(hematology
and
serum
chemistry)
were
conducted
at
the
end
of
the
exposure
period.
Complete
necropsies
were
performed
on
all
animals
and
selected
organs
were
weighed.
Selected
tissues
were
examined
microscopically.

For
the
pharmacokinetic
assessment,
36
female
Fischer
344
CDF@(
F­
344)
Crl:
BR
rats
and
36
female
B6C3FlKrl:
BR
mice
(Groups
5
and
6,
respectively),
were
exposed
five
days
per
week,
as
a
six­
hour
exposure,
for
four
consecutive
weeks
(minimum
of
20
exposures).
The
targeted
exposure
concentration
was
100
ppm.
Blood
samples
were
collected
at
4,
6,
6.25
and
8
hours
after
the
start
of
exposure
from
three
animals/
specie/
timepoint
on
the
first,
third
and
fifth
days
of
study
week
4.
Following
9
of
619
WIL­
417002
HAP
Task
Force
1,
1,2­
Trichloroethane
blood
collection,
the
anesthetized
animals
were
exsanguinated
and
organs/
tissues
were
collected
and
were
frozen
using
liquid
nitrogen
for
potential
analysis.

1.3.
RESULTS
There
were
no
test
article­
related
deaths.
Clinical
observations,
body
weights,
food
consumption,
hematology
parameters
and
organ
weights
were
unaffected
by
test
article
exposure.
No
test
article­
related
ophthalmic
findings
were
noted,
and
no
test
article­

related
macroscopic
changes
were
observed
at
the
scheduled
necropsy.

Test
article­
related
effects
noted
in
the
15
ppm
group
consisted
of:

l
Minimal
hepatocellular
vacuolization
in
3/
l
0
females.

l
Microscopic
lesions
in
the
olfactory
epithelium
of
the
nasal
turbinates
(vacuolization'microcyst
formation
in
2/
l
0
males
and
4/
l
0
females).

Test
article­
related
effects
noted
in
the
40
ppm
group
consisted
of:

l
Minimal
hepatocellular
vacuolization
in
3/
10
females.

l
Microscopic
lesions
in
the
olfactory
epithelium
of
the
nasal
turbinates
(atrophy
in
6/
10
males
and
7/
10
females,
vacuolizatiommicrocyst
formation
in
6/
10
males
and
4/
10
females
and
respiratory
epithelial
metaplasia
in
l/
10
males
and
l/
10
females).

Possible
test
article­
related
effects
noted
in
the
100
ppm
group
consisted
of:

l
Decreased
absolute
body
weights
and
body
weight
gains
from
study
week
0
to
1
in
females.

l
Increased
mean
cholesterol
levels
in
the
males
and
females
and
decreased
mean
glucose
in
females.

l
Minimal
hepatocellular
vacuolization
in
5/
l
0
males
and
1
O/
l
0
females.

l
Microscopic
lesions
in
the
olfactory
epithelium
of
the
nasal
turbinates
(atrophy
in
7/
l
0
males
and
lo/
10
females,
vacuolization'microcyst
formation
in
lO/
lO
males
and
8/
10
females
and
respiratory
epithelial
metaplasia
in
300
males
and
5/
10
females).

lOof
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
1.4.
CONCLUSIONS
Based
on
the
results
of
this
study,
the
no­
observed­
effect
level
(NOEL)
for
whole­
body
inhalation
of
1,
1,
2­
Trichloroethane
to
rats
for
13
weeks
was
less
than
15
ppm.

However,
the
no­
observed­
adverse­
effect
level
(NOAEL)
was
less
than
40
ppm
since
the
hepatic
and
nasal
effects
observed
for
the
low
concentration
group
were
not
considered
toxicologically
significant.
In
addition,
a
major
difference
in
chemical
sensitivity
of
the
nasal
airways
between
the
rat
and
human
may
exist
because
of
the
vastly
greater
presence
of
olfactory
epithelium
in
the
rat.

11
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
2.
INTRODUCTION
2.1.
GENERAL
STUDY
INFORMATION
This
report
presents
the
data
from
"A
90­
Day
Inhalation
Toxicity
Study
of
1,
1,2­
Trichloroethane
(1,
1,
2­
TCE)
in
Rats
(With
Satellite
Groups
for
Pharmacokinetic
Evaluations
in
Rats
and
Mice)".
Due
to
software
spacing
constraints,
the
study
title
appears
as,
"90­
Day
Inhal.
Study
of
1,
1,
2­
TCE
in
Rats
with
PK
in
Rats
and
Mice"
on
the
report
tables.

The
following
computer
protocols
were
used
for
data
collection
during
the
study:

Computer
Protocol
Type
of
Data
Collected
WIL­
4
17002..
..........................................
Main
study
data
WIL­
4
17002R..
.......................................
Rat
pharmacokinetic
group
data
WIL­
417002M..
......................................
Mouse
pharmacokinetic
group
data
WIL­
4
17002P
.........................................
Pretest
rat
data
WIL­
4
17002Q..
.......................................
Pretest
mouse
data
2.2.
KEY
STUDY
DATES
Date(
s)
Event(
s)

May
15,200l
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Experimental
starting
date
(animal
receipt)
May
29,200l
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Assignment
to
study
groups
(Toxicology
Phase)
June
1,200l
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Assignment
to
study
groups
(Pharmacokinetic
Phase)
May
31,
2001
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Initiation
of
dosing
for
Toxicology
Phase
(study
week
0)
June
5,200l
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Initiation
of
dosing
for
Pharrnacokinetic
Phase
(study
week
0)
June
25,
27
and
29,
2001
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Pharmacokinetic
blood
collection
August
30
and
3
1,
200
1
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Primary
necropsy
(study
week
13)
December
3
1,
2001
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Experimental
termination
date
(last
histopathological
examination)

12of619
.­
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
3.
STUDY
DESIGN
Acclimation
and
Pretest
Period
Assignment
of
Animals
to
Study
Groups
10
Animals/
Sex/
Group
(1
­
4)
Treated
Six
Hours/
Day,
5
Days/
Week
for
13
Weeks
for
a
Minimum
of
65
Exposures
I
I
Clinical
Observations
Recorded
/
Daik;;
zeFod
Clinical
Pathology
Evaluations
Conducted
at
Appropriate
Intervals
pzz?
QkJ
36
Females/
Specie/
Group
(5
­
6)

Clinical
Observations
Recorded
Daily;
Body
Weights
Recorded
as
Appropriate
/
Blood
Samples
for
Plasma
Level
1
DeteArm$
atiF
gll;;;
d
at
Ophthalmic
Examinations
Performed
at
Appropriate
Intervals
I
I
Animals
Found
Dead
or
Euthanized
1
Necropsies
Performed
on
All
Surviving
Animals/
Sex/
Group
During
Week
13;
Selected
Organs
Weighed;
Selected
Tissues
Examined
Microscopically
13
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
4.
EXPERIMENTALPROCEDURES­
MATERIALS
AND
METHODS
4.1.
TESTARTICLE
4.1.1.
TESTARTICLEIDENTIFICATION
The
test
article,
1,
1,
2­
Trichloroethane,
was
received
from
Dow
Chemical,
Freeport,

Texas,
as
follows:

Identification
Quantity
Physical
Received
Description
Date
of
Receint
1,
1,2­
Trichloroethane
Lot
No.
NH06019301
[WIL
Log
No.:
5015A]
3
Buckets
Total
gross
weight:
81059.
Og
Clear,
colorless
liquid
12/
29/
01
The
purity
of
the
test
article
was
99.55%
by
weight
based
on
the
analyses
of
the
test
article
samples
provided
by
WIL
Research
Laboratories,
Inc.
to
the
sponsor
(Appendix
A).
Purity
(Appendix
B)
and
stability
data
for
the
test
article
were
conducted
by
the
Analytical
Chemistry
Department,
WIL
Research
Laboratories,
Inc.
The
test
article
was
stored
at
room
temperature,
and
was
considered
stable
under
these
conditions.
A
reserve
sample
of
the
test
article
(11.7
grams)
was
collected
on
February
20,
200
1,
and
stored
in
the
Archives
of
WIL
Research
Laboratories,
Inc.

4.1.2.
EXPOSURE
METHODS
The
exposures
were
conducted
in
2
m3
stainless
steel
and
glass
whole­
body
exposure
chambers.
One
chamber
was
dedicated
for
each
group
for
the
duration
of
the
study.
For
the
high
concentration
groups,
the
toxicology
and
pharrnacokinetic
group
rats
(with
the
exception
of
blood
collection
days,
discussed
below)
and
pharmacokinetic
group
mice
were
exposed
in
the
same
inhalation
chamber.
This
is
considered
to
be
acceptable
for
6­
hour
exposures
and
for
the
short
duration
of
the
pharmacokinetic
study
(28
days).
The
chambers
were
operated
under
dynamic
conditions
from
a
HEPA
and
charcoal
filtered
air
source.

Animal
cage
batteries
were
rotated
on
a
daily
basis
through
various
chamber
locations
in
order
to
reduce
the
potential
differences
in
exposure
due
to
any
residual
non­
homogeneity
in
chamber
concentrations.

14
of
619
WIL­
417002
HAP
Task
Force
1,
1,2­
Trichloroethane
Air
flow
rate
through
the
chamber
was
such
that
there
was
at
least
10
air
changes
per
hour.

Protocol­
defined
ranges
for
daily
average
chamber
temperature
and
relative
humidity
were
22k2"
C
and
30­
70%,
respectively.
These
parameters
were
monitored
continuously
and
recorded
approximately
every
30
or
35
minutes
during
each
day's
exposure.
Oxygen
content
of
the
exposure
atmosphere
was
measured
during
the
methods
developmental
phase
of
the
study
and
was
at
least
19%.

The
animals
were
caged
individually,
without
food
and
water,
during
the
exposures
with
the
exception
of
the
mice
in
the
pharmacokinetic
phase,
which
were
allowed
access
to
water.
The
exposure
period
was
six
hours
per
day,
five
days
per
week
for
13
consecutive
weeks
(minimum
of
65
exposures).
For
each
exposure,
all
animals
were
housed
in
normal
animal
colony
rooms
during
non­
exposure
hours.
For
each
day's
exposure,
the
animals
were
transferred
to
exposure
caging,
transported
to
the
exposure
chamber
room,
exposed
for
the
requisite
duration
and
returned
to
their
home
cages.
The
control
group
was
exposed
to
clean,
filtered
air
under
conditions
otherwise
identical
to
the
test
article­
treated
groups.

Mean
exposure
temperature
ranged
from
21
to
25°
C
and
relative
humidity
ranged
from
42
to
49%.
Exposure
methods
and
conditions
are
detailed
in
Appendix
C.

On
each
day
of
PK
blood
collection
(lS*,
3rd
and
5'
days
of
exposure
of
the
fourth
exposure
week),
the
female
rats
designated
for
blood
collection
on
the
specific
day
were
exposed
to
the
target
concentration
of
100
ppm
in
a
500­
L
NYU­
type
whole­
body
chamber
(that
is,

separate
from
the
remaining
animals
in
the
group).
This
was
a
completely
separate
exposure
system
with
its
own
test
atmosphere
vapor
generator,
chamber
dilution
airflow
and
calibrated
exhaust
airflow.
The
methods
used
for
this
generation
and
exposure
system
were
similar
to
those
for
the
other
test
article
systems.
This
change
for
the
pharmacokinetic
(PK)

study
rats
facilitated
blood
collection
at
the
appropriate
time
points
relative
to
the
start
of
exposure
and
prompt
collection
of
blood
after
animals
were
removed
from
the
exposure
chamber
(4­
and
6­
hour
time
points).
The
use
of
different
exposure
systems
for
PK
study
rats
and
mice
allowed
the
PK
rat
exposure
to
be
started
approximately
30
minutes
after
or
15of619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
before
the
mouse
exposure.
Exposure
methods
and
conditions
are
detailed
in
Appendix
C.

4.1.3.
GENERATION
OF
EXPOSURE
ATMOSPHERE
Vapors
of
the
test
article
were
generated
using
a
glass­
bead
vaporization
system.
The
vaporization
column
consisted
of
a
glass
tube
filled
with
glass
beads.
Compressed
air
was
metered
to
the
bottom
of
the
column
using
calibrated
flowmeters.
Vaporization
occurred
as
the
test
article
flowed
down
through
the
beads
and
the
compressed
air
flowed
up
through
the
column.
The
concentrated
vapors
were
piped
to
the
chamber
inlet
where
the
concentration
was
reduced
to
the
desired
level
by
mixing
with
the
chamber
ventilation
air.
The
vaporization
columns
were
heated
by
heating
tapes
operated
from
Omega
CN370
temperature
controllers.
Exposure
methods
and
conditions
are
detailed
in
Appendix
C.

4.1.4.
CHARACTERIZATION
OF
EXPOSURE
ATMOSPHERES
Nominal
exposure
concentrations
were
determined
by
weighing
the
containers
of
test
article
prior
to
and
again
after
each
day's
exposure,
and
calculating
the
concentration
from
the
weight
difference
and
the
total
volume
of
air
passed
through
each
chamber
during
that
day's
exposure.

Actual
exposure
concentrations
were
determined
approximately
every
30
or
35
minutes
using
a
gas
chromatographic
method.
Exposure
methods
and
conditions
are
detailed
in
Appendix
C.

4.1.5.
ORGANIZATION
AND
TREATMENT
REGIMEN
The
study
consisted
of
six
groups.
The
toxicological
phase
of
the
study
consisted
of
four
groups
of
Fischer
344
CDF@(
F­
344)
Crl:
BR
rats
which
were
exposed
five
days
per
week,

as
a
six­
hour
exposure,
for
13
consecutive
weeks
(minimum
of
65
exposures).
The
pharmacokinetic
phase
consisted
of
one
group
of
female
Fischer
344
CDF@(
F­
344)
Crl:
BR
rats
and
one
group
of
female
B6C3FlKrl:
BR
mice
which
were
exposed
five
days
per
week,
as
a
six­
hour
exposure,
for
four
consecutive
weeks
.

16
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
The
following
table
presents
the
study
group
assignment:

Toxicology
Groups
(WIL­
4
17002)

Group
Number
Test
Article
Svecie
Target
Exposure
Number
of
Animals
Level
(pvm)
Males
Females
1
Filtered
Air
Rat
0
10
10
2
Low
1
,l
,2­
TCE
Rat
15
10
10
3
Mid
1,1,2­
TCE
Rat
40
10
10
4
High
1,1,2­
TCE
Rat
100
10
10
Toxicokinetic
Groups
(WIL­
4
17002R
[Rat1
4
17002M
IMousel)

Group
Target
Exposure
Number
of
Animals
Number
Test
Article
Specie
Levela
(ppm)
Males
Females
5
High
1,1,2­
TCE
Rat
100
36
6
High
1,1,2­
TCE
Mouse
100
36
a
=
Groups
5
and
6
were
exposed
using
the
same
exposure
system
and
methods
used
for
Group
4
(except
for
Group
5
PK
animals
on
day
of
animals'
blood
collection).

Exposure
concentrations
were
selected
based
on
results
from
a
prior
dose
range­
finding
study
(4
1700
1').

The
selected
route
of
administration
was
whole­
body
inhalation
exposure
as
this
is
a
potential
route
of
human
exposure.
The
animal
models,
the
Fischer
344
CDF@(
F­

344)
Crl:
BR
rat
and
the
B6C3Fl/
Crl:
BR
mouse,
are
recognized
as
appropriate
for
subchronic
inhalation
toxicity
and
pharmacokinetic
studies
and
are
recommended
in
the
TSCA
guideline.

On
July
26,
2001
(study
day
56),
Groups
1
and
2
were
loaded
into
the
incorrect
cage
batteries.
This
error
resulted
in
the
control
group
animals
(Group
1)
receiving
a
single
six­
hour
exposure
to
15
ppm
1,
1,
2­
TCE
and
the
Group
2
(15
ppm
group)
animals
receiving
a
six­
hour
exposure
to
filtered
air.
The
error
was
discovered
upon
returning
the
animals
to
their
home
cages.
Although
this
error
would
have
been
avoided
if
the
single
responsible
individual
followed
normal
verification
procedures,
a
second,
independent
17
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
verification
step
was
added
and
all
remaining
exposures
were
completed
without
further
exposure
errors.

At
the
time
of
this
incident,
there
was
approximately
five
weeks
of
scheduled
exposures
remaining
prior
to
conduct
of
the
primary
toxicity
evaluations.
Since
the
study
was
designed
to
evaluate
potential
subchronic
effects
of
1,1,2­
TCE
following
repeated
six­

hour,
five
day/
week
exposures
for
13
weeks,
it
is
considered
unlikely
that
a
single
exposure
of
the
control
animals
to
the
low
level
of
15
ppm
would
affect
the
study
outcome.
Even
if
a
single
exposure
to
15
ppm
had
some
slight
acute
effect,
complete
resolution
would
be
expected
during
the
approximately
five
weeks
remaining
before
end
of
the
exposure
phase.
Previous
toxicity
testing
of
1,1,2­
TCE
cited
in
Patty's
Industrial
Hygiene
and
Toxicology
indicated
that
inhalation
exposure
of
rats
to
15
ppm
for
six
months
(7
hours/
day,
5
days/
week)
had
no
toxic
effects
as
indicated
by
all
standard
endpoints2.

In
order
to
ensure
that
there
was
no
significant
acute
effect
on
the
control
group
animals,

blood
was
collected
from
six
males
and
six
females
in
the
control
group
at
approximately
18
hours
following
the
exposure
(presented
in
Appendix
D).
In
addition,
blood
was
collected
from
five
untreated
male
Fischer
344
rats
from
the
original
shipment
(no
untreated
females
from
the
original
shipment
were
available).
Serum
enzyme
levels,

including
alkaline
phosphatase,
aspartate
aminotransferase,
alanine
aminotransferase
and
lactate
dehydrogenase
levels
were
determined
to
evaluate
possible
effects
on
the
liver
since
this
was
a
primary
target
tissue
of
1,
1,
2­
TCE
toxicity.
The
results
of
the
serum
enzyme
evaluation
did
not
suggest
an
effect
that
would
interfere
with
the
interpretation
of
the
results
of
this
study
As
will
be
described
in
the
results
and
conclusions
sections
of
this
report
(sections
6
and
7),
the
results
of
this
study
support
the
conclusion
that
the
single
exposure
of
the
control
group
at
15
ppm
did
not
affect
the
study
interpretation
or
objectives.
Since
there
were
no
adverse
effects
for
the
animals
in
the
15
ppm
group
following
13
weeks
of
exposure,
no
18
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
adverse
or
confounding
effects
would
be
present
approximately
five
weeks
following
a
single
exposure.

4.2.
ANIMAL
RECEIPT
Am
ACCLIMATION/
PRETEST
PERIOD
Fifty
male
and
eighty­
six
female
Fischer
344
CDF@(
F­
344)
Crl:
BR
rats
and
forty­
seven
female
B6C3Fl
mice
in
good
health
were
received
on
May
15,
2001,
from
Charles
River
Laboratories,
Raleigh,
North
Carolina
and
Portage,
Michigan,
respectively.
The
animals
were
41
days
old
at
receipt.
Each
animal
was
examined
by
a
qualified
technician
on
the
day
of
receipt
and
weighed
three
days
later.
Animals
were
uniquely
identified
by
Monel@

metal
ear­
tags
(rats)
or
by
a
tail
tattoo
(mice)
displaying
the
permanent
identification
number.
All
animals
were
housed
for
a
minimum
16­
day
acclimation
period.
During
this
period,
each
animal
was
observed
twice
daily
for
mortality
and
general
changes
in
appearance
or
behavior.

Serological
screening
was
conducted
on
five
rats
of
each
sex
and
five
female
mice
approximately
one
week
following
receipt.
Blood
was
collected
via
the
vena
cava
from
the
anesthetized
animals.
The
animals
were
then
exsanguinated
and
discarded.
Serum
samples
for
rats
were
analyzed
for
antibodies
to
the
following
pathogens:
Sendai,

RCVSDA,
Reo,
KRV,
LCM,
H­
l,
PVM,
Ropv
viruses,
M
pulmonis
and
CARB.
Serum
samples
for
mice
were
analyzed
for
Sendai,
EDIM,
GDVII,
MHV,
PVM,
MPV,
MVM
and
M
pulmonis.
The
results
are
presented
in
Appendix
F.

Pretest
data
collection
began
on
May
18,
2001.
Individual
body
weights
were
recorded
and
detailed
physical
examinations
were
performed
four
times
for
the
rats
and
four
times
for
the
mice
prior
to
the
initiation
of
exposure.
Food
consumption,
clinical
pathology
parameters
and
ophthalmic
examinations
were
also
recorded
for
pretest
animals
prior
to
the
initiation
of
dosing.
Pretest
clinical
observations
are
presented
in
Appendix
E.

4.3.
ANIMAL
HOUSING
Upon
arrival,
all
animals
were
housed
individually
in
clean,
wire­
mesh
cages
suspended
above
cage­
board.
Animals
were
maintained
in
accordance
with
the
"Guide
for
the
Care
19
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
and
Use
of
Laboratory
Animalstt3.
The
animal
facilities
at
WIL
Research
Laboratories,

Inc.,
are
accredited
by
the
Association
for
Assessment
and
Accreditation
of
Laboratory
Animal
Care
International
(AAALAC
International).

4.4.
DIET,
DRINKING
WATER
AND
MAINTENANCE
The
basal
diet
used
in
this
study,
PM1
Nutrition
International,
Inc.
Certified
Rodent
LabDiet@
5002,
is
a
certified
feed
with
appropriate
analyses
performed
by
the
manufacturer
and
provided
to
WIL
Research
Laboratories,
Inc.
Municipal
water
supplying
the
facility
is
sampled
for
contaminants
according
to
the
standard
operating
procedures.
The
results
of
the
diet
and
water
analyses
are
maintained
at
WIL
Research
Laboratories,
Inc.
No
contaminants
were
present
in
animal
feed
or
water
at
concentrations
sufficient
to
interfere
with
the
objectives
of
this
study.
Reverse­
osmosis­

treated
(on­
site)
drinking
water,
delivered
by
an
automatic
watering
system,
and
the
basal
diet
were
provided
ad
Zibitum
throughout
the
study
(except
during
exposures
for
rats
and
during
exposures
for
mice
which
had
access
to
water
only).

4.5.
ENVIRONMENTAL
CONDITIONS
All
animals
were
housed
throughout
the
acclimation
period
and
during
the
study
in
an
environmentally
controlled
room.
Controls
were
set
to
maintain
a
temperature
of
72
f
4°
F
(22
&
3°
C)
and
a
relative
humidity
of
approximately
30­
70%.
Room
temperature
and
relative
humidity
were
monitored
continuously
and
recorded
daily.
The
actual
temperature
ranged
from
70.1"
F
to
74.2"
F
(21.2"
C
to
23.4"
C)
and
humidity
ranged
from
39.6%
to
62.2%
during
the
study.
Light
timers
were
set
to
provide
a
12­
hour
light/
l2­
hour
dark
photoperiod.
The
12­
hour
light/
l2­
hour
dark
photoperiod
was
interrupted
as
necessary
to
allow
for
the
performance
of
protocol­
specified
activities.

4.6.
ASSIGNMENT
OF
ANIMALS
To
TREATMENT
GROUPS
Two
and
four
days
prior
to
exposure
(May
29,
and
June
1,2001,
for
the
main
study
and
the
pharmacokinetic
phase,
respectively),
all
available
animals
were
weighed
using
the
WIL
Toxicology
Data
Management
System
(WTDMSTM)
and
examined
in
detail
for
20of619
WIL­
417002
HAP
Task
Force
1,
1,2­
Trichloroethane
physical
abnormalities.
These
data
were
reviewed
by
the
study
director
and
animals
judged
suitable
for
assignment
to
the
study
were
selected
for
use
in
the
computerized
randomization
procedure.
The
main
study
was
randomized
by
stratification
in
a
block
design.
The
randomization
for
the
pharmacokinetic
groups
was
conducted
using
an
unstratified
method
for
the
mice
and
the
remaining
rats.
A
printout
containing
the
animal
numbers,
corresponding
body
weights
and
individual
group
assignments
was
generated.

The
animals
then
were
arranged
according
to
the
printout.
For
the
toxicology
groups,
the
control
and
15,
40
and
100
ppm
groups
(Groups
1
­
4,
respectively)
each
consisted
of
10
males
and
10
females.
Each
pharmacokinetic
group
(Groups
5
and
6)
consisted
of
36
females.
The
selected
animals
were
approximately
eight
weeks
old
at
the
initiation
of
dosing;
body
weight
values
ranged
from
153
g
to
191
g
for
males
and
from
118
g
to
140
g
for
females
in
the
toxicology
groups
and
from
122
g
to
143
g
for
rats
and
from
19.3
g
to
21.9
g
for
mice
in
the
pharmacokinetic
groups.
Individual
body
weights
at
randomization
were
within
+
20%
of
the
mean
for
each
sex.

4.7.
DATA
RETENTION
The
sponsor
has
title
to
all
documentation
records,
raw
data,
specimens
or
other
work
product
generated
during
the
performance
of
the
study.
All
work
product
including
raw
paper
data
and
specimens
are
retained
in
the
Archives
at
WIL
Research
Laboratories,

Inc.,
as
specified
in
the
study
protocol.

The
raw
data,
reserve
samples
of
the
test
and
control
articles,
if
appropriate,
and
the
original
final
report
are
retained
in
the
Archives
at
WIL
Research
Laboratories,
Inc.,
in
compliance
with
regulatory
requirements.

21
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
5.
PARAMETERSEVALUATED
5.1.
CLINICALOBSERVATIONSANDSURVIVAL(
ALLGROUPS)

All
animals
were
observed
twice
daily,
once
in
the
morning
and
once
in
the
afternoon,
for
mortality
and
moribundity.

For
the
toxicology
group
animals,
clinical
examinations
were
performed
twice
daily
on
exposure
days,
prior
to
exposure
and
O­
2
hours
following
exposure
(designated
as
2­
hours
post­
dosing
for
report
presentation
purposes).
On
non­
exposure
days,
clinical
observations
were
performed
once
in
the
morning.
For
the
pharmacokinetic
animals,

clinical
observations
were
performed
prior
to
exposure
and
on
non­
exposure
days
they
were
performed
once
in
the
morning.
All
significant
findings
were
recorded.
Detailed
physical
examinations
were
conducted
on
all
main
study
animals
weekly,
beginning
one
week
prior
to
randomization,
on
the
day
of
randomization,
weekly
during
the
exposure
period
and
prior
to
the
scheduled
necropsy.
In
addition,
a
detailed
physical
examination
was
conducted
on
all
animals
that
were
euthanized
in
extremis,
to
assist
in
the
determination
of
the
cause
of
death.

5.2.
BODYWEIGHTS(
ALLGROWS)

Individual
body
weights
were
recorded
weekly,
beginning
at
least
one
week
prior
to
test
article
administration
(study
week
­1).
Mean
body
weights
and
mean
body
weight
changes
were
calculated
for
the
corresponding
intervals.
Final
body
weights
(fasted
for
rats)
were
recorded
prior
to
each
scheduled
necropsy.
Individual
body
weights
for
the
toxicokinetic
group
animals
are
presented
in
Appendix
G.

5.3.
FOODCONSUMPTION(
TOXICOLOGYGROUPQ
Individual
food
consumption
was
recorded
weekly,
beginning
at
least
one
week
prior
to
test
article
administration
(study
week
­1).
Food
intake
was
calculated
as
g/
animal/
day
for
the
corresponding
body
weight
intervals.

22
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
5.4.
CLINICALPATHOLOGY(
TOXICOLOGYGROWS)

Blood
samples
for
clinical
pathology
evaluations
(hematology
and
serum
chemistry)
were
collected
from
all
animals
at
the
scheduled
necropsy
(study
week
13).
The
animals
were
fasted
overnight
prior
to
the
collection
of
blood
samples.
Blood
was
collected
from
the
vena
cava
at
the
time
of
necropsy
from
animals
under
deep
anesthesia
from
isoflurane
inhalation,
Clinical
pathology
methods,
procedures
and
references
are
presented
in
Appendix
G.
In
addition,
blood
samples
were
collected
from
the
control
animals
during
study
week
8
and
analyzed
for
possible
effects
on
the
liver
(Appendix
D).

The
following
parameters
were
evaluated.

5.4.1.
HEMATOLOGY
Total
Leukocyte
Count
(White
Cell)
Prothrombin
Time
(Pro
Time)
Erythrocyte
Count
(Red
Cells)
Activated
Partial
Thromboplastin
Time
Hemoglobin
(APTT)
Hematocrit
Differential
Leukocyte
Count
­
Mean
Corpuscular
Volume
(MCV)
Percent
and
Absolute
Mean
Corpuscular
Hemoglobin
­Neutrophil
(MCH)
­Lymphocyte
Mean
Corpuscular
Hemoglobin
­Monocyte
Concentration
(MCHC)
­Eosinophil
Platelet
Count
(Platelet)
­Basophil
(
)
­
Designates
tabular
abbreviation
23
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
5.4.2.
SERUM
CHEMISTRY
Albumin
Aspartate
Aminotransferase
Total
Protein
(Aspartat
Transfer)
Globulin
[by
calculation]
Gamma
Glutamyltransferase"
Albumin/
Globulin
Ratio
(Glutamyl
Transfer)
(A/
G
Ratio)
[by
calculation]
Glucose
Total
Bilirubin
(Total
Bili)
Total
Cholesterol
(Cholesterol)
Urea
Nitrogen
Calcium
Creatinine
Chloride
Alkaline
Phosphatase
Phosphorus
(Alkaline
Phos'tse)
Potassium
Alanine
Aminotransferase
Sodium
(Alanine
Transfer)
Triglycerides
(Triglyceride)

(
)
­
Designates
tabular
abbreviation
a
­
Formerly
gamma
glutamyl
transpeptidase
5.5.
PLASMA
LEVEL
DETERMINATIONS
(PJXARMOCOKINETIC
GROIJPS)

Blood
samples
for
test
article
plasma
level
determination
were
collected
on
the
first,
third
and
fifth
days
of
the
fourth
week
at
4,
6,
6.25
and
8
hours
following
the
exposure
start.

Three
animals/
specie
were
sampled
at
each
time
point.
To
accommodate
the
4­
hour
timepoint,
the
high
concentration
chambers
were
opened
quickly,
the
designated
animals
(three
rats
and
three
mice)
were
removed
and
the
chambers
were
resealed.
The
animals
were
anesthetized
as
quickly
as
possible
and
blood
was
collected
via
the
vena
cava
into
hepranized
syringes.
The
blood
was
transferred
in
duplicate
directly
into
headspace
vials
for
analysis,
and
the
remaining
sample
was
collected
and
saved
in
vacutainers
with
dry
sodium
heparin.
For
the
headspace
vial
samples,
duplicate
blood
samples
of
100
l..
tL
from
each
animal
were
aliquoted
into
cold,
pre­
weighed
20
mL
headspace
vials
with
crimp
tops
and
PTFE­
silicone
septa.
The
vials
were
sealed
as
quickly
as
possible.
The
headspace
vials
were
weighed
before
and
after
the
addition
of
blood
to
verify
volumes
added
gravimetrically.
Immediately
after
weighing,
the
vials
were
placed
on
dry
ice.
For
each
animal,
the
remaining
blood
was
placed
in
a
pre­
weighed,
pre­
cooled
vacutainer
tube,
which
was
sealed
and
reweighed.

24
of
619
WIL­
417002
HAP
Task
Force
1,
1,2­
Trichloroethane
Following
blood
collection,
the
anesthetized
animals
were
exsanguinated
to
complete
euthanasia.
The
lungs,
liver,
kidneys,
spleen
and
whole
brain
were
collected
at
stored
at
­70°
C
at
WIL
Research
Laboratories,
Inc.
In
order
to
minimize
chemical
loss,
all
sample
manipulations
were
conducted
on
ice.
Each
organ
was
double
wrapped
in
plastic
wrap,

placed
in
a
labeled
aluminum,
foil
pouch,
frozen
in
liquid
nitrogen
and
sealed
in
a
plastic
storage
bag.
At
the
time
of
necropsy,
storage
stability
spike
standards
were
prepared
in
headspace
vials
using
control
blood
(from
untreated
rats)
spiked
with
known
quantities
of
1,
1,
2­
Trichloroethane.
In
addition,
unspiked
control
blood
(from
untreated
rats)
was
frozen
and
shipped
to
Battelle
Northwest
Laboratories,
Richland,
Washington,
for
preparation
of
standards
(for
calibration
curves)
and
samples
of
1,
1,
2­
Trichloroethane
solution
used
to
prepare
the
storage
spike
samples
included.
Plasma
was
prepared
and
frozen
at
­70°
C.
The
plasma
samples
were
shipped
in
Styrofoam
containers
on
dry
ice
via
overnight
courier
to
Battelle
Warehouse,
Richland,
Washington.
The
analytical
laboratory
and/
or
the
sponsor
are
responsible
for
subsequent
data
analysis
and
reporting
of
the
pharmacokinetic
evaluations.
Individual
dispositions
and
body
weights
for
the
pharmacokinetic
animals
are
presented
in
Appendix
I.

5.6.
OPHTHALMIC
EXAMINATIONS
(TOXICOLOGY
GROUPS)

Ocular
examinations
were
conducted
on
all
animals
prior
to
the
initiation
of
dosing
(May
23,200l;
study
week
­l),
near
the
end
of
the
dosing
period
(August
23,200l;
study
week
12).
All
ocular
examinations
were
conducted
using
an
indirect
ophthalmoscope
(or
other
suitable
equivalent
equipment),
preceded
by
pupillary
dilation
with
an
appropriate
mydriatic
agent.
Examinations
were
performed
by
David
A.
Wilkie,
D.
V.
M.,
M.
S.,

D.
A.
C.
V.
O.
(Appendix
J).

5.7.
ANATOMIC
PATHOLOGY
(TOXICOLOGY
GROUPS)

5.7.1.
MACROSCOPIC
EXAMINATION
A
complete
necropsy
was
conducted
on
all
animals.
Animals
were
euthanized
by
isoflurane
anesthesia
followed
by
exsanguination.
The
necropsies
included,
but
were
not
limited
to,
examination
of
the
external
surface,
all
orifices,
and
the
cranial,
thoracic,

25
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
abdominal
and
pelvic
cavities
including
viscera.
The
following
tissues
and
organs
were
collected
and
placed
in
10%
neutral
buffered
formalin
(except
as
noted):

Adrenals
(2)
Aorta
Bone
with
marrow
Sternum
Bone
marrow
smear
(taken
from
femur)*
Brain
(forebrain,
midbrain,
hindbrain)
Epididymidesb
Eyes
with
optic
nerve
(2)
'
Exorbital
lacrimal
glands
(2)
Gastrointestinal
tract
Esophagus
Stomach
Duodenum
Jej
unum
Ileum
Cecum
Colon
Rectum
Harderian
glands
(2)
Heart
Kidneys
(2)
Larynx
(3
levels)
d
Liver
(sections
of
two
lobes)
Lungs
(including
bronchi,
fixed
by
inflation
with
fixative)
Lymph
nodes
Mediastinal
Tracheobronchial
Mamrnary
gland
(females
only)
Nasal
Tissuese
Ovaries
with
oviducts
(2)
Pancreas
Parathyroidsf
Peripheral
nerve
(sciatic)
Pituitary
Prostate
Salivary
glands
[mandibular
(2)]
Seminal
vesicles
(2)
Skeletal
muscle
(rectus
femoris)
Skin
Spinal
cord
(cervical,
thoracic,
lumbar)
Spleen
Testes
(2)
b
Thymus
Thyroids
Trachea
Urinary
bladder
Uterus
with
vagina
All
gross
lesions
(when
possible)

a
=
Bone
marrow
smears
were
obtained
at
necropsy
but
not
placed
in
formalin.
b
=
Fixed
in
Bouin's
solution.
'
=
Fixed
in
Davidson's
solution.
d
=
Three
cross
sections
were
examined
in
accordance
with
the
method
described
by
Renne4.
e
=
The
entire
head
was
removed
and
preserved.
Following
decalcification,
six
cross­
sections
of
the
nasal
cavities
were
prepared
for
microscopic
examination
in
accordance
with
the
method
described
by
Morgan'.
f
=
Parathyroid
glands
were
examined
microscopically
if
in
the
plane
of
section
and
in
all
cases
when
a
gross
lesion
was
noted.

26
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
5.7.2.
ORGAN
WEIGHTS
The
following
organs
were
weighed
from
all
animals
at
the
scheduled
necropsies:

Adrenals
Brain
Epididymides
Heart
Kidneys
Liver
Lungs
(prior
to
inflation
with
fixative)
Ovaries
Spleen
Testes
Thymus
Thyroids
(with
parathyroids)"

a
=
Weighed
after
fixation.

Paired
organs
were
weighed
together.
Organ
to
final
body
weight
and
organ
to
brain
weight
ratios
were
calculated.

5.7.3.
SLIDEPREPARATION
AND
MICROSCOPICEXAMINATION
Following
fixation,
protocol­
specified
tissues
were
shipped
to
Experimental
Pathology
Laboratories,
Inc.
(EPL),
Herndon,
Virginia,
for
preparation
of
blocks
and
slides.
EPL
is
responsible
for
the
GLP
compliance
of
the
work
conducted
at
their
facility.

Microscopic
examination
was
performed
on
all
tissues
listed
in
Section
5.7.1.
from
all
animals
in
the
control
and
100
ppm
groups
at
the
scheduled
necropsies.
The
larynx,

kidneys,
liver,
lungs,
nasal
tissues,
trachea,
and
all
gross
lesions
were
examined
from
all
animals
in
the
15
and
40
ppm
groups
at
the
primary
necropsy.
Missing
tissues
were
identified
as
not
found
at
necropsy,
lost
at
necropsy,
lost
during
processing,
not
in
plane
of
section
or
other
reasons
as
appropriate.
Microscopic
examinations
were
conducted
by
Frederick
A.
Ruecker,
D.
V.
M.,
M.
S.,
D.
A.
C.
V.
P.,
Experimental
Pathology
Laboratories,

Inc.
(Appendix
K).

5.8.
STATISTICALMETHODS
All
analyses
were
conducted
using
two­
tailed
tests
for
minimum
significance
levels
of
1%
and
5%,
comparing
each
test
article­
treated
group
to
the
control
group
by
sex.
Each
mean
was
presented
with
the
standard
deviation
(S.
D.)
and
the
number
of
animals
(N)

27
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
used
to
calculate
the
mean.
Statistical
analyses
were
not
conducted
if
the
number
of
animals
was
two
or
less.

All
statistical
tests
were
performed
using
appropriate
computing
devices
or
programs.

Body
weight,
body
weight
change,
food
consumption,
clinical
pathology
and
organ
weight
data
were
subjected
to
a
parametric
one­
way
analysis
of
variance
(ANOVA)
to
determine
intergroup
differences.
If
the
ANOVA
revealed
statistical
significance
(p<
O.
O5),
Dunnett's
test7
was
used
to
compare
the
test
article­
treated
groups
to
the
control
group.
Clinical
pathology
values
for
white
blood
cell
types
that
occur
at
a
low
incidence
(i.
e.,
monocytes,
eosinophils
and
basophils)
were
not
subjected
to
statistical
analysis.

28
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
6.
RESULTS
AND
DISCUSSION
(TOXICOLOGY
GROUPS)

6.1.
CLINICAL
OBSERVATIONS
AND
SURVIVAL
Summary
Data:
Tables
1,2,3,4,5
Individual
Data:
Table
20,
Appendix
F
One
female
(no.
69377)
in
the
15
ppm
group
was
euthanized
in
extremis
on
study
day
30.

Clinical
findings
noted
prior
to
euthanasia
consisted
of
impaired
use
of
hindlimbs,
dried
red
material
around
both
eyes,
red
discharge
from
both
eyes
and
decreased
defecation.

These
findings
were
not
considered
test
article­
related
since
they
were
not
noted
in
the
40
and
100
ppm
groups.

All
other
animals
survived
to
the
scheduled
necropsy
(study
week
13).
No
test
article­
related
clinical
signs
were
noted
during
the
study.
Clinical
signs
observed
in
the
test
article­
treated
groups
were
noted
similarly
in
the
control
group,
were
limited
to
single
occasions
for
one
animal,
were
not
present
in
a
dose­
related
manner
and/
or
were
those
types
of
findings
commonly
observed
in
laboratory
rats
of
this
strain
and
age.

6.2.
BODY
WEIGHTS
Summary
Data:
Tables
6,
7,
7A
Individual
Data:
Tables
2
1,22
Test
article­
related
decreased
mean
body
weights
and
body
weight
gains
were
noted
during
study
week
0
to
1
in
the
100
ppm
group
females.
These
differences
were
statistically
significant
(`~~
0.05
or
p<
O.
Ol)
when
compared
to
the
control
group.

There
were
no
other
test
article­
related
effects
on
body
weights.
However,
several
statistically
significant
(~~
0.05
or
p<
O.
Ol)
differences
in
absolute
body
weight
and
body
weight
gains
were
noted
when
compared
to
the
control
group.
Decreased
mean
body
weights
were
noted
in
the
15
and
100
ppm
group
females
at
study
week
7.
Increased
mean
body
weight
gains
were
noted
in
the
15
and
100
ppm
group
males
during
study
week
1
to
2,
in
the
15,
40
and
100
ppm
group
females
during
study
week
7
to
8
and
29
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
decreased
body
weight
gains
were
noted
in
the
15
and
100
ppm
group
females
during
study
week
6
to
7.
Since
there
were
no
time­
or
dose­
related
trends
apparent,
these
differences
were
not
test
article­
related.
No
other
remarkable
differences
were
noted.

6.3.
FOODCONSUMPTION
Summary
Data:
Table
8
Individual
Data:
Table
23
There
were
no
test
article­
related
effects
on
food
consumption.
However,
several
statistically
significant
(+
O.
OS
or
~~
0.01)
differences
in
food
consumption
were
noted
when
compared
to
the
control
group.
Increased
mean
food
consumption
was
noted
in
the
15
ppm
group
males
during
study
week
1
to
2
and
in
the
15
and
100
ppm
group
males
during
study
weeks
8
to
10.
Decreased
food
consumption
was
noted
in
the
40
and
100
ppm
group
females
during
study
week
0
to
1,
the
100
ppm
group
females
during
study
week
6
to
7
and
in
the
15
and
100
group
females
during
study
week
12
to
13.
Since
there
were
no
time­
or
dose­
related
trends
apparent
and/
or
the
differences
from
the
control
group
were
very
small,
these
differences
were
not
test
article­
related.
No
other
remarkable
differences
were
noted.

6.4.
CLINICALPATHOLOGY
6.4.1.
HEMATOLOGY
Summary
Data:
Tables
9,
10,
11
Individual
Data:
Tables
24,25,26
There
were
no
test
article­
related
effects
on
hematology
parameters.

30
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
6.4.2.
SERUM
CHEMISTRY
Summary
Data:
Table
12
Individual
Data:
Table
27
Possible
test
article­
related
increased
mean
cholesterol
was
noted
in
the
100
ppm
group
males
and
40
and
100
ppm
group
females
(statistically
significant
at
~~
0.01
or
~~
0.05
when
compared
to
the
control
group).
Mean
glucose
was
decreased
and
statistically
significant
(pcO.
05)
in
the
100
ppm
group
females
when
the
control
and
treated
groups
were
compared.
The
difference
from
the
control
group
appeared
to
be
test
article­
related
for
females
exposed
to
the
high
concentration.
There
were
no
other
potential
test
article­

related
effects
on
serum
chemistry
parameters.

6.5.
OPHTHALMIC
EXAMINATIONS
Summary
Data:
Tables
13,
14,
Appendix
G
Individual
Data:
Tables
28,29
No
treatment­
related
ophthalmic
findings
were
noted
at
the
study
week
12
examination.

6.6.
ANATOMIC
PATHOLOGY
6.6.1.
MACROSCOPIC
EXAMINATION
Summary
Data:
Tables
15,
16
Individual
Data:
Tables
30,3
1
There
were
no
treatment­
related
macroscopic
findings
at
the
scheduled
necropsy
or
for
the
animal
euthanized
in
extremis.
Findings
in
the
test
article­
treated
groups
were
noted
similarly
in
the
control
group,
were
noted
at
a
low
incidence,
typically
single
animals
and/
or
were
findings
common
in
laboratory
rats.

31
of
619
1,
1,2­
Trichloroethane
6.6.2.
ORGAN
WEIGHTS
Summary
Data:
Tables
17,
18,
19
Individual
Data:
Tables
32,33,34
There
were
no
test
article­
related
effects
on
organ
weights.
However,
several
statistically
significant
(~~
0.05
or
pcO.
01)
differences
were
noted
when
the
control
and
treated
groups
were
compared.
Mean
kidney
and
heart
weights
relative
to
final
body
weight
were
increased
in
the
100
ppm
group
females
and
mean
adrenal
weights
relative
to
final
body
weight
and
relative
to
brain
weight
were
increased
in
the
15
ppm
group
females.

Since
the
absolute
organ
weights
were
not
affected
and
no
dose­
related
trends
were
apparent,
these
differences
were
not
considered
test
article­
related.

6.6.3.
MICROSCOPIC
EXAMINATION
Summary
Data:
Appendix
K
Individual
Data:
Appendix
K
Test
article­
related
effects
were
noted
in
the
liver
and
nasal
turbinates
of
all
test
article­

treated
groups.
Minimal
hepatocellular
vacuolization
was
noted
in
3/
10
females
each
from
the
15
and
40
ppm
groups
and
5/
l
0
males
and
lO/
lO
females
from
the
100
ppm
group.
The
lesion
was
characterized
by
the
presence
of
small
vacuoles
within
the
cytoplasm
of
the
hepatocytes
in
a
focal
to
multifocal
distribution
within
the
sections
examined.
In
the
females,
there
was
no
apparent
dose­
related
increase
in
severity
between
the
three
exposure
groups,
nor
any
dose­
related
increase
in
incidence
between
the
15
and
40
ppm
groups.
While
special
stains
were
not
employed
to
identify
the
material
in
the
vacuoles,
their
morphology
was
consistent
with
lipid
accumulation.

However,
after
13
weeks
of
exposure
to
concentrations
up
to
100
ppm
there
were
no
microscopic
findings
indicative
of
centrilobular
hepatocellular
necrosis,
the
primary
and
most
toxicologically
significant
effect
on
the
liver
of
exposure
to
chlorinated
short­
chain
hydrocarbons,
including
1,1,2­
TCE.
Centrilobular
hepatocellular
necrosis
was
observed
in
rats
following
a
single
exposure
to
1,1,2­
TCE
at
concentrations
from
5
8
to
1527
ppm'.

32
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
Similarly,
there
were
no
test­
article­
related
increases
in
serum
levels
of
enzymes
known
to
be
increased
following
hepatocellular
injury
(e.
g.
increased
levels
of
serum
alanine
aminotransferase).

Several
microscopic
lesions
were
noted
in
the
nasal
turbinates
in
the
40
and
100
ppm
group
males
and
all
test
article­
treated
groups
of
females.
The
incidences
of
these
lesions
are
delineated
in
the
following
text
table:

Text
Table
1:
Incidence
of
Selected
Microscopic
Lesions
in
Nasal
Turbinates
Group:

Atrophy,
Olfactory
Epithelium
VacuolizationiCyst,
Olfactory
Epithelium
Respiratory
Epithelium
Metaplasia,
Olfactory
Epithelium
1
0
ppm
M
F
O/
loa
o/
10
(O/
60)
b
(O/
60)

l/
IO
l/
l0
(l/
60)
(1160)

o/
10
o/
10
(O/
60)
(O/
60)
15
ppm
M
F
o/
10
o/
10
(0160)
(OW
2110
4110
(2/
60)
(4/
60)

l/
l0
o/
10
(1160)
(0160)

"
=
Number
of
animals
affected/
number
of
animals
examined
3
40
ppm
M
F
6110
7/
10
(S/
60)
(7/
60)

6tlO
4/
10
(11160)
(4160)

l/
l0
l/
10
(2/
60)
(l/
60)
4
100
ppm
M
F
7110
lo/
lo
(15/
60)
(13160)

lo/
lo
8/
10
(E/
60)
(12/
60)

3110
5/
10
(3/
60)
(5160)

b
=
Total
number
of
individual
sections
affected/
total
number
of
individual
sections
examined
Please
note:
bolded
numbers
are
test
article­
related
Atrophy
of
the
olfactory
epithelium
was
characterized
by
a
thinning
of
the
olfactory
epithelial
mucosa
primarily
due
to
a
reduction
in
the
thickness
of
the
nuclear
cell
layer.

The
lesions
were
generally
observed
in
sections
from
Levels
3,
4,
and
5,
of
minimal
to
mild
severity,
and
focal
in
distribution,
primarily
affecting
the
epithelium
of
the
nasal
septum
in
the
dorsal
medial
meatus.
Occasionally,
there
was
a
complete
absence
of
the
olfactory
mucosa
in
the
affected
area.
The
mechanism
for
the
cell
loss
was
not
microscopically
obvious;
however,
since
the
lesion
was
only
observed
in
animals
from
the
40
and
100
ppm
groups,
it
was
interpreted
as
related
to
test
article
exposure.
The
focal
nature
of
the
lesion
could
not
be
explained.

Vacuolization
and/
or
microcyst
formation
in
the
olfactory
epithelium
was
characterized
by
the
presence
of
small
focal
to
multifocal
vacuoles/
microcysts
within
the
basilar
regions
of
the
olfactory
mucosa.
Again,
the
most
commonly
affected
area
was
the
33
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
olfactory
epithelium
lining
the
dorsal
medial
meatus
at
Levels
2
through
5.
Typically,
the
wall
of
these
vacuoles/
cysts
was
devoid
of
any
structure,
but
occasionally,
they
were
lined
by
a
cuboidal
epithelium,
which
most
resembled
the
epithelium
of
Bowman's
glands.
In
general,
the
vacuoles
were
devoid
of
any
content;
however,
occasionally
an
eosinophilic
globular
material
was
observed
within.
While
the
change
was
also
observed
in
one
control
group
male
and
female,
the
incidence
of
animals
affected
and
levels
per
animal
affected
generally
increased
with
exposure
to
increasing
concentrations
to
the
test
article.
In
the
low
concentration
group,
the
incidence
of
this
finding
was
low
(2
of
10
males
and
4
of
10
females)
and
was
observed
in
only
one
nasal
section
(i.
e,
level)
per
animal.
Although
test­
article
related,
this
effect
is
considered
to
represent
a
slight
response
in
the
low
exposure
group.
Although
the
pathogenesis
of
the
lesion
was
not
apparent,
the
character
of
the
lesion
suggests
that
it
is
probably
degenerative
in
nature.

Whether
exposure
to
the
test
article
directly
induced
the
formation
of
these
vacuoles/
cysts
or
secondarily
accelerated
a
process
that
is
normally
present
within
the
nasal
olfactory
mucosa
could
not
be
determined.

Respiratory
epithelial
metaplasia
of
the
olfactory
epithelium
was
observed
in
males
from
the
15,40
and
100
ppm
groups
and
females
from
the
40
and
100
ppm
groups.
This
lesion
was
characterized
by
the
presence
of
focal
areas
wherein
the
olfactory
epithelium
underwent
metaplastic
change
to
respiratory
epithelium.
Again,
these
changes
were
only
observed
in
the
olfactory
epithelium
lining
the
dorsal
medial
meatus
at
Levels
4
and
5.

Although
one
male
in
the
15
ppm
group
(no.
69335)
also
was
affected,
the
lesion
in
this
animal
was
considered
incidental
and
not
related
to
test
article
exposure
since
it
was
associated
with
inflammation
within
the
nasal
cavity
interpreted
as
spontaneous
in
origin.

Respiratory
epithelial
metaplasia
is
commonly
considered
to
be
a
sequela
to
atrophy
and
degeneration
of
the
olfactory
epithelium
with
replacement
by
ciliated
and
non­
ciliated
respiratory
epithelium.
It
may
be
seen
as
a
spontaneous
focal
lesion
in
aged
rats'.

Whether
test
article
exposure
directly
induced
this
change
or
accelerated
the
normal
aging
process
could
not
be
determined.

34of619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
Additional
microscopic
findings
(described
below)
noted
in
rats
from
control
and
test
article­
treated
groups
included
mononuclear
cell
infiltrates
in
various
tissues,

granulomatous
inflammation
in
the
larynx
and
trachea,
and
mineralization
or
mineral
deposition
in
the
kidney,
larynx,
nasal
turbinates,
and
cornea
of
the
eye.
In
general,
there
were
no
significant
differences
in
the
incidence
of
these
lesions
between
control
and
test
article­
treated
groups.
Therefore,
these
findings
were
considered
incidental
and
unrelated
to
test
article
exposure.
Since
the
test
article
exposure
was
via
inhalation,
it
should
be
emphasized
that
no
test
article­
related
effects
were
observed
for
respiratory
tract
tissues
other
than
the
nasal
tissues.

Mononuclear
cell
infiltrates,
observed
in
various
tissues,
typically
consisted
of
foci
of
lymphocytes
and
plasma
cells
generally
accompanied
by
a
few
neutrophils
as
a
minor
component.
This
morphology
was
consistent
with
subacute
inflammation.

Granulomatous
inflammation
was
observed
in
the
larynx
at
all
three
levels
examined.

The
lesion
was
characterized
by
the
presence
of
histiocytes
and
an
occasional
multinucleated
giant
cell
forming
discrete
focal
microgranulomas
surrounding
a
mineralized
center
located
just
below
the
mucosal
epithelial
layer.
Similar
lesions
were
also
occasionally
observed
in
the
trachea.
This
lesion
is
typically
observed
as
a
response
to
a
penetrating
foreign
body,
and
its
location
suggests
that
it
may
have
resulted
from
the
penetration
of
food
material
aspirated
into
the
larynx
and
trachea.
However,
any
such
material,
if
present
in
the
mineralized
core,
could
not
be
identified.

Mineralization
in
the
kidney
of
both
control
and
treated
male
and
female
rats
was
characterized
by
the
accumulation
of
lightly
to
intensely
staining
basophilic
material
within
the
lurnina
of
the
renal
tubules.
The
mineral
deposition
observed
in
the
larynx
was
located
within
the
central
core
of
the
microgranulomas,
as
already
discussed.
These
changes
were
considered
incidental
and
not
related
to
treatment.

Mineral
deposition
in
the
nasal
turbinates
was
observed
in
sections
from
Levels
2
through
6
of
both
control
and
test
article­
treated
male
and
female
rats.
This
lesion
was
35
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
characterized
by
the
deposition
of
basophilic
material
just
underlying
the
epithelium
of
the
transitional,
respiratory,
and
olfactory
mucosae.
In
some
cases,
the
mineral
could
be
localized
to
the
basement
membrane.
Similar
deposits
associated
with
the
basement
membrane
of
the
respiratory
and
olfactory
mucosae
have
been
reported
to
increase
in
frequency
with
age5.

Mineral
deposition
within
the
cornea
of
the
eye
was
characterized
by
the
presence
of
lightly
staining
basophilic
material
within
lamina
propria
of
the
cornea
just
underlying
the
cornea1
epithelium.
The
lesion
was
focal
in
distribution,
typically
located
in
the
central
region
of
the
cornea,
and
of
minimal
severity.
The
pathogenesis
of
this
lesion
was
not
determined.
However,
since
the
incidence
was
not
significantly
different
between
controls
and
test
article­
treated
rats,
it
was
considered
incidental
and
not
related
to
treatment.

Other
findings
in
the
test
article­
treated
groups
were
noted
similarly
in
the
control
group,

were
noted
at
a
low
incidence,
typically
single
animals
and/
or
were
findings
common
in
laboratory
rats.

36
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
7.
CONCLUSIONS
There
were
no
test
article­
related
deaths.
Clinical
observations,
body
weights,
food
consumption,
hematology
parameters
and
organ
weights
were
unaffected
by
test
article
exposure.
No
test
article­
related
ophthalmic
findings
were
noted,
and
no
test
article­

related
macroscopic
changes
were
observed
at
the
scheduled
necropsy.

Test
article­
related
effects
noted
in
the
15
ppm
group
consisted
of:

l
Minimal
hepatocellular
vacuolization
in
3/
l
0
females.

l
Microscopic
lesions
in
the
olfactory
epithelium
of
the
nasal
turbinates
(vacuolizatiotimicrocyst
formation
in
2/
l
0
males
and
4/
l
0
females).

Test
article­
related
effects
noted
in
the
40
ppm
group
consisted
of:

l
Minimal
hepatocellular
vacuolization
in
3/
l
0
females.

l
Microscopic
lesions
in
the
olfactory
epithelium
of
the
nasal
turbinates
(atrophy
in
6/
10
males
and
7/
l
0
females,
vacuolization/
microcyst
formation
in
6/
l
0
males
and
4/
10
females
and
respiratory
epithelial
metaplasia
in
l/
10
males
and
l/
10
females).

Possible
test
article­
related
effects
noted
in
the
100
ppm
group
consisted
of:

l
Decreased
absolute
body
weights
and
body
weight
gains
from
study
week
0
to
1
in
females.

l
Increased
mean
cholesterol
levels
in
the
males
and
females
and
decreased
mean
glucose
in
females.

l
Minimal
hepatocellular
vacuolization
in
5/
10
males
and
lo/
10
females.

l
Microscopic
lesions
in
the
olfactory
epithelium
of
the
nasal
turbinates
(atrophy
in
7/
l
0
males
and
lo/
10
females,
vacuolization/
microcyst
formation
in
lO/
lO
males
and
S/
10
females
and
respiratory
epithelial
metaplasia
in
3/
10
males
and
5/
10
females).

Chlorinated,
short
chain
hydrocarbons
are
believed
to
be
activated
to
oxidative
species
by
cytochrome
P450
metabolizing
enzymes
of
hepatocytes
in
the
centrilobular
regions
of
the
liver.
Following
13
weeks
of
inhalation
exposure
to
1,1,2­
TCE,
test
article­
related
microscopic
findings
in
the
liver
were
limited
to
minimal
hepatocellular
vacuolization,

which
might
represent
lipid
accumulation.
However,
the
presence
of
this
finding
without
37
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
centrilobular
necrosis
or
an
increase
in
serum
levels
of
enzymes
indicative
of
hepatocellular
injury
suggests
that
this
minimal
degree
of
vacuolization
(in
particular
where
only
3
of
10
females
were
affected)
lacks
toxicological
significance'.
It
is
possible
that
the
rate
of
oxidative
events
is
too
slow
at
these
exposure
levels
to
produce
frank
cellular
injury
or
the
hepatocytes
have
become
insensitive
to
such
events.

A
relatively
high
concentration
of
microsomal
metabolizing
enzymes
is
present
in
the
rodent
nasal
olfactory
epithelium.
As
a
result,
the
nasal
olfactory
epithelium
of
the
rat
is
extremely
sensitive
to
agents
that
may
be
activated
by
cytochrome
P­
450
metabolizing
enzymes.
It
has
been
reported
that
the
fraction
of
the
nasal
airways
covered
by
olfactory
epithelium
is
approximately
50%
in
the
F344
rat
compared
to
3%
in
the
human".
In
addition,
based
on
information
cited
by
Haschek
and
Witschi,
the
relative
surface
area
of
the
nasal
airways
(normalized
to
body
weight)
is
approximately
16
times
greater
in
the
rat
compared
to
the
human'
I.
Therefore,
the
rat
may
be
considered
one
of
the
most
sensitive
animal
models
for
chemical
injury
to
the
olfactory
epithelium.
Olfactory
epithelial
necrosis
was
observed
in
rats
following
a
single
exposure
to
1,1,2­
TCE
in
an
earlier
study'.
Following
the
subchronic
exposures
in
the
current
study,
animals
in
the
high
and
mid­
concentration
groups
had
changes
in
the
olfactory
epithelium,
including
atrophy
and
respiratory
epithelial
metaplasia.
A
third
test
article­
related
finding
in
the
olfactory
epithelium,
vacuolizationimicrocyst
formation,
was
observed
for
animals
in
all
1,1,2­

TCE
exposed
groups.
However,
the
slight
response
observed
in
the
low
concentration
group
was
not
considered
to
represent
an
adverse
response
since
the
finding
was
not
accompanied
by
frank
cellular
injury
(i.
e.,
necrosis,
atrophy
or
metaplasia).
Since
the
test
article
exposure
was
via
inhalation,
it
should
also
be
emphasized
that
no
test
article­

related
effects
were
observed
for
respiratory
tract
tissues
other
than
the
nasal
tissues.

Based
on
the
results
of
this
study,
the
no­
observed­
effect
level
(NOEL)
for
whole­
body
inhalation
of
1,
1,
2­
Trichloroethane
to
rats
for
13
weeks
was
less
than
15
ppm.

However,
the
no­
observed­
adverse­
effect
level
(NOAEL)
was
less
than
40
ppm
since
the
hepatic
and
nasal
effects
observed
for
the
low
concentration
group
were
not
considered
38
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
toxicologically
significant.
In
addition,
a
major
difference
in
chemical
sensitivity
of
the
nasal
airways
between
the
rat
and
human
may
exist
because
of
the
vastly
greater
presence
of
olfactory
epithelium
in
the
rat.
Therefore,
the
presence
of
atrophy
and
metaplasia
in
a
tissue
that
is
extremely
sensitive
in
the
rat
compared
to
other
species
may
be
misleading
in
estimating
human
risk.

39of619
WEL­
417002
HAP
Task
Force
I
)
1,2­
Trichloroethane
8.
KEYSTUDYPERSONNELANDREPORTSUBMISSION
Study
Supervisors:

Susan
C.
Haley,
B.
S.
Jonathan
M.
Hurley,
B.
S.
Sally
A.
Keets,
A.
S.
Carol
A.
Kopp.
B.
S.

Michael
A.
Safron,
AS.,
H.
T.
(A.
S.
C.
P.)
Daniel
W.
Sved,
Ph.
D.,
Acting
Group
Supervisor,
Clinical
Pathology
Operations
Manager,
Genera!
Toxicology
Acting
Senior
Operations
Manager,
Vivarium
Manager,
Gross
Pathology
and
Developmental
Toxicology
Laboratory
Manager,
Histology
Director,
MetaboIism
and
Analytical
Chemistry
Report
Prepared
By:
`A
Study
Analyst
Reviewed
By:

Robert
A.
W"
ally,
B.
S#­
Group
Supervisor,
Study
A.
nalysi&
d
Reports
Director,
Inhalati6n
Toxicology
40
of
619
WIL­
4
17002
HAP
Task
Force
9.
QUALITYASSURANCE
UNITSTATEMENT
9.1.
PHASESINSPECTED
Date(
s)
of
Insnection(
s)
6/
20/
O
1
612710
1
7/
l
l/
O1
713
o/
o
1
x/
30/
0
1
1
l/
15/
01
11115,
16/
01
1
l/
16,26/
01
1
l/
16/
01
1
l/
16/
01
11/
28,29/
01,
1131,
217102
1
l/
28,29/
01,
2/
4,7/
02
1
l/
28,29/
01,
2/
1,7/
02
12/
27/
01,
l/
30,
217102
l/
30,2/
7/
02
211,3,7,
X102
217102
217102
1120,22,24,25,
28102,2/
4/
02
Phase
Insnected
Test
Article
Exposure
Blood
Collection
Detailed
Physicals/
Body
WeightslFood
Weights
Animal
Care
and
Equipment
Necropsy
Study
Records
(I­
l)
Study
Records
(I­
2)
Study
Records
(I­
3)
Study
Records
(N­
1)
Study
Records
(C­
1,2,3)
Date(
s)
Findings
Reported
to
Studv
Director
6/
2010
1
612710
1
Date(
s)
Findings
Reported
to
Management
7/
30/
01
7130/
01
7/
l
l/
O1
713
l/
O1
813010
1
1
l/
26/
01
1112610
1
1
l/
29/
01
1
l/
26/
01
1
l/
2910
1
8/
3
l/
O1
Xl3
l/
01
9128/
O
1
12/
26/
01
12/
26/
O
1
12/
26101
12/
26/
O
1
12126101
Study
Records
(Ex­
3)
217102
3128102
Study
Records
(Ex­
4)
217102
3128102
Study
Records
(Ex­
5)
217102
3128102
Study
Records
(Ex­
1)
217102
3128102
Study
Records
(Ex­
2)
217102
3128102
Draft
Report
(Inhalation)
218102
3128102
Study
Records
(A­
l)
217102
3128102
Draft
Report
(Purity
Assessment)
218102
3128102
Draft
Report
(w/
o
Inhalation
and
Purity
Reports)
215102
3
/28/
02
1,
1,2­
Trichloroethane
This
study
was
inspected
in
accordance
with
the
U.
S.
Environmental
Protection
Agency
TSCA
guideline
799.9346:
90­
Day
Inhalation
Toxicity
Study,
the
standard
operating
procedures
of
WIL
Research
Laboratories,
Inc.,
and
the
sponsor's
protocol
and
protocol
amendments
with
the
following
exceptions.
The
data
located
in
Appendix
A
(Certificate
of
Analysis)
were
the
responsibility
of
the
sponsor.
The
data
located
in
Appendix
F
(Serological
Screening)
were
the
responsibility
of
BioReliance
Corporation.
The
data
located
in
Appendix
K
(Histopathology
Report)
were
the
responsibility
of
Experimental
Pathology
Laboratories,
Inc.
Quality
Assurance
findings,
derived
from
the
inspections
during
the
conduct
of
the
study
and
from
the
inspections
of
the
raw
data
and
draft
report,

41
of
619
1,
1,2­
Trichloroethane
are
documented
and
have
been
reported
to
the
study
director.
A
status
report
is
submitted
to
management
monthly.

This
report
accurately
reflects
the
data
generated
during
the
study.
The
methods
and
procedures
used
in
the
study
were
those
specified
in
the
protocol,
its
amendments
and
the
standard
operating
procedures
of
WIL
Research
Laboratories,
Inc.

42
of
619
WIL4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
9.2.
APPROVAL
This
study
was
inspected
according
to
the
criteria
discussed
in
Section
9.1.

ReDot­
t
Audited
BY:

F&
byn
N.
Durr,
B.
S.
Auditor
I,
Quality
Assurance
Report
Reviewed
BY:

Margaret
A.
Franklin
Unit
Supervisor,
Quality
Assurance
a
Date
43
of
619
WIL­
417002
HAP
Task
Force
1,
1,2­
Trichloroethane
10.
REFERENCES
1.
WIL­
417001.
(2001)
Acute
Inhalation
Toxicity
(with
Histopathology)
Study
of
1,1,2­
Trichloroethane
(1,1,2­
TCE)
in
Rats.
WIL
Research
Laboratories,
Inc.,
Ashland,
OH.

2.
Torkelson,
T.
R.
(1994)
Halogenated
aliphatic
hydrocarbons
containing
chlorine,
bromine,
and
iodine.
In:
Patty's
Industrial
Hygiene
and
Toxicology,
Fourth
Edition
(Clayton,
G.
D.
and
Clayton,
F.
E.,
eds.)
John
Wiley
&
Sons,
Inc.,
New
York,
NY.,
pp.
41284132.

3.
National
Resource
Council
(1996)
Guide
for
the
Care
and
Use
of
Laboratory
Animals,
Institute
of
Laboratory
Animal
Resources,
Commission
on
Life
Sciences.
National
Academy
Press,
Washington,
DC.

4.
Snedecor,
G.
W.
and
Co&
ran,
W.
G.
(1980)
One
way
classifications;
analysis
of
variance.
In:
Statistical
Methods,
Seventh
Edition.
The
Iowa
State
University
Press,
Ames,
IA,
pp.
215­
237.

5.
Dunnett,
C.
W.
(1964)
New
tables
for
multiple
comparisons
with
a
control.
Biometrics,
20:
482­
49
1,

6.
Renne,
R.
A.,
Gideon,
K.
M.,
Miller,
R.
A.,
Mellnick,
P.
W.,
and
Grumbein,
S.
L.
(1992).
Histologic
methods
and
interspecies
variations
in
the
laryngeal
histology
of
F344/
N
rats
and
B6C3Fl
mice.
Toxicologic
Pathology
20(
1);
44­
5
1.

7.
Morgan,
K.
T.
(199
1)
Approaches
to
the
identification
and
recording
of
nasal
lesions
in
toxicology
studies.
Toxicologic
Pathology,
19(
4):
337­
351.

8.
Greaves,
P.
(2000)
Histopathology
of
Preclinical
Toxicity
Studies:
Interpretation
and
Relevance
in
Drug
Safety
Evaluation,
Second
Edition.
Elsevier
Science,
Amsterdam,
The
Netherlands,
pg.
2
11.

9.
Cattley,
R.
C.
and
Popp,
J.
A.
(2002)
Liver.
In:
Handbook
of
Toxicologic
Pathology,
Second
Edition,
(Haschek,
W.
M.,
Rousseaux,
C.
G.
and
Wallig,
M.
A.,
eds.)
Academic
Press,
San
Diego,
CA,
pp.
187­
225.

10.
Dungworth,
D.
L.,
Hahn
F.
F.
and
Nikula,
K.
J.
(1995)
Noncarcinogenic
responses
of
the
respiratory
tract
to
inhaled
toxicants.
In:
Concepts
in
Inhalation
Toxicology,
Second
Edition,
(McClellan,
R.
O.
and
Henderson,
R.
F.,
eds.)
Taylor
&
Francis,
Washington,
D.
C.,
pp.
533­
576.

44of619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
11.
Haschek,
W.
M
and
Wits&
i,
H.
R.
(1991)
Respiratory
system.
In:
Handbook
of
Toxicologic
Pathology
(Haschek,
.M.
and
Rousseaux,
C.
G.,
eds.)
Academic
Press,
Inc.,
San
Diego,
CA,
pp.
761­
827.

45
of
619
WIL­
4
17002
Hap
Task
Force
1,
1,2­
Trichloroethane
11.
DEVIATIONS
FROM
THE
PROTOCOL
This
study
was
conducted
in
accordance
with
the
protocol
and
protocol
amendments,

except
for
the
following.

l
Section
4.1.2.
On
July
26,
2001,
the
Group
1
(0
ppm)
animals
were
inadvertently
placed
in
the
15
ppm
exposure
chamber
and
the
Group
2
(15
ppm)
animals
were
inadvertently
placed
in
the
0
ppm
exposure
chamber
for
the
six­
hour
exposure
period.

l
Section
4.1.2.
The
negative
pressure
and
chamber
ventilation
rates
for
chambers
l­
4
were
not
recorded
at
one
interval
on
August
3,
2001;
therefore,
the
mean
negative
pressure
and
CVR
were
calculated
from
nine
readings.

l
Section
4.1.2.
The
mean
chamber
ventilation
rate
for
chamber
3
descended
below
the
stated
range
of
400­
500
LPM
on
August
14,28
and
30,200l.

l
Section
4.1.3.
Eight
mm
glass
beads
were
also
used
in
the
vaporization
column.

l
Section
4.1.4.
The
standards
prepared
on
July
26,
2001
and
August
16,
2001
were
out
of
the
+
10%
range
as
specified
by
the
protocol.
The
low
standard
(9
ppm),
prepared
on
July
26,2001,
was
approved
by
the
study
director
for
a
range
of
+
15%.

l
Section
4.1.5.
On
July
27,
2001,
chamber
1
was
exposed
for
only
four
and
one
half
hours.
This
exposure
yielded
nine
environmental
samples
and
eight
concentration
samples.

l
Section
5.7.
On
August
30,2001,
the
heart
for
animal
no.
69346
(Group
4
male)
was
lost
at
necropsy
prior
to
weighing.
Therefore,
a
weight
was
not
recorded
and
histopathological
examination
was
not
possible.

These
deviations
did
not
negatively
impact
the
quality
or
integrity
of
the
data
nor
the
outcome
of
the
study.

46
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
TABLES
1
­
31
47
of
619
m
II
e
r­
4
48
of
619
TABLE
1
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
2
SPONSOR:
HAP
TASK
FORCE
SUMMARY
OF
SURVIVAL
AND
DISPOSITION
FEMALES
GROUP
:
1
2
3
4
_____­­_________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
WEEK
LIVE
FD
EE
SE
LIVE
FD
EE
SE
LIVE
FD
EE
SE
LIVE
FD
EE
SE
0
10
0
0
0
10
0
0
0
10
0
0
0
10
0
0
0
1
10
0
0
0
10
0
0
0
10
0
0
0
10
0
0
0
2
10
0
0
0
10
0
0
0
10
0
0
0
10
0
0
0
3
10
0
0
0
10
0
0
0
10
0
0
0
10
0
0
0
4
10
0
0
0
9
010
10
0
0
0
10
0
0
0
5
10
0
0
0
9
0
0
0
10
0
0
0
10
0
0
0
6
10
0
0
0
9
0
0
0
10
0
0
0
10
0
0
0
7
10
0
0
0
9
0
0
0
10
0
0
0
10
0
0
0
a
10
0
0
0
9
0
0
0
10
0
0
0
10
0
0
0
9
10
0
0
0
9
0
0
0
10
0
0
0
la
0
0
0
10
10
0
0
0
9
0
0
0
10
0
0
0
10
0
0
0
11
10
0
0
0
9
0
0
0
10
0
0
0
10
0
0
0
12
10
0
0
0
9
0
0
0
10
0
0
0
10
0
0
0
_'"_____"__"__"_
'"__________________"__"­­~­­~­­­­­­­­­­­­­­­­­­~~­~­­~­~~­­­­­­­~­­­­­­­­­­~­­~­­~­~~­­­­~­~­­­~­­­­­­­­­­­~­­­­­­

WEEK
=
WEEK
OF
STUDY
FD
=
FOUND
DEAD
EE
=
EUTHANIZED
IN
EXTREMIS
SE
=
SCHEDULED
EUTHANASIA
__­___­_________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

l­
0
PPM
2­
15
PPM
3­
40
PPM
4­
100
PPM
PSURVv4.02
1x/
28/
2001
TABLE
2
(DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
1
SPONSOR:
HAP
TASK
FORCE
SUMMARY
OF
CLINICAL
FINDINGS:
TOTAL
OCCURRENCE/
NO.
OF
ANIMALS
­
MALE
­_­__
__________________­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
GROUP:
1
2
3
4
_________­_____­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

NORMAL
­NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
DISPOSITION
­PRIMARY
NECROPSY
(WEEK
13)

EYES/
EARS/
NOSE
­DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
­DRIED
RED
MATERIAL
AROUND
LEFT
EYE
­RED
DISCHARGE
RIGHT
EYE
­RED
DISCHARGE
LEFT
EYE
­OPACITY
LEFT
EYE
EXCRETA
­DECREASED
DEFECATION
0"
_
SOFT
FECES
%
o\
BODY/
INTEG
II
z
­SCABBING
END
OF
TAIL
ORAL/
DENTAL
­UPPER
INCISOR(
S)
MALALIGNED
___­____­____­_­_­_­_________________
l­
0
PPM
2­
15
PPM
115/
10
lO/
lO
I/
1
4/
3
1/
1
2/
2
1/
1
1/
1
1/
1
o/
0
o/
0
__­_________­­____________________
3­
40
PPM
4­
100
PPM
123/
10
118/
10
124/
10
lO/
lO
1/
1
3/
2
o/
0
3/
3
o/
0
o/
0
1/
1
o/
0
o/
0
_______­_________­_­__
lO/
lO
lO/
lO
01
0
1/
1
4/
2
o/
0
o/
0
I/
1
2/
1
o/
0
::
f
3/
1
o/
0
2/
1
o/
0
51
of
619
TABLE
2
(DETAILED
PHYSICAL
EXAMINATIONS~
DISPOSITI~
N~)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
3
SPONSOR:
HAP
TASK
FORCE
SUMMARY
OF
CLINICAL
FINDINGS:
TOTAL
OCCURRENCE/
NO.
OF
ANIMALS
_____
F
E
M
A
L
E
_____
_________­____­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
GROUP:
1
2
3
4
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

NORMAL
­NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
102/
10
92/
10
104/
10
lOP/
lO
DISPOSITION
­EUTHANIZED
IN
EXTREMIS
DUE
PHYSICAL
Q/
0
1/
1
o/
0
Q/
0
CONDITION
­PRIMARY
NECROPSY
(WEEK
13)
lO/
lO
g/
9
lO/
lO
10/
3.0
BEHAVIOR/
CNS
­IMPAIRED
USE
OF
LEFT
HINDLIMB
Q/
0
11
1
o/
0
o/
0
­IMPAIRED
USE
OF
RIGHT
HINDLIMB
Q/
0
1/
1
o/
0
Q/
0
CARDIO­
PULMONARY
­RALES
Q/
0
Q/
0
2/
2
1/
1
EYES/
EARS/
NOSE
­DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
Q/
0
1/
1
o/
0
o/
0
­DRIED
RED
MATERIAL
AROUND
LEFT
EYE
2/
2
2/
2
2/
1
Q/
0
­RED
DISCHARGE
RIGHT
EYE
I/
J.
1/
1
o/
0
o/
0
­RED
DISCHARGE
LEFT
EYE
o/
cl
2/
2
o/
0
o/
0
­OPACITY
RIGHT
EYE
3/
1
Q/
0
Q/
0
Q/
0
­PUPIL
DILATED
RIGHT
EYE
l/
1
o/
0
o/
0
Q/
0
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

l­
0
PPM
2­
15
PPM
3­
40
PPM
4­
100
PPM
TABLE
2
(DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITI~
NS)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
4
SPONSOR:
HAP
TASK
FORCE
SUMMARY
OF
CLINICAL
FINDINGS:
TOTAL
OCCURRENCE/
NO.
OF
ANIMALS
­­­­­
F
E
M
A
L
E
­­_­­
__________­­________­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
GROUP:
1
2
3
4
__­_____­­­­________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

EXCRETA
­DECREASED
DEFECATION
o/
0
1/
1
o/
0
o/
0
­SOFT
FECES
o/
0
o/
0
o/
0
I/
1
BODY/
INTEG
II
­SCABBING
END
OF
TAIL
o/
0
41
1
2/
1
o/
0
SPECIAL
I
­WET
YELLOW
MATERIAL
UROGENITAL
AREA
19/
8
16/
8
8/
4
lO/
5
­DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
5/
3
4/
2
12/
6
v/
5
­DRIED
YELLOW
MATERIAL
VENTRAL
TRUNK
o/
0
o/
0
1/
1
o/
0
­WET
YELLOW
MATERIAL
DORSAL
TRUNK
o/
0
1/
1
o/
0
o/
0
SPECIAL
II
2
­END
OF
TAIL
MISSING
o/
0
lO/
1
o/
0
o/
0
­TAIL
BROKEN
o/
0
1/
1
o/
0
o/
0
or
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
OY
l­
0
PPM
2­
15
PPM
3­
40
PPM
4­
100
PPM
s
PCSUV4.03
02/
06/
2002
TABLE
3
(PRIOR
~0
DOSING)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
1
SPONSOR:
HAP
TASK
FORCE
SUMMARY
OF
CLINICAL
FINDINGS:
TOTAL
OCCURRENCE/
NO.
OF
ANIMALS
____­
MALE
__­­­
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
GROUP:
1
2
3
4
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

EYES/
EARS/
NOSE
­DRIED
RED
MATERIAL
AROUND
NOSE
o/
0
­DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
4/
4
­DRIED
RED
MATERIAL
AROUND
LEFT
EYE
3/
2
­RED
DISCHARGE
RIGHT
EYE
I/
1
­RED
DISCHARGE
LEFT
EYE
1/
1
EXCRETA
­DECREASED
DEFECATION
o/
0
­SOFT
FECES
I/
1
SPECIAL
I
­WET
YELLOW
MATERIAL
UROGENITAL
AREA
2/
1
­DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
o/
0
3
­WET
BROWN
MATERIAL
ANOGENITAL
AREA
o/
0
_­
_____­
________­­_____­____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
g
l­
O­
PPM
2­
15
PPM
3­
40
PPM
4­

0\

6
2/
1
o/
0
o/
0
o/
0
01
0
2/
1
4/
1
3/
1
o/
0
o/
0
o/
0
o/
0
o/
0
o/
0
o/
0
1/
1
o/
0
o/
0
11
1
o/
0
2/
2
o/
0
o/
0
I/
1
l/
1
o/
0
4/
3
o/
0
o/
0
I/
1
___­­­_­________________________________­­­­­­­­­­­­­­­­­­­­­­­­­
100
PPM
PROJECT
NO.:
WIL­
417002
TABLE
3
(PRIOR
TO
DOSING)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
2
SPONSOR:
HAP
TASK
FORCE
SUMMARY
OF
CLINICAL
FINDINGS:
TOTAL
OCCURRENCE/
NO.
OF
ANIMALS
_____
F
E
M
A
L
E
_­___
__________­­________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
GROUP:
1
2
3
4
__­­___­­­­­­­_____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

BODY/
INTEGUMENT
­DERMAL
ATONIA
l/
1
EYES/
EARS/
NOSE
­DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
3/
2
­DRIED
RED
MATERIAL
AROUND
LEFT
EYE
3/
2
EXCRETA
­DECREASED
DEFECATION
SPECIAL
I
­WET
YELLOW
MATERIAL
UROGENITAL
AREA
­DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
13/
6
7/
6
­DRIED
YELLOW
MATERIAL
VENTRAL
TRUNK
o/
0
s
­DRIED
BROWN
MATERIAL
ANOGENITAL
AREA
o/
0
­WET
YELLOW
MATERIAL
HINDLIMB
1/
1
%
­WET
YELLOW
ANOGENITAL
AREA
21
1
o
PPM
2­
15
PPM
3­
40
PPM
4­
100
PPM
­­__
o/
0
o/
0
1/
1
o/
0
2/
1
I/
1
o/
0
o/
0
14/
5
lO/
4
9/
4
4/
3
11
1
o/
0
o/
0
o/
0
o/
0
o/
0
o/
0
o/
0
__­­­­­­­_­­­­­­____­­­­­­­­
o/
0
o/
0
o/
0
o/
0
12/
5
16/
6
o/
0
1/
1
o/
0
o/
0
_­­­­_­_­­­­­­_­­____

PCSUv4.03
02/
06/
2002
R:
02/
06/
2002
TABLE
4
(FOLLOWING
EXPOSURE)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
1
SPONSOR:
HAP
TASK
FORCE
SUMMARY
OF
CLINICAL
FINDINGS:
TOTAL
OCCURRENCE/
NO.
OF
ANIMALS
__­­­
MALE
­___­
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

TABLE
RANGE:
GROUP:

EYES/
EARS/
NOSE
­DRIED
RED
MATERIAL
AROUND
NOSE
­DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
­WET
RED
MATERIAL
AROUND
LEFT
EYE
­DRIED
RED
MATERIAL
AROUND
LEFT
EYE
­RED
DISCHARGE
RIGHT
EYE
­RED
DISCHARGE
LEFT
EYE
­CLEAR
DISCHARGE
RIGHT
EYE
­CLEAR
DISCHARGE
LEFT
EYE
­RED
NASAL
DISCHARGE
EXCRETA
­SOFT
FECES
DERMAL
OBS
­WET
YELLOW
MATERIAL
UROGENITAL
AREA
­DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
­DRIED
BROWN
MATERIAL
ANOGENITAL
AREA
­WET
YELLOW
ANOGENITAL
AREA
___________________­____________________­­­­­

l­
o
PPM
2­
15
PPM
3­
__
1
___­­­_­­­_­____
05­
31­
01
TO
08­
30­
01
2
3
_­­­­­­_­­__­____­­_­­­­­­­­­­­­­­­­­­­­­­

I/
1
o/
0
o/
0
53/
2
o/
0
2/
1
o/
0
1/
1
o/
0
o/
0
o/
0
o/
0
2/
1
o/
0
2/
2
o/
0
o/
0
o/
0
o/
0
o/
0
o/
0
01
0
o/
0
o/
0
o/
0
o/
0
o/
0
o/
0
4
_­___­__________­____

o/
0
8/
2
o/
0
1/
1
4/
1
o/
0
1/
1
o/
0
o/
0
o/
0
4/
2
4/
2
o/
0
01
0
40
PPM
4­
100
PPM
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
4
(FOLLOWING
EXPOSURE)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SUMMARY
OF
CLINICAL
FINDINGS:
TOTAL
OCCURRENCE/
NO.
OF
ANIMALS
PAGE
2
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
GROUP:
1
2
3
4
________________________________________­­­­­­­­­­­­­­­­
______­______­_­­_­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

BODY/
INTEGUMENT
­DERMAL
ATONIA
EYES/
EARS/
NOSE
­DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
­DRIED
RED
MATERIAL
AROUND
LEFT
EYE
­RED
DISCHARGE
RIGHT
EYE
­RED
DISCHARGE
LEFT
EYE
EXCRETA
­SOFT
FECES
ORAL/
DENTAL
­UPPER
INCISOR(
S)
MALALIGNED
2
DERMAL
OBS
0,
­WET
YELLOW
MATERIAL
UROGENITAL
AREA
OY
­DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
;;
­DRIED
YELLOW
MATERIAL
VENTRAL
TRUNK
­WET
BROWN
MATERIAL
ANOGENITAL
AREA
­WET
YELLOW
MATERIAL
HINDLIMB
­WET
YELLOW
ANOGENITAL
AREA
41
3
2/
1
a/
2
o/
0
o/
0
o/
0
21/
7
13/
7
o/
0
o/
0
11
1
2/
1
o/
0
42/
8
12/
5
o/
0
1/
1
o/
0
o/
0
o/
0
1/
1
o/
0
o/
0
o/
0
o/
0
55/
10
7/
5
I/
1
o/
0
o/
0
o/
cl
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
l­
0
PPM
2­
15
PPM
3­
40
PPM
4­
100
PPM
PCSUV4.03
02/
06/
2002
R:
02/
06/
2002
TABLE
5
(NON­
EXPOSURE
DAYS)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
SUMMARY
OF
CLINICAL
FINDINGS:
TOTAL
OCCURRENCE/
NO.
OF
ANIMALS
PAGE
1
­__­­
MALE
_­___
­
_
_
_
­
_
_
­
­

TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
GROUP:
1
2
3
4
EYES/
EARS/
NOSE
­DRIED
RED
MATERIAL
AROUND
NOSE
­DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
­DRIED
RED
MATERIAL
AROUND
LEFT
EYE
­RED
DISCHARGE
LEFT
EYE
EXCRETA
­SOFT
FECES
SPECIAL
­WET
YELLOW
MATERIAL
UROGENITAL
AREA
­DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
­WET
BROWN
MATERIAL
ANOGENITAL
AREA
­DRIED
BROWN
MATERIAL
ANOGENITAL
AREA
___________­________­­­­­­­­­­­­­­­­­­­
kz
1­
0
PPM
2­
15
PPM
0,
o\

s
1/
1
o/
0
2/
2
o/
0
1/
1
1/
1
o/
0
2/
2
o/
0
1/
1
o/
0
1/
1
2/
2
o/
0
2/
1
o/
0
1/
1
o/
0
1/
1
o/
0
_____­_____­__­_____­­­­­­~­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
3­
40
PPM
4­
100
PPM
59
of
619
J
60of619
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
6
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SUMMARY
OF
BODY
WEIGHTS
[G]
PAGE
2
­__­­
MALE
__­__
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
__________­_____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

WEEK
3
MEAN
235.
243.
237.
239.
S.
D.
10.3
15.7
18.0
10.5
N
10
10
10
10
4
MEAN
248.
257.
250.
254.
S.
D.
11.4
15.9
21.4
11.3
N
10
10
10
9
5
MEAN
257.
267.
261.
265.
S.
D.
13.0
16.3
22.2
12.9
N
10
10
10
10
6
MEAN
268.
277.
270.
275.

S.
D.
N
15.6
10
20.0
10
22.1
10
12.8
10
7
MEAN
280.
290.
280.
284.
S.
D.
15.8
21.4
24.9
10.5
N
10
10
10
10
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

None
significantly
different
from
control
group
TABLE
6
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
3
SPONSOR:
HAP
TASK
FORCE
SUMMARY
OF
BODY
WEIGHTS
tG1
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GROUP:
________________________________________

WEEK
8
MEAN
S.
D.
N
9
MEAN
S.
D.
N
10
MEAN
S.
D.
N
11
s
MEAN
S.
D.

0,
N
m
5;
12
MEAN
S.
D.
N
0
PPM
___­­­­__­­­­­_

285.

15.3
10
292.
306.
294.
302.
16.2
19.3
23.2
13.4
10
10
10
10
286.
300.
294.
304.
19.4
23.6
24.7
12.9
10
10
10
10
299.
320.
307.
317.

29.0
23.3
29.0
13.4
10
10
10
10
308.
326.
311.
322.

22.2
23.4
28.8
14.3
10
10
10
10
MALE
­____
15
PPM
300.

20.0
10
40
PPM
100
PPM
289.
294.

24.6
14.5
10
10
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
None
significantly
different
from
control
group
63
of
619
TABLE
6
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
5
SPONSOR:
HAP
TASK
FORCE
SUMMARY
OF
BODY
WEIGHTS
[Gl
___________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

_____
F
E
M
A
L
E
_­_­_

GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
___________________­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
WEEK
­2
MEAN
95.
91.
98.
94.
S.
D.
8.1
9.5
9.6
1.7
N
10
10
10
10
­1
MEAN
110.
108.
109.
107.
S.
D.
7.0
7.3
6.6
6.9
N
10
10
10
10
127.
128.
128.
127.
5.8
5.9
6.1
5.5
10
10
10
10
0
MEAN
S.
D.
N
1
2
MEAN
145.
141.
140.
S.
D.
5.4
6.1
5.9
137.*
3.7
0
N
10
10
10
10
ch
o\

G
2
MEAN
155.
152.
149.
148.
S.
D.
5.1
6.8
9.1
6.2
N
10
10
10
10
_________­­_____­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
*
=
Significantly
different
from
the
control
group
at
0.05
using
Dunnett's
test
TABLE
6
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
6
SPONSOR:
HAP
TASK
FORCE
SUMMARY
OF
BODY
WEIGHTS
[G]

_____­­____­__­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
__­__
F
E
M
A
L
E
_____
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
­_­­____­__­__­_____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­~­­­­­­­­­­­­­­­
WEEK
3
MEAN
164.
159.
159.
157.
S.
D.
5.7
8.0
7.5
6.0
N
10
10
10
10
4
MEAN
171.
166.
167.
164.
S.
D.
5.8
7.9
9.0
8.2
N
10
10
10
9
5
MEAN
177.
172.
173.
171.
S.
D.
9.1
8.3
7.7
7.5
N
10
9
10
10
6
MEAN
182.
175.
175.
175.
S.
D.
8.5
8.1
9.1
8.5
N
10
9
10
10
7
MEAN
189,
178.*
180.
178.*
S.
D.
9.1
8.5
8.9
7.3
N
10
9
10
10
_____­___­___­­_____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
*
=
Significantly
different
from
the
control
group
at
0.05
using
Dunnett's
test
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
6
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SUMMARY
OF
BODY
WEIGHTS
[G]
PAGE
7
_____________­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

_____
F
E
M
A
L
E
__­__

GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
_________­________­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

WEEK
8
MEAN
190.
182.
185.
182.
S.
D.
10.1
8.5
9.9
6.7
N
10
9
10
10
9
MEAN
S.
D.
N
10
MEAN
S.
D.
N
11
MEAN
S.
D.
N
12
MEAN
S.
D.
N
194.
188.
188.
187.
11.7
8.7
11.5
7.9
10
9
10
10
191.
184.
188.
185.
7.4
9.7
10.3
9.4
10
9
10
10
197.
192.
195.
192.
20.3
9.8
10.8
7.8
10
9
10
10
202.
192.
197.
193.
13.5
10.1
11.9
9.6
10
9
10
10
_­_______­______________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
­
­
_
_
_
­
_

None
significantly
different
from
control
group
67
of
619
I
*

68
of
619
TABLE
7
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
2
SPONSOR:
HAP
TASK
FORCE
SUMMARY
OF
BODY
WEIGHT
CHANGES
[G]

_____­____­_____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
_­__­
MALE
__­­­
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
__________­___­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
WEEK
3T0
4
MEAN
13.
15.
13.
14.
S.
D.
2.1
7.7
4.1
3.3
N
10
10
10
9
4T0
5
MEAN
9.
9.
10.
13.
S.
D.
6.1
4.7
4.0
3.7
N
10
10
10
9
5T0
6
MEAN
10.
11.
9.
10.
S.
D.
5.4
5.6
4.1
3.2
N
10
10
10
10
6T0
7
%
MEAN
12.
12.
10.
9.
S.
D.
2.7
3.8
3.9
4.2
OH,
N
10
10
10
10
OY
G
7T0
MEAN
8
5.
10.
9.
10.
S.
D.
6.3
3.5
4.9
5.5
N
10
10
10
10
I
I
I
I
.
.

70
of
619
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
7
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SUMMARY
OF
BODY
WEIGHT
CHANGES
[Gl
PAGE
4
­­­______­__­­­___­_____________________­~~~~~~~~~~­­~~­~~~­~~~­~~~~~~~­~~~~~~­~~~­~~~~~~~~~~­~~~~~~~~~~~­~~~~~­~~~~~~~~~~~~~~~~~~­
___­_
F
E
M
A
L
E
_____

GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
________________­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

WEEK
­2
TO
­1
MEAN
14.
11.
S.
D.
2.9
2.9
N
10
10
­lTO
0
MEAN
18.
19.
S.
D.
3.9
3.2
N
10
10
OTO
1
MEAN
17.
14.
S.
D.
5.3
4.3
N
10
10
1TO
2
MEAN
11.
10.
S.
D.
3.2
3.9
N
10
I.
0
2T0
3
MEAN
9.
8.
S.
D.
2.7
1.9
N
10
10
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

**
=
Significantly
different
from
the
control
group
at
0.01
using
Dunnett's
test
10.
13.
5.0
2.6
10
10
19.
20.
3.1
2.8
10
10
12.
5.4
10
9.
10.
4.3
4.8
10
10
10.
9.
3.8
3.0
10
10
lo.**
4.7
10
72
of
619
.mo
d
.r­
l
N
.mo
r­­
.r­
l
cr
73
of
619
TABLE
?A
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
SUMMARY
OF
CUMULATIVE
BODY
WEIGHT
CHANGES
[Gl
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
­­_­­
MALE
____­
GROUP:
0
PPM
15
PPM
_________­______________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
WEEK
OTO
1
MEAN
30.
32.
S.
D.
7.6
4.6
N
10
10
OTO
2
MEAN
48.
57.
S.
D.
10.9
8.3
N
10
10
OTO
3
MEAN
66.
73.
S.
D.
10.8
13.5
N
10
10
2
OTO
4
MEAN
79.
87.
S.
D.
12.2
14.2
0
­­
i
N
10
10
o\

5,
OTO
MEAN
5
88.
97.
S.
D.
13.9
14.8
N
10
10
40
PPM
___

27.
27.
7.1
7.6
10
10
49.
51.
8.4
9.9
10
10
67.
69.
11.6
12.4
10
10
80.
85.
14.8
12.7
10
9
91.
15.5
10
None
significantly
different
from
control
group
PAGE
1
___­____________­

100
PPM
__­___­­­___­_­­­

95.
16.0
10
75
of
619
76
of
619
77
of
619
PROJECT
NO.:
WIL­
417002
.SPONSOR:
HAP
TASK
FORCE
TABLE
7A
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SUMMARY
OF
CUMULATIVE
BODY
WEIGHT
CHANGES
[Gl
PAGE
5
___________________­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

____­
F
E
M
A
L
E
_____

GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
WEEK
OTO
6
MEAN
55.
48.
48.
48.
S.
D.
11.9
10.2
11.0
12.3
N
10
9
10
10
OTO
7
MEAN
62.
50.
52.
50.
S.
D.
11.8
11.5
9.6
11.3
N
10
9
10
10
OTO
8
MEAN
63.
55.
57.
55.
S.
D.
13.7
11.1
10.9
10.4
N
10
9
10
10
OTO
9
2
MEAN
67.
60.
60.
59.
S.
D.
14.6
11.9
12.3
11.8
0
++
J,
N
10
9
10
10
6\

;;;
OTO
MEAN
10
63.
56.
60.
58.
S.
D.
10.4
13.2
11.4
12.4
N
10
9
10
10
___________­____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
None
significantly
different
from
control
group
79
of
619
80
of
619
TABLE
8
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
2
SPONSOR:
HAP
TASK
FORCE
SUMMARY
OF
WEEKLY
~00~
CONSUMPTION
[G/
ANIMAL/
DAY]

____________­_­___­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
­__­­
MALE
­__­­
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

WEEK
4T0
5
MEAN
17.
17.
17.
17.
S.
D.
1.2
0.9
1.1
0.9
N
10
10
10
10
5T0
6
MEAN
17.
18.
17.
17.
S.
D.
1.1
1.4
1.4
0.8
N
10
10
10
10
6T0
7
MEAN
17.
17.
16.
17.
S.
D.
1.0
1.4
1.3
0.9
N
10
10
10
10
7T0
8
MEAN
17.
S.
D.
0.9
N
10
18.
17.
17.
1.3
1.2
0.7
10
10
10
8T0
9
MEAN
16.
18.**
17.
18.*
S.
D.
1.2
1.1
1.0
0.8
N
10
10
10
10
_­______________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
*
=
Significantly
different
from
the
control
group
at
0.05
using
Dunnett's
test
**
=
Significantly
different
from
the
control
group
at
0.01
using
Dunnett's
test
82
of
619
83
of
619
84of619
85
of
619
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
ANALYSIS
GROUP:
_­_____­­_______­­_­­­­­­­
WHITE
CELL
(thous/
uL)
MEAN
S.
D.
N
RED
CELLS
(mil/
uL)
MEAN
S.
D.
N
HEMOGLOBIN
(g/
dL)
MEAN
S.
D.
N
HEMATOCRIT
(%)
MEAN
S.
D.
N
MCV
(fL)
MEAN
S.
D.
N
TABLE
9
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SUMMARY
OF
HEMATOLOGY
VALUES
PAGE
1
WEEK
13
0
PPM
­_­­­
MALE
_____
15
PPM
40
PPM
100
PPM
7.3
7.3
7.1
6.6
1.43
1.27
1.36
1.18
10
10
10
10
8.44
8.64
8.50
8.60
0.522
0.357
0.409
0.620
10
10
10
10
14.7
15.2
14.7
15.0
0.93
0.66
0.74
0.98
10
10
10
10
41.1
41.8
40.8
41.9
2.49
1.84
2.50
3.06
10
10
10
10
48.7
48.4
47.9
48.7
0.71
0.73
1.80
0.53
10
10
10
10
_____­_________­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
g/
dL
=
GRAMS/
DECILITER,
thous/
uL
=
THOUSANDS/
MICROLITER,
mil/
uL
=
MILLIONS/
MICROLITER,
uug
=
PICOGRAMS,
fL
=
FEMTOLITERS
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

None
significantly
different
from
control
group
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
9
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SUMMARY
OF
HEMATOLOGY
VALUES
PAGE
2
WEEK
13
ANALYSIS
GROUP:

MCH
(uug)
MEAN
S.
D.
N
MCHC
(g/
dL)
MEAN
S.
D.
N
PLATELET
(thous/
uL)
MEAN
S.
D.
N
0
PPM
17.4
0.25
10
35.8
0.42
10
906.
192.7
10
___­_
MALE
_____
15
PPM
40
PPM
100
PPM
17.6
17.3
17.4
0.23
0.51
0.31
10
10
10
36.3
36.0
35.8
0.34
0.43
0.47
10
10
10
900.
873.
929.
202.2
262.8
262.5
10
10
10
PROTIME
(seconds)

3
MEAN
S.
D.

r?,
N
CA
G
APTT
(seconds)
MEAN
S.
D.
N
13.9
13.7
13.9
13.6
1.10
0.78
1.04
0.46
9
8
9
7
24.0
24.7
23.2
23.5
4.29
3.19
4.43
2.85
9
8
9
7
___­____________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
­­­­­­

g/
dL
=
GRAMS/
DECILITER,
thous/
uL
=
THOUSANDS/
MICROLITER,
mil/
uL
=
MILLIONS/
MICROLITER,
uug
=
PICOGRAMS,
fL
=
FEMTOLITERS
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

None
significantly
different
from
control
group
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
9
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SUMMARY
OF
HEMATOLOGY
VALUES
PAGE
3
WEEK
13
___­
­­__
­­­
e­
F
E
M
A
L
E
_____
ANALYSIS
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

WHITE
CELL
(thous/
uL)
MEAN
5.3
5.6
5.2
4.1
S.
D.
1.13
1.44
1.49
1.06
N
8
8
8
9
RED
CELLS
(mil/
uL)
MEAN
7.65
7.69
7.71
7.87
S.
D.
0.311
0.400
0.211
0.394
N
8
8
8
9
HEMOGLOBIN
(g/
dL)
MEAN
S.
D.
N
14.5
14.2
14.5
14.7
0.59
1.06
0.29
0.72
8
8
8
9
HEMATOCRIT
(%)

E
MEAN
39.9
40.1
39.9
S.
D.
1.67
2.21
1.05
41.3
2.11
0,
N
m
55
MCV
(fL)
MEAN
52.2
52.2
51.7
52.4
8
8
9
S.
D.
0.56
0.78
0.7%
0.88
N
8
8
8
9
___­_­­­_­_­­­­­
_____­_______­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

g/
dL
=
GRAMS/
DECILITER,
thous/
uL
=
THOUSANDS/
MICROLITER,
mil/
uL
=
MILLIONS/
MICROLITER,
uug
=
PICOGRAMS,
fL
=
FEMTOLITERS
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

None
significantly
different
from
control
group
89
of
619
s­
i*`
0
co
.ri
m
NO­
IO
.!­
I
3­
l
90of619
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
10
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SUMMARY
OF
LEUKOCYTE
DIFFERENTIAL
COUNTS
[%
I
PAGE
2
WEEK
13
­w­­­
F
E
M
A
L
E
_____

ANALYSIS
GROUP:
0
PPM
15
PPM
________­________­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
NEUTROPHIL
MEAN
17
15
S.
D.
3.3
3.5
N
8
8
LYMPHOCYTE
MEAN
81
83
S.
D.
4.2
4.9
N
8
8
MONOCYTE
MEAN
2
2
S.
D.
1.4
1.8
N
8
8
EOSINOPHIL
a
MEAN
0
0
r
2
S.
D.
N
0.4
8
0.0
8
z
BASOPHIL
MEAN
0
0
S.
D.
0.0
0.0
N
8
8
None
significantly
different
from
control
group
___­__
40
PPM
100
PPM
_____________­__­­__­­­­­­­­­­­­­­­­­­­­­­­­

15
15
3.8
2.4
8
9
81
81
4.7
3.7
8
9
3
3
1.8
1.5
8
9
0
0
0.0
0.4
8
9
0
0
0.0
0.0
8
9
__­_____­­­­__­­­___­­­­­­­­­­­­­­­­­­­­­­­­

PCPSV4.04
01/
18/
2002
"22
l­
4
.
0
92of619
I
,
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
12
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SUMMARY
OF
SERUM
CHEMISTRY
VALUES
PAGE
1
WEEK
13
___________­________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
__­­­
MALE
_­__­
ANALYSIS
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
ALBUMIN
(g/
dL)
MEAN
4.2
4.3
4.2
4.3
S.
D.
0.26
0.25
0.27
0.32
N
10
10
10
10
TOTAL
PROTEIN
(g/
dL)
MEAN
S.
D.
N
7.3
7.4
7.2
7.3
0.60
0.48
0.51
0.65
10
10
10
10
GLOBULIN
(g/
dL)
MEAN
S.
D.
N
3.1
3.1
3.0
3.0
0.38
0.26
0.29
0.34
10
10
10
10
A/
G
RATIO
MEAN
1.38
1.38
1.40
1.42
S.
D.
0.123
0.077
0.089
0.074
N
10
10
10
10
TOTAL
BILI
(mg/
dL)
MEAN
S.
D.
N
0.2
0.2
0.1
0.2
0.11
0.10
0.07
0.11
10
10
10
10
________­_______________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
U/
L
=
INTERNATIONAL
UNIT/
LITER,
g/
dL
=
GRAMS/
DECILITER,
mg/
dL
=
MILLIGRAMS/
DECILITER,
mEq/
L
=
milliEquivalents/
Liter
__­_____­__________­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
None
significantly
different
from
control
group
95
of
619
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
12
YO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SUMMARY
OF
SERUM
CHEMISTRY
VALUES
PAGE
3
WEEK
13
­­___
MALE
_­­­_
ANALYSIS
GROUP:
0
PPM
15
PPM
40
P­
PM
100
PPM
________­__­____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GLUTAMYLTRANSFER
(U/
L)
MEAN
0.
0.
0.
0.
S.
D.
0.0
0.0
0.0
0.0
N
10
10
10
10
GLUCOSE
(mg/
dL)
MEAN
152.
151.
154.
146.
S.
D.
16.1
20.8
18.3
18.2
N
10
10
10
10
CHOLESTEROL
(mg/
dL)
MEAN
53.
58.
55.
63.**
S.
D.
5.3
7.2
5.6
3.4
N
10
10
10
10
CALCIUM
(mg/
dL)
z
MEAN
11.5
11.6
11.7
11.8
S.
D.
0.51
0.54
0.40
0.70
on,
N
10
10
10
10
a
G
CHLORIDE
(mEq/
L)
MEAN
101.
100.
100.
100.
S.
D.
1.4
1.1
1.5
1.7
N
10
10
10
10
____­__­________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

U/
L
=
INTERNATIONAL
UNIT/
LITER,
g/
dL
=
GRAMS/
DECILITER,
mg/
dL
=
MILLIGRAMS/
DECILITER,
mEq/
L
=
milliEquivaIents/
Liter
_____­_____­_____­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
**
=
Significantly
different
from
the
control
group
at
0.01
using
Dunnett's
test
97
of
619
TABLE
12
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
5
SPONSOR:
HAP
TASK
FORCE
SUMMARY
OF
SERUM
CHEMISTRY
VALUES
WEEK
13
ANALYSIS
GROUP:
______­___­­___­­­­_­­­­­­­­­­­­­­­

ALBUMIN
(g/
dL)
MEAN
S.
D.
N
TOTAL
PROTEIN
(g/
dL)
MEAN
S.
D.
N
GLOBULIN
(g/
dL)
MEAN
S.
D.
N
A/
G
RATIO
MEAN
S.
D.
N
TOTAL
BILI
(mg/
dL)
MEAN
S.
D.
N
­e­­­
F
E
M
A
L
E
____­

0
PPM
15
PPM
40
PPM
100
PPM
_________­__________­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

3.9
3.9
4.1
4.2
0.17
0.27
0.23
0.20
9
9
9
9
6.7
6.6
7.0
7.0
0.36
0.49
0.45
0.53
8
9
9
9
2.7
2.7
2.9
0.24
0.24
0.24
8
9
9
1.44
1.48
1.42
1.49
0.099
0.073
0.069
0.118
8
9
9
9
0.2
0.2
0.2
0.2
0.10
0.10
0.20
0.20
8
9
9
9
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
U/
L
=
INTERNATIONAL
UNIT/
LITER,
g/
dL
=
GRAMS/
DECILITER,
mg/
dL
=
MILLIGRAMS/
DECILITER,
mEq/
L
=
milliEquivalents/
Liter
None
significantly
different
from
control
group
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
ANALYSIS
GROUP:
___­___­­____­­­­­__­­­­­­­­­
UREA
NITROGEN
(mg/
dL)
MEAN
S.
V.
N
CREATININE
(mg/
dL)
MEAN
S.
D.
N
ALKALINEPHOS'TSE
(U/
L)
MEAN
S.
D.
N
ALANINE
TRANSFER
(U/
L)
MEAN
S.
D.
N
ASPARTATTRANSFER
(U/
L)
MEAN
S.
D.
N
_­_
TABLE
12
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SUMMARY
OF
SERUM
CHEMISTRY
VALUES
PAGE
6
WEEK
13
_­______________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
­
_
_
_
_
_
_
­
_

­­
w­­
F
E
M
A
L
E
___­_

0
PPM
15
PPM
40
PPM
100
PPM
16.2
17.0
17.5
16.9
2.77
0.72
1.41
1.67
8
9
9
9
0.2
0.2
0.2
0.2
0.05
0.07
0.07
0.08
8
9
9
9
65.
68.
70.
71.
12.4
6.2
7.5
7.5
9
9
9
9
57.
21.7
9
50.
55.
49.
6.8
11.9
8.5
9
9
9
138.
111.
93.
114.
83.1
45.7
17.8
69.5
9
9
9
9
U/
L
=
INTERNATIONAL
UNIT/
LITER,
g/
dL
=
GRAMS/
DECILITER,
mg/
dL
=
MILLIGRAMS/
DECILITER,
mEq/
L
=
milliEquivalents/
Liter
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
None
significantly
different
from
control
group
lOOof
101
of619
102of619
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
14
(WEEK
12
EVALUATION)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SUMMARY
OF
OPHTHALMIC
EXAMINATION
FINDINGS
PAGE
1
___________________­____________________­­­­~
NUMBER
OF
ANIMALS
IN
DOSE
GROUP
NUMBER
OF
ANIMALS
EXAMINED
EXAM
2(
WEEK
12)

­CORNEAL
CRYSTALS
­
BILATERAL
­CORNEAL
CRYSTALS
­
UNILATERAL
­KERATITIS
­
UNILATERAL
­CATARACT
­
UNILATERAL
___­_­_____________

l­
0
PPM
2­
15
PPM
3­
__­­­
M
A
L
E
­­­­
____
F
E
M
A
L
E
­­­­
GROUP:
1
2
3
4
1
2
3
4
_____­__­­­__
10
10
10
10
10
10
10
10
10
10
10
10
10
9
10
10
10
10
10
10
9
9
10
10
0
0
0
0
2
0
0
0
0
0
0
0
1
0
0
0
0
0
0
1
0
0
0
0
_____­__________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
­____
40
PPM
4­
100
PPM
POPSIv4.0
01/
18/
2002
104of619
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
16
(PRIMARY
NEcRopsY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
GROSS
NECROPSY
OBSERVATIONS
INCIDENCE
SUMMARY
PAGE
1
SCHEDULED
NECROPSY
___­________

GROUP:
1
2
NUMBER
OF
ANIMALS
IN
DOSE
GROUP
NUMBER
OF
ANIMALS
EXAMINED
WEEK
M
A
L
E
­­­­
­­
F
E
M
A
L
E
­­­­
3
4
1
2
3
4
___________­­­______­­­­­­­­­­­­­­­­­­­­­­­­­­­
_­
______
__
10
9
0
0
1
0
0
0
0
0
1
10
10
0
0
0
0
0
0
0
0
0
EYES/
OPTIC
N.
­EYE(
S)­
OPACITY
LIVER
­AREA(
S),
RAISED
LUNGS
­AREA(
S),
WHITE
LYMPH
NODE,
TR/
BR
­DISCOLORATION,
DARK
RED
LYMPH
NODE,
MED
%
­DISCOLORATION,
DARK
RED
o\
OVARIES
G
­AREA(
S),
WHITE
PANCREAS
­PALE
THYMUS
­DISCOLORATION,
DARK
RED
PITUITARY
­SMALL
__________­­______­­­­­­
l­
0
PPM
2­
NA
=
NOT
APPLICABLE
10
10
10
10
10
10
13
10
10
10
10
10
10
0
0
0
0
0
0
0
1
1
1
0
1
1
0
0
0
1
1
0
0
NA
NA
NA
1
0
1
0
0
0
0
0
0
0
0
0
0
15
PPM
3­
40
PPM
4­
100
PPM
TABLE
16
(PRIMARY
NECROPSY)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
2
SPONSOR:
HAP
TASK
FORCE
GROSS
NECROPSY
OBSERVATIONS
INCIDENCE
SUMMARY
SCHEDULED
NECROPSY
_­­­_
M
A
L
E
­­­­
___­
F
E
M
A
L
E
­­­­
GROUP:
1
2
3
4
1
2
3
4
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
NUMBER
OF
ANIMALS
NUMBER
OF
ANIMALS
SEMINAL
VESICLES
IN
DOSE
GROUP
EXAMINED
WEEK
10
10
0
0
2
0
0
0
0
10
10
10
10
10
10
10
9
10
10
10
10
1
0
0
NA
NA
NA
NA
0
0
0
0
1
1
0
0
0
2
0
0
0
0
1
0
1
0
0
0
0
1
0
0
0
0
0
0
1
NA
NA
NA
6
8
6
0
9
0
6
0
0
0
0
0
0
0
10
13
­SMALL
SKELETAL
MUSCLE
­DISCOLORATION,

SKIN
­MATTING,
RED
DARK
RED
­MATTING,
YELLOW
SPLEEN
­ACCESSORY
STOMACH
­CONTENTS,
DARK
RED
LYMPH
NODE,
MAN
­DISCOLORATION,
DARK
RED
UTERUS
­CONTENTS,
CLEAR
FLUID
NA
NO
SIGNIFICANT
CHANGES
OBSERVED
­
ALL
EXAMINED
TISSUES
8
_______________­____

PGRSIv4.02
11/
28/
2001
_____­___­___­__________________________­­­­­­­­­­­­­­­­­­­­­­
l­
o
PPM
2­
15
PPM
3­
40
PPM
4
NA
=
NOT
APPLICABLE
____
100
PPM
107
of
619
108of619
109of619
llOof619
TABLE
17
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
5
SPONSOR:
HAP
TASK
FORCE
ORGAN
WEIGHTS
(GRAMS)
­
SUMMARY
OF
MEANS
WEEK
13
_
_
_
_
_
_
_
_
_
SPLEEN
OVARIES
THYMUS
GROUP:
0
PPM
_____
F
E
M
A
L
E
­­___

15
PPM
_­­­
40
PPM
100
PPM
­­_­­­­­­­­____­­­­_____________________­­

MEAN
0.48
0.45
0.46
0.45
S.
D.
0.030
0.050
0.022
0.027
N
10
9
10
10
MEAN
0.0957
0.0989
S.
D.
0.00928
0.01719
N
10
9
MEAN
0.2163
0.1910
0.2042
0.2048
S.
D.
0.02952
0.02205
0.01427
0.02387
N
10
9
10
10
ADRENAL
GLANDS
F
F
MEAN
0.0536
0.0589
F
S.
D.
0.00691
0.00529
0
N
10
9
2
G
THYROIDS/
PARA
MEAN
0.0150
0.0135
S.
D.
0.00316
0.00187
N
10
9
__________________­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
None
significantly
different
from
control
group
0.0925
0.0977
0.01308
0.01334
10
10
0.0544
0.00479
10
0.0141
0.0142
0.00246
0.00349
10
10
__­­

POFBSTv4.1
11/
28/
2001
TABLE
18
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
1
SPONSOR:
HAP
TASK
FORCE
ORGAN
WEIGHTS
RELATIVE
TO
FINAL
BODY
WEIGHTS
(GRAMS/
100
GRAMS)
WEEK
13
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
_____
MALE
_­_­­
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
FINAL
BODY
WT(
G)
MEAN
S.
D.
N
BRAIN
LIVER
KIDNEYS
w
L
oy
cn
LUNGS
;;
MEAN
0.636
0.629
0.634
0.609
S.
D.
0.0347
0.0450
0.0466
0.0228
N
10
10
10
10
MEAN
2.791
2.809
2.707
2.791
S.
D.
0.1170
0.1521
0.1315
0.1323
N
10
10
10
10
MEAN
0.682
0.696
S.
D.
0.0303
0.0315
N
10
10
288.
302.
294.
305.
17.9
23.5
28.3
12.5
10
10
10
10
MEAN
0.416
0.413
S.
D.
0.0231
0.0224
N
10
10
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
__
None
significantly
different
from
control
group
__
0.715
0.712
0.0362
0.0348
10
10
0.399
0.400
0.0318
0.0154
10
10
______________­_________________________­­
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
18
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
ORGAN
WEIGHTS
RELATIVE
TO
FINAL
BODY
WEIGHTS
(GRAMS/
100
GRAMS)
PAGE
2
WEEK
13
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
_____
MALE
___­_
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
_­______________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
____

HEART
MEAN
0.326
0.317
0.328
0.321
S.
D.
0.0246
0.0130
0.0136
0.0182
N
10
10
10
9
SPLEEN
MEAN
S.
D.
N
0.198
0.203
0.198
0.205
0.0264
0.0123
0.0159
0.0159
10
10
10
10
EPIDIDYMIDES
MEAN
0.339
0.326
0.327
0.332
S.
D.
0.0253
0.0228
0.0187
0.0200
N
10
10
10
10
TESTES
+

t;
MEAN
S.
D.
0
N
1.055
1.036
1.060
1.029
0.0459
0.0770
0.0735
0.0364
10
10
10
10
THYMUS
G
MEAN
0.063
0.067
0.065
0.066
S.
D.
0.0047
0.0060
0.0107
0.0074
N
10
10
10
10
___________­­­_­____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
None
significantly
different
from
control
group
114
of
619
­

115of619
TABLE
18
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
5
SPONSOR:
HAP
TASK
FORCE
ORGAN
WEIGHTS
RELATIVE
TO
FINAL
BODY
WEIGHTS
(GRAMS/
100
GRAMS)
WEEK
13
_­______________­­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
­____
__­__
F
E
M
A
L
E
­­___
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
_______­­___­___________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

HEART
MEAN
0.348
0.359
0.354
0.375*
S.
D.
0.0187
0.0217
0.0239
0.0204
N
10
9
10
10
SPLEEN
MEAN
0.256
0.255
0.251
0.251
S.
D.
0.0128
0.0277
0.0207
0.0110
N
10
9
10
10
OVARIES
MEAN
0.051
0.056
0.051
0.055
S.
D.
0.0058
0.0103
0.0088
0.0066
N
10
9
10
10
THYMUS
+
MEAN
0.115
0.108
0.112
0.115
z
S.
D.
0.0120
0.0147
0.0075
0.0131
0,
N
10
9
10
10
cn
ADRENAL
GLANDS
5;
MEAN
0.028
0.033**
0.030
0.032
S.
D.
0.0031
0.0035
0.0030
0.0028
N
10
9
10
10
*
=
Significantly
different
from
the
control
group
at
0.05
using
Dunnett's
test
**
=
Significantly
different
from
the
control
group
at
0.01
using
Dunnett's
test
117of619
PROJECT
NO.:
WIL­
417002
S!?
ONSOR:
HAP
TASK
FORCE
TABLE
19
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
ORGAN
WEIGHTS
RELATIVE
TO
BRAIN
WEIGHTS
(GRAMS/
100
GRAMS)
PAGE
1
WEEK
13
__­­­
MALE
­­___
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
­­_____­________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
BRAIN
WT
(GRAMS)
MEAN
1.82
1.89
1.85
1.86
S.
D.
0.051
0.073
0.099
0.054
N
10
10
10
10
LIVER
MEAN
439.593
448.832
429.621
458.881
S.
D.
19.3561
40.0560
40.3947
30.4098
N
10
10
10
10
KIDNEYS
MEAN
107.459
111.060
113.389
117.063
S.
D.
5.1934
7.0516
10.2130
7.2201
N
10
10
10
10
LUNGS
MEAN
S.
D.
N
65.419
66.000
63.224
65.720
2.9922
6.8888
6.2541
3.1061
10
10
10
10
HEART
MEAN
51.290
50.603
51.986
52.517
S.
D.
3.1086
3.6834
2.9534
3.0131
N
10
10
10
9
____________­___­___­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­~­­~
None
significantly
different
from
control
group
119of619
120of619
121
of
619
122of619
TABLE
20
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
1
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
SURVIVAL
AND
DISPOSITION
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
TYPE
OF
AGE
IN
DATE
OF
DAYS
ON
DEATH
WEEKS
A
DEATH
STUDY
___.
ANIMAL
SEX
_________­­­­
69302
M
69306
M
69308
M
69310
M
69312
M
69314
M
69317
M
69322
M
69337
M
69343
M
GROUP
_
_
_
_
_
­
­
0
PPM
0
PPM
0
PPM
0
PPM
0
PPM
0
PPM
0
PPM
0
PPM
0
PPM
0
PPM
_____­­________________

SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
.___­
30­
AUG­
01
30­
AUG­
01
30­
AUG­
01
31­
AUG­
01
31­
AUG­
01
31­
AUG­
01
31­
AUG­
01
31­
AUG­
01
30­
AUG­
01
30­
AUG­
01
69305
M
69316
M
69320
M
69323
M
69326
M
69335
M
69336
M
%
69338
69345
M
M
cn
69347
M
G
69303
M
69309
M
69313
M
69315
M
69324
M
69328
M
69339
M
69344
M
15
PPM
15
PPM
15
PPM
15
PPM
15
PPM
15
PPM
15
PPM
15
PPM
15
PPM
15
PPM
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
_
_
_
_
_
_
_
_
_
_
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
30­
AUG­
01
30­
AUG­
01
31­
AUG­
01
31­
AUG­
01
30­
AUG­
01
31­
AUG­
01
31­
AUG­
01
30­
AUG­
01
31­
AUG­
01
30­
AUG­
01
40
PPM
40
PPM
40
PPM
40
PPM
40
PPM
40
PPM
40
PPM
40
PPM
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
21
21
21
21
21
21
21
21
30­
AUG­
01
31­
AUG­
01
30­
AUG­
01
30­
AUG­
01
31­
AUG­
01
31­
AUG­
01
30­
AUG­
01
31­
AUG­
01
91
91
91
92
92
92
92
92
91
91
91
91
92
92
91
92
92
91
92
91
91
92
91
91
92
92
91
92
A
=
CALCULATED
TO
THE
NEAREST
WHOLE
WEEK
USING
THE
MEAN
AGE
IN
WEEKS
AT
INITIATION
OF
DOSING
(8)
TABLE
20
go­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
SURVIVAL
AND
DISPOSITION
PAGE
2
TYPE
OF
AGE
IN
DATE
OF
DAYS
ON
DEATH
WEEKS
A
DEATH
STUDY
SCHEDULED
EUTHANASIA
21
30­
AUG­
01
91
SCHEDULED
EUTHANASIA
21
31­
AUG­
01
92
SCHEDULED
EUTHANASIA
21
31­
AUG­
01
92
SCHEDULED
EUTHANASIA
21
30­
AUG­
01
91
SCHEDULED
EUTHANASIA
21
30­
AUG­
01
91
SCHEDULED
EUTHANASIA
21
31­
AUG­
01
92
SCHEDULED
EUTHANASIA
21
31­
AUG­
01
92
SCHEDULED
EUTHANASIA
21
30­
AUG­
01
91
SCHEDULED
EUTHANASIA
21
31­
AUG­
01
92
SCHEDULED
EUTHANASIA
21
30­
AUG­
01
91
SCHEDULED
EUTHANASIA
21
31­
AUG­
01
92
SCHEDULED
EUTHANASIA
21
30­
AUG­
01
91
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
ANIMAL
SEX
GROUP
_____­­____________­_______

69348
M
40
PPM
69350
M
40
PPM
69304
M
100
PPM
69307
M
100
PPM
69318
M
100
PPM
69319
M
100
PPM
69327
M
100
PPM
69329
M
100
PPM
69332
M
100
PPM
69334
M
100
PPM
69342
M
100
PPM
69346
M
100
PPM
_.

A
=
CALCULATED
TO
THE
NEAREST
WHOLE
WEEK
USING
THE
MEAN
AGE
IN
WEEKS
AT
INITIATION
OF
DOSING
(8)
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
ANIMAL
SEX
GROUP
TABLE
20
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
SURVIVAL
AND
DISPOSITION
TYPE
OF
AGE
IN
DATE
OF
DAYS
ON
DEATH
WEEKS
A
DEATH
STUDY
PAGE
3
69354
69366
69367
69378
69384
69398
69404
69416
69419
69432
69362
69376
69377
69382
69390
L
69393
WI
69396
0
69409
69413
69435
io
69359
69369
69370
69380
69388
69394
69426
69428
_________­______________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
A
=
CALCULATED
TO
THE
NEAREST
WHOLE
WEEK
USING
THE
MEAN
AGE
IN
WEEKS
AT
INITIATION
OF
DOSING
(8)
0
PPM
SCHEDULED
EUTHANASIA
0
PPM
SCHEDULED
EUTHANASIA
0
PPM
SCHEDULED
EUTHANASIA
0
PPM
SCHEDULED
EUTHANASIA
0
PPM
SCHEDULED
EUTHANASIA
0
PPM
SCHEDULED
EUTHANASIA
0
PPM
SCHEDULED
EUTHANASIA
0
PPM
SCHEDULED
EUTHANASIA
0
PPM
SCHEDULED
EUTHANASIA
0
PPM
SCHEDULED
EUTHANASIA
15
PPM
SCHEDULED
EUTHANASIA
15
PPM
SCHEDULED
EUTHANASIA
15
PPM
EUTHANIZED
IN
EXTREMIS
15
PPM
SCHEDULED
EUTHANASIA
15
PPM
SCHEDULED
EUTHANASIA
15
PPM
SCHEDULED
EUTHANASIA
15
PPM
SCHEDULED
EUTHANASIA
15
PPM
SCHEDULED
EUTHANASIA
15
PPM
SCHEDULED
EUTHANASIA
15
PPM
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
40
PPM
40
PPM
40
PPM
40
PPM
40
PPM
40
PPM
40
PPM
40
PPM
21
21
21
21
21
21
21
21
21
21
21
21
12
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
31­
AUG­
01
31­
AUG­
01
30­
AUG­
01
31­
AUG­
01
30­
AUG­
01
30­
AUG­
01
31­
AUG­
01
30­
AUG­
01
30­
AUG­
01
31­
AUG­
01
31­
AUG­
01
30­
AUG­
01
30­
JUN­
01
31­
AUG­
01
31­
AUG­
01
30­
AUG­
01
30­
AUG­
01
30­
AUG­
01
31­
AUG­
01
30­
AUG­
01
30­
AUG­
01
31­
AUG­
01
30­
AUG­
01
31­
AUG­
01
30­
AUG­
01
31­
AUG­
01
31­
AUG­
01
31­
AUG­
01
92
92
91
92
91
91
92
91
91
92
92
91
30
92
92
91
91
91
92
91
91
92
91
92
91
92
92
92
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
20
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
SURVIVAL
AND
DISPOSITION
PAGE
4
ANIMAL
SEX
GROUP
­­­­­­­­­­­­­
____­_
­
_____­.
69433
F
40
PPM
69436
F
40
PPM
TYPE
OF
DEATH
SCHEDULED
EUTHANASIA
SCHEDULED
EUTHANASIA
69375
F
100
PPM
SCHEDULED
EUTHANASIA
69379
F
100
PPM
SCHEDULED
EUTHANASIA
69383
F
100
PPM
SCHEDULED
EUTHANASIA
69385
F
100
PPM
SCHEDULED
EUTHANASIA
69392
F
100
PPM
SCHEDULED
EUTHANASIA
69402
F
100
PPM
SCHEDULED
EUTHANASIA
69408
F
100
PPM
SCHEDULED
EUTHANASIA
69415
F
100
PPM
SCHEDULED
EUTHANASIA
69427
F
100
PPM
SCHEDULED
EUTHANASIA
69431
F
100
PPM
SCHEDULED
EUTHANASIA
AGE
IN
WEEKS
A
____­­­­­­­­
21
21
21
21
21
21
21
21
21
21
21
21
DATE
OF
DAYS
ON
DEATH
STUDY
_­­_______­­­
____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­
_____
30­
AUG­
01
91
30­
AUG­
01
91
30­
AUG­
01
91
30­
AUG­
01
91
31­
AUG­
01
92
31­
AUG­
01
92
31­
AUG­
01
92
31­
AUG­
01
92
31­
AUG­
01
92
30­
AUG­
01
91
30­
AUG­
01
91
30­
AUG­
01
91
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­
A
=
CALCULATED
TO
THE
NEAREST
WHOLE
WEEK
USING
THE
MEAN
AGE
IN
WEEKS
AT
INITIATION
OF
DOSING
(8)
PDEADv4.02
r
x
01/
18/
2002
TABLE
21
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
1
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
BODY
WEIGHTS
[Gl
MALE
GROUP:
0
PPM
WEEK
­2
­1
0
1
2
3
4
5
_____­__­_______________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
69302
69306
69308
69310
69312
69314
69317
69322
69337
69343
98.
99.
110.
111.
221.
239.
221.
242.

107.
107.
105.
90.
108.
110.
123.
128.
136.
137.
133.
134.
134.
114.
130.
132.
161.
201.
165.
206.
178.
203.
171.
186.
175.
205.
169.
194.
179.
211.
153.
187.
166.
195.
172.
200.
207.
230.
208.
225.
233.
251.
208.
224.
234.
252.
212.
230.
209.
226.
218.
234.
252.
257.
241.
234.
264.
238.
266.
245.
236.
248.
258.
268.
256.
229.
268.
250.
277.
257.
251.
259.

MEAN
105.
130.
169.
199.
217.
235.
248.
257.
S.
D.
6.8
7.0
8.0
8.2
10.2
10.3
11.4
13.0
N
10
10
10
10
10
10
10
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
­­­­­­_____

ANIMAL
69305
69316
69320
69323
69326
69335
69336
69338
69345
107.
99.
114.
104.
106.
106.
110.
108.
103.
69347
100.

MEAN
106.
S.
D.
4.5
N
10
­1
­
­
­
­
­
­
­
_
_

130.
126.
145.
131.
130.
123.
136.
135.
126.
123.

131.
170.
203.
227.
243.
257.
267.
6.8
8.6
8.7
11.5
15.7
15.9
16.3
10
10
10
10
10
10
10
90­
DAY
INHAL.

0
.­­­­­­­­­_____

165.
191.
210.
225.
169.
205.
232.
254.
188.
216.
239.
255.
171.
206.
230.
254.
176.
212.
242.
268.
168.
207.
233.
220.
175.
203.
232.
244.
171.
201.
219.
234.
157.
194.
223.
245.
161.
190.
208.
227.
TABLE
21
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
BODY
WEIGHTS
[Gl
PAGE
2
MALE
GROUP:
15
PPM
1
2
3
4
5
233.
269.
265.
271.
284.
255.
257.
243.
259.
238.
240.
278.
275.
276.
291.
276.
262.
254.
270.
244.
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
_­_­­_­__
ANIMAL
69303
69309
69313
69315
69324
69328
69339
69344
69348
69350
__

101.
124.
160.
175.
195.
213.
225.
236.
101.
129.
169.
210.
232.
251.
265.
274.
104.
129.
174.
207.
229.
252.
268.
272.
106.
124.
157.
179.
198.
212.
221.
225.
106.
128.
167.
193.
219.
243.
261.
277.
111.
133.
175.
207.
229.
254.
269.
283.
103.
126.
163.
185.
202.
213.
218.
232.
117.
145.
191.
218.
239.
256.
273.
284.
114.
139.
176.
205.
228.
242.
257.
269.
107.
131.
170.
196.
219.
236.
246.
255.
MALE
GROUP:
40
PPM
0
1
2
3
4
5
MEAN
107.
131.
170.
198.
219.
237.
250.
261.
S.
D.
5.4
6.7
9.7
14.3
15.5
18.0
21.4
22.2
N
10
10
10
10
10
10
10
10
TABLE
21
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
BODY
WEIGHTS
[Gl
PAGE
3
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
21
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDJVIDUAL
BODY
WEIGHTS
[Gl
WEEK
_
_
_
_
_
_
_
_
_
_
_
.
ANIMAL
69304
69307
69318
69319
69327
69329
69332
69334
69342
69346
PAGE
4
­2
­1
0
MALE
GROUP:
100
PPM
1
2
3
4
5
_____­­________­____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­~­­­­~­­­­

100.
129.
168
205
233
256.
268.
286.
105.
129.
170
204
229
248.
265.
280.
104.
128.
166
189
214
235.
253.
263.
95.
117.
156
185
212
235.
248.
265.
112.
139.
178
195
216
231.
NA
247.
108.
131.
170
188
207
224.
233.
250.
112.
135.
172
194
218
234.
245.
256.
115.
140.
180
200
224
236.
251.
260.
115.
140.
175
209
237
255.
266.
278.
95.
120.
161
195
218
235.
253.
262.

MEAN
106.
131.
170.
196.
221.
239.
254.
265.
S.
D.
7.6
8.0
7.4
7.9
9.7
10.5
11.3
12.9
N
10
10
10
10
10
10
9
10
NA
=
NOT
APPLICABLE
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
_­­
­­__­.

ANIMAL
69302
69306
69308
69310
69312
69314
69317
69322
69337
69343
6
7
___­_­­____­__­__

272.
286.
278.
289.
265.
272.
241.
255.
290.
305.
253.
269.
291.
303.
264.
274.
259.
269.
264.
276.

MEAN
268.
280.
285.
292.
286.
299.
308.
313.
S.
D.
15.6
15.8
15.3
16.2
19.4
29.0
22.2
17.6
N
10
10
10
10
10
10
10
10
TABLE
21
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
BODY
WEIGHTS
[G]

MALE
GROUP:
10
PAGE
5
8
9
_______­­­­________
0
PPM
11
12
13
__­___­____­­___________________________­­­­­­­­­­­­­­­­­­­­­­­

298.
302
309.
321.
328.
324.
SCHEDULED
EUTH
WEEK
13
285.
287
292.
307.
312.
322.
SCHEDULED
EUTH
WEEK
13
275.
282
292.
303.
305.
311.
SCHEDULED
EUTH
WEEK
13
261.
312.
281.
302.
271.
282.
281.
266
261.
276.
284.
285.
SCHEDULED
EUTH
WEEK
13
320
318.
335.
340.
345.
SCHEDULED
EUTH
WEEK
13
278
261.
288.
296.
304.
SCHEDULED
EUTH
WEEK
13
313
287.
328.
334.
328.
SCHEDULED
EUTH
WEEK
13
289
267.
297.
301.
304.
SCHEDULED
EUTH
WEEK
13
288
277.
298.
306.
308.
SCHEDULED
EUTH
WEEK
13
290
295.
234.
269.
294.
SCHEDULED
EUTH
WEEK
13
WEEK
­
­
_
_
­
­
­
­
­
ANIMAL
69305
69316
69320
69323
69326
69335
69336
69338
69345
69347
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
­__
6
7
_­__­­__­_­­___­

241.
250.
291.
304.

MEAN
217.
290.
300.
306.
300.
320.
326.
329.
S.
D.
20.0
21.4
20.0
19.3
23.6
23.3
23.4
25.5
N
10
10
10
10
10
10
10
10
282.
302.
291.
301.
307.
319.
293.
305.
268.
285.
259.
270.
282.
295.
260.
267.
TABLE
21
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
BODY
WEIGHTS
[G]

MALE
GROUP:
15
PPM
8
9
10
11
12
13
______­_________________________________­­­­­­­­­­­­­­­­~­­­­­­­­­­~

266.
271.
269,
280.
283.
282.
316.
317.
301.
330.
338.
342.
312.
323.
325.
331.
336.
338.
313.
317.
314.
334.
339.
345.
323.
329.
328.
354.
358.
364.
314.
316.
324.
339.
344.
351.
291.
305.
282.
314.
326.
327.
278.
286.
263.
295.
299.
301.
308.
315.
308.
324.
330.
335.
277.
284.
289.
294.
302.
304.
PAGE
6
­__.

SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
90­
DAY
INHAL.
STUDY
OF
1,2,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
BODY
WEIGHTS
[G]

WEEK
6
7
8
_
­
_
_
_
_
_
­
_
_
­
.
ANIMAL
69303
69309
69313
69315
69324
69328
69339
MALE
9
­_____­_____­___­__­­­­­­­­­­­­­­­

69344
69348
244.
287.
280.
238.
286.
294.
241.
299.
269.
TABLE
21
PAGE
7
251.
296.
288.
246.
304.
308.
251.
310.
311
321
315.
332.
280.
293
298
298.
304.
254
303
301
258
317
312
257
261
253.
262.
310
319.
320.
304
301.
325.
262
265.
266.
322
315.
345.
310
321.
334.
272
276.
285.
GROUP:
40
PPM
10
11
_­­_­____­­­________
12
_________
­___

266.
276.
321.
317.
333.
335.
273.
274.
352.
363.
341.
344,
289.
293.
326.
341.
306.
317.
13
______

69350
263.
267.
281.
284.
275.
299.
301.
306.

MEAN
270.
280.
289.
294.
294.
307.
311.
317.
S.
D.
22.7
24.9
24.6
23.2
24.7
29.0
28.8
29.8
N
10
10
10
10
10
10
10
10
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
­
_
_
_
_
­
­
­
ANIMAL
69304
69307
69318
69319
69327
69329
69332
69334
69342
69346
6
7
_­__­________­___
_­_.

294.
300.
316.
324
312
337
341.
349.
SCHEDULED
EUTH
WEEK
13
293.
299.
318.
322
324
340
350.
352.
SCHEDULED
EUTH
WEEK
13
278.
287.
295.
304
314
318
328.
334.
SCHEDULED
EUTH
WEEK
13
272.
282.
297.
300
303
314
322.
329.
SCHEDULED
EUTH
WEEK
13
260.
274.
281.
294
303
314
318.
327.
SCHEDULED
EUTH
WEEK
13
260.
272.
281.
292
294
303
310.
320.
SCHEDULED
EUTH
WEEK
13
261.
272.
278.
282
292
302
309.
318.
SCHEDULED
EUTH
WEEK
13
271.
276.
280.
292
279
303
305.
314.
SCHEDULED
EVTH
WEEK
13
285.
288.
300.
309
312
323
321.
330.
SCHEDULED
EUTH
WEEK
13
274.
290.
292.
302
304
319
315.
326.
SCHEDULED
EUTH
WEEK
13
____
MALE
GROUP:
100
PPM
8
9
10
11
12
_
_
_
_
_
_
_
_
_
13
­­­_­

MEAN
275.
284.
294.
302.
304.
317.
322.
330.
S.
D.
12.8
10.5
14.5
13.4
12.9
13.4
14.3
12.4
N
10
10
10
10
10
10
10
10
TABLE
21
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
TNDJVIDUAL
BODY
WEIGHTS
[Gl
PAGE
8
TABLE
21
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
BODY
WEIGHTS
[G]
PAGE
9
FEMALE
GROUP:
0
PPM
­1
0
1
2
3
4
5
._____­________­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­.
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
__­_­
____­_.
ANIMAL
69354
69366
­2
._­__­­_­­_­_

95.
104
114.
126
122
141
140
147
127
140
121
140
131
142
131
152
130
154
122
139
126
148
124
142
153.
158.
157.
149.
148.
162.
165.
173.
182
164.
169.
171
167.
172.
181
69367
88.
105
69378
89.
107
159.
170.
171
152.
158.
158
171.
176.
184
69384
69398
69404
69416
69419
104.
116
97.
111
89.
104
90.
104
93.
111
94.
107
164.
170.
177.
190
154.
164.
172.
180
69432
156.
168.
175.
182
153.
161.
164.
172
MEAN
95.
110.
127.
145.
155.
164.
171.
177.
S.
D.
8.1
7.0
5.8
5.4
5.1
5.7
5.8
9.1
N
10
10
10
10
10
10
10
10
TABLE
21
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
BODY
WEIGHTS
[G]

WEEK
­
_
_
_
_
_
_
_
_
ANIMAL
69362
69376
69377
69382
69390
69393
69396
69409
69413
69435
­_
­2
._____
­
_____

107.
116.
131.
145.
157.
164.
166.
176.
106.
116.
130.
143.
145.
153.
160.
165.
95.
107.
126.
140.
151.
162.
168.
EUTH
IN
EXTREMIS
WEEK
4
90.
106.
130.
146.
163.
173.
180.
184.
108.
116.
134.
146.
154.
162.
173.
170.
109.
116.
137.
144.
151.
157.
159.
165.
92.
104.
123.
145.
156.
165.
171.
182.
87.
100.
122.
138.
149.
158.
168.
172.
84.
96.
118.
126.
138.
143.
152.
158.
92.
107.
124.
140.
151.
157.
166.
172.
­1
0
_
­
_
_
­
_
_
_
_
_
­
_
FEMALE
GROUP:
15
PPM
1
2
3
._______­________­___
­__­­­­__­
PK
IN
RATS
&
MICE
PAGE
10
4
5
__­­_­___­_­­_­_____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

MEAN
97.
108.
128.
141.
152.
159.
166.
172.
S.
D.
9.5
7.3
5.9
6.1
6.8
8.0
7.9
8.3
N
10
10
10
10
10
10
10
9
TABLE
21
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
11
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
BODY
WEIGHTS
[G]

WEEK
____­__­__
ANIMAL
69359
69369
69370
69380
69388
69394
69426
69428
69433
112.
90.
116.
102.
107.
111.
102.
99.
131
119
126
130
122
121
146.
154.
165.
176.
137.
148.
156.
160.
138
150.
159.
168.
69436
85.
138
149.
159.
171.

MEAN
98.
109.
128.
140.
149.
159.
167.
S.
D.
9.6
6.6
6.1
5.9
9.1
7.5
9.0
N
10
10
10
10
10
10
10
­2
­­­_­­­­­_­­_­

105.
112.
126
105.
115.
135
104.
92.
109.
91.
90.
­1
117.
104.
0
­_­___

138
128
FEMALE
GROUP:
1
2
__­___________­_______________

129
129.
148.
152.
147
156.
166.
174.
147
161.
167.
173.
144
158.
169.
3.76.
139
144.
150.
154.
135
145.
152.
162.
40
PPM
3
4
__­_­_____

160.
178.
178.
180.
163.
171.
182.
167.
171.
179.

173.
7.7
10
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
BODY
WEIGHTS
IGI
WEEK
________­­__

ANIMAL
69375
69379
92
69383
87
69385
97
69392
104
69402
96
69408
91
69415
86
69427
88
69431
88
­2
___

109
MEAN
94.
S.
D.
7.7
N
10
NA
=
NOT
APPLICABLE
TABLE
21
FEMALE
GROUP:
100
PPM
­1
0
1
2
3
4
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

120.
138.
143.
145.
153
156.
106.
130.
137.
145.
153
160.
96.
121.
134.
141.
149
163.
108.
129.
140.
157.
165
174.
115.
131.
133.
138.
147
149.
111.
131.
139.
153.
158
172.
104.
126.
143.
156.
161
167.
102.
120.
136.
149.
163
172.
104.
125.
135.
145.
157
NA
104.
123.
134.
149.
161
165.

107.
127.
137.
148.
157.
164.
6.9
5.5
3.7
6.2
6.0
8.2
10
10
10
10
10
9
PAGE
12
5
_________­­­­­­­_­­­­­­­­­­­­­­­­­­­­

163.
169.
171.
175,
157.
180.
177.
178.
165.
176.

171.
7.5
10
TABLE
21
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
13
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
BODY
WEIGHTS
[Gl
FEMALE
GROUP:
0
PPM
WEEK
6
7
8
9
10
11
12
13
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
69354
189.
197.
199.
204.
202.
214.
215.
218.
SCHEDULED
EUTH
WEEK
13
69366
172.
182.
117.
184.
187.
193.
195.
194.
SCHEDULED
EUTH
WEEK
13
69367
181.
193.
192,
195.
191.
199.
207.
209.
SCHEDULED
EUTH
WEEK
13
69378
180.
182.
184.
183.
183.
198.
198.
199.
SCHEDULED
EUTH
WEEK
13
69384
l.
66.
171.
172.
171.
179.
180.
181.
185.
SCHEDULED
EUTH
WEEK
13
69398
190.
196.
195.
203.
196.
210.
213.
212.
SCHEDULED
EUTH
WEEK
13
69404
193.
199.
200.
204.
194.
214.
212.
214.
SCHEDULED
EUTH
WEEK
13
69416
184.
193.
196.
204.
198.
207.
209.
209.
SCHEDULED
EUTH
WEEK
13
69419
189.
194.
201.
204.
192.
209.
209.
211.
SCHEDULED
EUTH
WEEK
13
69432
179.
182.
185.
191.
183.
148.
177.
195.
SCHEDULED
EUTH
WEEK
13
MEAN
182.
189.
190.
194.
191.
197.
202.
205.
S.
D.
8.5
9.1
10.1
11.7
1.4
20.3
13.5
10.7
N
10
10
10
10
10
10
10
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
6
.__­­
­___
7
8
FEMALE
GROUP:
15
PPM
9
10
11
12
13
_
­
_
­
_
_
_
­
­
_
_
.

ANIMAL
69362
69376
69382
69390
69393
69396
69409
69413
69435
_­

117.
182.
186.
191.
191.
194.
188.
196.
SCHEDULED
EUTH
WEEK
13
165.
171.
173.
180.
166.
181.
179.
181.
SCHEDULED
EUTH
WEEK
13
187.
188.
193.
201.
195.
208.
208.
213.
SCHEDULED
EUTH
WEEK
13
179.
176.
183.
188.
182.
194.
192.
200.
SCHEDULED
EUTH
WEEK
13
167.
166.
172.
173.
171.
175.
111.
183.
SCHEDULED
EUTH
WEEK
13
182.
190.
193.
198.
190.
202.
203.
201.
SCHEDULED
EUTH
WEEK
13
180.
182.
186.
189.
184.
192.
197.
196.
SCHEDULED
EUTH
WEEK
13
164.
168.
171.
182.
183.
192.
191.
189.
SCHEDULED
EUTH
WEEK
13
176.
179.
184.
187.
191.
193.
194.
196.
SCHEDULED
EUTH
WEEK
13
MEAN
175.
178.
182.
188.
184.
192.
192.
195.
S.
D.
8.1
8.5
8.5
8.7
9.7
9.8
10.1
9.8
N
9
9
9
9
9
9
9
9
TABLE
21
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
INDIVIDUAL
BODY
WEIGHTS
[G]
PK
IN
RATS
&
MICE
PAGE
14
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
6
__­­_­_­­­­
WEEK
_____
­___
ANIMAL
69359
69369
69370
69380
69388
69394
69426
69428
69433
69436
160.
166.
179.
186.
179.
188.
185.
191.
165.
170.
172.
174.
188.
186.
166.
172.
176.
178.
181.
187.

MEAN
175.
180.
185.
188.
188.
195.
197.
199.
S.
D.
9.1
8.9
9.9
11.5
10.3
10.8
11.9
11.8
N
10
10
10
10
10
10
10
10
TABLE
21
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
BODY
WEIGHTS
[G]

FEMALE
GROUP:
40
PPM
7
8
9
10
11
12
13
_­_­_­_­_­­­­___­­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

172.
188.
193.
197.
174.
179.
194.
175.
179.
196.
171.
177
183
184
181
SCHEDULED
EUTH
WEEK
13
194.
183
198
201
201
SCHEDULED
EUTH
WEEK
13
196.
200
197
204
206
SCHEDULED
EUTH
WEEK
13
206.
202
212
214
216
SCHEDULED
EUTH
WEEK
13
176.
182
184
181
188
SCHEDULED
EUTH
WEEK
13
184.
184
191
194
196
SCHEDULED
EUTH
WEEK
13
199.
197
209
208
212
SCHEDULED
EUTH
WEEK
13
175.
177
180
182
185
SCHEDULED
EUTH
WEEK
13
186.
178
194
194
197
SCHEDULED
EUTH
WEEK
13
193.
199
201
208
208
SCHEDULED
EUTH
WEEK
13
PAGE
15
WEEK
_
_
_
_
_
­
_
­
_
ANIMAL
69375
69379
63383
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
__­
6
7
_­_­_­­­_­_­­___

69385
69392
69402
69408
69415
69427
69431
166.
170.
175.
171.
176.
181.
176.
176.
178.
180.
181.
184.
157.
162.
169.
184.
184.
187.
181.
181.
188.
182.
186.
186.
176.
177.
180.
181.
184.
191.
194.
198.
197.
189.
182.
178.
189.
195.
193.
193.
199.
SCHEDULED
EUTH
WEEK
13
198.
198.
203.
SCHEDULED
EUTH
WEEK
13
178.
174.
179.
SCHEDULED
EUTH
WEEK
13
199.
201.
204.
SCHEDULED
EUTH
WEEK
13
199.
201.
198.
SCHEDULED
EUTH
WEEK
13
197.
200'.
199.
SCHEDULED
EUTH
WEEK
13
186.
190.
198.
SCHEDULED
EUTH
WEEK
13
198.
201.
199.
SCHEDULED
EUTH
WEEK
13
MEAN
175.
178.
182.
187.
185.
192.
193.
196.
S.
D.
8.5
7.3
6.7
7.9
9.4
7.8
9.6
8.2
N
10
10
10
10
10
10
10
10
TABLE
21
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
BODY
WEIGHTS
[Gl
FEMALE
GROUP:
8
9
10
___­­­­­_­­­­­_
__________________
___
100
PPM
11
12
13
__­____­­_____­­___­­­­­­­­­­­­­

177.
173.
185.
184.
186.
177.
193.
197.
172.
175.
191.
188.
181.
179.
183.
SCHEDULED
EUTH
WEEK
13
193.
19s.
198.
SCHEDULED
EUTH
WEEK
13
PAGE
16
PBFTSv4.24
05/
01/
2002
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
­2
­­­_­­__­­
ANIMAL
69302
69306
69308
69310
69312
69314
69317
69322
69337
69343
TO
­1
­1
­_­______­__

25.
29.
26.
26.
26.
27.
29.
24.
22.
22.
TO
0
38.
37.
42.
34.
42.
35.
45.
39.
36.

MEAN
26.
39.
30.
18.
18.
13.
9.
10.
S.
D.
2.5
3.5
7.6
6.9
2.2
2.1
6.1
5.4
N
10
10
10
10
10
10
10
10
TABLE
22
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
BODY
WEIGHT
CHANGES
[G]
PAGE
1
MALE
GROUP:
0
PPM
OTO
1
1TO
2
2T0
3
3T0
4
4T0
5
5T0
6
.____­­­___­__­_­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­~­­­­~

40.
20
18
13
6
14
41.
15
21
15
11
10
25.
4
23
11
15
9
15.
22
17
9
­5
12
30.
28
18
13
4
22
25.
14
16
14
12
3
32.
23
18
14
11
14
34.
25
18
15
12
29.
14
17
10
15
8
28.
18
16
14
11
5
TABLE
22
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
l,
l.,
2­
TCE
IN
RATS
WITH
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
BODY
WEIGHT
CHANGES
MALE
GROUP:
15
PPM
WEEK
­2
TO
­1
­lTO
0
OTO
1
1TO
2
2T0
3
3T0
4
_________­__
ANIMAL
69305
69316
69320
69323
69326
69335
17.
69336
26.
69338
27.
69345
23.
69347
23.
23.
27.
31.
27.
24.
35
26
43
36
43
28
40
35
46
36
45
39
39
28
36
30
31
37
38
29
19
27
23
24
30
26
29
18
29
18
15.
22.
16.
24.
26.
­13.
12.
15.
22.
19.
8.
15.
10.
17.
16.
35.
13.
9.
14.
11.

MEAN
25.
40.
32.
24.
16.
15.
9.
11.
S.
D.
3.7
4.8
4.6
4.7
11.1
7.7
4.7
5.6
N
10
10
10
10
10
10
10
10
PK
IN
RATS
&
MICE
[Gl
PAGE
2
4T0
5
5T0
6
_­­__­­­­­­­_­­__­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

7.
1.
9.
13.
10.
I.
5.
15.
7.
16.
21.
17.
5.
6.
11.
5.
11.
12.
6.
16.
TABLE
22
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1.1.2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
3
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
BODY
WEIGHT
CHANGES
[Gl
MALE
GROUP:
40
PPM
WEEK
­2
TO
­1
­lTO
0
OTO
1
1TO
2
2T0
3
3T0
4
4T0
5
___________________­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
69303
23.
36.
15.
20.
18.
12.
11.
69309
28.
40.
41.
22.
19.
14.
9.
69313
25.
45.
33.
22.
23.
16.
4.
69315
18.
33.
22.
19.
14.
9.
4.
69324
22.
39.
26.
26.
24.
18.
16.
69328
22.
42.
32.
22.
25.
15.
14.
69339
23.
37.
22.
17.
11.
5.
14.
69344
28.
46.
27.
21.
17.
17.
11.
69348
25.
37.
29.
23.
14.
15.
12.
69350
24.
39.
26.
23.
17.
10.
9.

MEAN
24.
39.
27.
22.
18.
13.
10.
S.
D.
3.0
4.0
7.1
2.5
4.6
4.1
4.0
N
10
10
10
10
10
10
10
s
ul
%
m
G
5T0
6
8.
13.
8.
13.
9.
l.
1.
9.
15.
0.
8.

9.
4.1
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
22
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
BODY
WEIGHT
CHANGES
[G]

WEEK
­2
TO
­1
­1
_____­_________________
ANIMAL
69304
29.
69307
24.
69318
24.
69319
22.
69327
27.
69329
23.
69332
23.
69334
25.
69342
25.
69346
25.
TO
0
OTO
1
39.
37.
28.
41.
34.
25.
38.
23.
25.
39.
29.
27.
39.
17.
21.
39.
18.
19.
37.
22.
24.
40.
20.
24.
35.
34.
28.
41.
34.
23.
MALE
1TO
2
GROUP:
100
PPM
2T0
3
3T0
4
____
­
______
_
_
­
­
­
_
­
_
_
_
_
_

23.
12.
19.
17.
21.
18.
23.
13.
15.
NA
17.
9.
16.
11.
12.
15.
18.
11.
17.
18.
4T0
5
.__­­
­___­
___.

18.
15.
10.
17.
NA
17.
11.
9.

12.
9.
5
TO
6
8
13
15
7
13
10
5
11
7
12
MEAN
25.
39.
27.
24.
18.
14.
13.
10.
S.
D.
2.1
1.8
7.6
2.9
3.5
3.3
3.7
3.2
N
10
10
10
10
10
9
9
10
NA
=
NOT
APPLICABLE
PAGE
4
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
6
___________
ANIMAL
69302
69306
69308
69310
69312
69314
69317
69322
69337
69343
TO
7
7
14.
11.
7.
14.
15.
16.
12.
10.
10.
12.
TO
8
______
­__

12.
­4.
3.
6.
I.
12.
­1.
­3.
13.
5.

MEAN
12.
5.
7.
­6.
13.
9.
5.
S.
D.
2.7
6.3
5.6
12.8
27.6
9.4
8.6
N
10
10
10
10
10
10
10
TABLE
22
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
BODY
WEIGHT
CHANGES
[G]
PAGE
5
MALE
GROUP:
0
PPM
8T0
9
9TO
10
10
TO
11
11
TO
12
I.
2
TO
13
.______­__­_____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

4.
7.
12.
7.
­4.
SCHEDULED
EUTH
WEEK
13
2.
5.
15.
5.
10.
SCHEDULED
EUTH
WEEK
13
7.
10.
11.
2.
6.
SCHEDULED
EUTH
WEEK
13
5.
­5.
15.
8.
1.
SCHEDULED
EUTH
WEEK
13
8.
­2.
17.
5.
5.
SCHEDULED
EUTH
WEEK
13
­3.
­17.
27.
8.
8.
SCHEDULED
EUTH
WEEK
13
11.
­26.
41.
6.
­6.
SCHEDULED
EUTH
WEEK
13
18.
­22.
30.
4.
3.
SCHEDULED
EUTH
WEEK
13
6.
­11.
21.
8.
2.
SCHEDULED
EUTH
WEEK
13
9.
5.
­61.
35.
25.
SCHEDULED
EUTH
WEEK
13
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
6T0
7
­­­­­­_­­­­______
ANIMAL
69305
9.
69316
13.
69320
20.
69323
10.
69326
12.
7T0
a
­
_
_
_
_
_
_
_

16.
5.
­2.
11.
3.
12.
1.
­16.
29.
8.
10.
11.
2.
6.
5.
12.
4.
­3.
20.
5.
4.
6.
­1.
26.
4.
9.
2.
8.
15.
5.
6.
14.
­23.
32.
12.
8.
8.
­23.
32.
4.
13.
7.
­7.
16.
6.
10.
7.
5.
5.
8.
69335
12.
69336
17.
69338
11.
69345
13.
69341
I.

MEAN
12.
S.
D.
3.8
N
LO
8T0
9
­­­­__­­­_
MALE
GROUP:
15
PPM
9TO
10
10
TO
11
11
TO
12
______­_______________
___­_____­­__
_­­
12
TO
13
­1.
4.
2.
6.
6.
7.
1.
2.
5.
2.

10.
7.
­6.
19.
6.
3.
3.5
3.9
11.1
10.2
2.7
2.6
10
10
10
10
10
10
TABLE
22
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
BODY
WEIGHT
CHANGES
[G]
PAGE
6
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
1;
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
ANIMAL
69303
69309
69313
69315
69324
69328
69339
69344
69348
69350
6T0
I
7.
3.
7.
9.
7.
7.
8.
13.
3.
8.
12.
4.
18.
13.
5.
14.
4.
­2.
10.
6.
15.
11.
1.
10.
11.
13.
5.
4.
14.
3.
7T0
8
­
­
­
_
­
­
_
_
­

MEAN
10.
9.
6.
S.
D.
3.9
4.9
4.5
N
10
10
10
TABLE
22
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
BODY
WEIGHT
CHANGES
[G]

MALE
GROUP:
40
PPM
9TO
10
10
TO
11
11
TO
12
__­_­­­­_____­__­_­___
__­_________

­8.
9.
9.
1.
­3.
24.
3.
1.
­7.
30.
11.
13.
4.
9.
­6.
17.
0.
6.
­9.
24.

­1.
13.
7.2
10.1
10
10
4.
10.
1.
­4.
8.
2.
7.
7.
7.
3.
4.
4.
­6.
15.
2.
11.
2.
5.

4.
6.
4.2
5.8
10
10
12
TO
13
­­__­­­_­­__.

1.
11.
PAGE
7
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
6TO
7
ANIMAL
69304
6.
69307
6.
69318
9.
69319
10.
69327
14.
69329
12.
69332
11.
69334
5.
69342
3.
69346
16.

MEAN
9.
S.
D.
4.2
N
10
7T0
8
8T0
9
­
­
_
_
_
_
_
_
_­________
MALE
GROUP:
100
PPM
9TO
10
10
TO
11
11
TO
12
12
TO
13
__­__­____­_____________________________­­­­­­

16.
8.
19.
4.
8.
9.
15.
3.
7.
13.
9.
11.
6.
4.
4.
12.
12.
9.
2.
10.
­12.
2.
10.
3.
4
10
9.
2.
25.
16.
4.
11.
11.
9.
10.
24.
10
8
8
2
4
10.
­13.
3.
2.
11.
15.
2
­2
­4
9
10
9
9
9
11
10.
8.
2.
14.
5.
8.
5.5
3.5
8.2
6.6
4.8
2.5
10
10
10
10
10
10
TABLE
22
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
BODY
WEIGHT
CHANGES
[G]
PAGE
8
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
TABLE
22
PROJECT
NO.:
WIL­
417002
go­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HA??
TASK
FORCE
INDIVIDUAL
BODY
WEIGHT
CHANGES
[G]

WEEK
­2
__________
ANIMAL
69354
69366
69367
69378
69384
69398
69404
69416
69419
69432
TO
­1
­­__­__­­­

9.
18
19
12.
12.
8.
9.
7.
12.
14
7
11.
6.
5.
2.
1.
17.
22
13
17.
10.
5.
9.
0.
18.
14
19
9.
10.
11.
1.
9.
12.
15
11
6.
4.
6.
0.
8.
14.
20
21
10.
9.
5.
8.
6.
15.
26
24
10.
6.
7.
13.
3.
14.
18
17
15.
10.
8.
8.
4.
18.
15
22
8.
12.
7.
7.
7.
13.
17
18
11.
8.
3.
8.
7.
­1
TO
0
0
TO
FEMALE
GROUP:
0
PPM
1
1TO
2
2T0
3
3T0
4
_­­­­­­­­_­_____­­__­­­­­­­­­­­­­­­­­­­­­
4T0
5
PAGE
9
MEAN
14.
18.
17.
11.
9.
7.
7.
5.
S.
D.
2.9
3.9
5.3
3.2
2.7
2.2
4.1
3.0
N
10
10
10
10
10
10
10
10
5T0
6
__­_­________­_________________________
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
­2
­­_­
­
_­­­_.
ANIMAL
69362
69376
69377
69382
69390
69393
69396
69409
69413
69435
TO
­1
­lTO
0
OTO
1
.______­___________­
­__­­­_­__

9.
15.
14.
10.
14.
13.
12.
19.
14.
16.
24.
16.
8.
18.
12.
7.
21.
7.
12.
19.
22.
13.
22.
16.
12.
22.
8.
15.
17.
16.

MEAN
11.
19.
14.
10.
8.
7.
5.
4.
S.
D.
2.9
3.2
1.3
i.
9
1.9
3.1
4.0
3.4
N
10
10
10
10
10
10
9
9
TABLE
22
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
10
INDIVIDUAL
BODY
WEIGHT
CHANGES
[Gl
FEMALE
GROUP:
15
PPM
1TO
2
2T0
3
3T0
4
­­­­­­______­__________
­
­
_
­
_
_
_
­
­

12.
I.
2.
8.
11.
11.
11.
10.
8.
8.
7.
6.
11.
9.
11.
9.
12.
5.
11.
6.
2.
10.
1
7.
5.
0
6.
EUTH
IN
EXTREMIS
I.
4.
3
11.
­3.
9
2.
6.
2
6.
11.
0
10.
4.
8
9.
6.
6
9.
6.
4
4T0
5
5T0
6
.__­­______________­____________________­­­­­­­­­­­­­

WEEK
4
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
22
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
BODY
WEIGHT
CHANGES
[G]

WEEK
­2
TO
­1
­1
­­___­­__­­­_­­­­__­___

ANIMAL
69359
7.
69369
10.
69370
13.
69380
12.
69388
7.
69394
11.
69426
17.
69428
­1.
69433
12.
69436
14.
TO
0
OTO
1
1
_
_
_
­
­
_
­
­
­
­_­­­­____­­__.

14.
3.
0.
19.
4.
8.
0.
20.
12.
9.
10.
8.
4.
1.
21.
9.
14.
6.
6.
5.
1.
24.
16.
14.
11.
7.
4.
5.
15.
8.
5.
6.
4.
9.
2.
17.
16.
10.
7.
10.
9.
1.
19.
20.
8.
11.
11.
6.
6.
19.
7.
11.
8.
4.
7.
­1.
20.
16.
12.
9.
9.
3.
5.
22.
17.
11.
10.
12.
8.
2.
FEMALE
GROUP:
TO
2
2T0
3
40
PPM
3T0
4
_­__­___­­_
PAGE
11
4T0
5
5T0
6
­­­­­___­­__­­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

MEAN
10.
19.
12.
9.
10.
8.
6.
2.
S.
D.
5.0
3.1
5.4
4.3
3.8
3.0
2.2
2.3
N
10
10
10
10
10
10
10
10
TABLE
22
PROJECT
NO.:
WIL­
417002
PO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
BODY
WEIGHT
CHANGES
[G]
PAGE
12
WEEK
­2
TO
­1
­
___________­__­______
ANIMAL
69375
11.
69379
14.
69383
9.
69385
11.
69392
11.
69402
15.
69408
13.
69415
16.
69427
16.
69431
16.
1TO
0
OTO
1
___­______­____________

18.
5.
2.
8.
3.
7.
3.
24.
7.
8.
8.
7.
9.
2.
25.
13.
7.
8.
14.
8.
5.
21.
11.
17.
8.
9.
1.
5.
16.
2.
5.
9.
2.
8.
0.
20.
8.
14.
5.
14.
8.
4.
22.
17.
13.
5.
6.
10.
4.
18.
16.
13.
14.
9.
6.
4.
21.
10.
10.
12.
NA
NA
11.
19.
11.
15.
12.
4.
11.
5.
FEMALE
GROUP:
100
PPM
1TO
2
2T0
3
3T0
4
4T0
5
5T0
6
,­­­_­_­­­­__­­­­___­­­­­
________­_______­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~

MEAN
13.
20.
10.
10.
9.
8.
8.
4.
S.
D.
2.6
2.8
4.7
4.8
3.0
4.4
2.9
2.8
N
10
10
10
10
10
9
9
10
NA
=
NOT
APPLICABLE
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
l,
L,
2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
BODY
WEIGHT
CHANGES
[G]

TO
WEEK
6
_
_
_
_
­
_
_
_
_
_
ANIMAL
69354
69366
69367
69378
69384
I
7T0
8
_­­­_­_________

8
2.
10
­5.
12
­1.
2
2.
5
1.
69398
­1.
69404
6
1.
69416
9
3.
69419
5
7.
69432
3.
5.
­2.
12.
1.
3.
SCHEDULED
EUTH
WEEK
13
7.
3.
6.
2.
­1.
SCHEDULED
EUTH
WEEK
13
3.
­4.
8.
8.
2.
SCHEDULED
EUTH
WEEK
13
­1.
0.
15.
0.
1.
SCHEDULED
EUTH
WEEK
13
­1.
8.
1.
1.
4.
SCHEDULED
EUTH
WEEK
13
8.
­7.
14.
3.
­1.
SCHEDULED
EUTH
WEEK
13
4.
­10.
20.
­2.
2.
SCHEDULED
EUTH
WEEK
13
8.
­6.
9.
2.
0.
SCHEDULED
EUTH
WEEK
13
3.
­12.
17.
0.
2.
SCHEDULED
EUTH
WEEK
13
6.
­8.
­35.
29.
18.
SCHEDULED
EUTH
WEEK
13
MEAN
7.
1.
4.
­4.
7.
4.
3.
S.
D.
3.1
3.2
3.3
6.2
15.7
9.0
5.5
N
10
10
10
10
10
10
10
TABLE
22
PAGE
13
FEMALE
GROUP:
0
PPM
8TO
9
9TO
10
10
TO
11
11
TO
12
12
TO
13
­_____­__­­_____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
6
____­______

ANIMAL
69362
69376
69382
69390
69393
69396
69409
69413
69435
TO
7
7TO
a
5.
4.
6.
2.
1.
5.
­3.
7.
­1.
6.
8.
3.
2.
4.
4.
3.
3.
5.

MEAN
3.
4.
5.
­4.
S.
D.
3.5
1.6
3.0
5.4
N
9
9
9
9
TABLE
22
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
t
MICE
INDIVIDUAL
BODY
WEIGHT
CHANGES
[G]
PAGE
14
FEMALE
GROUP:
15
PPM
8TO
9
PTO
10
10
TO
11
11
TO
12
12
TO
13
_____­­­­___________­­­­­­­~­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

5.
0.
7.
­14.
15.
a.
­6.
13.
5.
­6.
1.
­2.
5.
­8.
3.
­5.
11.
1.
3.
4.
3.

12.
4.
12.
8.
9.
2.

9.
4.1
9
­6.
­2.
0.
­2.
2.
1.
5.
­1.
1.

0.
3.1
9
a.
2.
5.
a.
6.
­2.
­1.
­2.
2.

3.
4.0
9
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
6T0
7
7T0
8
____­____­___________________
ANIMAL
69359
6.
6.
69369
7.
2.
69370
9.
5.
69380
6.
6.
69388
5.
4.
69394
2.
5.
69426
­2.
8.
69428
6.
3.
69433
2.
1.
69436
6.
9.
­1.
6.
6.
1.
6.
­11.
15.
3.
3.
4.
­3.
I.
9.
­4.
10.
2.
2.
6.
2.
­3.
5.
0.
7.
3.
5.
­2.
12.
­1.
0.
2.
3.
2.
I.
­8.
16.
0.
­3.
6.
2.
7.
3.
SCHEDULED
EUTH
WEEK
13
0.
SCHEDULED
EUTH
WEEK
13
MEAN
5.
5.
3.
0.
7.
2.
2.
S.
D.
3.2
2.5
3.8
6.1
6.2
3.2
2.7
N
10
10
10
10
10
10
10
TABLE
22
90­
DAY
INHAL.
STUDY
OF
1.1.2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
BODY
WEIGHT
CHANGES
EGI
PAGE
15
ET0
9
__­­­­­­__
FEMALE
GROUP:
40
PPM
9TO
10
10
TO
11
11
TO
12
__­­­______­_____­______________
12
TO
13
__________­_­___­_______________________­­­­­­­­­­­­­

­3
0
2
2
7
2
4
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
22
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
16
INDIVIDUAL
BODY
WEIGHT
CHANGES
[G]

WEEK
­
­
­
­
_
_
_
­
_
ANIMAL
69375
69379
69383
69385
69392
69402
69408
69415
69427
69431
6T0
7
7
TO
8
8
TO
­­__­­_­_­___
_­­­___­­­___­___

4.
5.
0.
1.
5.
0.
0.
4.
1.
3.
5.
2
­4.
8.
­2.
5.
4
­1.
9.
2.
2.
8
­9.
16.
0.
3.
9
4.
1.
0.
7.
3
3.
3.
­4.
3.
4
­3.
11.
2.
7.
6
4.
1.
2.
0.
11
­8.
8.
3.
3.
2
­4.
8.
4.
7.
­2
6.
3.
3.
FEMALE
GROUP:
100
PPM
9
9TO
10
10
TO
11
11
TO
12
_____­­­______­____________
_­­_­­­­­­_
12
TO
13
_
­
­
_
_
_
­
_
_
_
_
_
­
­

4:
3.
6.
5.
5.
3.
­3.
­1.
8.
­2.
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
MEAN
2.
4.
S.
D.
2.1
2.4
N
10
10
5.
­1.
I.
1.
3.
3.9
5.3
4.8
2.5
3.6
10
10
10
10
10
PBFTSv4.24
05/
01/
2002
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
23
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
FOOD
CONSUMPTION
[G/
ANIMAL/
DAY]
PAGE
1
WEEK
­1
_­_­_______
ANIMAL
69302
69306
69308
69310
69312
69314
69317
69322
69337
69343
TO
0
16.
16.
17.
18.
17.
17.
17.
15.
16.
17.
OTO
1
1
TO
2
______­_______­_
_­_­­__

19.
19.
19.
18.
20.
17.
19.
20.
19.

MEAN
17.
19.
17.
17.
16.
17.
17.
17.
S.
D.
0.8
0.9
1.1
0.5
0.7
1.2
1.1
1.0
N
10
10
10
10
10
10
10
10
18.
17.
17.
15
18.
17.
17.
17
17.
16.
16.
17
17.
16.
15.
14
19.
17.
17.
17
15.
16.
16.
16
18.
17.
17.
17
17.
17.
17.
17
17.
16.
16.
17
18.
17.
16.
18
MALE
GROUP:
2T0
3
3T0
4
_­__­­­­­___­­________
___
0
PPM
4
TO
_
_
_
_
_
_
_
5
5T0
6
6T0
7
__­­­___­_­___
_____­____­____­­______________________

17.
17.
16.
16.
19.
15.
17.
16.
17.
16.
18.
18.
17.
16.
19.
17.
18.
16.
16.
17.
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
­1
­­__­___­_.
ANIMAL
69305
69316
69320
69323
69326
69335
69336
69338
69345
69347
TO
0
0
­
­
­
­
­
­
_
_
_
_
_
_
MALE
GROUP:
15
PPM
TO
1
1TO
2
2TO
3
3T0
4
4T0
5
5T0
6
.__­­__­_________­__­­­­­­­­­­­­­­
­­­_­­­­­­­­__­­___­­­­­­­­­­­­­­

17.
18.
17.
20.
20.
21.
17.
20.
17.
21.
17.
19.
17.
20.
17.
19.
15.
19.
16.
18.
TABLE
23
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
FOOD
CONSUMPTION
[G/
ANIMAL/
DAY]

18.
20.
20.
19.
19.
19.
20.
18.
16
16
15.
19
17
19.
18
18
18.
18
18
19.
19
17
19.
19
19
20.
17
16
18.
16
17
17.
19.
18.
18
18
18.
17.
17.
17
17
17.
17.
18.
19.
18.
19.
10.
17.
16.
14.
18.
19.
18.
18.
18.
17.
16.
17.
16.

MEAN
17.
20.
19.
17.
18.
17.
18.
17.
S.
D.
1.2
1.1
1.0
2.6
1.2
0.9
1.4
1.4
N
10
10
10
10
10
10
10
10
PAGE
2
6T0
7
TABLE
23
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
FOOD
CONSUMPTION
[G/
ANIMAL/
DAY]

WEEK
­lTO
0
___________­______
ANIMAL
69303
16.
69309
18.
69313
18.
69315
16.
69324
17.
69328
17.
69339
16.
69344
18.
69348
17.
69350
17.
_­­
OTO
1
­­___
­__
1TO
2
_______­­­
MALE
GROUP:
2T0
3
3T0
4
­­_­­_­­____­­___­­­_
.__
40
PPM
4T0
5
ST0
6
6T0
7
­­­­_­­­­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

17.
16.
20.
20.
20.
18.
16.
16.
19.
18.
17.
18.
18.
16.
20.
19.
18.
17.
19.
17.
15.
16.
18.
18.
18.
18.
17.
16.
18.
18.
18.
18.
15.
14.
18.
18.
17.
17.
16.
16.

17.
17.
1.2
1.4
10
10
16.
15.
14.
17.
18.
3.6.
17.
17.
15.
16.
17.
16.
18.
18.
17.
18.
18.
18.
15.
16.
16.
18.
20.
18.
18.
16.
16.
17.
17.
15.

MEAN
17.
18.
18.
S.
D.
0.8
1.4
1.4
N
10
10
10
PAGE
3
17.
17.
16.
1.1
1.4
1.3
10
10
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
­1
_________­
ANIMAL
69304
69307
69318
69319
69327
69329
69332
69334
69342
69346
TO
0
­­________

17.
18
16.
19
16.
16
16.
17
18.
18
17.
16
17.
18
17.
18
16.
19
16.
19
0
TO
MEAN
17.
18.
18.
18.
17.
17.
17.
17.
S.
D.
0.7
1.1
0.9
1.0
1.1
0.9
0.8
0.9
N
10
10
10
10
10
10
10
10
TABLE
23
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
FOOD
CONSUMPTION
[G/
ANIMAL/
DAY]
PAGE
4
MALE
GROUP:
100
PPM
1TO
2
2T0
3
3T0
4
4T0
5
5T0
6
.­___­__­­_______­­____
­__
­­­­__­­___
6T0
7
._­­­­­_­­­__­­­___­____________________

18.
19.
16.
11.
18.
17.
11.
18.
19.
18.
19.
18.
18.
18.
17.
18.
17.
17.
17.
15.
16.
16.
17.
16.
17.
17.
19.
18.
18.
18.
18.
19.
17.
18.
17.
16.
16.
17.
18.
17.
18.
17.
18.
18.
19.
16.
17.
17.
17.
17.
17.
17.
16.
15.
17.
16.
17.
16.
18.
18.
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
23
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
FOOD
CONSUMPTION
[G/
ANIMAL/
DAY]
PAGE
5
MALE
GROUP:
WEEK
7T0
8
8T0
9
9TO
10
10
TO
11
_­­
_______­_­
_.
_
_
_
_
­
­
­
­
­
ANIMAL
69302
69306
69308
69310
69312
69314
69317
69322
69337
69343
___
11
TO
12
12
17.
17.
17.
15.
17.
16.
15.
16.
18.
19.
16.
15.
18.
17.
16.
16.
17.
16.
17.
17.
17.
17.
17.
17.
SCHEDULED
EUTH
WEEK
13
16.
17.
16.
17.
SCHEDULED
EUTH
WEEK
13
17.
17.
16.
17.
SCHEDULED
EUTH
WEEK
13
15.
16.
17.
16.
SCHEDULED
EUTH
WEEK
13
17.
19.
18.
18.
SCHEDULED
EUTH
WEEK
13
15.
16.
17.
17.
SCHEDULED
EUTH
WEEK
13
16.
16.
17.
17.
SCHEDULED
EUTH
WEEK
13
16.
17.
15.
15.
SCHEDULED
EUTH
WEEK
13
17.
17.
16.
17.
SCHEDULED
EUTH
WEEK
13
17.
7.
13.
22.
SCHEDULED
EUTH
WEEK
13
0
PPM
TO
13
_­_____

MEAN
11.
16.
16.
16.
16.
17.
S.
D.
0.9
1.2
0.8
3.2
1.4
1.8
N
10
10
10
10
10
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
23
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
FOOD
CONSUMPTION
[G/
ANIMAL/
DAY]

WEEK
_
­
­
­
­
­
_
­
_

ANIMAL
69305
69316
69320
69323
69326
69335
69336
69338
69345
69347
7T0
8
8TO
9
_
­
­
­
­
_
_
_
_
_
­
_
_
_
_
­
_
_
_
_
_

15.
16.
16
16
15.
15.
SCHEDULED
EUTH
WEEK
13
19.
19.
18
18
18.
19.
SCHEDULED
EUTH
WEEK
13
19.
19.
19
18
18.
19.
SCHEDULED
EUTH
WEEK
13
18.
19.
19
18
18.
19.
SCHEDULED
EUTH
WEEK
13
19.
19.
19
19
19.
19.
SCHEDULED
EUTH
WEEK
13
18.
19.
19
18
18.
19.
SCHEDULED
EUTH
WEEK
13
11.
18.
11
17
17.
18.
SCHEDULED
EUTH
WEEK
13
16.
17.
16
16
16.
16.
SCHEDULED
EUTH
WEEK
13
18.
18.
18
18
19.
19.
SCHEDULED
EUTH
WEEK
13
17.
17.
18
17
18.
18.
SCHEDULED
EUTH
WEEK
13
MALE
GROUP:
15
PPM
9TO
10
10
TO
11
11
TO
12
12
TO
13
­­­­­_­__­­_­­­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­.
PAGE
6
MEAN
18.
18.
18.
18.
18.
18.
S.
D.
1.3
1.1
1.2
1.0
1.3
1.4
N
10
10
10
10
10
10
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
FOOD
CONSUMPTION
[G/
ANIMAL/
DAY]

WEEK
7T0
0
__­_­­­______­___
ANIMAL
69303
14.
69309
17.
69313
17.
69315
16.
69324
18.
69328
17.
69339
16.
69344
18,
69348
17.
69350
17.
__­
8T0
9
9TO
10
­__­
_____
___­
_____
MALE
GROUP:
40
PPM
10
TO
11
11
TO
12
12
TO
13
_­_____________­__________________
­­.

15.
15.
17.
17.
18.
17.
17.
16.
18.
19.
18.
17.
16.
17.
18.
18.
17.
17.
18.
18.
14.
15.
14.
18.
17.
17.
18.
18.
17.
15.
16.
15.
19.
18.
20.
18.
18.
17.
17.
16.
16.
19.
19.
18.
16.
17.
18.
17.
17.
17.
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
MEAN
17.
S.
D.
1.2
N
10
17.
1.0
10
TABLE
23
17.
1.1
10
17.
17.
17.
1.7
1.2
1.7
10
10
10
PAGE
7
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
23
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
FOOD
CONSUMPTION
[G/
ANIMAL/
DAY]

MALE
GROUP:
100
PPM
T"___"­___"_
T'3___"____"_
'"__
1"___
'"_
T'1­~~~­­­~~­~~­­~~­­­­~­­­­­­~­­­­­­~­­­­­­~~­­­~­­­­­­­~­­­­­­~­­­­­­­­
WEEK
7
___________
ANIMAL
69304
69307
69318
69319
69327
69329
69332
69334
69342
69346
18
18
18
18.
17.
18.
18
19
18
18.
18.
18.
17
18
18
18.
17.
18.
18
17
16
17.
17.
17.
17
18
18
18.
18.
18.
17
17
17
17.
17.
17.
17
16
17
17.
16.
17.
16
17
17
16.
16.
17.
18
18
18
18.
17.
18.
18
18
17
18.
18.
19.

MEAN
17.
18.
17.
18.
17.
18.
S.
D.
0.7
0.8
0.7
0.7
0.7
0.7
N
10
10
10
10
10
10
PAGE
8
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
PROJECT
NG.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
­1
__­­­­__­­_
ANIMAL
69354
69366
69367
69378
69384
69398
69404
69416
69419
69432
TO
0
OTO
1
11.
12.
13.
12.
12.
13.
13.
13.
13.
12.

12.
0.7
10
13.
13.
14.
14.
12.
14.
15.
14.
14.
14.

MEAN
S.
D.
N
1TO
2
­
­
­
­
­
_
­
­
­

12.
12.
13.
13.
12.
14.
13.
13.
13.
13.

14.
13.
0.8
0.6
10
10
TABLE
23
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
9
INDIVIDUAL
FOGD'CONSUMPTION
[G/
ANIMAL/
DAY]

FEMALE
GROUP:
2T0
3
3T0
4
_­­__­­______­­____­__

13.
13.
12.
11.
13.
13.
13.
14.
11.
12.
12.
12.
13.
12.
12.
13.
13.
14.
12.
13.

12.
13.
0.7
0.9
10
10
___­
0
PPM
4T0
5
_­
___­___

13.
12.
14.
14.
11.
12.
14.
14.
14.
13.

13.
1.1
10
5T0
6
_­
_______
6T0
7
­­­

13.
12.
13.
14.
13.
14.
13.
13.
14.
13.
13.
11.
13.
13.
12.
13.
13.
14.
13.
13.

13.
13.
0.6
0.8
10
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
­1
ANIMAL
69362
69376
69377
69382
69390
69393
69396
69409
69413
69435
TO
0
OTO
1
__­­­
­­­___­­­______­

12
13.
13.
13.
13.
13
14
13
12
13.
12.
12.
12.
12
12
12
12
13.
12.
13.
12.
EUTH
IN
EXTREMIS
WEEK
4
13
15.
14.
13.
13.
13
13
13
13
13.
12.
13.
13.
12
14
11
13
13.
13.
11.
11.
12
11
9
13
13.
13.
13.
12.
14
13
12
12
14.
13.
12.
13.
14
13
12
11
12.
12.
11.
11.
12
12
11
13
14.
13.
13.
13.
14
12
12
MEAN
12.
13.
13.
12.
12.
13.
13.
12.
S.
D.
0.7
0.8
0.7
0.8
0.8
0.9
1.0
1.2
N
10
10
10
10
10
9
9
9
TABLE
23
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
FOOD
CONSUMPTION
[G/
ANIMAL/
DAY]
PAGE
10
FEMALE
GROUP:
15
PPM
1TO
2
2TO
3
3T0
4
4T0
5
5TO
6
6TO
7
­­­­­__­­­­­________­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
23
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
FOOD
CONSUMPTION
[G/
ANIMAL/
DAY]
PAGE
11
WEEK
­1
__­__­___­
ANIMAL
69359
69369
69370
69380
69388
69394
69426
69428
69433
69436
TO
0
OTO
1
1TO
2
__________
._________­____­_­_______

12.
12.
13.
13.
12.
12.
13.
11.
12.
12.
11.
11.
13.
13.
13.
13.
14.
13.
11.
11.
12.
11.
13.
13.
11.
11.
13.
13.
13.
13.
FEMALE
GROUP:
2T0
3
3T0
4
___________­­___­_­______

11.
11.
12.
12.
12.
12.
13.
12.
12.
12.
12.
12.
13.
14.
12.
12.
13.
12.
14.
13.
40
PPM
4T0
5
11.
14.
13.
13.
13.
13.
14.
12.
13.
14.
5T0
6
6T0
7
_­_____­­___
.___­__________­­_______________________

12.
13.
13.
14.
12.
13.
13.
12.
13.
14.
10.
12.
13.
12.
12.
11.
12.
12.
11.
14.

MEAN
12.
12.
12.
12.
12.
13.
13.
12.
S.
D.
0.6
1.1
1.0
0.8
0.8
0.9
0.7
1.1
N
10
10
10
10
10
10
10
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
­lTO
0
_­___­___­_______
ANIMAL
69375
12.
69379
13.
69383
12.
69385
14.
69392
11.
69402
13.
69408
12.
69415
13.
69427
13.
69431
12.

MEAN
13.
S.
D.
0.8
N
10
OTO
1
_
_
_
_
­
­
­
­
_
FEMALE
GROUP:
1TO
2
2T0
3
3T0
4
12.
13.
11.
12.
11.
12.
13.
12.
13.
13.
12.
11.
19.
12.
12.
12.
12.
12.
12.
13.
13.
13.
11.
11.
11.
12.
13.
13.
13.
20.
12.
13.
14.
13.
13.
12.
13.
13.
13.
13.

12.
12.
13.
13.
0.8
0.7
2.6
2.2
10
10
10
10
TABLE
23
YO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
FObD'CONSUMPTION
[G/
ANIMAL/
DAY]

100
PPM
4T0
5
_____­__­­

12.
13.
13.
13.
12.
14.
13.
13.
12.
14.

13.
0.7
10
5T0
6
12.
13.
12.
13.
12.
14.
13.
13.
12.
14.

13.
0.8
10
PAGE
12
6T0
7
­­­__­__­­_______­____________________

10.
12.
11.
12.
10.
11.
11.
13.
11.
13.

11.
1.1
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
23
90­
DAY
INHAL.
STUDY
OF
l,
l.,
2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
FOOD
CONSUMPTION
[G/
ANIMAL/
DAY]

FEMALE
GROUP:
WEEK
IT0
8
ET0
9
PTO
10
10
TO
11
11
TO
12
__­___­­­­­­_____­______________________­­­­­­­~­­­­­­­­­­­­­­­­­
ANIMAL
69354
13.
13.
14.
14.
13.
69366
12.
11.
12.
12.
12.
69367
14.
13.
13.
13.
14.
69378
13.
12.
13.
14.
14.
69384
12.
12.
12.
12.
12.
69398
12.
13.
13.
13.
12.
69404
13.
13.
13.
13.
12.
PAGE
13
0
PPM
12
TO
13
_____­_____________­­­­­­­­­­~~~­­­­­­­­­­­­­­­­­­~~­­­­­­­­­­­

13.
SCHEDULED
EUTH
WEEK
13
13.
SCHEDULED
EUTH
WEEK
13
13.
SCHEDULED
EUTH
WEEK
13
14.
SCHEDULED
EUTH
WEEK
13
13.
SCHEDULED
EUTH
WEEK
13
13.
SCHEDULED
EUTH
WEEK
13
13.
SCHEDULED
EUTH
WEEK
13
14.
SCHEDULED
EUTH
WEEK
13
14.
SCHEDULED
EUTH
WEEK
13
16.
SCHEDULED
EUTH
WEEK
13
69416
14.
14.
13.
14.
14.
69419
13.
14.
14.
13.
14.
69432
12.
13.
13.
4.
11.

MEAN
13.
13.
13.
12.
13.
14.
S.
D.
0.8
0.9
0.7
3.0
1.1
1.0
N
10
10
10
10
10
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
WEEK
7T0
8
___­­­_________­__
ANIMAL
69362
13.
69376
11.
69382
13.
69390
13.
69393
11.
69396
12.
69409
12.
69413
12.
69435
13.

MEAN
12.
S.
D.
0.8
N
9
8TO
9
__­_____­_­_

13.
13.
13.
13.
11.
13.
12.
13.
13.

13.
0.7
9
TABLE
23
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
FOOD
CONSUMPTION
[G/
ANIMAL/
DAY]
PAGE
14
FEMALE
GROUP:
15
PPM
9TO
10
10
TO
11
11
TO
12
12
TO
13
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

13.
13.
12.
11.
13.
13.
13.
13.
11.
11.
13.
12.
13.
12.
13.
13.
13.
13.

13.
12.
0.7
0.9
9
9
13.
11.
13.
13.
11.
12.
12.
13.
13.

12.
0.9
9
14.
12.
13.
13.
12.
12.
12.
12.
12.

12.
0.7
9
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
SCHEDULED
EUTH
WEEK
13
TABLE
23
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
FOOD
CONSUMPTION
[G/
ANIMAL/
DAY]

WEEK
­_____
­__
ANIMAL
69359
69369
69370
69380
69388
69394
69426
69428
69433
69436
7T0
8
ET0
9
_­_______­____­­_________

11.
11.
12.
13.
13.
13.
13.
14.
12.
13.
12.
12.
14.
14.
11.
12.
12.
12.
13.
12.
9TO
10
12.
13.
13.
14.
13.
12.
14.
12.
12.
13.
FEMALE
GROUP:
40
PPM
10
TO
11
11
TO
12
12
TO
13
___­____­____­­____­_____
.___________
­

12.
11.
13.
13.
12.
12.
14.
13.
13.
12.
12.
12.
14.
13.
11.
12.
13.
12.
14.
14.
11.
SCHEDULED
EUTH
WEEK
13
13.
SCHEDULED
EUTH
WEEK
13
12.
SCHEDULED
EUTH
WEEK
13
14.
SCHEDULED
EUTH
WEEK
13
14.
SCHEDULED
EUTH
WEEK
13
12.
SCHEDULED
EUTH
WEEK
13
14.
SCHEDULED
EUTH
WEEK
13
12.
SCHEDULED
EUTH
WEEK
13
13.
SCHEDULED
EUTH
WEEK
13
13.
SCHEDULED
EUTH
WEEK
13
MEAN
12.
13.
13.
13.
12.
13.
S.
D.
0.9
1.0
0.8
1.0
0.8
1.0
N
10
10
10
10
10
10
PAGE
15
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
23
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
FOOD
CONSUMPTION
[G/
ANIMAL/
DAY]

WEEK
_
_
_
_
_
_
­
_
_
ANIMAL
69375
69379
69383
69385
69392
69402
69408
69415
69427
69431
7
TO
11
13
12
13
11
14
12
13
12
14
8
8T0
9
_­__­­­_­­­­­___­

12.
13.
13.
13.
12.
14.
13.
13.
13.
14.
YTO
10
11.
12.
12.
13.
12.
13.
13.
12.
12.
13.
FEMALE
GROUP:
100
PPM
10
TO
11
11
TO
12
12
TO
13
_____­­_____________­­­­­
_
_
_
_
_
_
_
_
_
_
_
_

11.
10.
13.
12.
12.
12.
14.
13.
12.
10.
13.
12.
12.
12.
13.
12.
12.
12.
13.
13.
11.
SCHEDULED
EUTH
WEEK
13
12.
SCHEDULED
EUTH
WEEK
13
12.
SCHEDULED
EUTH
WEEK
13
13.
SCHEDULED
EUTH
WEEK
13
11.
SCHEDULED
EUTH
WEEK
13
14.
SCHEDULED
EUTH
WEEK
13
12.
SCHEDULED
EUTH
WEEK
13
12.
SCHEDULED
EUTH
WEEK
13
13.
SCHEDULED
EUTH
WEEK
13
13.
SCHEDULED
EUTH
WEEK
13
PAGE
16
MEAN
13.
13.
12.
13.
12.
12.
S.
D.
1.1
0.7
0.7
0.8
1.0
0.9
N
10
10
10
10
10
10
PBFTSv4.23
01/
18/
2002
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
24
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
HEMATOLOGY
VALUES
PAGE
1
WEEK
13
______­_____­______­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
WHITE
RED
HEMO­
HEMATO­
PLATELET
PROTIME
APTT
ANIMAL
CELL
CELLS
GLOBIN
CRIT
MCV
MCH
MCHC
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

thous/
uL
mil/
uL
g/
dL
'i;
fL
uw3
g/
dL
thous/
uL
seconds
seconds
__­­_­_____­_______­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GROUP:
0
PPM
MALES
69302
8.2
8
52
15.0
41.7
49.0
17.6
35.9
701.
14.2
26.3
69306
9.9
8
91
15.8
43.6
48.9
17.7
36.3
742.
CLT
CLT
69308
6.1
9
43
16.2
45.3
48.0
17.1
35.7
762.
13.2
23.3
69310
6.9
8
97
15.6
43.4
48.4
17.3
35.8
1088.
16.5
28.2
69312
5.9
8
11
14.3
39.7
49.0
17.6
36.0
1047.
13.5
26.0
69314
6.2
8
21
14.2
39.2
41.7
17.2
36.1
885.
13.2
19.8
69317
7.7
8
09
14.2
39.0
48.2
17.6
36.5
1236.
13.9
24.5
69322
6.6
8
37
14.6
41.2
49.1
17.5
35.5
1035.
13.1
27.1
69337
6.1
7
71
13.1
37.1
48.1
17.0
35.4
650.
14.3
26.0
69343
9.3
8
06
14.2
40.4
50.1
17.6
35.1
915.
13.0
14.6
MEAN
1.3
8.44
14.7
41.1
48.7
17.4
35.8
906.
13.9
24.0
S.
D.
1.43
0.522
0.93
2.49
0.71
0.25
0.42
192.7
1.10
4.29
N
10
10
10
10
10
10
10
10
9
9
CLT
=
CLOTTED
__­­___­____­_____­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
g/
dL
=
GRAMS/
DECILITER,
thous/
uL
=
THOUSANDS/
MICROLITER,
mil/
uL
=
MILLIONS/
MICROLITER,
uug
=
PICOGRAMS,
fL
=
FEMTOLITERS
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
24
PO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
HEMATOLOGY
VALUES
PAGE
2
WEEK
13
____­___­_______________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
WHITE
RED
HEMO­
HEMATO­
PLATELET
PROTIME
APTT
ANIMAL
CELL
CELLS
GLOBIN
CRIT
MCV
MCH
MCHC
____­­____________­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

thous/
uL
mil/
uL
g/
dL
%
fL
UP3
ddL
thous/
uL
seconds
seconds
___­__________­___­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GROUP:
15
PPM
MALES
69305
7
0
9.18
16.3
44.4
48.4
17.7
36.7
742.
CLT
CLT
69316
6
6
9.29
16.2
44.5
47.9
17.4
36.3
686.
13.3
19.7
69320
4
5
8.20
14.4
38.8
47.3
17.5
37.0
985.
15.2
26.4
69323
6
9
8.49
15.2
42.2
49.1
17.9
35.9
1126.
13.5
26.1
69326
8
5
8.51
15.0
41.4
48.6
17.7
36.3
756.
12.7
21.3
69335
7
6
8.24
14.3
39.4
47.8
17.4
36.3
1056.
13.5
29.5
69336
8
9
8.57
15.3
42.2
49.3
17.8
36.2
1103.
13.1
24.7
69338
8
1
8.52
15.0
41.4
48.6
17.6
36.3
682.
14.3
23.2
69345
8
0
8.78
15.4
42.7
48.7
17.5
36.0
1159.
14.0
26.8
69347
6
5
8.62
14.8
41.2
47.8
17.1
35.9
705.
CLT
CLT
MEAN
7.3
8.64
15.2
41.8
48.4
17.6
36.3
900.
13.7
24.7
r
2
S.
D.
N
1.27
10
0.357
10
0.66
10
1.84
10
0.73
10
0.23
10
0.34
10
202.2
10
0.78
8
3.19
8
g
________­_______­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
m
CLT
=
CLOTTED
5,
____­_______­__­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

g/
dL
=
GRAMS/
DECILITER,
thous/
uL
=
THOUSANDS/
MICROLITER,
mil/
uL
=
MILLIONS/
MICROLITER,
uug
=
PICOGRAMS,
fL
=
FEMTOLITERS
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
24
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
HEMATOLOGY
VALUES
PAGE
3
WEEK
13
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
_
­
_
_
_
_
_

WHITE
RED
HEMO­
HEMATO­
PLATELET
PROTIME
APTT
ANIMAL
CELL
CELLS
GLOBIN
CRIT
MCV
MCH
MCHC
____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

________­_____
r"
oUs!~~­­~~~!~~­­­­­­­~!~~­­­­­­~­­­­­­~~~­~­~­­­­~­~~~­­~~­~~~!~~­­­­­­­­­­­­­~~~~~~~­~­~~~~~~~­­­­­­­­­­­­­­­­­­­­
thous/
uL
GROUP:
40
PPM
MALES
69303
6.9
8
79
15.2
42.2
48.0
17.4
36.2
668.
13.1
21.4
69309
6.5
8
41
14.7
40.9
48.6
17.5
35.9
1139.
16.3
26.6
69313
10.1
9
05
16.1
45.5
50.2
17.8
35.5
555.
CLT
CLT
69315
5.6
8
90
14.1
38.6
43.4
15.9
36.6
690.
13.2
13.7
69324
6.9
8
14
14.2
39.3
48.3
17.4
36.1
955.
13.4
26.5
69328
8.1
9
05
15.6
44.5
49.2
17.3
35.2
1273.
14.1
26.4
69339
6.3
8
29
14.2
39.3
47.4
17.2
36.2
574.
13.0
18.9
69344
7.7
7
99
13.9
38.9
48.7
17.5
35.8
1084.
13.6
25.8
69348
5.4
8
33
14.4
39.5
47.4
17.2
36.3
705.
14.6
25.5
69350
7.0
8
07
14.1
38.8
48.1
17.5
36.4
1086.
13.5
23.6
MEAN
7.1
8.50
14.7
40.8
47.9
17.3
36.0
873.
13.9
23.2
S.
D.
1.36
0.409
0.74
2.50
1.80
0.51
0.43
262.8
1.04
4.43
N
10
10
10
10
10
10
10
10
9
9
______________­­­­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
CLT
=
CLOTTED
g/
dL
=
GRAMS/
DECILITER,
thous/
uL
=
THOUSANDS/
MICROLITER,
mil/
uL
=
MILLIONS/
MICROLITER,
uug
=
PICOGRAMS,
fL
=
FEMTOLITERS
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
24
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
HEMATOLOGY
VALUES
PAGE
4
WEEK
13
WHITE
RED
HEMO­
HEMATO­
PLATELET
PROTIME
APTT
ANIMAL
CELL
CELLS
GLOBIN
CRIT
MCV
MCH
MCHC
thous/
uL
mil/
uL
g/
dL
%
fL
uug
g/
a
thous/
uL
seconds
seconds
GROUP:
100
PPM
MALES
69304
6
3
8.14
14.0
39.5
48.5
17.2
35.6
1070.
12.8
22.6
69307
9
0
9.32
16.4
45.9
49.3
17.6
35.7
538.
CLT
CLT
69318
5
6
8.32
14.4
40.1
48.2
17.4
36.0
621.
CLT
CLT
69319
7
4
8.91
15.0
42.6
47.8
16.9
35.4
1246.
13.4
23.5
69327
6
0
8.37
14.8
41.6
49.7
17.7
35.6
1193.
13.7
25.1
69329
8
0
9.34
16.3
45.5
48.7
17.4
35.8
870.
13.3
17.6
69332
5
8
7.98
14.1
38.8
48.6
17.7
36.4
1224.
14.2
26.4
69334
5
6
7.86
14.1
38.3
48.8
17.9
36.8
637.
CLT
CLT
69342
5
6
8.23
14.4
40.2
48.8
17.5
35.8
999.
13.5
24.3
69346
6
8
9.54
16.3
46.4
48.6
17.1
35.2
887.
14.0
24.7
MEAN
6.6
8.60
15.0
41.9
48.7
17.4
35.8
929.
13.6
23.5
S.
D.
1.18
0.620
0.98
3.06
0.53
0.31
0.47
262.5
0.46
2.85
N
10
10
10
10
10
10
10
10
7
7
____­_­__­________­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
CLT
=
CLOTTED
_____­­­_­___­____­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
g/
dL
=
GRAMS/
DECILITER,
thous/
uL
=
THOUSANDS/
MICROLITER,
mil/
uL
=
MILLIONS/
MICROLITER,
uug
=
PICOGRAMS,
fL
=
FEMTOLITERS
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
24
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
HEMATOLOGY
VALUES
PAGE
5
WEEK
13
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
WHITE
RED
HEMO­
HEMATO­
PLATELET
PROTIME
APTT
ANIMAL
CELL
CELLS
GLOBIN
CRIT
MCV
MCH
MCHC
____________­___________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

___________­­­""
ous!~~­­~~~!~~~­­­­­­~!~~­­­­­­~­­­­­­~~­­­­­­­­­­­~~~­­­­­­­~!~~­­­­­­­­­­­­­~~~~~~~­­­~~~~~~~­­­­­­­­­­­­­­­­­­­­
thous/
uL
GROUP:
0
PPM
FEMALES
69354
69366
69367
69378
69384
69398
69404
69416
69419
69432
6.8
5.0
QNS
3.5
6.5
5.4
;Nz
4.0
5.8
8.19
7.52
QNS
7.45
7.72
7.64
7.53
QNS
7.96
7.19
15.5
14.2
QNS
14.3
14.3
14.5
14.3
QNS
15.0
13.5
43.4
53.0
39.1
52.0
QNS
QNS
38.6
51.9
40.1
51.9
39.8
52.1
39.2
52.1
QNS
QNS
40.8
51.3
38.0
52.9
18.9
35.7
1338.
13.5
20.3
18.8
36.2
1127.
13.6
17.6
QNS
QNS
QNS
13.1
18.8
19.2
37.0
973.
14.0
19.4
18.6
35.8
86.
CLT
CLT
18.9
36.4
715.
13.0
14.1
19.0
36.4
1280.
13.3
16.0
QNS
QNS
QNS
12.9
17.1
18.8
36.7
745.
13.5
17.0
18.8
35.6
1182.
13.1
20.5
MEAN
5.3
7.65
14.5
39.9
52.2
18.9
36.2
931.
13.3
17.9
S.
D.
1.13
0.311
0.59
1.67
0.56
0.18
0.50
411.6
0.35
2.10
N
8
8
8
8
8
8
8
0
9
9
CLT
=
CLOTTED,
QNS
=
QUANTITY
NOT
SUFFICIENT
_­­­__­_­______­__­­­­­­­­­­­­­­­­­­­­­

g/
dL
=
GRAMS/
DECILITER,
thous/
uL
=
THOUSANDS/
MICROLITER,
mil/
uL
=
MILLIONS/
MICROLITER,
uug
=
PICOGRAMS,
fL
=
FEMTOLITERS
180of619
TABLE
24
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
7
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
HEMATOLOGY
VALUES
WEEK
13
__­_____________­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
WHITE
RED
HEMO­
HEMATO­
PLATELET
PROTIME
APTT
ANIMAL
CELL
CELLS
GLOBIN
CRIT
MCV
MCH
MCHC
_______________­________
m13"
11"_______
9~­~
thous/
uL
I
GROUP:
40
PPM
FEMALES
69359
3.6
7.45
14.0
69369
4.5
1.58
14.3
69370
5.5
7.92
14.8
69380
5.2
7.59
14.3
69388
6.5
8.08
14.8
69394
5.1
7.61
14.6
69426
3.5
7.84
14.7
69428
8.0
7.64
14.3
69433
su
su
su
69436
RU
RU
RU
MEAN
5.2
7.71
14.5
;;;;
S.
D.
1.49
0.211
0.29
v
N
8
8
8
13,
______­­­___________­­­­­­­­­­­­­­­­­­­­­­­­
%
fL
uw
g/
dL
thous/
uL
seconds
seconds
38.1
51.2
18.8
36.6
536.
CLT
CLT
39.4
52.0
18.8
36.2
1097.
14.1
17.6
41.0
51.8
18.6
36.0
627.
CLT
CLT
38.9
51.3
18.8
36.6
1098.
13.5
18.1
41.2
51.0
18.3
36.0
729.
12.1
13.9
40.2
52.8
19.2
36.4
1241.
13.5
20.2
40.0
50.9
18.8
36.9
1185.
13.4
16.1
40.4
52.9
18.7
35.4
1131.
13.2
21.3
su
su
su
su
su
CLT
CLT
RU
RU
RU
RU
RU
14.0
19.7
39.9
51.7
18.8
36.3
956.
13.4
18.1
1.05
0.78
0.25
0.47
277.9
0.66
2.55
8
8
8
8
8
7
I
­­
a
CLT
=
CLOTTED,
SU
=
SAMPLE
UNOBTAINABLE,
RU
=
RESULT
UNOBTAINABLE
_____
­__­

\o
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
g/
dL
=
GRAMS/
DECILITER,
thous/
uL
=
THOUSANDS/
MICROLITER,
mil/
uL
=
MILLIONS/
MICROLITER,
uug
=
PICOGRAMS,
fL
=
FEMTOLITERS
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
24
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
HEMATOLOGY
VALUES
PAGE
8
WEEK
13
_____­__­­____­­________________________­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
WHITE
RED
HEMO­
HEMATO­
PLATELET
PROTIME
APTT
ANIMAL
CELL
CELLS
GLOBIN
CRIT
MCV
MCH
MCHC
___­_______­_____­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
thous/
uL
mil/
uL
g/
dL
%
fL
uw
g/
dL
thous/
uL
seconds
seconds
_____­__________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GROUP:
100
PPM
FEMALES
69375
QNS
QNS
QNS
QNS
QNS
QNS
QNS
QNS
CLT
CLT
69379
5.6
8.32
15.6
44.7
53.7
18.7
34.8
635.
CLT
CLT
69383
3.9
8.29
15.6
43.6
52.6
18.8
35.8
1313.
13.4
19.6
69385
3.3
7.26
13.7
37.8
52.1
18.8
36.1
1087.
13.8
20.2
69392
5.3
7.63
14.3
40.0
52.5
18.8
35.8
1236.
13.8
20.5
69402
5.8
8.20
15.2
42.2
51.5
18.6
36.1
1295.
11.0
20.2
69408
4.3
7.77
14.4
40.3
51.8
18.6
35.9
1207.
13.9
18.6
69415
6.3
7.37
13.8
39.6
53.8
18.8
34.9
751.
13.9
17.8
69427
4.5
7.90
15.0
41.6
52.6
19.0
36.2
744.
13.8
16.2
69431
3.6
8.12
15.1
41.7
51.3
18.6
36.1
731.
14.5
24.2
MEAN
4.7
7.87
14.7
41.3
52.4
18.7
35.7
1000.
13.5
19.7
S.
D.
1.06
0.394
0.72
2.11
0.88
0.13
0.53
279.3
1.06
2.34
N
9
9
9
9
9
9
9
9
8
8
CLT
=
CLOTTED,
QNS
=
QUANTITY
NOT
SUFFICIENT
g/
dL
=
GRAMS/
DECILITER,
thous/
uL
=
THOUSANDS/
MICROLITER,
mil/
uL
=
MILLIONS/
MICROLITER,
uug
=
PICOGRAMS,
fL
=
FEMTOLITERS
PHEMv4.0
01/
18/
2002
183
of
619
TABLE
25
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
2
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
LEUKOCYTE
DIFFERENTIAL
COUNTS
[%
I
WEEK
13
NEUTRO­
LYMPH­
EOSIN­
ANIMAL
PHIL
OCYTE
MONOCYTE
OPHIL
BASOPHIL
__­______
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GROUP:
15
PPM
MALES
69305
14
85
0
1
0
69316
14
84
2
0
0
69320
21
75
4
0
0
69323
17
78
5
0
0
69326
14
83
3
0
0
69335
22
77
1
0
0
69336
17
79
4
0
0
69338
14
83
3
0
0
69345
17
83
0
0
0
69347
21
79
0
0
0
MEAN
17
81
2
0
0
S.
D.
3.2
3.4
1.9
0.3
0.0
_­"­­­_­­___
'"___­___
'"_______
'"_______
'~­­­­­­­~~­­­­~~­~­­­~­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­~­­­­­­­­­­
TABLE
25
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
3
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
LEUKOCYTE
DIFFERENTIAL
COUNTS
[%
I
WEEK
13
ANIMAL
GROUP:
40
PPM
69303
14
82
4
69309
18
78
4
69313
16
78
5
69315
19
81
0
69324
19
77
4
69328
20
73
7
69339
19
79
2
69344
24
72
4
69348
18
76
6
69350
16
83
1
MEAN
18
S.
D.
2.7
NEUTRO­
PHIL
N
10
LYMPH­
OCYTE
MONOCYTE
________________
MALES
78
4
3.6
2.2
10
10
__
EOSIN­
OPHIL
BASOPHIL
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.3
0.0
10
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
25
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
LEUKOCYTE
DIFFERENTIAL
COUNTS
[%
I
PAGE
4
WEEK
13
NEUTRO­
LYMPH­
EOSIN­
ANIMAL
PHIL
OCYTE
MONOCYTE
OPHIL
BASOPHIL
______­_____­___________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­~~­­~­­­­­­
GROUP:
100
PPM
MALES
69304
25
70
5
0
0
69307
14
82
4
0
0
69318
23
76
1
0
0
69319
15
79
5
1
0
69327
17
79
4
0
0
69329
18
82
0
0
0
69332
16
81
3
0
0
69334
19
78
3
0
0
69342
24
72
4
0
0
69346
18
76
5
1
0
MEAN
19
78
3
0
0
S.
D.
3.8
4.1
1.7
0.4
0.0
__
'­"_________
'"_______
'"_______
'"______­~~­­­­­­­~~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­~­­
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
25
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
LEUKOCYTE
DIFFERENTIAL
COUNTS
[%]
PAGE
5
WEEK
13
______­­____________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
NEUTRO­
LYMPH­
EOSIN­
ANIMAL
PHIL
OCYTE
MONOCYTE
OPHIL
BASOPHIL
_­______________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GROUP:
0
PPM
FEMALES
69354
69366
69367
69378
69384
69398
69404
69416
69419
69432
20
80
0
16
QUANTIT?
NOT
SUFFkIENT
16
80
3
14
85
1
14
85
1
19
QUANTIT;
SNOT
SUFFZCIENT
14
85
1
23
73
4
0
0
MEAN
17
81
2
0
0
S.
D.
3.3
4.2
1.4
0.4
0.0
N
8
8
8
8
8
__­­___­___­_______­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
25
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
LEUKOCYTE
DIFFERENTIAL
COUNTS
[%
I
PAGE
6
WEEK
13
NEUTRO­
LYMPH­
EOSIN­
ANIMAL
PHIL
OCYTE
MONOCYTE
OPHIL
BASOPHIL
GROUP:
15
PPM
FEMALES
69362
69376
69382
69390
69393
69396
69409
69413
69435
15
85
15
83
16
81
12
86
13
86
22
Q~
ANTIT;~
NOT
15
80
10
90
0
2
3
2
1
4
SUFFICIENT
5
0
MEAN
15
83
2
0
0
S.
D.
3.5
4.9
1.8
0.0
0.0
N
8
8
8
8
8
___________­­___________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
TABLE
25
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
7
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
LEUKOCYTE
DIFFERENTIAL
COUNTS
[%
I
WEEK
13
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ANIMAL
­­­­_­____

GROUP:

69359
69369
69370
69380
69388
69394
69426
69428
NEUTRO­
PHIL
_
_
_
_
_
_
_
_

40
PPM
10
16
17
13
14
15
23
14
LYMPH­
EOSIN­
OCYTE
MONOCYTE
OPHIL
BASOPHIL
____­_­____­_­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

FEMALES
88
2
0
0
81
3
0
0
81
2
0
0
84
3
0
0
81
5
0
0
79
6
0
0
72
5
0
0
85
1
0
0
69433
SAMPLE
UNOBTAINABLE
69436
RESULT
UNOBTAINABLE
MEAN
15
81
3
0
0
S.
D.
3.8
4.7
1.8
0.0
0.0
N
CI
8
8
8
8
8
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
25
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
LEUKOCYTE
DIFFERENTIAL
COUNTS
[%
I
PAGE
8
WEEK
13
___­­________­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­~
NEUTRO­
LYMPH­
EOSIN­
ANIMAL
PHIL
OCYTE
MONOCYTE
OPHIL
BASOPHIL
GROUP:

69375
69379
69383
69385
69392
69402
69408
69415
69427
69431
MEAN
S.
D.
N
100
PPM
FEMALES
QUANTITY
NOT
SUFFICIENT
13
17
15
17
19
15
11
16
16
15
2.4
9
84
80
83
78
76
81
89
81
80
81
3.7
9
________­_
2
3
2
4
5
4
0
3
4
3
1.5
9
1
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0.4
0.0
9
9
­_­______­________­_____________________­­­­­­­­­­­­­
__­_____________­_______________________
PDIFFv4.1
01/
18/
2002
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
26
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
LEUKOCYTE
COUNTS
PAGE
1
WEEK
13
0
PPM
MALE
_______________­___­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
TOTAL
NEUTRO­
LYMPH­
EOSIN­
LEUKOCYTES
PHIL
OCYTE
MONOCYTE
OPHIL
BASOPHIL
ANIMAL
thous/
uL
thous/
uL
thous/
uL
thous/
uL
thous/
uL
thous/
uL
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

69302
8.2
1.4
6.5
0.3
0.0
0.0
69306
9.9
1.5
8.4
0.0
0.0
0.0
69308
6.1
1.0
4.9
0.1
0.0
0.0
69310
6.9
1.3
5.2
0.3
0.1
0.0
69312
5.9
1.2
4.4
0.2
0.0
0.0
69314
6.2
1.5
4.7
0.1
0.0
0.0
69317
7.7
1.6
5.8
0.3
0.0
0.0
69322
6.6
1.3
5.1
0.2
0.0
0.0
69337
6.1
1.2
4.9
0.0
0.0
0.0
69343
9.3
1.6
7.7
0.0
0.0
0.0
MEAN
7.3
1.4
5.8
0.2
0.0
0.0
S.
D.
1.43
0.19
1.36
0.14
0.02
0.00
N
10
10
10
10
10
10
5;
___­____­_______________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
w
thous/
uL
=
THOUSANDS/
MICROLITER
%
o\

G
TABLE
26
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
PAGE
2
INDIVIDUAL
LEUKOCYTE
COUNTS
WEEK
13
15
PPM
MALE
TOTAL
NEUTRO­
LYMPH­
EOSIN­
LEUKOCYTES
PHIL
OCYTE
MONOCYTE
ANIMAL
OPHIL
thous/
uL
thous/
uL
BASOPHIL
thous/
uL
thous/
uL
thous/
uL
thous/
uL
69305
7.0
1.0
6.0
0.0
0.1
69316
6.6
0.9
0.0
5.5
0.1
0.0
69320
4.5
0.9
0.0
3.4
0.2
0.0
69323
6.9
1.2
0.0
5.4
0.3
0.0
69326
8.5
1.2
0.0
7.1
0.3
69335
7.6
0.0
1.7
0.0
5.9
0.1
0.0
69336
8.9
1.5
0.0
7.0
0.4
0.0
69338
8.1
1.1
0.0
6.7
0.2
0.0
69345
8.0
1.4
0.0
6.6
0.0
0.0
69347
6.5
1.4
0.0
5.1
0.0
0.0
0.0
______­_________­___­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
MEAN
7.3
1.2
5.9
0.2
S.
D.
1.27
0.0
0.0
0.25
N
1.12
0.14
10
0.02
0.00
10
10
10
10
10
_______­_________­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­~­­­­­­­­­­­­~~­­­~­­­
thous/
uL
=
THOUSANDS/
MICROLITER
%
a
s
193of619
TABLE
26
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
PAGE
4
INDIVIDUAL
LEUKOCYTE
COUNTS
WEEK
13
100
PPM
MALE
________­­­­­­_­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

TOTAL
NEUTRO­
LYMPH­
LEUKOCYTES
PHIL
EOSIN­
OCYTE
ANIMAL
thous/
uL
MONOCYTE
OPHIL
thous/
uL
thous/
uL
BASOPHIL
thous/
uL
thous/
uL
thous/
uL
____­­­­_________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69304
6.3
1.6
4.4
69307
9.0
0.3
1.3
0.0
7.4
0.0
69318
5.6
0.4
1.3
0.0
4.3
0.0
69319
7.4
0.1
1.1
0.0
5.8
0.0
69327
6.0
0.4
1.0
0.1
4.7
0.0
69329
8.0
0.2
1.4
0.0
6.6
0.0
69332
5.8
0.0
0.9
0.0
4.7
0.0
69334
5.6
0.2
1.1
0.0
4.4
0.0
69342
5.6
0.2
1.3
0.0
4.0
0.0
69346
6.8
0.2
1.2
0.0
5.2
0.0
0.3
0.1
0.0
____­____________­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~
MEAN
6.6
1.2
5.1
S.
D.
0.2
1.18
0.0
0.20
1.11
0.0
N
0.13
10
0.03
10
0.00
10
10
10
10
g
­­____________­____­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

thous/
uL
=
THOUSANDS/
MICROLITER
0
Lt
z
195
of
619
TABLE
26
PROJECT
NO.:
WIL­
417002
PO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
PAGE
6
INDIVIDUAL
LEUKOCYTE
COUNTS
WEEK
13
15
PPM
FEMALE
___­_­__________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
TOTAL
NEUTRO­
LYMPH­
LEUKOCYTES
EOSIN­
PHIL
OCYTE
MONOCYTE
ANIMAL
thous/
uL
OPHIL
thous/
uL
thous/
uL
BASOPHIL
thous/
uL
thous/
uL
thous/
uL
69362
5.7
0.9
4.8
0.0
69376
9.0
1.4
0.0
7.5
0.0
0.2
69382
5.7
0.9
0.0
4.6
0.0
69390
5.4
0.2
0.6
0.0
4.6
0.0
0.1
69393
5.4
0.7
0.0
4.6
0.0
69396
0.1
1.0
0.0
3.5
0.0
QUkl;
ITY
NOT
SUFFICIENT
0.2
69409
0.0
0.0
69413
4.5
0.7
3.6
0.2
69435
4.7
0.5
0.0
4.2
0.0
0.0
0.0
0.0
_________________­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
MEAN
5.6
0.8
4.7
S.
D.
0.1
1.44
0.0
0.27
0.0
1.23
N
0.09
8
0.00
8
8
0.00
8
8
8
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
thous/
uL
=
THOUSANDS/
MICROLITER
~3LI~
omIW/
safsnoHL
=
v/
snow
_­­­_­­­__­__­­­­­__­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

8
8
8
8
8
00'0
8
00'0
N
OK.
0
ZE'K
ZZ'O
6P'T
­_
'1:~_____­__­­_________":
0__­­___________­­__":~______________­____
4:"________­­­­­­­­­­­~~~­­­­~­­­~­­­­­­­­­­~~~­­­­­­­­­­­~~~­
'a's
318VNI'FIL00Nll
LTnS3~
YEP69
0'0
0'0
31ffYNIVLLBONn
3TdNVS
K.
0
EEf769
8.9
0'0
K'K
0'0
0'8
8ZP69
2'0
S'Z
0'0
8'0
0.0
S'E
E'O
92869
O'P
0'0
8'0
0'0
K.
S
E.
0
P6E69
E'S
0'0
6'0
0'0
S'P
88E69
Z'O
P'P
0'0
L'O
0'0
Z'S
K'O
08E69
S'P
0'0
6'0
0`
0
S'S
T.
0
OLE69
P'E
L`
O
S'P
__":"_____­______­­­____":"_____________­­­­­­~~~­­­­­~­­­­­~­­­~­­­~~~­­­­­­­~­­~­­­­­­­­~~~­~­­~­­­­­­­­~­­­~­~~~­­­­­­­­~~~~~­~­
69E69
m/
snoq3
m/
snoya
lnjsnoy?
w/
snow
m/
snow
TIHdOSV8
Tn/
snoy>
TIHdO
TiWINv
3LA30NOW
3LA30
TIHd
­NISOS
S3~
h~
OXfl31
­HdWAT
­08Ln3N
lb­
LO6
_­­­­_­___­_____­­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
31VW3d
Wdd
OP
EK
X33M
L
smnoa
3Lh3oxn37
wnaImaN1
33Vd
3XOd
XSBL
dVH:
XOSNOdS
331W
'9
SLYkl
NI
Xd
HLIM
SLV8
NI
3X­
Z'I'T
d0
hCInX­
5
'TVHNI
hVCI­
06
ZOOLKP­
'IIM:
'ON
LL33POXd
92
318V.
L
1980f
619
TABLE
27
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
1
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
SERUM
CHEMISTRY
VALUES
WEEK
13
__­__­____­__­­___­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­~­­­­­~­­­­­­­~­~~­­­
ALBUMIN
TOTAL
GLOBULIN
A/
G
TOTAL
UREA
CREAT­
ALKALINE
ALANINE
ASPARTAT
GLUTAMYL
ANIMAL
PROTEIN
RATIO
BILI
NITROGEN
ININE
PHOS'TSE
TRANSFER
TRANSFER
TRANSFER
_________________
9!"~­­­­­­~!~~­­­­­­~!~~­­­­­­­­­~­­­­­~~!~~­­­­­~~!~~­­­­­~~!~~­­­­­­~!~­­­­­­­~!~~­­­­­­~!~­­­­­­­~!~­­­­­­­­­­­
GROUP:
0
PPM
MALES
69302
4.2
69306
4.6
69308
4.6
69310
4.3
69312
3.9
69314
3.9
69317
3.9
69322
4.3
69337
4.3
69343
4.1
7
I
4
3
2
1.31
0.2
13.8
0.2
85
106.
174.
0.
3
3
7
1.24
0.3
17.2
0.3
110
105.
144.
0.
0
3
4
1.35
0.4
19.3
0.3
96
86.
114.
0.
1
2
8
1.54
0.1
13.8
0.2
106
64.
106.
0.
4
2
5
1.56
0.1
15.3
0.0
76
51.
68.
0.
6
2
7
1.44
0.1
16.6
0.3
85
62.
85.
0.
8
2
9
1.34
0.1
17.3
0.2
68
63.
102.
0.
3
3
0
1.43
0.1
15.6
0.3
94
55.
84.
0.
4
3
1
1.39
0.1
18.9
0.2
101
51.
83.
0.
6
3
5
1.17
0.2
17.2
0.3
112
56.
100.
0.

MEAN
4.2
7.3
3.1
1.38
0.2
16.5
0.2
93.
70.
106.
0.
S.
D.
0.26
0.60
0.38
0.123
0.11
1.89
0.09
14.7
21.3
31.8
0.0
______"
1'_­____­____""________
4"________~~­­­­~­­­~~­­­­­­­­~~­­­­­­­­~~­­­­­­­­~~­­­­­­­­~~­~­­­­­­~~­­­­~­­­~~­­­­~~­­~~­­­­­­­­­­­
U/
L
=
INTERNATIONAL
UNIT/
LITER,
g/
dL
=
GRAMS/
DECILITER,
mg/
dL
=
MILLIGRAMS/
DECILITER
TABLE
27
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
2
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
SERUM
CHEMISTRY
VALUES
WEEK
13
_______________­___­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GLUCOSE
CHOL­
CALCIUM
CHLORIDE
PHOS­
POTAS­
SODIUM
TRIGLY­
ANIMAL
ESTEROL
PHORUS
SIUM
CERIDE
__­_____________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

_­______________
m4!"~­~­­­~~!~~­­­~­~~!~~­­­­­­~~~!~­­­­­­­­­­­­­­~­~­­­­­­­­­­­­­­­­­~~!~~­­­­­­­­~­­­­­­­­­­­­­­­­~­­~­­­­­­­­~­­
mg/
dL
mEq/
L
mEq/
L
GROUP:
0
PPM
MALES
69302
181.
52.
11
8
100.
11.8
5
59
150
70.
69306
143.
56.
12
3
98.
14.0
5
81
153
142.
69308
126.
50.
11
7
101.
12.8
7
68
149
116.
69310
165.
43.
11
3
102.
9.8
5
89
151
78.
69312
144.
54.
10
a
102.
9.0
4
15
148
51.
69314
161.
46.
10
8
102.
8.4
4
66
148
58.
69317
136.
58.
11
0
102.
9.3
5
53
147
100.
69322
152.
53.
11
1
103.
8.7
5
63
148
38.
63337
163.
53.
11
I
101.
11.5
5
74
149
84.
69343
146.
61.
11
5
100.
10.3
5
72
148
80.

g
MEAN
S.
D.
152.
16.1
53.
5.3
11.5
0.51
101.
1.4
10.6
5.64
149.
1.89
0.911
1.8
27.3
88.

0
%
______"__________­
1"________""________
'"­­­~­­­­~~­­­­­­­­~~­­­­­­­­~~­­­­­­­­~~­­­­­­­­~~­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­
mg/
dL
=
MILLIGRAMS/
DECILITER,
mEq/
L
=
milliEquivalents/
Liter
0­
J
s
TABLE
27
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
3
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
SERUM
CHEMISTRY
VALUES
WEEK
13
___­__­­___

ALBUMIN
TOTAL
GLOBULIN
A/
G
TOTAL
UREA
CREAT­
ALKALINE
ALANINE
ASPARTAT
GLUTAMYL
ANIMAL
PROTEIN
RATIO
BILI
NITROGEN
ININE
PHOS'TSE
TRANSFER
TRANSFER
TRANSFER
___­­_­_________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

mg/
dL
mg/
dL
mg/
dL
U/
L
U/
L
U/
L
U/
L
GROUP:
15
PPM
MALES
69305
69316
69320
69323
69326
69335
69336
69338
69345
69347
g
MEAN
S.
D.

;;
N
_­­_______

2
s
4.8
8.2
3.4
41
4.6
8.1
3.5
31
4.0
6.6
2.6
54
4.3
1.3
3.0
43
4.2
7.3
3.1
35
4.1
7.1
3.0
37
4.1
7.0
2.9
1
41
4.3
7.5
3.2
1
34
4.1
7.2
3.1
1
32
4.2
7.5
3.3
1
21
4.3
7.4
3.1
1.38
0.25
0.48
0.26
0.077
10
10
10
10
.____________­_­__­_____________________­­
U/
L
=
INTERNATIONAL
UNIT/
LITER,
g/
dL
0.2
14.6
0.4
17.2
0.1
14.1
0.1
15.7
0.2
17.5
0.1
17.5
0.1
16.6
0.2
17.3
0.1
15.9
0.1
17.2
0.2
16.4
0.10
1.24
10
10
__________­­­­­­­­­
=
GRAMS/
DECILITER,
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
2
114.
3
98.
2
86.
3
95.
2
91.
2
89.
3
92.
3
94.
2
84.
2
95.
75.
109.
66.
98.
74.
98.
89.
136.
78.
118.
55.
80.
74.
96.
58.
86.
62.
86.
71.
110.

0.2
94.
70.
0.05
8.3
10.2
10
10
10
._____­___­­__________________

mg/
dL
=
MILLIGRAMS/
DECILITER
102.
17.0
10
_­_­­­­­­­­­
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
27
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
SERUM
CHEMISTRY
VALUES
PAGE
4
WEEK
13
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GLUCOSE
CHOL­
CALCIUM
CHLORIDE
PHOS­
POTAS­
SODIUM
TRIGLY­
ANIMAL
ESTEROL
PHORUS
SIUM
CERIDE
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

________________
m~!~~~~~­~~~!~~­­­~­~~!~~­­~­­~~~~!~~­­­~~!~~­­­­~­~~~!~­­­­­~~~!~­~­­~~!~~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GROUP:
15
PPM
MALES
69305
69316
69320
69323
69326
69335
69336
69338
69345
69347
148.
170.
124.
176.
132.
154.
167.
131.
176.
128.
51.
70.
51.
63.
58.
52.
59.
49.
67.
57.
12
12
11
11
11
11
11
11
11
11
9
100.
14.5
6
48
155
101
0
100.
12.6
6
46
149
179
0
101.
8.4
5
22
148
74
5
100.
8.2
5
38
148
104
0
99.
9.3
4
27
146
107
7
101.
10.5
5
62
148
84
5
98.
9.5
6
01
146
135
4
98.
10.5
4
81
149
60
8
100.
9.8
5
97
148
49
6
100.
11.4
6
09
147
52
MEAN
151.
58.
11.6
100.
10.5
5.63
148.
95.
S.
D.
20.8
7.2
0.54
1.1
1.94
0.718
2.5
40.4
__­___"____­__­___
'"________
'"________
'"­­­­~­­­~~­~­­­­­­~~­­­­­­­­~~­­­­~~­­~~~­­­­­~~~~­­­­­­­­­­­­­­­~­­­­­­~­­­­~­­­­­­­­­­­­­
mg/
dL
=
MILLIGRAMS/
DECILITER,
mEq/
L
=
milliEquivalents/
Liter
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
5
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
SERUM
CHEMISTRY
VALUES
WEEK
13
TABLE
27
ALBUMIN
TOTAL
GLOBULIN
A/
G
TOTAL
UREA
CREAT­
ALKALINE
ALANINE
ASPARTAT
GLUTAMYL
ANIMAL
PROTEIN
RATIO
BILI
NITROGEN
ININE
PHOS`
TSE
TRANSFER
TRANSFER
TRANSFER
________­_____­­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

g/
dL
LT/
dL
ddL
mg/
dL
mg/
dL
mg/
dL
U/
L
U/
L
U/
L
U/
L
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GROUP:
40
PPM
MALES
69303
4.4
7.5
3.1
1.42
0
2
69309
4.2
7.0
2.8
1.50
0
1
69313
4.3
7.9
3.6
1.19
0
3
69315
4.4
7.6
3.2
1.38
0
1
69324
4.1
6.9
2.8
1.46
0
1
69328
4.0
6.9
2.9
1.38
0
1
69339
4.6
7.7
3.1
1.48
0
2
69344
3.8
6.6
2.8
1.36
0
1
69348
4.4
7.6
3.2
1.38
0
1
69350
3.8
6.4
2.6
1.46
0
1
MEAN
S.
D.
N
4.2
7.2
3.0
0.27
0.51
0.29
10
10
10
U/
L
=
INTERNATIONAL
UNIT/
LITER,
1.40
0.1
15.8
0.2
92.
79.
0.089
0.07
1.62
0.09
9.9
35.7
10
10
10
10
10
10
_______________­­_________
____­_______­­____________________
g/
dL
=
GRAMS/
DECILITER,
mg/
dL
=
MILLIGRAMS/
DECILITER
.­_
13
15
15
14
18
14
18
16
14
16
6
:3
0.2
0.2
7
:6
0.3
0.2
.4
0.3
5
:3
0.0
0.3
.6
0.2
7
:6
0.2
0.1
97.
63
107.
88.
70
97.
87.
163
347.
97.
64
83.
98.
59
86.
82.
62
85.
113.
98
170.
81.
54
78.
94.
111
128.
83.
45
66.

125.
83.7
10
__­__­­___
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.

0.
0.0
10
______­_____­­_
TABLE
27
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
6
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
SERUM
CHEMISTRY
VALUES
WEEK
13
______________­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GLUCOSE
CHOL­
CALCIUM
CHLORIDE
PHOS­
POTAS­
SODIUM
TRIGLY­
ANIMAL
ESTEROL
PHORUS
SIUM
CERIDE
____­­­­­_­_____
m~!"~­­­­~~~!~~­­~­­~~!~~­­­­­­~~~!~­­­­~~!~~­­­­­­~~~!~­­­­­~~~!~­­­­~~!~~­­­­­­­­~~­­­­­­­­­­­­­~­~­­­~~­­­­­­­­~
GROUP:
40
PPM
MALES
69303
179.
54.
12.2
99
12.6
6
29
148
­69
69309
142.
53.
11.5
99
10.3
5
55
148
53
69313
153.
67.
12.2
98
13.9
5
58
150
94
69315
148.
54.
11.9
98
12.5
7
39
148
62
69324
152.
57.
11.2
101
9.1
5
21
148
100
69328
144.
57.
11.7
100
10.9
6
27
148
34
69339
134.
48.
11.9
100
13.3
5
97
151
79
69344
150.
54.
11.4
99
10.5
5
28
147
47
69348
193.
55.
11.8
100
12.5
8
61
146
61
69350
141.
46.
11.0
103
9.9
5
26
148
36
MEAN
154.
55.
11.7
100.
11.6
6.14
148.
64.
S.
D.
18.3
5.6
0.40
1.5
1.61
1.094
1.4
22.5
f%
______"____­______""________
'"________""­­­­­­­­~~­­­­­­­­~~­­­­­­­­~~­­­­­­­­~~~­­­­­­­~~­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­
mg/
dL
=
MILLIGRAMS/
DECILITER,
ch
mEq/
L
=
milliEquivalents/
Liter
;;
TABLE
27
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
Ez
MICE
PAGE
7
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
SERUM
CHEMISTRY
VALUES
WEEK
13
ALBUMIN
TOTAL
GLOBULIN
A/
G
TOTAL
UREA
CREAT­
ALKALINE
ALANINE
ASPARTAT
GLUTAMYL
ANIMAL
PROTEIN
RATIO
BILI
NITROGEN
ININE
PHOS'TSE
TRANSFER
TRANSFER
TRANSFER
g/
dL
g/
dL
g/
dL
mg/
dL
mg/
dL
w/
dL
U/
L
U/
L
U/
L
U/
L
GROUP:
100
PPM
MALES
69304
4.1
69307
4.6
69318
4.2
69319
4.3
69327
3.9
69329
4.6
69332
3.7
69334
4.4
69342
4.2
69346
4.7
7.0
8.0
7.3
7.1
6.5
7.9
6.2
7.6
7.0
8.2
2.9
1.41
0.1
15.2
3.4
1.35
0.3
14.4
3.1
1.35
0.1
13.9
2.8
1.54
0.1
13.5
2.6
1.50
0.1
14.5
3.3
1.39
0.1
14.7
2.5
1.48
0.1
14.2
3.2
1.38
0.2
17.9
2.8
1.50
0.1
15.2
3.5
1.34
0.4
15.3
kz
MEAN
4.3
7.3
3.0
S.
D.
0.32
0.65
0.34
ti
N
10
10
10
%
____________­_­____­_____________
_­________
U/
L
=
INTERNATIONAL
UNIT/
LITER,
6\
1.42
0.074
10
g/
dL
0.2
14.9
0.11
1.21
10
10
=
GRAMS/
DECILITER,
.­­
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
2
95.
101.
116.
3
103.
102.
213.
2
84.
56.
75.
2
93.
57.
88.
2
91.
56.
85.
3
96.
94.
167.
1
79.
46.
69.
2
100.
79.
110.
2
92.
96.
118.
2
109.
115.
136.

0.2
94.
80.
0.06
8.7
24.6
10
10
10
mg/
dL
=
MILLIGRAMS/
DECILITER
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.

118.
0.
44.8
0.0
10
10
__­­_­_________
TABLE
27
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
8
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
SERUM
CHEMISTRY
VALUES
WEEK
13
_________­_­_­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GLUCOSE
CHOL­
CALCIUM
CHLORIDE
PHOS­
POTAS­
SODIUM
TRIGLY­
ANIMAL
ESTEROL
PHORUS
SIUM
CERIDE
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GROUP:
100
PPM
MALES
69304
126
59.
11
7
100.
11
4
5.75
148.
45.
69307
166
66.
12
6
98.
14
6
6.12
152.
105.
69318
125
65.
11
7
99.
12
0
5.85
147.
78.
69319
138
67.
11
7
99.
10
2
5.52
148.
34.
69327
136
64.
10
9
101.
9
7
4.56
147.
81.
69329
168
58.
12
8
97.
13
1
7.22
150.
67.
69332
133
59.
10
8
102.
9
9
5.10
147.
37.
69334
173
66.
12
5
100.
14
9
8.45
150.
67.
69342
138
66.
11
4
102.
9
8
5.04
148.
64.
69346
157
63.
12
3
101.
14
4
8.30
150.
65.

!s
MEAN
146.
63.
11.8
100.
12.0
6.19
149.
S.
D.
18.2
3.4
0.70
1.7
2.12
1.356
1.7
m
N
10
10
10
10
10
10
10
%
_­­____________­­­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
mg/
dL
=
MILLIGRAMS/
DECILITER,
mEq/
L
=
milliEquivalents/
Liter
ch
s
64.
21.5
10
TABLE
21
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
9
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
SERUM
CHEMISTRY
VALUES
WEEK
13
ALBUMIN
TOTAL
GLOBULIN
A/
G
TOTAL
UREA
CREAT­
ALKALINE
ALANINE
ASPARTAT
GLUTAMYL
ANIMAL
PROTEIN
RATIO
BILI
NITROGEN
ININE
PHOS'TSE
TRANSFER
TRANSFER
TRANSFER
___­­_____­___­­________________________­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

g/
dL
g/
dL
g/
dL
W/
dL
mg/
dL
w/
a
U/
L
U/
L
U/
L
U/
L
____­­_____­­___­_______________________­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­
GROUP:
0
PPM
FEMALES
69354
4.0
7.2
69366
3.9
6.5
69367
4.1
QNS
69378
3.8
6.3
69384
3.8
6.7
69398
3.9
6.5
69404
3.8
6.4
69416
su
su
69419
4.3
7.2
69432
3.8
6.4
3.2
;iG
2.5
2.9
2.6
2.6
su
2.9
2.6
1.25
0.1
15.2
0.1
80.
40.
81.
1.50
0.1
15.3
0.2
58.
67.
117.
QNS
QNS
QNS
QNS
50.
98.
296.
1.52
0.1
19.2
0.2
67.
43.
73.
1.31
0.3
18.2
0.2
60.
82.
163.
1.50
0.3
13.5
0.2
69.
46.
252.
1.46
0.2
13.9
0.2
57.
39.
75.
su
su
su
su
su
su
SU
1.48
0.3
20.5
0.2
53.
63.
117.
1.46
0.1
13.4
0.1
87.
37.
72.
1.
0.
0.
0.
1.
0.
0.
su
0.
0.

MEAN
3.9
6.7
2.7
1.44
0.2
16.2
0.2
65.
57.
138.
0.
S.
D.
0.17
0.36
0.24
0.099
0.10
2.77
0.05
12.4
21.7
83.1
0.4
N
9
8
8
8
8
8
8
9
9
9
9
K
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
z
QNS
=
QUANTITY
NOT
SUFFICIENT,
SU
=
SAMPLE
UNOBTAINABLE
\o
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
U/
L
=
INTERNATIONAL
UNIT/
LITER,
g/
dL
=
GRAMS/
DECILITER,
mg/
dL
=
MILLIGRAMS/
DECILITER
TABLE
27
PROJECT
NO.:
WIL­
417002
YO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
10
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
SERUM
CHEMISTRY
VALUES
WEEK
13
_­_­_­_­_______­_­_­____________________­­­­­­­­­~~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GLUCOSE
CHOL­
CALCIUM
CHLORIDE
PHOS­
POTAS­
SODIUM
TRIGLY­
ANIMAL
ESTEROL
PHORUS
SIUM
CERIDE
__­__­_­­_­__­_­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GROUP:
0
PPM
FEMALES
69354
69366
69367
69378
69384
69398
69404
69416
69419
69432
140.
136.
107.
122.
115.
124.
125.
su
146.
102.
80.
11.8
101.
70.
10.9
104.
QNS
QNS
QNS
74.
10.4
105.
76.
10.8
103.
73.
10.6
104.
64.
10.8
102.
su
su
su
85.
11.4
103.
66.
11.5
103.
10.9
;,:
8.3
10.6
9.4
8.9
su
10.8
10.7
7.06
147.
41.
5.82
146.
24.
QNS
QNS
45.
4.79
148.
31.
4.98
146.
24.
5.25
146.
34.
5.38
146.
27.
su
su
su
5.94
146.
30.
6.18
148.
26.

MEAN
124.
74.
11.0
103.
9.7
5.68
147.
31.
S.
D.
14.8
7.0
0.49
1.2
1.28
0.737
0.9
7.4
N
9
8
8
8
8
8
8
9
_­__­_______­___________________________­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
QNS
=
QUANTITY
NOT
SUFFICIENT,
SU
=
SAMPLE
UNOBTAINABLE
_________________­­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

mg/
dL
=
MILLIGRAMS/
DECILITER,
mEq/
L
=
milliEquivalents/
Liter
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
27
YO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
SERUM
CHEMISTRY
VALUES
PAGE
11
WEEK
13
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­~­­­­­­­­­~­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ALBUMIN
TOTAL
GLOBULIN
A/
G
TOTAL
UREA
CREAT­
ALKALINE
ALANINE
ASPARTAT
GLUTAMYL
ANIMAL
PROTEIN
RATIO
BILI
NITROGEN
ININE
PHOS'TSE
TRANSFER
TRANSFER
TRANSFER
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­

____________­____
9!"~­­­­­­~!~~­­­­­­~!~~­­­­­­­­­­­­­­­~~!~~­~~­­­­­~~­­­­­­­­­­­­­­­­~!~­­­­­­­­­­­­­­­­­­~~­~­­~~~~!~­~~­~~~~~~~
W/
dL
V/
dL
U/
L
U/
L
GROUP:
15
PPM
FEMALES
69362
3.4
5.7
69376
4.0
6.6
69382
4.0
6.7
69390
3.1
6.0
69393
4.1
7.1
69396
3.9
6.7
69409
4.2
7.0
69413
3.9
6.6
69435
4.3
7.2
2
2
3
1.48
6
1.54
7
1.48
3
1.61
0
1.37
8
1.39
8
1.50
7
1.44
9
1.48
2
16
3
16
1
16
1
17
2
17
2
16
4
17
1
17
2
15
0.2
65.
44.
75
0.3
79.
60.
159
0.1
71.
52.
89
0.1
59.
46.
79
0.1
69.
48.
83
0.2
62.
61.
199
0.2
72.
51.
148
0.1
70.
41.
74
0.2
62.
48.
92
MEAN
3.9
6.6
2.7
1.48
0.2
17.0
0.2
68.
50.
111.
0.

g
0.24
S.
D.
N
0.27
9
0.49
9
9
0.073
9
0.10
9
0.72
9
0.07
9
6.2
9
6.8
9
45.7
9
0.5
9
\o
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

0,
U/
L
=
INTERNATIONAL
UNIT/
LITER,
g/
dL
=
GRAMS/
DECILITER,
mg/
dL
=
MILLIGRAMS/
DECILITER
m
6
I
.
.
.
.
.
.
.
.
.

210
of
619
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
27
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
SERUM
CHEMISTRY
VALUES
PAGE
13
WEEK
13
__________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ALBUMIN
TOTAL
GLOBULIN
A/
G
TOTAL
UREA
CREAT­
ALKALINE
ALANINE
ASPARTAT
GLUTAMYL
ANIMAL
PROTEIN
RATIO
BILI
NITROGEN
ININE
PHOS'TSE
TRANSFER
TRANSFER
TRANSFER
______________­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GROUP:
40
PPM
FEMALES
69359
4.3
7.3
3.0
1.43
0.3
19.8
69369
3.8
6.3
2.5
1.52
0.1
15.4
69370
4.1
7.1
3.0
1.37
0.7
18.1
69380
3.7
6.4
2.7
1.37
0.1
16.8
69388
4.4
7.6
3.2
1.38
0.2
19.2
69394
4.0
6.6
2.6
1.54
0.1
16.6
69426
4.2
7.3
3.1
1.35
0.1
17.7
69428
4.0
6.9
2.9
1.38
0.1
17.5
69433
su
su
su
su
su
su
69436
4.2
7.2
3.0
1.40
0.1
16.2
MEAN
4.1
7.0
2.9
1.42
0.2
17.5
S.
D.
0.23
0.45
0.24
0.069
0.20
1.41
N
9
9
9
9
9
9
0.3
0.1
0.3
0.2
0.2
0.2
0.2
0.2
su
0.3
0.2
0.07
9
U/
L
U/
L
U/
L
U/
L
___­­­­_____­____­_­____________________­­~­­

68.
73.
122.
0.
69.
35.
71.
0.
62.
56.
109.
0.
61.
42.
71.
0.
63.
65.
112.
0.
76.
49.
85.
0.
69.
52.
86.
0.
84.
55.
90.
1.
su
su
su
su
75.
65.
93.
2.

70.
55.
93.
0.
7.5
11.9
17.8
0.7
9
9
9
9
___­­_­­_­__________________________
SU
=
SAMPLE
UNOBTAINABLE
_­_­_­__­­__________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
U/
L
=
INTERNATIONAL
UNIT/
LITER,
g/
dL
=
GRAMS/
DECILITER,
mg/
dL
=
MILLIGRAMS/
DECILITER
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
27
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
SERUM
CHEMISTRY
VALUES
PAGE
14
WEEK
13
_____­­­­__­___­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GLUCOSE
CHOL­
CALCIUM
CHLORIDE
PHOS­
POTAS­
SODIUM
TRIGLY­
ANIMAL
ESTEROL
PHORUS
SIUM
CERIDE
_______­________­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

KJ/
dL
mg/
dL
W/
dL
mEq/
L
W/
dL
mEq/
L
mEq/
L
w/
dL
GROUP:
40
PPM
FEMALES
69359
69369
69370
69380
69388
69394
69426
69428
69433
69436
101.
116.
142.
125.
98.
110.
108.
107.
su
135.
86.
68.
84.
85.
99.
88.
93.
78.
su
83.
11.7
10.6
11.3
10.8
12.0
11.4
11.2
11.3
su
12.0
102.
105.
106.
103.
100.
102.
104.
103.
su
103.
13.4
9.3
13.3
9.0
12.9
9.5
8.9
10.8
su
11.6
7.07
5.21
7.62
4.92
7.20
5.77
5.99
6.17
su
7.39
149.
149.
148.
146.
147.
148.
149.
147.
su
148.
31.
25.
39.
24.
31.
21.
27.
22.
su
37.

MEAN
116.
85.
11.4
103.
11.0
6.37
148.
29.
S.
D.
15.2
8.8
0.48
1.8
1.89
0.986
1.1
6.4
N
9
9
9
9
9
9
9
9
__________­­____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
SU
=
SAMPLE
UNOBTAINABLE
___________­­___________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~­­­­­­­­­­­­­­­­­­­­­­­~~­­~~~­­
mg/
dL
=
MILLIGRAMS/
DECILITER,
­
mEq/
L
=
milliEquivalents/
Liter
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
27
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
SERUM
CHEMISTRY
VALUES
PAGE
15
WEEK
13
ALBUMIN
TOTAL
GLOBULIN
A/
G
TOTAL
UREA
CREAT­
ALKALINE
ALANINE
ASPARTAT
GLUTAMYL
ANIMAL
PROTEIN
RATIO
BILI
NITROGEN
ININE
PHOS'TSE
TRANSFER
TRANSFER
TRANSFER
______­__­_____­__­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ddL
sJ/
dL
g/
a
mg/
dL
mg/
dL
mg/
dL
U/
L
U/
L
U/
L
U/
L
­_­__­_____­___­__­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GROUP:
100
PPM
FEMALES
69375
4.4
69379
4.4
69383
4.3
69385
4.0
69392
3.9
69402
4.2
69408
3.9
69415
4.1
69427
su
69431
4.3
7.9
7.5
7.1
6.4
6.4
7.2
6.4
6.8
su
7.2
3.5
1.26
3.1
1.42
2.8
1.54
2.4
1.67
2.5
1.56
3.0
1.40
2.5
1.56
2.7
1.52
su
su
2.9
1.48
0.7
0.4
0.1
0.1
0.1
0.1
0.1
0.2
su
0.2
20.0
0.3
14.2
0.2
15.8
0.2
17.6
0.2
16.4
0.1
16.3
0.2
16.1
0.1
18.4
0.3
su
su
17.2
0.3
83.
73.
60.
62.
78.
66.
14.
70.
su
75.
70.
293.
51.
119.
45.
83.
43.
74.
40.
81.
50.
82.
50.
85.
49.
127.
su
SU
47.
84.
0.
0.
0.
0.
0.
0.
1.
0.
su
1.

MEAN
4.2
7.0
2.8
1.49
0.2
16.9
0.2
71.
49.
114.
0.
S.
D.
0.20
0.53
0.35
0.118
0.20
1.67
0.08
7.5
8.5
69.5
0.4
N
9
9
9
9
9
9
9
9
9
9
9
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
SU
=
SAMPLE
UNOBTAINABLE
_______­______­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
U/
L
=
INTERNATIONAL
UNIT/
LITER,
g/
dL
=
GRAMS/
DECILITER,
mg/
dL
=
MILLIGRAMS/
DECILITER
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
27
PO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
SERUM
CHEMISTRY
VALUES
PAGE
16
WEEK
13
__­­­­______­_______­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GLUCOSE
CHOL­
CALCIUM
CHLORIDE
PHOS­
POTAS­
SODIUM
TRIGLY­
ANIMAL
ESTEROL
PHORUS
SIUM
CERIDE
__­­­­___________­__­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GROUP:
100
PPM
FEMALES
69375
76.
89.
12.0
QNS
13.9
QNS
QNS
34.
69379
97.
90.
12.1
101.
14.5
6.42
151.
38.
69383
114.
87.
11.7
101.
10.8
6.20
148.
24.
69385
98.
78.
10.8
104.
9.2
5.22
148.
23.
69392
113.
83.
10.9
102.
10.2
6.33
147.
22.
69402
113.
97.
11.9
99.
11.8
6.25
146.
29.
69408
118.
92.
11.2
99.
10.0
5.81
144.
29.
69415
114.
78.
11.0
102.
11.0
4.31
147.
33.
69427
su
su
su
su
su
su
su
,su
69431
109.
81.
11.3
105.
10.6
6.52
148.
30.

MEAN
S.
D.
N
106.
13.3
9
86.
11.4
102.
11.3
5.88
147.
29.
6.6
0.50
2.1
1.78
0.760
2.0
5.4
9
9
8
9
8
8
9
____­________­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

QNS
=
QUANTITY
NOT
SUFFICIENT,
SU
=
SAMPLE
UNOBTAINABLE
_____________­­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

mg/
dL
=
MILLIGRAMS/
DECILITER,
mEq/
L
=
milliEquivalents/
Liter
PCHEv4.01
01/
18/
2002
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
28
(WEEK
­1
PRETEST
EVALUATION)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
OPHTHALMIC
EXAMINATION
FINDINGS
PAGE
1
______­­­________­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­~­­­­­­~~~­­­­­­~~­~~­~­­­­
EXAMINER:
DAW
INPUT
BY:
JLK
EXAM
l(
WEEK
­1)
ANIMAL
NO.
DOSE
GROUP
SEX
FINDING
GRADE
__­________­____________________________­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­~­­~~­­­~­­

69302
0
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69306
0
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69308
0
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69310
0
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69312
0
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69314
0
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69317
0
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69322
0
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69337
0
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69343
0
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69305
15
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69316
15
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69320
15
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69323
15
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69326
15
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69335
15
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69336
15
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69338
15
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69345
15
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69347
15
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69303
40
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69309
40
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69313
40
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69315
40
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
SEVERE,
P­
PRESENT,
O.
D.­
RIGHT
EYE,
O.
S.­
LEFT
EYE
TABLE
28
(WEEK
­I
PRETEST
EVALUATION)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
2
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
OPHTHALMIC
EXAMINATION
FINDINGS
_____­____­­_______­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
EXAMINER:
DAW
INPUT
BY:
JLK
EXAM
l(
WEEK
­1)
ANIMAL
NO.
DOSE
GROUP
SEX
FINDING
GRADE
__­_____­_______________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69324
40
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69328
40
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69339
40
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69344
40
RPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69348
40
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69350
40
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69304
100
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69307
100
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69318
100
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69319
100
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69327
100
PPM
69329
100
PPM
MALE
C~
RNEAL
CRYSTALS
­
BILATERAL
i
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69332
100
PPM
69334
100
PPM
69342
100
PPM
69346
100
PPM
69354
0
PPM
69366
0
PPM
69367
0
PPM
69378
0
PPM
69384
0
PPM
69398
0
PPM
69404
0
PPM
69416
0
PPM
MALE
MALE
MALE
MALE
FEMALE
FEMALE
FEMALE
FEMALE
FEMALE
FEMALE
FEMALE
FEMALE
CORNEAL
CRYSTALS
CORNEAL
CRYSTALS
CORNEAL
CRYSTALS
CORNEAL
CRYSTALS
CORNEAL
CRYSTALS
CORNEAL
CRYSTALS
CORNEAL
CRYSTALS
CORNEAL
CRYSTALS
CORNEAL
CRYSTALS
CORNEAL
CRYSTALS
CORNEAL
CRYSTALS
CORNEAL
CRYSTALS
­
BILATERAL
­
BILATERAL
­
BILATERAL
­
BILATERAL
­
BILATERAL
­
BILATERAL
­
BILATERAL
­
BILATERAL
­
BILATERAL
­
BILATERAL
­
BILATERAL
­
BILATERAL
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
SEVERE,
P­
PRESENT,
O.
D.­
RIGHT
EYE,
O.
S.­
LEFT
EYE
TABLE
28
(WEEK
­1
PRETEST
EVALUATION)
PROJECT
NO.:
WIL­
417002
VO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
3
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
OPHTHALMIC
EXAMINATION
FINDINGS
EXAMINER:
DAW
INPUT
BY:
JLK
ANIMAL
NO.
DOSE
GROUP
SEX
69419
0
PPM
FEMALE
69432
0
PPM
FEMALE
69362
15
PPM
FEMALE
69376
15
PPM
FEMALE
69377
15
PPM
FEMALE
69382
15
PPM
FEMALE
69390
15
PPM
FEMALE
69393
15
PPM
FEMALE
69396
15
PPM
FEMALE
69409
15
PPM
FEMALE
69413
15
PPM
FEMALE
69435
15
PPM
FEMALE
69359
40
PPM
FEMALE
69369
40
PPM
FEMALE
69370
40
PPM
FEMALE
t9
69380
40
PPM
FEMALE
2
69388
69394
40
40
PPM
PPM
FEMALE
FEMALE
%
69426
40
PPM
FEMALE
69428
40
PPM
FEMALE
a
69433
40
PPM
FEMALE
G
69436
40
PPM
FEMALE
69375
100
PPM
FEMALE
69379
100
PPM
FEMALE
EXAM
l(
WEEK
­1)
FINDING
GRADE
­­_________________­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CORNEAL
CRYSTALS
­
BILATERAL
1
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
SEVERE,
P­
PRESENT,
O.
D.­
RIGHT
EYE,
O.
S.­
LEFT
EYE
TABLE
28
(WEEK
­1
PRETEST
EVALUATION)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
4
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
OPHTHALMIC
EXAMINATION
FINDINGS
_____________­­­­­_­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­~~­~­­­­­­
EXAMINER:
DAW
INPUT
BY:
JLK
EXAM
~(
WEEK
­1)
ANIMAL
NO.
DOSE
GROUP
SEX
FINDING
GRADE
69383
100
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69385
100
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69392
100
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69402
100
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69408
100
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69415
100
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69427
100
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69431
100
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
SEVERE,
P­
PRESENT,
O.
D.­
RIGHT
EYE,
O.
S.­
LEFT
EYE
PEXv4.0
01/
18/
2002
TABLE
29
(WEEK
12
EVALUATION)
PROJECT
NO.:
WIL­
417002
PO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
PAGE
1
INDIVIDUAL
OPHTHALMIC
EXAMINATION
FINDINGS
­­_______­­__­_____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­
EXAMINER:
DAW
INPUT
BY:
HGG
EXAM
2(
WEEK
12)
ANIMAL
NO.
DOSE
GROUP
SEX
FINDING
GRADE
­­___________­____­_____________________­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­~­­­­
69302
0
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69306
0
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69308
0
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69310
0
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69312
0
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69314
0
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69317
0
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69322
0
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69337
0
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69343
0
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69305
15
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69316
1
15
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69320
15
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69323
15
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69326
1
15
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69335
1
15
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69336
15
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69338
1
15
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69345
1
15
PPM
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69347
15
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69303
40
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69309
40
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69313
40
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
69315
40
PPM
1
MALE
CORNEAL
CRYSTALS
­
BILATERAL
1
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
SEVERE,
P­
PRESENT,
O.
D.­
RIGHT
EYE,
O.
S.­
LEFT
EYE
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
29
(WEEK
12
EVALUATION)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
OPHTHALMIC
EXAMINATION
FINDINGS
PAGE
2
­­­­­­­­­­­­­­­­­­­­____________________­­~­~­­­­­­­­­­­~­­­­­~~~~­­­~­­­­­­­­­­­­­­­­­­­~­~­­­­­~­­­­­­­­­­~~~­­­~­~­­­­~­­­­­­­­­
EXAMINER:
DAW
INPUT
BY:
HGG
EXAM
2(
WEEK
12)
ANIMAL
NO.
DOSE
GROUP
SEX
FINDING
GRADE
69324
40
PPM
MALE
CORNEAL
­
CRYSTALS
BILATERAL
1
69328
40
PPM
MALE
CORNEAL
CRYSTALS
BILATERAL
­
1
69339
40
PPM
MALE
CORNEAL
­
CRYSTALS
BILATERAL
1
69344
40
PPM
MALE
CORNEAL
CRYSTALS
BILATERAL
­
69348
1
40
PPM
MALE
CORNEAL
CRYSTALS
BILATERAL
­
1
69350
40
PPM
MALE
CORNEAL
­
CRYSTALS
BILATERAL
1
69304
100
PPM
MALE
CORNEAL
­
CRYSTALS
BILATERAL
1
69307
100
PPM
MALE
CORNEAL
CRYSTALS
BILATERAL
­
1
69318
100
PPM
MALE
CORNEAL
CRYSTALS
BILATERAL
­
1
69319
100
PPM
MALE
CORNEAL
CRYSTALS
BILATERAL
­
1
69327
100
PPM
MALE
CORNEAL
CRYSTALS
BILATERAL
­
1
69329
100
PPM
MALE
CORNEAL
CRYSTALS
BILATERAL
­
1
69332
100
PPM
MALE
CORNEAL
CRYSTALS
BILATERAL
­
1
69334
100
PPM
MALE
CORNEAL
­
CRYSTALS
BILATERAL
1
69342
100
PPM
MALE
CORNEAL
­
CRYSTALS
BILATERAL
1
69346
100
PPM
MALE
CORNEAL
CRYSTALS
BILATERAL
­
1
CATARACT
­
UNILATERAL
3
O.
S.
69354
0
PPM
FEMALE
CORNEAL
­
CRYSTALS
BILATERAL
1
69366
0
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69367
0
PPM
FEMALE
CORNEAL
­
CRYSTALS
UNILATERAL
1
O.
S.
CORNEAL
CRYSTALS
­
UNILATERAL
2
O.
D.
KERATITIS
­
UNILATERAL
2
O.
D.

CODE:
l­
SLIGHT,
2­
MODERATE,
3­
SEVERE,
P­
PRESENT,
O.
D.­
RIGHT
EYE,
O.
S.­
LEFT
EYE
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
29
(WEEK
12
EVALUATION)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
OPHTHALMIC
EXAMINATION
FINDINGS
PAGE
3
EXAMINER:
DAW
INPUT
BY:
HGG
EXAM
~(
WEEK
12)
ANIMAL
NO.
DOSE
GROUP
SEX
FINDING
GRADE
_­___________­_­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69378
0
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69384
0
PPM
69398
0
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
i
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69404
0
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69416
0
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69419
0
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69432
0
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69362
15
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69376
15
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69382
15
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69390
15
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69393
15
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69396
15
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69409
15
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69413
15
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
8
69435
69359
40
15
PPM
PPM
FEMALE
FEMALE
CORNEAL
CORNEAL
CRYSTALS
CRYSTALS
­
­
BILATERAL
BILATERAL
1
1
r
69369
69370
40
40
PPM
PPM
FEMALE
FEMALE
CORNEAL
CORNEAL
CRYSTALS
CRYSTALS
­
­
BILATERAL
BILATERAL
1
1
r
69380
40
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
cn
69388
40
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
z
69394
40
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69426
40
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
69428
40
PPM
FEMALE
CORNEAL
CRYSTALS
­
BILATERAL
1
I
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
SEVERE,
P­
PRESENT,
O.
D.­
RIGHT
EYE,
O.
S.­
LEFT
EYE
I
TABLE
29
(WEEK
12
EVALUATION)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
4
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
OPHTHALMIC
EXAMINATION
FINDINGS
_____­____­­__­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
EXAMINER:
DAW
INPUT
BY:
HGG
EXAM
2tWEEK
12)
ANIMAL
NO.
DOSE
GROUP
__­­­­____
________________
69433
40
PPM
69436
40
PPM
69375
100
PPM
69379
100
PPM
69383
100
PPM
69385
100
PPM
69392
100
PPM
69402
100
PPM
69408
100
PPM
69415
100
PPM
69427
100
PPM
69431
100
PPM
__
SEX
____­­__________
FEMALE
FEMALE
FEMALE
FEMALE
FEMALE
FEMALE
FEMALE
FEMALE
FEMALE
FEMALE
FEMALE
FEMALE
FINDING
________­____­­_____
CORNEAL
CRYSTALS
­
CORNEAL
CRYSTALS
­
CORNEAL
CRYSTALS
­
CORNEAL
CRYSTALS
­
CORNEAL
CRYSTALS
­
CORNEAL
CRYSTALS
­
CORNEAL
CRYSTALS
­
CORNEAL
CRYSTALS
­
CORNEAL
CRYSTALS
­
CORNEAL
CRYSTALS
­
CORNEAL
CRYSTALS
­
CORNEAL
CRYSTALS
­
BILATERAL
BILATERAL
BILATERAL
BILATERAL
BILATERAL
BILATERAL
BILATERAL
BILATERAL
BILATERAL
BILATERAL
BILATERAL
BILATERAL
GRADE
_______­­____­________

1
1
1
1
1
1
1
1
1
1
1
1
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
SEVERE,
P­
PRESENT,
O.
D.­
RIGHT
EYE,
O.
S.­
LEFT
EYE
PEXv4.0
01/
18/
2002
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
30
(UNSCHEDULED
DEATH)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
1
ANIMAL
NO.
69377
GROUP
2:
15
PPM
FEMALE
EUTH
IN
EXTREMIS
06/
30/
01
DATE
OF
DEATH:
06/
30/
01
STUDY
DAY:
30
GRADE
______________­__­_­____________________­­­­­­­­­­­~­­­­~~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
JEJUNUM
GROSS:
CONTENTS,
DARK
RED
P
LIVER
GROSS:
PALE
P
ALL
LOBES
LUNGS
GROSS:
AREA(
S),
DARK
RED
P
FEW,
IRREGULARLY
SHAPED,
RIGHT
DIAPHRAGMATIC
LOBE
SKIN
GROSS:
MATTING,
RED
P
OCULAR,
BILATERAL
STOMACH
GROSS:
CONTENTS,
DARK
RED
P
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
KIDNEYS
AORTA
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
PANCREAS
OVIDUCTS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SPINAL
CORD
SPLEEN
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PGRHv4.28
01/
18/
2002
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
1
ANIMAL
NO.
69302
GROUP
1:
0
__­______­­­­­­­­.
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
.___
­
____
ABS.(
G)
1.83
8.57
1.89
1.25
0.99
0.55
0.99
2.87
0.1814
0.0451
0.0197
305.
_
_
_
_
_
_
_
_
_
_
REL.
0.600
2.810
0.620
0.410
0.325
0.180
0.325
0.941
0.059
0.015
0.006
PPM
MALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
TESTES
THYMUS
RECTUM
PITUITARY
PROSTATE
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
TABLE
31
(PRIMARY
NECROPSY)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
2
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
MACROSCOPIC
FINDINGS
ANIMAL
NO.
69306
GROUP
1:

________­­­­_­__.
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PAPA
FINAL
BODY
WT(
G)
ABS.
(G)
1.81
8.25
2.09
1.15
0.90
0.53
0.98
3.16
0.1619
0.0595
0.0212
REL.
0.622
2.835
0.718
0.395
0.309
0.182
0.337
1.086
0.056
0.020
0.007
0
PPM
MALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
__________________­_____________________­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
TESTES
THYMUS
RECTUM
PITUITARY
PROSTATE
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
291.
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
3
ANIMAL
NO.
69308
GROUP
1:

___­­____­­­­­_­­­__­­­­­­.
ORGAN
WEIGHT
ABS.(
G)
BRAIN
1.88
LIVER
8.40
KIDNEYS
1.97
LUNGS
1.10
HEART
0.98
SPLEEN
0.58
EPIDIDYMIDES
1.00
TESTES
3.03
0
PPM
MALE
._______­­­___­_____­­­­­­­.
REL.
LUNGS
0.667
2.979
LYMPH
NODE,
TR/
BR
0.699
LYMPH
NODE,
MED
0.390
SKIN
0.348
0.206
NO
SIGNIFICANT
0.355
CHANGES
OBSERVED
1.074
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
GROSS:
AREA(
S),
WHITE
FEW,
IRREGULARLY
SHAPED,
GROSS:
DISCOLORATION,
DARK
RED
GROSS:
DISCOLORATION,
DARK
RED
GROSS:
MATTING,
RED
OCULAR,
LEFT
P
ALL
LOBES
P
P
P
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND.
EXOR
EPIDIDYMIDES
THYMUS
0.1835
0.065
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN'GLANDS
HEART
ADRENAL
GLANDS
0.0627
0.022
ILEUM
JEJUNUM
KIDNEYS
LIVER
THYROIDS/
PARA
0.0208
0.007
AORTA
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
FINAL
BODY
WT(
G)
282.
PANCREAS
TESTES
THYMUS
RECTUM
PITUITARY
PROSTATE
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
TABLE
31
(PRIMARY
NECR~
PSY)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
4
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
MACROSCOPIC
FINDINGS
ANIMAL
NO.
69310
GROUP
1:
0
PPM
MALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
_______­­­_____­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ORGAN
WEIGHT
ABS.(
G)
REL.
GENERAL
COMMENT
GROSS:
MECHANICAL
TRAUMA
P
BRAIN
1.73
0.655
DISTAL
TAIL
BROKEN
LIVER
7.35
2.784
NO
SIGNIFICANT
KIDNEYS
1.87
0.708
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
LUNGS
1.15
0.436
COLON
DUODENUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HEART
0.95
0.360
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
0.54
0.205
ILEUM
JEJUNUM
KIDNEYS
LIVER
0.99
0.375
AORTA
LUNGS
LARYNX
NERVE.
SCIATIC
2.79
1.057
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
0.1835
0.070
TESTES
THYMUS
RECTUM
PITUITARY
ADRENAL
GLANDS
0.0546
0.021
PROSTATE
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
THYROIDS/
PARA
0.0112
0.004
SKIN
SPINAL
CORD
SPLEEN
STOMACH
FINAL
BODY
WT(
G)
264.
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
TABLE
31
(PRIMARY
NECROPSY)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
5
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
MACROSCOPIC
FINDINGS
ANIMAL
NO.
69312
GROUP
1:
0
PPM
MALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
_________­­­____
._________.
ORGAN
WEIGHT
ABS.
(G)
BRAIN
1.88
LIVER
8.46
KIDNEYS
2.16
LUNGS
1.25
HEART
1.01
SPLEEN
0.66
EPIDIDYMIDES
1.04
TESTES
3.43
THYMUS
0.2075
ADRENAL
GLANDS
0.0638
THYROIDS/
PARA
0.0148
FINAL
BODY
WT(
G)
316.
._____
­__
REL.
0.595
2.677
0.684
0.396
0.320
0.209
0.329
1.085
0.066
0.020
0.005
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJUNUM
AORTA
LUNGS
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
TESTES
THYMUS
PROSTATE
SAL.
GLAND
MAND
SKIN
SPINAL
CORD
THYROID
GLANDS
TRACHEA
GRADE
BRAIN
CECUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HARDERIAN'GLANDS
HEART
KIDNEYS
LIVER
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
PANCREAS
RECTUM
PITUITARY
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPLEEN
STOMACH
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
TABLE
31
(PRIMARY
NECROPSY)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
6
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
MACROSCOPIC
FINDINGS
ANIMAL
NO.
69314
GROUP
1:
0
PPM
_________________
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
ABS.(
G)
1.74
7.49
1.87
1.19
0.85
0.57
0.90
2.98
0.1740
0.0487
0.0151
281.
REL.
0.619
2.665
0.665
0.423
0.302
0.203
0.320
1.060
0.062
0.017
0.005
MALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
SKIN
GROSS:
MATTING,
RED
P
OCULAR,
LEFT
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
TESTES
THYMUS
RECTUM
PITUITARY
PROSTATE
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
ANIMAL
NO.
69317
GROUP
1:
0
PPM
MALE
­­___­___________
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
____­­___­
ABS.(
G)
1.84
8.37
2.02
1.21
0.69
0.59
0.91
3.13
0.2070
0.0393
0.0105
309.
TABLE
31
(PRIMARY
NECROPSY)
PO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
FATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
I
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
REL.
NO
SIGNIFICANT
0.595
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
2.709
COLON
DUODENUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
0.654
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
0.392
ILEUM
JEJUNUM
KIDNEYS
LIVER
0.288
AORTA
LUNGS
LARYNX
NERVE.
SCIATIC
0.191
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
0.294
TESTES
THYMUS
RECTUM
PITUITARY
1.013
0.067
0.013
0.003
PROSTATE
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
TABLE
31
(PRIMARY
NECROPSY)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
8
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
MACROSCOPIC
FINDINGS
ANIMAL
NO.
69322
GROUP
1:
0
PPM
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
ABS.(
G)
1.85
7.44
2.00
1.26
0.87
0.50
0.94
2.99
0.1670
0.0602
0.0146
280.
MALE
REL.
NO
SIGNIFICANT
0.661
CHANGES
OBSERVED
2.657
0.714
0.450
0.311
0.179
0.336
1.068
0.060
0.021
0.005
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJIJNUM
AORTA
LUNGS
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
TESTES
THYMUS
PROSTATE
SAL.
GLAND
MAND
SKIN
SPINAL
CORD
THYROID
GLANDS
TRACHEA
BRAIN
CECUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HARDERIAN
GLANDS
HEART
KIDNEYS
LIVER
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
PANCREAS
RECTUM
PITUITARY
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPLEEN
STOMACH
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
9
ANIMAL
NO.
69337
GROUP
1:
0
PPM
MALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
____________­­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
ABS.(
G)
1.84
8.03
1.92
1.18
1.02
0.55
1.07
3.10
0.1882
0.0592
0.0228
284.
REL.
NO
SIGNIFICANT
0.648
CHANGES
OBSERVED
2.827
0.676
0.415
0.359
0.194
0.377
1.092
0.066
0.021
0.008
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJUNUM
AORTA
LUNGS
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
TESTES
THYMUS
PROSTATE
SAL.
GLAND
MAND
SKIN
SPINAL
CORD
THYROID
GLANDS
TRACHEA
BRAIN
LAC
GLAND,
EXOR
HARDERIAN
GLANDS
KIDNEYS
LARYNX
NASAL
TISSUES
RECTUM
SEMINAL
VESICLES
SPLEEN
URINARY
BLADDER
CECUM
EPIDIDYMIDES
HEART
LIVER
NERVE,
SCIATIC
PANCREAS
PITUITARY
SKELETAL
MUSCLE
STOMACH
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
TABLE
31
(PRIMARY
NECROPSY)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
10
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
MACROSCOPIC
FINDINGS
ANIMAL
NO.
69343
GROUP
1:
0
PPM
MALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
____­_____________
_
_
_
_
_
_
_
_
_
ORGAN
WEIGHT
ABS.(
G)
BRAIN
1.83
LIVER
7.80
KIDNEYS
1.80
LUNGS
1.18
HEART
0.89
SPLEEN
0.61
EPIDIDYMIDES
0.91
TESTES
2.83
THYMUS
0.1493
ADRENAL
GLANDS
0.0518
THYROIDS/
PARA
0.0192
FINAL
BODY
WT(
G)
263.
.____­_
REL.
0.696
2.966
0.684
0.449
0.338
0.232
0.346
1.076
0.057
0.020
0.007
__­­_____________________________
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJUNUM
AORTA
LUNGS
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
TESTES
THYMUS
PROSTATE
SAL.
GLAND
MAND
SKIN
SPINAL
CORD
THYROID
GLANDS
TRACHEA
GRADE
_______­__­­­_____­___________________

BRAIN
CECUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HARDERIAN
GLANDS
HEART
KIDNEYS
LIVER
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
PANCREAS
RECTUM
PITUITARY
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPLEEN
STOMACH
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
11
ANIMAL
NO.
69305
GROUP
2:
15
PPM
MALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
_________­­_­___________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
ABS.
(G)
1.87
7.12
1.87
0.96
0.81
0.49
0.96
3.04
1.165
0.1574
0.060
0.0607
0.0213
261.
REL.
0.716
2.728
0.716
0.368
0.310
0.188
0.368
0.023
0.008
LYMPH
NODE,
MED
GROSS:
DISCOLORATION,
DARK
RED
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJUNUM
AORTA
LUNGS
LYMPH
NODE,
TR/
BR
NASAL
TISSUES
THYMUS
RECTUM
SAL.
GLAND
MAND
SEMINAL
VESICLES
SPINAL
CORD
SPLEEN
TRACHEA
URINARY
BLADDER
P
BRAIN
CECUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HARDERIAN
GLANDS
HEART
KIDNEYS
LIVER
LARYNX
NERVE,
SCIATIC
PANCREAS
TESTES
PITUITARY
PROSTATE
SKELETAL
MUSCLE
SKIN
STOMACH
THYROID
GLANDS
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
12
ANIMAL
NO.
69316
GROUP
2:
15
PPM
MALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
______­__________­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ORGAN
WEIGHT
ABS.(
G)
BRAIN
1.92
LIVER
9.78
KIDNEYS
2.25
LUNGS
1.34
HEART
1.00
SPLEEN
0.70
EPIDIDYMIDES
0.99
TESTES
3.39
THYMUS
0.2055
ADRENAL
GLANDS
0.0629
THYROIDS/
PARA
0.0208
FINAL
BODY
WT(
G)
307.
REL.
0.625
3.186
0.733
0.436
0.326
0.228
0.322
1.104
0.067
0.020
0.007
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJUNUM
AORTA
LUNGS
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
TESTES
THYMUS
PROSTATE
SAL.
GLAND
MAND
SKIN
SPINAL
CORD
THYROID
GLANDS
TRACHEA
BRAIN
CEC­
UM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HARDERIAN
GLANDS
HEART
KIDNEYS
LIVER
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
PANCREAS
RECTUM
PITUITARY
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPLEEN
STOMACH
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
TABLE
31
(PRIMARY
NECROPSY)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH'PK
IN
RATS
&
MICE
PAGE
13
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
MACROSCOPIC
FINDINGS
ANIMAL
NO.
69320
GROUP
2:
15
PPM
MALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
__
___________^____
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
LUNGS
GROSS:
AREA(
S),
WHITE
FEW,
IRREGULARLY
SHAPED,
ALL
LOBES
PANCREAS
GROSS:
PALE
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
_______­­­_­­­­_­

ABS.(
G)
REL.
1.87
0.590
a.
75
2.760
2.20
0.694
1.40
0.442
1.00
0.315
0.62
0.196
0.95
0.300
3.08
0.972
0.2047
0.065
0.0537
0.017
P
P
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJUNUM
AORTA
LARYNX
LYMPH
NODE,
MED
NASAL
TISSUES
RECTUM
PITUITARY
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPLEEN
STOMACH
URINARY
BLADDER
LAC
GLAND,
EXOR
HARDERIAN
GLANDS
KIDNEYS
NERVE,
SCIATIC
TESTES
PROSTATE
SKIN
THYROID
GLANDS
CECUM
EPIDIDYMIDES
HEART
LIVER
LYMPH
NODE,
TR/
BR
THYMUS
SAL.
GLAND
MAND
SPINAL
CORD
TRACHEA
0.0170
0.005
317.

GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
14
INDIVIDUAL
MACROSCOPIC
FINDINGS
ANIMAL
NO.
69323
GROUP
2:
15
PPM
MALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
___­­­­__­­­­­­­­___­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ORGAN
WEIGHT
ABS.(
G)
REL.
NO
SIGNIFICANT
BRAIN
1.84
0.570
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
LIVER
8.85
2.740
COLON
DUODENUM
LAC
GLAND.
EXOR
EPIDIDYMIDES
KIDNEYS
2.11
0
LUNGS
1.31
0
HEART
0.99
0
SPLEEN
0.60
0
EPIDIDYMIDES
0.96
0
TESTES
3.11
0
THYMUS
0.1898
0
ADRENAL
GLANDS
0.0577
0
THYROIDS/
PARA
0.0178
0
FINAL
BODY
WT(
G)
323.
653
ESOPHAGUS
EYES/
OPTIC
N.
406
ILEUM
JEJUNUM
307
186
297
963
059
018
006
AORTA
LUNGS
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
TESTES
THYMUS
PROSTATE
SAL.
GLAND
MAND
SKIN
SPINAL
CORD
THYROID
GLANDS
TRACHEA
HARDERIAN'GLANDS
HEART
KIDNEYS
LIVER
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
PANCREAS
RECTUM
PITUITARY
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPLEEN
STOMACH
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
Z­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
15
ANIMAL
NO.
69326
GROUP
2:
15
PPM
MALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
________­­________­_____________________­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ORGAN
WEIGHT
ABS.(
G)
BRAIN
1.98
LIVER
8.99
KIDNEYS
2.19
LUNGS
1.40
HEART
0.98
SPLEEN
0.67
EPIDIDYMIDES
1.09
TESTES
3.39
THYMUS
0.2244
ADRENAL
GLANDS
0.0521
THYROIDS/
PARA
0.0249
FINAL
BODY
WT(
G)
334.
REL.
0.593
2.692
0.656
0.419
0.293
0.201
0.326
1.015
0.067
0.016
0.007
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
COLON
ESOPHAGUS
ILEUM
AORTA
LYMPH
NODE,
TR/
BR
TESTES
PROSTATE
SKIN
THYROID
GLANDS
STERNUM
BRAIN
CECUM
DUODENUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
JEJUNUM
KIDNEYS
LIVER
LUNGS
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPINAL
CORD
SPLEEN
STOMACH
TRACHEA
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
ANIMAL
NO.
69335
GROUP
2:

____­­­­­_­­­___­
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
___­­­­­­
_
_
_
_
_
_
_
_
ABS.
(G)
REL.
1.95
0.609
8.86
2.769
2.24
1.26
1.08
0.67
1.03
3.24
0.1967
0.0541
0.0145
320.
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
16
0.700
0.394
0.338
0.209
0.322
1.012
0.061
0.017
0.005
15
PPM
MALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
TESTES
THYMUS
RECTUM
PITUITARY
PROSTATE
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
17
ANIMAL
NO.
69336
GROUP
2:
15
PPM
MALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
_____________­__­­_­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDSIPARA
FINAL
BODY
WT(
G)
ABS.(
G)
1.86
8.71
2.08
1.21
REL.
0.620
0.99
0.60
0.94
2.90
0.2001
0.0618
0.0146
300.
2.903
0.693
0.403
0.330
0.200
0.313
0.967
0.067
0.021
0.005
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJUNUM
AORTA
LUNGS
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
TESTES
THYMUS
PROSTATE
SAL.
GLAND
MAND
SKIN
SPINAL
CORD
THYROID
GLANDS
TRACHEA
BRAIN
CECUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HARDERIAN
GLANDS
HEART
KIDNEYS
LIVER
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
PANCREAS
RECTUM
PITUITARY
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPLEEN
STOMACH
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
18
ANIMAL
NO.
69338
GROUP
2:
15
PPM
MALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
___________________­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
ABS.(
G)
1.87
7.22
1.81
1.11
0.88
0.56
0.94
3.13
0.1938
0.0564
0.0146
273.
REL.
0.685
2.645
0.663
0.407
0.322
0.205
0.344
1.147
0.071
0.021
0.005
SKIN
GROSS:
MATTING,
RED
P
OCULAR,
LEFT
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TRj
/BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
TESTES
THYMUS
RECTUM
PITUITARY
PROSTATE
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
TABLE
31
(PRIMARY
NECROPSY)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
Es
MICE
PAGE
19
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
MACROSCOPIC
FINDINGS
ANIMAL
NO.
69345
GROUP
2:
15
PPM
MALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
ORGAN
WEIGHT
ABS.(
G)
BRAIN
2.01
LIVER
8.66
KIDNEYS
2.29
LUNGS
1.27
HEART
0.98
SPLEEN
0.65
EPIDIDYMIDES
1.08
TESTES
3.20
THYMUS
0.2254
ADRENAL
GLANDS
0.0587
THYROIDS/
PARA
0.0139
FINAL
BODY
WT(
G)
307.
REL.
NO
SIGNIFICANT
0.655
CHANGES
OBSERVED
2.821
0.746
0.414
0.319
0.212
0.352
1.042
0.073
0.019
0.005
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJUNUM
AORTA
LUNGS
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
TESTES
THYMUS
PROSTATE
SAL.
GLAND
MAND
SKIN
SPINAL
CORD
THYROID
GLANDS
TRACHEA
BRAIN
CECUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HARDERIAN
GLANDS
HEART
KIDNEYS
LIVER
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
PANCREAS
RECTUM
PITUITARY
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPLEEN
STOMACH
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
20
ANIMAL
NO.
69347
GROUP
2:
15
PPM
MALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
_­_­__­­­_­_­___________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ORGAN
WEIGHT
ABS.(
G)
REL.
SEMINAL
VESICLES
GROSS:
SMALL
P
BRAIN
1.76
0.624
RIGHT
LIVER
8.02
2.844
NO
SIGNIFICANT
KIDNEYS
1.99
LUNGS
1.23
HEART
0.87
SPLEEN
0.59
EPIDIDYMIDES
0.88
TESTES
2.73
THYMUS
0.2210
ADRENAL
GLANDS
0.0519
THYROIDS/
PARA
0.0253
FINAL
BODY
WT(
G)
282.
706
436
309
209
312
968
078
018
009
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJUNUM
AORTA
LUNGS
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
TESTES
THYMUS
PROSTATE
SAL.
GLAND
MAND
SPINAL
CORD
SPLEEN
TRACHEA
URINARY
BLADDER
BRAIN
CECUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HARDERIAN
GLANDS
HEART
KIDNEYS
LIVER
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
PANCREAS
RECTUM
PITUITARY
SKELETAL
MUSCLE
SKIN
STOMACH
THYROID
GLANDS
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
21
INDIVIDUAL
MACROSCOPIC
FINDINGS
ANIMAL
NO.
69303
GROUP
3:
40
PPM
MALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
____­_____­_______­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
NT(
G)
ABS.
(G)
1.61
6.40
1.76
0.99
0.89
0.47
0.184
0.80
0.314
2.68
0.0972
0.0495
0.0144
255.
REL.
0.631
2.510
0.690
0.388
0.349
1.051
0.038
0.019
0.006
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJUNUM
AORTA
LUNGS
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
TESTES
THYMUS
PROSTATE
SAL.
GLAND
MAND
SKIN
SPINAL
CORD
THYROID
GLANDS
TRACHEA
BRAIN
CECUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HARDERIAN
GLANDS
HEART
KIDNEYS
LIVER
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
PANCREAS
RECTUM
PITUITARY
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPLEEN
STOMACH
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
22
INDIVIDUAL
MACROSCOPIC
FINDINGS
ANIMAL
NO.
69309
GROUP
3:

_­­____________­­
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
____
­
__­_
ABS.(
G)
1.89
8.02
2.44
1.39
0.97
0.315
AORTA
LUNGS
LARYNX
NERVE`
SCIATIC
0.59
0.192
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
1.01
3.25
0.2094
0.0654
0.0151
308.
REL.
0.614
2.604
0.792
0.451
0.328
1.055
0.068
0.021
0.005
40
PPM
MALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
______­___­_____­_______________________­­­­~­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
TESTES
THYMUS
RECTUM
PITUITARY
PROSTATE
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
YO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
23
ANIMAL
NO.
69313
GROUP
3:
40
PPM
MALE
_______­­­_____­
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
ABS.(
G)
1.91
9.01
2.26
1.22
1.03
0.64
0.96
3.13
0.2268
0.0598
THYROIDS/
PARA
0.0162
FINAL
BODY
WT(
G)
310.
._________________________
REL.
NO
SIGNIFICANT
0.616
CHANGES
OBSERVED
2.906
0.729
0.394
0.332
0.206
0.310
1.010
0.073
0.019
0.005
_.
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJUNUM
AORTA
LUNGS
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
TESTES
THYMUS
PROSTATE
SAL.
GLAND
MAND
SKIN
SPINAL
CORD
THYROID
GLANDS
TRACHEA
BRAIN
CECUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HARDERIAN
GLANDS
HEART
KIDNEYS
LIVER
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
PANCREAS
RECTUM
PITUITARY
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPLEEN
STOMACH
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
TABLE
31
(PRIMARY
NECROPSY)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
MACROSCOPIC
FINDINGS
ANIMAL
NO.
69315
GROUP
­­__­____­­__­­__________
3:

__
REL.
0.731
2.625
0.688
0.415
0.344
0.166
0.372
1.111
0.071
0.019
0.007
40
PPM
MALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
__­______­_________­____________________­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
TESTES
THYMUS
RECTUM
PITUITARY
PROSTATE
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
ORGAN
WEIGHT
ABS.(
G)
BRAIN
1.85
LIVER
6.64
KIDNEYS
1.74
LUNGS
1.05
HEART
0.87
SPLEEN
0.42
EPIDIDYMIDES
0.94
TESTES
2.81
THYMUS
0.1794
ADRENAL
GLANDS
0.0474
THYROIDS/
PAR­
A
0.0188
FINAL
BODY
WT(
G)
253.
PAGE
24
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
25
ANIMAL
NO.
69324
GROUP
3:

­­­­­­­­­________
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
­
­
_
­
­
­
_
_
_
_
.____­­_
ABS.(
G)
REL.
1.95
0.586
8.96
2.691
2.24
0.673
1.25
0.375
1.01
0.303
0.70
0.210
1.08
0.324
3.22
0.967
0.2108
0.063
0.0601
0.018
0.0163
333.
0.005
40
PPM
MALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
___­________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECTJM
COLON
DUODENUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
TESTES
THYMUS
RECTUM
PITUITARY
PROSTATE
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
I­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
26
ANIMAL
NO.
69328
GROUP
3:
40
PPM
MALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
_­­­­­­­­­­_­­­__­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
pARA
FINAL
BODY
WT(
G)
ABS.(
G)
REL.
SPLEEN
1.90
0.590
8.59
2.668
NO
SIGNIFICANT
2.20
0.683
CHANGES
OBSERVED
1.30
0.404
1.06
0.329
0.63
0.196
1.08
0.335
3.95
1.227
GROSS:
ACCESSORY
P
ONE,
3
MM
IN
DIAMETER
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
THYMUS
RECTUM
PITUITARY
0.2050
0.064
TESTES
0.0478
0.015
PROSTATE
0.0163
0.005
SKIN
322.
TRACHEA
GROSS
GRADE
CODE:
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPINAL
CORD
STOMACH
THYROID
GLANDS
URINARY
BLADDER
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
9O­
DAY
INHAL.
STUDY
OF
l,
l,
Z­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
27
ANIMAL
NO.
69339
GROUP
3:
40
PPM
MALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDSjPARA
FINAL
BODY
WT(
G)
ABS.(
G)
REL.
1.77
0.656
7.44
2.756
1.94
0.719
0.90
0.333
0.91
0.337
0.51
0.189
0.88
0.326
2.80
1.037
0.1799
0.0572
0.0165
270.
0.067
0.021
0.006
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJUNUM
AORTA
LUNGS
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
TESTES
THYMUS
PROSTATE
SAL.
GLAND
MAND
SKIN
SPINAL
CORD
THYROID
GLANDS
TRACHEA
BRAIN
CECUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HARDERIAN
GLANDS
HEART
KIDNEYS
LIVER
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
PANCREAS
RECTUM
PITUITARY
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPLEEN
STOMACH
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
28
ANIMAL
NO.
69344
GROUP
3:
40
PPM
MALE
________­­_______­________
ORGAN
WEIGHT
ABS.(
G)
BRAIN
1.84
LIVER
9.00
KIDNEYS
2.32
LUNGS
1.24
HEART
1.01
SPLEEN
0.68
EPIDIDYMIDES
0.99
TESTES
3.11
THYMUS
0.2125
ADRENAL
GLANDS
0.0562
THYROIDS/
PARA
0.0148
FINAL
BODY
WT(
G)
316.
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
REL.
NO
SIGNIFICANT
0.582
CHANGES
OBSERVED
2.848
0.734
0.392
0.320
0.215
0.313
0.984
0.067
0.018
0.005
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND.
EXOR
EPIDIDYMIDES
ESOPHAGUS
ILEUM
AORTA
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
TESTES
THYMUS
RECTUM
PITUITARY
EYES/
OPTIC
N.
HARDERIAN'GLANDS
HEART
JEJUNUM
KIDNEYS
LIVER
LUNGS
LARYNX
NERVEsSCIATIC
PROSTATE
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
Z­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
29
ANIMAL
NO.
69348
GROUP
3:
40
PPM
MALE
_____­____­____­­
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
ABS.(
G)
1.92
8.36
2.17
1.19
0.95
0.60
0.99
3.16
0.1814
0.0565
0.0236
292.
_­_____­­_________­_­­­­­­.
REL.
STOMACH
0.658
NO
SIGNIFICANT
2.863
CHANGES
OBSERVED
0.743
0.408
0.325
0.205
0.339
1.082
0.062
0.019
0.008
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
GROSS:
CONTENTS,
DARK
RED
P
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJUNUM
AORTA
LUNGS
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
TESTES
THYMUS
PROSTATE
SAL.
GLAND
MAND
SKIN
SPINAL
CORD
TRACHEA
URINARY
BLADDER
BRAIN
CECUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HARDERIAN
GLANDS
HEART
KIDNEYS
LIVER
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
PANCREAS
RECTUM
PITUITARY
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPLEEN
THYROID
GLANDS
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
30
ANIMAL
NO.
69350
GROUP
3:
40
PPM
MALE
________________­_
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
pARA
FINAL
BODY
WT(
G)
.__­___­_
ABS.
(G)
1.88
7.28
1.95
1.20
0.92
0.61
0.87
3.00
0.2170
0.0566
0.0128
280.
_________­­___­___­________
REL.
NO
SIGNIFICANT
0.671
CHANGES
OBSERVED
2.600
0.696
0.429
0.329
0.218
0.311
1.071
0.077
0.020
0.005
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
TESTES
THYMUS
RECTUM
PITUITARY
PROSTATE
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
31
ANIMAL
NO.
69304
GROUP
4:
100
PPM
MALE
__­______________
______­_­_
ORGAN
WEIGHT
ABS.(
G)
BRAIN
1.91
LIVER
8.98
KIDNEYS
2.36
LUNGS
1.30
HEART
1.07
SPLEEN
0.76
EPIDIDYMIDES
1.09
TESTES
3.50
THYMUS
0.2438
ADRENAL
GLANDS
0.0674
THYROIDS/
PAPA
0.0140
FINAL
BODY
WT(
G)
323.
_____________­____________
REL.
THYMUS
0.591
NO
SIGNIFICANT
2.780
CHANGES
OBSERVED
0.731
0.402
0.331
0.235
0.337
1.084
0.075
0.021
0.004
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
________­­­­­_______­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GROSS:
DISCOLORATION,
DARK
RED
P
GROSS:
ADRENAL
GLANDS
COLON
ESOPHAGUS
ILEUM
AORTA
LYMPH
NODE,
TR/
BR
TESTES
SAL.
GLAND
MAND
SPINAL
CORD
TRACHEA
STERNUM
BRAIN
DUODENUM
LAC
GLAND,
EXOR
EYES/
OPTIC
N.
HARDERIAN
GLANDS
JEJUNUM
KIDNEYS
LUNGS
LARYNX
LYMPH
NODE,
MED
NASAL
TISSUES
RECTUM
PITUITARY
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPLEEN
STOMACH
URINARY
BLADDER
CECUM
EPIDIDYMIDES
HEART
LIVER
NERVE,
SCIATIC
PANCREAS
PROSTATE
SKIN
THYROID
GLANDS
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
32
ANIMAL
NO.
69307
GROUP
4:
100
PPM
MALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
ABS.(
G)
REL.
1.95
0.596
9.49
2.902
2.22
0.679
1.36
1.13
0.65
1.06
3.31
0.2473
0.0637
0.0197
327.
0.416
0.346
0.199
0.324
1.012
0.076
0.019
0.006
LUNGS
GROSS:
AREA(
S),
WHITE
FEW,
IRREGULARLY
SHAPED,
ALL
SKIN
GROSS:
MATTING,
RED
OCULAR,
RIGHT
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJUNUM
AORTA
LARYNX
LYMPH
NODE,
MED
NASAL
TISSUES
THYMUS
RECTUM
P
LOBES
P
BRAIN
CECUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HARDERIAN
GLANDS
HEART
KIDNEYS
LIVER
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
PANCREAS
TESTES
PITUITARY
PROSTATE
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
TABLE
31
(PRIMARY
NECROPSY)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
33
ANIMAL
NO.
69318
GROUP
4:
100
PPM
MALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
___­­_____­­____
__­­­­­­­­­______­.
ORGAN
WEIGHT
ABS.(
G)
REL.
BRAIN
1.83
0.594
LIVER
8.70
2.825
KIDNEYS
2.15
0.698
LUNGS
1.21
0.393
HEART
0.99
0.321
SPLEEN
0.64
0.208
EPIDIDYMIDES
0.95
0.308
TESTES
3.09
1.003
THYMUS
0.2204
0.072
ADRENAL
GLANDS
0.0538
0.017
THYROIDS/
PARA
0.0228
0.007
FINAL
BODY
WT(
G)
308.
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJUNUM
AORTA
LUNGS
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
TESTES
THYMUS
PROSTATE
SAL.
GLAND
MAND
SKIN
SPINAL
CORD
THYROID
GLANDS
TRACHEA
I
GRADE
­­­­­­­___­_______­___________________

BRAIN
CECUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HARDERIAN
GLANDS
HEART
KIDNEYS
LIVER
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
PANCREAS
RECTUM
PITUITARY
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPLEEN
STOMACH
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
34
ANIMAL
NO.
69319
GROUP
4:
100
PPM
MALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
ADRENAL
GLANDS
THYROIDS/
PAR?+
FINAL
BODY
WT(
G)
ABS.(
G)
1.87
8.46
2.19
1.27
0.94
0.66
1.01
3.30
0.1970
0.0508
0.0152
305.
REL.
0.613
2.774
0.718
0.416
0.308
0.216
0.331
1.082
0.065
0.017
0.005
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
COLON
ESOPHAGUS
ILEUM
AORTA
LYMPH
NODE,
TR/
BR
TESTES
PROSTATE
SKIN
THYROID
GLANDS
STERNUM
BRAIN
CECUM
DUODENUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
JEJUNUM
KIDNEYS
LIVER
LUNGS
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPINAL
CORD
SPLEEN
STOMACH
TRACHEA
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
35
ANIMAL
NO.
69327
GROUP
4:
100
PPM
MALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
ORGAN
WEIGHT
ABS.
(G)
BRAIN
1.84
LIVER
7.71
KIDNEYS
2.01
LUNGS
1.22
HEART
0.92
SPLEEN
0.64
EPIDIDYMIDES
0.98
TESTES
3.08
THYMUS
0.1762
ADRENAL
GLANDS
0.0472
THYROIDS/
PARA
0.0166
FINAL
BODY
WT(
G)
303.
REL.
0.607
2.564
0.663
0.403
0.304
0.211
0.323
1.017
0.058
0.016
0.005
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
COLON
ESOPHAGUS
ILEUM
AORTA
LYMPH
NODE,
TR/
BR
TESTES
PROSTATE
SKIN
THYROID
GLANDS
STERNUM
DUODENUM
EYES/
OPTIC
N.
JEJUNUM
LUNGS
LYMPH
NODE,
MED
THYMUS
SAL.
GLAND
MAND
SPINAL
CORD
TRACHEA
BRAIN
CECUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HARDERIAN
GLANDS
HEART
KIDNEYS
LIVER
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
PANCREAS
RECTUM
PITUITARY
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPLEEN
STOMACH
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
ANIMAL
NO.
69329
GROUP
______­­­_­______.
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
___­
_____.
ABS.(
G)
1.87
8.34
2.21
1.21
0.95
0.62
1.01
2.98
0.1926
0.0536
0.0224
293,
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
36
4:
100
PPM
MALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
REL.
0.638
2.846
0.754
0.413
0.324
0.212
0.345
1.017
0.066
0.018
0.008
________________________________________­­­­­­­­­­­­­­­­­­
SKIN
GROSS:
MATTING,
RED
OCULAR,
RIGHT
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJUNUM
AORTA
LUNGS
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
TESTES
THYMUS
PROSTATE
SAL.
GLAND
MAND
SPINAL
CORD
SPLEEN
TRACHEA
URINARY
BLADDER
BRAIN
LAC
GLAND,
EXOR
HARDERIAN
GLANDS
KIDNEYS
LARYNX
NASAL
TISSUES
RECTUM
SEMINAL
VESICLES
STOMACH
P
CECUM
EPIDIDYMIDES
HEART
LIVER
NERVE,
SCIATIC
PANCREAS
PITUITARY
SKELETAL
MUSCLE
THYROID
GLANDS
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
PO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
37
ANIMAL
NO.
69332
GROUP
4:
100
PPM
MALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
­­­­_­___________
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
ABS.
(G)
1.90
7.56
1.94
1.11
0.97
0.56
1.11
3.05
0.1944
0.0499
0.0150
293.
­_____­_
REL.
0.648
2.580
0.662
0.379
0.331
0.191
0.379
1.041
0.066
0.017
0.005
___­­_­__________­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
TESTES
THYMUS
RECTUM
PITUITARY
PROSTATE
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
TABLE
31
(PRIMARY
NECROPSY)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
MACROSCOPIC
FINDINGS
ANIMAL
NO.
69334
GROUP
4:
100
PPM
MALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
9l.
GRADE
PAGE
38
ORGAN
WEIGHT
ABS.
(G)
BRAIN
1.82
LIVER
8.48
KIDNEYS
2.17
LUNGS
1.19
HEART
0.97
SPLEEN
0.60
EPIDIDYMIDES
0.97
TESTES
3.06
THYMUS
0.1969
ADRENAL
GLANDS
0.0572
THYROIDSjPARA
0.0225
FINAL
BODY
WT(
G)
288.
REL.
NO
SIGNIFICANT
0.632
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
2.944
COLON
DUODENUM
0.753
ESOPHAGUS
EYES/
OPTIC
N.
0.413
ILEUM
JEJUNUM
0.337
AORTA
LUNGS
0.208
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
0.337
TESTES
THYMUS
1.063
0.068
0.020
0.008
PROSTATE
SAL.
GLAND
MAND
SKIN
SPINAL
CORD
THYROID
GLANDS
TRACHEA
BRAIN
CECUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HARDERIAN
GLANDS
HEART
KIDNEYS
LIVER
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
PANCREAS
RECTUM
PITUITARY
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPLEEN
STOMACH
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
39
ANIMAL
NO.
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:

ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
EPIDIDYMIDES
TESTES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
ABS.(
G)
1.79
8.46
2.22
1.14
0.88
0.55
0.96
3.01
0.1683
0.0562
0.0168
306.
REL.
0.585
2.765
0.725
0.373
0.288
0.180
0.314
0.984
0.055
0.018
0.005
GENERAL
COMMENT
GROSS:
ORGAN
DAMAGED
AT
NECROPSY
PITUITARY
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
ESOPHAGUS
EYES/
OPTIC
N.
ILEUM
JEJUNUM
AORTA
LUNGS
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
TESTES
THYMUS
PROSTATE
SAL.
GLAND
MAND
SKIN
SPINAL
CORD
THYROID
GLANDS
TRACHEA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
BRAIN
CECUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
HARDERIAN
GLANDS
HEART
KIDNEYS
LIVER
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
PANCREAS
RECTUM
PITUITARY
SEMINAL
VESICLES
SKELETAL
MUSCLE
SPLEEN
STOMACH
URINARY
BLADDER
­MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
40
ANIMAL
NO.
69346
GROUP
4:
100
PPM
MALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
__________­_­___­_­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­~­­­~~­­­­­­­­~­­­­­
ORGAN
WEIGHT
ABS.
(G)
REL.
EYES/
OPTIC
N.
GROSS:
EYE(
S)­
OPACITY
P
BRAIN
1.78
0.587
LEFT
LIVER
8.89
2.934
GENERAL
COMMENT
GROSS:
ORGAN
LOST
AT
NECROPSY
P
KIDNEYS
2.24
0.739
HEART
LUNGS
1.19
0.393
NO
SIGNIFICANT
SPLEEN
0.57
0.188
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
EPIDIDYMIDES
0.97
0.320
COLON
DUODENUM
LAC
GLAND,
EXOR
EPIDIDYMIDES
TESTES
3.00
0.990
ESOPHAGUS
HARDERIAN
GLANDS
HEART
ILEUM
THYMUS
0.1742
0.057
JEJUNUM
KIDNEYS
LIVER
AORTA
ADRENAL
GLANDS
0.0533
0.018
LUNGS
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
THYROIDS/
PARA
0.0159
0.005
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
TESTES
FINAL
BODY
MT(
G)
303.
THYMUS
RECTUM
PITUITARY
PROSTATE
SAL.
GLAND
MAND
SEMINAL
VESICLES
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
KAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
41
ANIMAL
NO.
69354
GROUP
____­­___­__­
_____­_
­_­
___.
ORGAN
WEIGHT
ABS.(
G)
BRAIN
1.90
LIVER
5.34
KIDNEYS
1.35
LUNGS
0.97
HEART
0.65
SPLEEN
0.49
OVARIES
0.0923
1:
0
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
_________­_________­____________________­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­
REL.
NO
SIGNIFICANT
0.969
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
2.724
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
0.689
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
0.495
JEJUNUM
KIDNEYS
LIVER
AORTA
0.332
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
0.250
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
0.047
PANCREAS
OVIDUCTS
THYMUS
RECTUM
THYMUS
0.2110
0.108
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
ADRENAL
GLANDS
0.0645
0.033
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
THYROIDS/
PARA
0.0128
0.007
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
FINAL
BODY
WT(
G)
196.

GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
42
ANIMAL
NO.
69366
GROUP
­­­­­­­______­___
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
ABS.(
G)
1.71
4.41
1.27
0.93
0.59
0.44
0.0885
0.1814
0.0493
0.0131
179.
1:

_­__­___
REL.
0.955
2.464
0.709
0.520
0.330
0.246
0.049
0.101
0.028
0.007
0
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
________________________________________­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­~­­­­­­­~~­~­­
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
PANCREAS
OVIDUCTS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
43
ANIMAL
NO.

ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
69367
GROUP
1:
0
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ABS.
(G)
REL.
EYES/
OPTIC
N.
GROSS:
EYE(
S)­
OPACITY
P
1.79
0.913
RIGHT
4.64
2.367
LYMPH
NODE,
MAN
GROSS:
DISCOLORATION,
DARK
RED
P
1.36
0.694
RIGHT
0.96
0.490
NO
SIGNIFICANT
0.62
0.316
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
0.52
0.265
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
0.0744
0.038
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
THYMUS
0.2682
0.137
KIDNEYS
LIVER
AORTA
LUNGS
ADRENAL
GLANDS
0.0457
0.023
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
THYROIDS/
PARA
0.0216
0.011
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
PANCREAS
FINAL
BODY
WT(
G)
196.
OVIDUCTS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
44
ANIMAL
NO,
69378
GROUP
ORGAN
WEIGHT
ABS.(
G)
BRAIN
1.81
LIVER
4.86
KIDNEYS
1.27
LUNGS
1.03
HEART
0.65
SPLEEN
0.44
OVARIES
0.0969
THYMUS
0.2174
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
0.0449
0.0109
180.
1:
0
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
_________­_­____­_______________________­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­~­
REL.
NO
SIGNIFICANT
1.006
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
2.700
COLON
DUODENUM
LAC
GLAND.
EXOR
ESOPHAGUS
0.706
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
'
ILEUM
0.572
JEJUNUM
KIDNEYS
LIVER
AORTA
0.361
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
0.244
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
0.054
PANCREAS
OVIDUCTS
THYMUS
RECTUM
0.121
PITUITARY
SAL,
GLAND
MAND
SKELETAL
MUSCLE
SKIN
0.025
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
0.006
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
TABLE
31
(PRIMARY
NECROPSY)
PROJECT
NO.:
WIL­
417OQ2
SPONSOR:
HAP
TASK
FORCE
ANIMAL
NO.
69384
GROUP
______­­­­­­­­___
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
ABS.(
G)
1.72
4.70
1.14
0.95
0.60
0.44
0.1006
0.1931
0.115
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
0.0491
0.029
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
0.0163
168.
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
45
1:
0
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
REL.
NO
SIGNIFICANT
1.024
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
2.798
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
0.679
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
0.565
JEJUNUM
KIDNEYS
LIVER
AORTA
0.357
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
0.262
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
0.060
PANCREAS
OVIDUCTS
THYMUS
RECTUM
0.010
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
TABLE
31
(PRIMARY
NECROPSY)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
PAGE
46
INDIVIDUAL
MACROSCOPIC
FINDINGS
ANIMAL
NO.
69398
GROUP
1:
0
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
______­_­__­­___________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ORGAN
WEIGHT
ABS.
(G)
REL.
NO
SIGNIFICANT
BRAIN
1.86
0.944
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
LIVER
STERNUM
BRAIN
4.72
2.396
CECUM
COLON
KIDNEYS
DUODENUM
1.32
0.670
LAC
GLAND,
EXOR
ESOPHAGUS
LUNGS
EYES/
OPTIC
N.
0.91
0.462
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
HEART
0.68
KIDNEYS
0.345
LIVER
AORTA
LUNGS
MAMMARY
GLAND
SPLEEN
LARYNX
NERVE,
SCIATIC
0.48
0.244
OVARIES
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
0.1011
0.051
OVARIES
PANCREAS
OVIDUCTS
THYMUS
0.2156
THYMUS
0.109
RECTUM
PITUITARY
ADRENAL
GLANDS
0.0639
0.032
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
THYROIDS/
PARA
0.0155
STOMACH
0.008
THYROID
GLANDS
TRACHEA
FINAL
BODY
WT(
G)
URINARY
BLADDER
UTERUS
197.
VAGINA
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
ANIMAL
NO.
69404
GROUP
._.
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PAR?+
FINAL
BODY
WT(
G)
_
_
_
_
_
_
_
_
ABS.(
G)
1.81
4.81
1.40
0.99
0.68
0.50
0.1018
0.2587
0.0567
0.0127
199.
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
47
1:

­
­
_
_
_
_
_
REL.
0.910
2.417
0.704
0.497
0.342
0.251
0.051
0.130
0.028
0.006
0
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
_­____________­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
PANCREAS
OVIDUCTS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NE~
ROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
48
ANIMAL
NO.
69416
GROUP
1:
0
__­­_______­­­___
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THyROIDS/
PARA
FINAL
BODY
WT(
G)
ABS.
(G)
1.84
5.16
1.40
0.98
0.67
0.50
0.1029
0.2011
0.0554
0.0181
192.
_
_
_
_
­
­
­
­
REL.
0.958
2.687
0.729
0.510
0.349
0.260
0.054
0.105
0.029
0.009
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
____­­­___­_____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~­­­~­­­­­­­­~
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE.
TR/
BR
LYMPH
NODE.
MED
NASAL
TISSUES
OVARIES
PANCREAS
'
OVIDUCTS
'
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
TRACHEA
URINARY
BLADDER
UTERUS
THYROID
GLANDS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
49
ANIMAL
NO.
69419
GROUP
1:
0
PPM
ORGAN
WEIGHT
ABS.(
G)
BRAIN
1.76
LIVER
4.90
KIDNEYS
1.31
LUNGS
0.96
HEART
0.70
SPLEEN
0.48
OVARIES
0.1059
THYMUS
0.2328
ADRENAL
GLANDS
0.0506
THYROIDS/
PARA
0.0161
FINAL
BODY
WT(
G)
193.
FEMALE
REL.
NO
SIGNIFICANT
0.912
CHANGES
OBSERVED
2.539
0.679
0.497
0.363
0.249
0.055
0.121
0.026
0.008
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
.__­___­________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
PANCREAS
OVIDUCTS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
50
ANIMAL
NO.
69432
GROUP
1:
0
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
_­___________­___­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ORGAN
WEIGHT
ABS.(
G)
REL.
NO
SIGNIFICANT
BRAIN
1.81
1.011
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
LIVER
4.93
KIDNEYS
1.34
LUNGS
0.94
HEART
0.68
SPLEEN
0.51
OVARIES
0.0924
THYMUS
0.1837
ADRENAL
GLANDS
0.0562
THYROIDS/
PARA
0.0132
FINAL
BODY
WT(
G)
179.
2
0
0
0
0
0
0
754
749
525
380
285
052
103
031
0
0.007
COLON
DUODENUM
EYES/
OPTIC
N.
HARDERIAN
GLANDS
JEJUNUM
KIDNEYS
LUNGS
MAMMARY
GLAND
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
PANCREAS
OVIDUCTS
PITUITARY
SAL.
GLAND
MAND
SPINAL
CORD
SPLEEN
TRACHEA
URINARY
BLADDER
LAC
GLAND,
EXOR
HEART
LIVER
LARYNX
NASAL
TISSUES
THYMUS
SKELETAL
MUSCLE
STOMACH
UTERUS
ESOPHAGUS
ILEUM
AORTA
NERVE,
SCIATIC
OVARIES
RECTUM
SKIN
THYROID
GLANDS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
TABLE
31
(PRIMARY
NEcROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
MACROSCOPIC
FINDINGS
ANIMAL
NO.
69362
GROUP
2:

ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
NT(
G)
ABS.
(G)
1.66
4.79
1.36
1.10
0.66
0.53
0.1351
0.2288
0.0687
0.0103
176.
REL.
0.943
2.722
0.773
0.625
0.375
0.301
0.077
0.130
0.039
0.006
PAGE
51
15
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
____­____­_____­___­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
LYMPH
NODE,
MAN
GROSS:
DISCOLORATION,
DARK
RED
P
BILATERAL
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
PANCREAS
OVIDUCTS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
52
ANIMAL
NO.
69376
GROUP
­­­_­­­_­­_­_­__­­­­_______
ORGAN
WEIGHT
ABS.(
G)
BRAIN
1.71
LIVER
4.49
KIDNEYS
1.15
LUNGS
0.80
HEART
il.
60
SPLEEN
0.42
OVARIES
0.0985
THYMUS
0.1878
ADRENAL
GLANDS
0.0558
THYROIDS/
PARA
0.0128
FINAL
BODY
WT(
G)
159,
2:

REL.
1.075
2.824
0.723
0.503
0.377
0.264
0.062
0.118
0.035
0.008
15
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
________­___­___________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~~­­­­­­­­­­­~­­~~­­­
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
PANCREAS
OVIDUCTS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
53
ANIMAL
NO.
69382
GROUP
2:
15
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
___­_____________­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
ABS.
(G)
1.79
4.64
1.27
0.93
0.65
0.46
0.0997
0.1678
0.0590
0.0129
195.
REL.
0.918
2.379
0.651
0.477
0.333
0.236
0.051
0.086
0.030
0.007
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
COLON
DUODENUM
LAC
GLAND,
EXOR
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
JEJUNUM
KIDNEYS
LIVER
LUNGS
MAMMARY
GLAND
LARYNX
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
OVIDUCTS
THYMUS
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SPINAL
CORD
SPLEEN
STOMACH
TRACHEA
URINARY
BLADDER
UTERUS
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
CECUM
ESOPHAGUS
ILEUM
AORTA
NERVE,
SCIATIC
OVARIES
RECTUM
SKIN
THYROID
GLANDS
VAGINA
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
$O­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
54
ANIMAL
NO.
69390
GROUP
2:
15
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
­­­­__­­­­_­­__­_­__­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­
ORGAN
WEIGHT
ABS.(
Gf
REL.
LUNGS
GROSS:
AREA(
S),
WHITE
P
BRAIN
1.74
0.956
FEW,
IRREGULARLY
SHAPED,
ALL
LOBES
LIVER
4.42
2.429
SKIN
GROSS:
MATTING,
YELLOW
P
KIDNEYS
1.37
0.753
UROGENITAL
LUNGS
1.04
0.571
NO
SIGNIFICANT
HEART
0.65
0.357
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
SPLEEN
0.51
0.280
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
OVARIES
0.0858
0.047
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
THYMUS
0.2184
0.120
JEJUNUM
KIDNEYS
LIVER
AORTA
ADRENAL
GLANDS
0.0564
0.031
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
THYROIDS/
PARA
0.0126
0.007
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
PANCREAS
FINAL
BODY
WT(
G)
182.
OVIDUCTS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
90­
DAY
SPONSOR:
HAP
TASK
FORCE
ANIMAL
NO.
69393
GROUP
2:
15
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
____­__________­____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­~­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­~­­­­­
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYROIDS/
pARA
FINAL
BODY
WT(
G)
ABS.
(G)
1.81
4.33
1.25
0.97
0.59
0.41
0.0869
0.1759
0.0550
0.0164
166.
REL.
1.090
2.608
0.753
0.584
0.355
0.247
0.052
0.106
0.033
GENERAL
COMMENT
GROSS:
MECWANICAL
TRAUMA
DISTAL
TAIL
BROKEN
GENERAL
COMMENT
GROSS:
MECHANICAL
TRAUMA
DISTAL
TAIL
MISSING
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
COLON
DUODENUM
LAC
GLAND,
EXOR
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
JEJUNUM
KIDNEYS
LIVER
LUNGS
MAMMARY
GLAND
LARYNX
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
OVIDUCTS
THYMUS
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SPINAL
CORD
SPLEEN
STOMACH
TRACHEA
URINARY
BLADDER
UTERUS
P
P
0.010
CECUM
ESOPHAGUS
ILEUM
AORTA
NERVE,
SCIATIC
OVARIES
RECTUM
SKIN
THYROID
GLANDS
VAGINA
TABLE
31
(PRIMARY
NECROPSY)
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
55
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
56
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
MACROSCOPIC
FINDINGS
ANIMAL
NO.
69396
GROUP
2:
15
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
______­____­_­_____­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­~­~­­­­­­­
ORGAN
WEIGHT
ABS.(
G)
BRAIN
1.76
LIVER
4.88
KIDNEYS
1.19
LUNGS
0.98
HEART
0.63
SPLEEN
0.47
OVARIES
0.1049
THYMUS
0.1716
ADRENAL
GLANDS
0.0601
THYROIDS/
PARA
0.0147
FINAL
BODY
WT(
G)
188.
REL.
0.936
2.596
0.633
0.521
0.335
0.250
0.056
0.091
0.032
0.008
PITUITARY
GROSS:
SMALL
SKELETAL
MUSCLE
GROSS:
DISCOLORATION,
DARK
RED
SURROUNDING
MECHANICAL
TRAUMA
GENERAL
COMMENT
GROSS:
MECHANICAL
TRAUMA
FRACTURE
OF
TIBIA
AND
FIBULA,
LEFT
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
COLON
DUODENUM
LAC
GLAND,
EXOR
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
JEJUNUM
KIDNEYS
LIVER
LUNGS
MAMMARY
GLAND
LARYNX
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
OVIDUCTS
THYMUS
SAL.
GLAND
MAND
SKIN
SPINAL
CORD
STOMACH
THYROID
GLANDS
TRACHEA
UTERUS
VAGINA
P
P
I?

CECUM
ESOPHAGUS
ILEUM
AORTA
NERVE,
SCIATIC
OVARIES
RECTUM
SPLEEN
URINARY
BLADDER
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROFSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
57
ANIMAL
NO.
69409
GROUP
2:
15
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
_­_____­________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­~­­­­­­­­­­~­­­
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
ABS.(
G)
1.80
4.75
1.21
0.96
0.64
0.43
0.0912
0.1997
0.0576
0.0152
180.
REL.
1.000
2.639
0.672
0.533
0.356
0.239
0.051
0.111
0.032
0.008
GENERAL
COMMENT
GROSS:
MECHANICAL
TRAUMA
DISTAL
TAIL
BROKEN
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
COLON
DUODENUM
LAC
GLAND,
EXOR
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
JEJUNUM
KIDNEYS
LIVER
LUNGS
MAMMARY
GLAND
LARYNX
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
OVIDUCTS
THYMUS
P
CECUM
ESOPHAGUS
ILEUM
AORTA
NERVE,
SCIATIC
OVARIES
RECTUM
SKIN
THYROID
GLANDS
OVARIES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
PITUITARY
SPINAL
CORD
;&,
LAND
MAND
SKELETAL
MUSCLE
STOMACH
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSORcHAP
TASK
FORCE
ANIMAL
NO.
69413
GROUP
2:
1
______­__________
____­___
­
ORGAN
WEIGHT
ABS.(
G)
BRAIN
1.87
LIVER
4.45
KIDNEYS
1.37
LUNGS
0.97
HEART
0.69
SPLEEN
0.47
OVARIES
0.1115
THYMUS
0.1989
ADRENAL
GLANDS
0.0656
THyROIDS/
PARA
0.0120
FINAL
BODY
WT(
G)
173.
TABLE
31
(PRIMARY
NE~
ROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
58
_
­
­
_
­
­
_
­
_
REL.
1.081
2.572
0.792
0.561
0.399
0.272
0.064
0.115
0.038
0.007
5
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
_­__­___________­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­~­­­­­~­­­
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
MAMMARY
GLAND
LARYNX
NERVE.
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,.
MED
NASAL
TISSUES
OVARIES
PANCREAS
OVIDUCTS
THYMUS
RECTUM
PITUITARY
SPINAL
CORD
TRACHEA
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPLEEN
STOMACH
THYROID
GLANDS
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
59
ANIMAL
NO.
63435
GROUP
ORGAN
WEIGHT
ABS.
(G)
BRAIN
1.72
LIVER
4.49
KIDNEYS
1.30
LUNGS
0.97
HEART
0.61
SPLEEN
0.37
OVARIES
0.0769
THYMUS
0.1705
ADRENAL
GLANDS
0.0519
THYROIDS/
PARA
0.0146
FINAL
BODY
WT(
G)
179.
2:
15
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
REL.
NO
SIGNIFICANT
0.961
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
2.508
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
0.726
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
0.542
JEJUNUM
KIDNEYS
LIVER
AORTA
0.341
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
0.207
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
0.043
PANCREAS
OVIDUCTS
THYMUS
RECTUM
0.095
PITUITARY
0.029
SPINAL
CORD
0.008
TRACHEA
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPLEEN
STOMACH
THYROID
GLANDS
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
60
ANIMAL
NO.
69359
GROUP
3:
40
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
_________­_____­_­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­~
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
ABS.(
G)
REL.
1.74
1.030
4.26
2.521
1.21
0.716
0.83
0.491
0.61
0.361
0.44
0.260
0.0943
0.056
0.2077
0.123
0.0557
0.033
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
EYES/
OPTIC
N.
HARDERIAN
GLANDS
JEJUNUM
KIDNEYS
LUNGS
MAMMARY
GLAND
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
PANCREAS
OVIDUCTS
PITUITARY
SAL.
GLAND
MAND
SPINAL
CORD
SPLEEN
URINARY
BLADDER
0.0165
0.010
TRACHEA
169.
BRAIN
CECUM
LAC
GLAND,
EXOR
ESOPHAGUS
HEART
ILEUM
LIVER
AORTA
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
OVARIES
THYMUS
RECTUM
SKELETAL
MUSCLE
SKIN
STOMACH
THYROID
GLANDS
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
p­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NEcROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
61
ANIMAL
NO.
69369
GROUP
3:

­­­­­_­_­­­_­_____
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
­
_
_
_
_
_
_
_
_
ABS.(
G)
1.82
4.41
1.31
1.00
0.62
0.42
0.0831
0.1986
0.0579
0.0113
184.
REL.
0.989
2.397
0.712
0.543
0.337
0.228
0.045
0.108
0.031
0.006
40
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
­_______________­­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­~~~­­­­
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
PANCREAS
OVIDUCTS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
62
ANIMAL
NO.
69370
GROUP
3:

__­­­­­­­­­­_­­_­
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYRQIDS/
PARA
FINAL
BODY
WT(
G)
­
_
_
­
_
_
_
_
_
_
­
_
_
_
_
_
ABS.
(G)
REL.
1.69
0.904
4.95
2.647
1.20
0.642
0.97
0.519
0.64
0.342
0.46
0.0924
0.1842
0.0578
0.0157
187.
0.246
0.049
0.099
0.031
0.008
40
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND.
EXOR
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
PANCREAS
OVIDUCTS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
63
ANIMAL
NO.
69380
GROUP
3:
40
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
­______­________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­~­­­~­~­­­~~­­­­~­­­­­~­­~­­­­~~­­­~­­~­
ORGAN
WEIGHT
ABS.(
G)
BRAIN
1.81
LIVER
4.77
KIDNEYS
1.34
LUNGS
0.97
HEART
0.66
SPLEEN
0.46
OVARIES
0.0870
THYMUS
0.2330
ADRENAL
GLANDS
0.0545
THYROIDS/
PARA
0.0123
FINAL
BODY
NT(
G)
202.
REL.
0.896
2.361
0.663
0.480
0.327
0.228
0.043
0.115
0.027
0.006
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
COLON
EYES/
OPTIC
N.
JEJUNUM
LUNGS
LYMPH
NODE,
TR/
BR
PANCREAS
PITUITARY
SPINAL
CORD
TRACHEA
STERNUM
BRAIN
CECUM
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
HARDERIAN
GLANDS
HEART
ILEUM
KIDNEYS
LIVER
AORTA
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
OVIDUCTS
THYMUS
RECTUM
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPLEEN
STOMACH
THYROID
GLANDS
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
64
ANIMAL
NO.
69388
GROUP
3:
40
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
_____­_____­__­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ORGAN
WEIGHT
ABS.(
G)
1.82
4.93
1.30
0.96
0.70
REL.
NO
SIGNIFICANT
1.040
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
2.817
COLON
DUODENUM
LAC
GLAND,
EXOR
0.743
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
0.549
JEJUNUM
KIDNEYS
LIVER
0.400
LUNGS
MAMMARY
GLAND
LARYNX
0.280
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
0.069
PANCREAS
OVIDUCTS
THYMUS
0.113
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
0.036
SPINAL
CORD
SPLEEN
STOMACH
0.009
TRACHEA
URINARY
BLADDER
UTERUS
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
0.49
0.1199
0.1980
0.0637
0.0154
175.
CECUM
ESOPHAGUS
ILEUM
AORTA
NERVE,
SCIATIC
OVARIES
RECTUM
SKIN
THYROID
GLANDS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
65
ANIMAL
NO.
69394
GROUP
3:
40
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
_­____­______­___
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
­__­__­____
ABS.(
G)
1.73
4.56
1.30
1.00
0.64
0.48
0.0891
0.2163
0.0488
0.0121
182.
­
­
­
_
_
_
_

REL
,

0.951
2.505
0.714
0.549
0.352
0.264
0.049
0.119
0.027
0.007
___­____________­_______________________­­­­­­­­­­­­~­­­­~.
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
EYES/
OPTIC
N.
HARDERIAN
GLANDS
JEJUNUM
KIDNEYS
LUNGS
MAMMARY
GLAND
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
PANCREAS
OVIDUCTS
PITUITARY
SAL.
GLAND
MAND
SPINAL
CORD
SPLEEN
TRACHEA
URINARY
BLADDER
BRAIN
CECUM
LAC
GLAND,
EXOR
ESOPHAGUS
HEART
ILEUM
LIVER
AORTA
LARYNX
NERVE,
SCIATIC
NASAL
TISSUES
OVARIES
THYMUS
RECTUM
SKELETAL
MUSCLE
SKIN
STOMACH
THYROID
GLANDS
UTERUS
VAGINA
GROSS
GRADE
CODE:
I­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
ANIMAL
NO.
69426
GROUP
_­­__­_____­____­________
ORGAN
WEIGHT
ABS.(
G)
BRAIN
1.79
LIVER
4.98
KIDNEYS
1.40
LUNGS
0.93
HEART
0.67
SPLEEN
0.47
OVARIES
0.0974
THYMUS
0.1986
ADRENAL
GLANDS
0.0553
THYROIDSjPARA
0.0128
FINAL
BODY
WT(
G)
193.
__
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
66
3:
40
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
­_­­_____­___­­­­_­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­~
REL.
NO
SIGNIFICANT
0.927
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
2.580
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
0.725
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
0.482
JEJUNUM
KIDNEYS
LIVER
AORTA
0.347
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
0.244
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
0.050
PANCREAS
OVIDUCTS
THYMUS
RECTUM
0.103
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
0.029
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
0.007
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
UAP
TASK
FORCE
ANIMAL
NO.
69428
GROUP
3:

­__­_­_­________­
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
ABS.
(G)
1.75
4.41
1.20
0.94
0.63
0.47
0.0808
0.1873
0.0495
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
67
REL.
1.042
2.625
0.714
0.560
0.375
0.280
0.048
0.111
0.029
THYROIDS/
PARA
0.0108
0.006
FINAL
BODY
WT(
G)
168.
40
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
.­­__­_____________­____________________­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­~­­­­~­~­­­­
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
PANCREAS
OVIDUCTS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
68
ANIMAL
NO.
69433
GROUP
3:
40
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ORGAN
WEIGHT
ABS.
(G)
BRAIN
1.79
LIVER
4.91
KIDNEYS
1.38
LUNGS
1.06
HEART
0.66
SPLEEN
0.46
OVARIES
0.1062
THYMUS
0.2110
ADRENAL
GLANDS
0.0488
THYROIDS/
PARA
0.0167
FINAL
BODY
WT(
G)
111.
REL.
1.011
2.714
0.780
0.599
0.373
0.260
0.060
0.119
0.028
0.009
GENERAL
COMMENT
GROSS:
ORGAN
DAMAGED
AT
NECROPSY
EYE,
LEFT
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
COLON
DUODENUM
LAC
GLAND,
EXOR
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
JEJUNUM
KIDNEYS
LIVER
LUNGS
MAMMARY
GLAND
LARYNX
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
OVIDUCTS
THYMUS
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SPINAL
CORD
SPLEEN
STOMACH
TRACHEA
URINARY
BLADDER
UTERUS
P
CECUM
ESOPHAGUS
ILEUM
AORTA
NERVE,
SCIATIC
OVARIES
RECTUM
SKIN
THYROID
GLANDS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
TABLE
31
(PRIMARY
NECRO~
SY)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
69
SPONS~
R:
HAP
TASK
FORCE
INDIVIDUAL
MACROSCOPIC
FINDINGS
ANIMAL
NO.
69436
GROUP
3:
40
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
__­_­_­____­_­____­­____________________­­­­­­­­­­­­­­­­­­~­~­­­­­­­­­­­­­­­­­~­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­
ORGAN
WEIGHT
ABS.
(G)
BRAIN
1.78
REL.
NO
SIGNIFICANT
0.927
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
2.615
COLON
DUODENUM
LAC
GLAND,
EXOR
0.724
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
0.495
JEJUNUM
KIDNEYS
LIVER
CECUM
ESOPHAGUS
ILEUM
AORTA
NERVE,
SCIATIC
OVARIES
RECTUM
SKIN
THYROID
GLANDS
VAGINA
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
5.02
1.39
0.95
0.62
0.323
0.43
0.224
0.0750
0.2076
0.0517
0.0173
192.
0.039
0.108
0.027
0.009
LUNGS
MAMMARY
GLAND
LARYNX
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
OVIDUCTS
THYMUS
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SPINAL
CORD
SPLEEN
STOMACH
TRACHEA
URINARY
BLADDER
UTERUS
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
70
ANIMAL
NO.
69375
GROUP
4:
100
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ORGAN
WEIGHT
BRAIN
ABS.(
G)
1.74
4.70
1.25
0.89
0.60
0.42
0.0816
0.2034
0.0505
REL.
1.018
2.749
0.731
0.520
0.351
0.246
SKIN
GROSS:
MATTING,
YELLOW
P
UROGENITAL
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
0.0160
171.
0.048
0.119
0.030
0.009
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
PANCREAS
OVIDUCTS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
71
ANIMAL
NO.
69379
GROUP
_______­__________________
ORGAN
WEIGHT
ABS.
(G)
BRAIN
1.79
LIVER
4.98
KIDNEYS
1.37
LUNGS
1.11
HEART
0.65
SPLEEN
0.46
OVARIES
0.1223
THYMUS
0.2146
ADRENAL
GLANDS
0.0633
THYROIDS/
PARA
0.0158
FINAL
BODY
WT(
G)
181.
4:
100
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
REL.
LIVER
GROSS:
AREA(
S),
RAISED
P
0.989
ONE,
3
X
3
X
1
MM,
WHITE,
MEDIAN
LOBE
2.751
LUNGS
GROSS:
AREA(
S),
WHITE
P
0.757
FEW,
IRREGULARLY
SHAPED,
ALL
LOBES
0.613
NO
SIGNIFICANT
0.359
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
0.254
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
0.068
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
0.119
0.035
0.009
JEJUNUM
KIDNEYS
AORTA
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
PANCREAS
OVIDUCTS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
TABLE
31
(PRIMARY
NECROPSY)
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
72
ANIMAL
NO.
69383
GROUP
.­
­­_­_­­­__­_­­__
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYROlDS/
PARA
FINAL
BODY
WT(
G)
_____
­__
ABS.(
G)
1.79
4.88
1.28
1.03
0.67
0.46
0.0952
0.1797
0.0572
0.0136
178.
4:

­_­_­­
REL.
1.006
2.742
0.719
0.579
0.376
0.258
0.053
0.101
0.032
0.008
.OO
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
___________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
OVARIES
GROSS:
AREA(
S),
WHITE
P
MULTIPLE,
PINPOINT,
BILATERAL
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
PANCREAS
OVIDUCTS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
ANIMAL
NO.
69385
GROUP
­__­­­_­__­__­­_­
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
0.0951
THYMUS
0.2063
ADRENAL
GLANDS
0.0547
THyROIDS/
PARA
0.0117
FINAL
BODY
WT(
G)
187.
ABS.
(G)
1.73
4.91
1.47
0.89
0.73
0.45
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
73
4:
100
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
____­_____­_­____­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
REL.
NO
SIGNIFICANT
0.925
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
2.626
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
0.786
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
0.476
JEJUNUM
KIDNEYS
LIVER
AORTA
0.390
LUNGS
MAMMARY
GLAND
LARYNX
NERVE.
SCIATIC
0.241
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIk
0.051
PANCREAS
OVIDUCTS
THYMUS
RECTUM
0.110
PITUITARY
0.029
SPINAL
CORD
0.006
TRACHEA
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPLEEN
STOMACH
THYROID
GLANDS
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
74
ANIMAL
NO.
69392
GROUP
_­­­­­__­__­­_­­__
­
__­_
­__.
ORGAN
WEIGHT
ABS.(
G)
BRAIN
1.74
LIVER
4.43
KIDNEYS
1.30
LUNGS
0.88
HEART
0.60
SPLEEN
0.39
OVARIES
0.0763
THYMUS
0.1873
ADRENAL
GLANDS
0.0508
THYROIDS/
PARA
0.0104
4:
100
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
_________­____­_­_­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­~­­­~­~­­­­­­­~­

REL.
NO
SIGNIFICANT
1.055
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
2.685
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
0.788
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
0.533
JEJUNUM
KIDNEYS
LIVER
AORTA
0.364
LUNGS
MAMMARY
GLAND
LARYNX
NERVE.
SCIATIf!
0.236
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
0.046
PANCREAS
OVIDUCTS
THYMUS
RECTUM
0.114
0.031
0.006
PITUITARY
SPINAL
CORD
TRACHEA
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPLEEN
STOMACH
THYROID
GLANDS
URINARY
BLADDER
UTERUS
VAGINA
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
75
ANIMAL
NO.
69402
GROUP
_­_­____­­_­_____
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
ABS.
(G)
1.72
5.30
1.38
0.96
0.66
0.45
0.0933
0.2100
0.0541
0.0099
186.
4:
100
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
_­_­___­_____­_­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­~­­­~­­
REL.
NO
SIGNIFICANT
0.925
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
2.849
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
0.742
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
0.516
JEJUNUM
KIDNEYS
LIVER
AORTA
0.355
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
0.242
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
0.050
PANCREAS
OVIDUCTS
THYMUS
RECTUM
0.113
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
0.029
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
0.005
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
76
ANIMAL
NO.
69408
GROUP
4:
100
PPM
FEMALE
SCHEDULED
EUTH
08/
31/
01
DATE
OF
DEATH:
08/
31/
01
STUDY
DAY:
92
GRADE
____­_____­­____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­~­­­­­­­­­~~­­­
ORGAN
WEIGHT
ABS.
(G)
REL.
GENERAL
COMMENT
GROSS:
ORGAN
DAMAGED
AT
NECROPSY
P
BRAIN
1.80
0.994
PITUITARY
LIVER
4.87
2.691
NO
SIGNIFICANT
KIDNEYS
1.40
0
LUNGS
1.00
0
HEART
0.67
0
SPLEEN
0.46
0
OVARIES
0.0958
0
THYMUS
0.1681
0
ADRENAL
GLANDS
0.0548
0
THYROIDS/
PARA
0.0106
0
FINAL
BODY
WT(
G)
181.
773
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
552
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
370
254
053
093
030
006
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
PANCREAS
OVIDUCTS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
77
ANIMAL
NO.
69415
GROUP
4:
100
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
ORGAN
WEIGHT
ABS.(
G)
REL.
BRAIN
1.80
0.984
LIVER
4.88
2.667
KIDNEYS
1.29
0.705
LUNGS
0.97
0.530
HEART
0.76
0.415
SKIN
GROSS:
MATTING,
YELLOW
UROGENITAL
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
COLON
DUODENUM
EYES/
OPTIC
N.
HARDERIAN
GLANDS
JEJUNUM
KIDNEYS
LUNGS
MAMMARY
GLAND
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
PANCREAS
OVIDUCTS
PITUITARY
SAL.
GLAND
MAND
SPLEEN
STOMACH
URINARY
BLADDER
UTERUS
P
CECUM
BRAIN
LAC
GLAND,
EXOR
HEART
LIVER
LARYNX
NASAL
TISSUES
THYMUS
SKELETAL
MUSCLE
THYROID
GLANDS
VAGINA
ESOPHAGUS
ILEUM
AORTA
NERVE,
SCIATIC
OVARIES
RECTUM
SPINAL
CORD
TRACHEA
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
0.45
0.246
0.1102
0.060
0.2245
0.0537
0.0182
183.
0.123
0.029
0.010
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
ANIMAL
NO.
69427
GROUP
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PAR?+
FINAL
BODY
WT(
G)
.___
­
____
ABS.
(G)
1.75
4.89
1.31
1.10
0.66
0.47
0.1062
0.2529
0.0619
0.0198
178.
TABLE
31
(PRIMARY
NECR~
PSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
78
4:
100
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
___________­­­_­_­_­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

REL.
SKIN
GROSS:
MATTING,
YELLOW
P
0.983
UROGENITAL;
ANOGENITAL
2.747
NO
SIGNIFICANT
0.736
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
0.618
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
0.371
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
0.264
JEJUNUM
KIDNEYS
LIVER
AORTA
0.060
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
0.142
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
0.035
PANCREAS
OVIDUCTS
THYMUS
RECTUM
0.011
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
UTERUS
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
31
(PRIMARY
NECROPSY)
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
MACROSCOPIC
FINDINGS
PAGE
79
ANIMAL
NO.
69431
GROUP
4:
100
PPM
FEMALE
SCHEDULED
EUTH
08/
30/
01
DATE
OF
DEATH:
08/
30/
01
STUDY
DAY:
91
GRADE
____­___­­______________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ORGAN
WEIGHT
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
ADRENAL
GLANDS
THYROIDS/
PARA
FINAL
BODY
WT(
G)
ABS.(
G)
1.78
4.91
1.47
1.04
0.72
REL.
0.983
2.713
0.812
0.575
0.398
UTERUS
GROSS:
CONTENTS,
CLEAR
FLUID
P
BOTH
HORNS
NO
SIGNIFICANT
CHANGES
OBSERVED
GROSS:
ADRENAL
GLANDS
STERNUM
BRAIN
CECUM
0.49
0.271
0.1014
0.056
COLON
DUODENUM
LAC
GLAND,
EXOR
ESOPHAGUS
EYES/
OPTIC
N.
HARDERIAN
GLANDS
HEART
ILEUM
0.2008
0.0645
0.0162
181.
0.111
0.036
0.009
JEJUNUM
KIDNEYS
LIVER
AORTA
LUNGS
MAMMARY
GLAND
LARYNX
NERVE,
SCIATIC
LYMPH
NODE,
TR/
BR
LYMPH
NODE,
MED
NASAL
TISSUES
OVARIES
PANCREAS
OVIDUCTS
THYMUS
RECTUM
PITUITARY
SAL.
GLAND
MAND
SKELETAL
MUSCLE
SKIN
SPINAL
CORD
SPLEEN
STOMACH
THYROID
GLANDS
TRACHEA
URINARY
BLADDER
VAGINA
GROSS
GRADE
CODE:
l­
SLIGHT,
2­
MODERATE,
3­
MARKED,
P­
PRESENT
PGRHv4.28
01/
18/
2002
FINAL
REPORT
Volume
2
of
2
(Individual
Tables
32
­
34
and
Appendices)

STUDY
TITLE
A
90­
Day
Inhalation
Toxicity
Study
of
1,
1,2­
Trichloroethane
(1,
1,2­
TCE)
in
Rats
(With
Satellite
Groups
for
Pharrnacokinetic
Evaluations
in
Rats
and
Mice)

STUDY
NUMBER
WIL­
4
17002
DATA
REQUIREMENT
U.
S.
EPA­
TSCA
799.9346
STUDY
DIRECTOR
Daniel
T.
Kirkpatrick,
Ph.
D.,
D.
A.
B.
T.

STUDY
INITIATION
DATE
May
15,200l
STUDY
COMPLETION
DATE
May
23,2002
PERFORMING
LABORATORY
WIL
Research
Laboratories,
Inc.
1407
George
Road
Ashland,
OH
44805­
928
1
SPONSOR
HAP
Task
Force
P.
O.
Box
331
Millwood,
VA
22646
303
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
TABLES
32
­
34
304of619
TABLE
32
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
1
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
ORGAN
WEIGHTS
AND
FINAL
BODY
WEIGHTS
[Gl
WEEK
13
MALE
GROUP:
0
PPM
________­_______­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ANIMAL
_
_
_
_
_
_
_
_
_
69302
69306
69308
69310
69312
69314
69317
69322
69337
69343
FBW(
G)
._­­­______­___­__________
305.
291.
282.
264.
316.
281.
309.
280.
284.
263.
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
1.83
1.81
1.88
1.73
1.88
1.74
1.84
1.85
1.84
1.83
MEAN
288.
1.82
S.
D.
17.9
0.051
N
10
10
FBW
=
FINAL
BODY
WEIGHT
__________­­____­_____
__________
8.57
1.89
8.25
2.09
8.40
1.97
7.35
1.87
8.46
2.16
7.49
1.87
8.37
2.02
7.44
2.00
8.03
1.92
7.80
1.80
1.25
1.15
1.10
1.15
1.25
1.19
1.21
1.26
1.18
1.18
­_­­­­­
0.99
0.90
0.98
0.95
1.01
0.85
0.89
0.87
1.02
0.89
8.02
1.96
1.19
0.94
0.463
0.111
0.052
0.062
10
10
10
10
TABLE
32
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
2
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
ORGAN
WEIGHTS
AND
FINAL
BODY
WEIGHTS
[G]
WEEK
13
MALE
GROUP:
15
PPM
­­______­_____­­­­­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­

ANIMAL
____
­­___

69305
69316
69320
69323
69326
69335
69336
69338
69345
69347
FBW(
G)
_____________­­­

261.
1.87
307.
1.92
317.
1.87
323.
1.84
334.
1.98
320.
1.95
300.
1.86
273.
1.87
307.
2.01
282.
1.76
BRAIN
LIVER
KIDNEYS
________­____­__­­______________________­­­­­~­

7.12
1.87
9.78
2.25
8.75
2.20
8.85
2.11
8.99
2.19
8.86
2.24
8.71
2.08
7.22
1.81
8.66
2.29
8.02
1.99
LUNGS
__­_______­­­__­­______
0.96
1.34
1.40
1.31
1.40
0.98
1.26
1.08
1.21
1.11
1.27
1.23
HEART
.__­­­
0.81
1.00
1.00
0.99
0.99
0.88
0.98
0.87
MEAN
302.
1.89
8.50
2.10
1.25
0.96
S.
D.
23.5
0.073
0.819
0.165
0.135
0.080
N
10
10
10
10
10
10
2
FBW
=
FINAL
BODY
WEIGHT
a
TABLE
32
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
3
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
ORGAN
WEIGHTS
AND
FINAL
BODY
WEIGHTS
[G]
WEEK
13
MALE
GROUP:
40
PPM
_____­­_________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ANIMAL
__­­­____.
69303
69309
69313
69315
69324
69328
69339
69344
69348
69350
FBW(
G)
__­___­­­___________­­­.
255.
308.
310.
253.
333.
322.
270.
316.
292.
280.

MEAN
294.
S.
D.
28.3
N
10
FBW
=
FINAL
BODY
WEIGHT
BRAIN
LIVER
.__­­
____
__­_______________________

1.61
6.40
1.89
8.02
1.91
9.01
1.85
6.64
1.95
8.96
1.90
8.59
1.77
7.44
1.84
9.00
1.92
8.36
1.88
7.28
1.85
7.97
2.10
1.17
0.96
0.099
0.980
0.240
0.149
0.064
10
10
10
10
10
KIDNEYS
LUNGS
­__­­­­­­_______­­­­__
____­__­­_­­______­_________________
1.76
0.99
2.44
1.39
2.26
1.22
1.74
1.05
2.24
1.25
2.20
1.30
1.94
0.90
2.32
1.24
2.17
1.19
1.95
1.20
HEART
­____
0.89
0.97
1.03
0.87
1.01
1.06
0.91
1.01
0.95
0.92
TABLE
32
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
4
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
ORGAN
WEIGHTS
AND
FINAL
BODY
WEIGHTS
[Gl
WEEK
13
MALE
GROUP:
100
PPM
____­________­__­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ANIMAL
FBW(
G)
___­___­­_
__­_______­___­­_­­__

69304
323.
69307
327.
69318
308.
69319
305.
69327
303.
69329
293.
69332
293.
69334
288.
69342
306.
69346
303.
BRAIN
___­_­______________­­­­­

1.91
1.95
1.83
1.87
1.84
1.87
1.90
1.82
1.79
1.78
LIVER
KIDNEYS
__­_________­­­__­­___
._____­­­___­__^­­__­­­­­
8.98
2.36
9.49
2.22
8.70
2.15
8.46
2.19
7.77
2.01
8.34
2.21
7.56
1.94
8.48
2.17
8.46
2.22
8.89
2.24
LUNGS
HEART
1.30
1.36
1.21
1.27
1.22
1.07
1.13
0.99
0.94
0.92
0.95
0.97
0.97
0.88
NA
1.21
1.11
1.19
1.14
1.19
MEAN
305.
1.86
8.51
2.1.7
1.22
S.
D.
12.5
0.054
0.562
0.119
0.074
N
10
10
10
10
10
w
E
FBW
=
FINAL
BODY
WEIGHT
NA
=
NOT
APPLICABLE
%
(3
;;
0.98
0.077
9
TABLE
32
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
5
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
ORGAN
WEIGHTS
AND
FINAL
BODY
WEIGHTS
[Gl
WEEK
13
MALE
GROUP:
0
PPM
______­­____________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­
EPIDID
ADRENAL
THYROIDS
ANIMAL
SPLEEN
YMIDES
TESTES
THYMUS
GLANDS
/PARA
__­______­__________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­
69302
0.55
0.99
2.87
0.1814
0.0451
0.0197
69306
0.53
0.98
3.16
0.1619
0.0595
0.0212
69308
0.58
1.00
3.03
0.1835
0.0627
0.0208
69310
0.54
0.99
2.79
0.1835
0.0546
0.0112
69312
0.66
1.04
3.43
0.2075
0.0638
0.0148
69314
0.57
0.90
2.98
0.1740
0.0487
0.0151
69317
0.59
0.91
3.13
0.2070
0.0393
0.0105
69322
0.50
0.94
2.99
0.1670
0.0602
0.0146
69337
0.55
1.07
3.10
0.1882
0.0592
0.0228
69343
0.61
0.91
2.83
0.1493
0.0518
0.0192
MEAN
0.57
0.97
3.03
0.1803
0.0545
0.0170
S.
D.
0.045
0.057
0.188
0.01842
0.00812
0.00432
N
10
10
10
10
10
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
32
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WEIGHTS
AND
FINAL
BODY
WEIGHTS
[G]

SPLEEN
_______­­_­____­_­__

0.49
0.70
0.62
0.60
0.67
0.67
0.60
0.56
0.65
0.59
ANIMAL
__________­­­____­__

69305
69316
69320
69323
69326
69335
69336
69338
69345
69347
MALE
GROUP:
15
PPM
_____­­­__________­_____________________­­­­­­­­­­~­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­
EPIDID
ADRENAL
THYROIDS
YMIDES
TESTES
THYMUS
GLANDS
/PARA
__­­­­_________­­­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

0.96
3.04
0.1574
0.0607
0.0213
0.99
3.39
0.2055
0.0629
0.0208
0,95
3.08
0.2047
0.0537
0.0170
0.96
3.11
0.1898
0.0577
0.0178
1.09
3.39
0.2244
0.0521
0.0249
1.03
3.24
0.1967
0.0541
0.0145
0.94
2.90
0.2001
0.0618
0.0146
0.94
3.13
0.1938
0.0564
0.0146
1.08
3.20
0.2254
0.0587
0.0139
0.88
2.73
0.2210
0.0519
0.0253
MEAN
0.62
0.98
3.12
0.2019
0.0570
0.0185
S.
D.
0.062
0.066
0.204
0.02018
0.00401
0.00435
N
10
10
10
10
10
10
PAGE
6
WEEK
13
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
32
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WEIGHTS
AND
FINAL
BODY
WEIGHTS
[G]
PAGE
I
WEEK
13
MALE
GROUP:
__­__________­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­

ANIMAL
SPLEEN
EPIDID
YMIDES
___________
69303
69309
69313
69315
69324
69328
69339
69344
69348
69350
MEAN
0.59
0.96
3.11
0.1919
0.0557
0.0165
S.
D.
0.091
0.090
0.353
0.03725
0.00581
0.00296
N
10
10
10
10
10
10
0
0
41
59
64
42
70
63
51
68
60
61
__­______­_______
0.80
1.01
0.96
0.94
1.08
1.08
0.88
0.99
0.99
0.87
40
PPM
_____­­­________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~
ADRENAL
THYROIDS
TESTES
THYMUS
GLANDS
/PARA
2.68
0.0972
0.0495
0.0144
3.25
0.2094
0.0654
0.0151
3.13
0.2268
0.0598
0.0162
2.81
0.1794
0.0474
0.0188
3.22
0.2108
0.0601
0.0163
3.95
0.2050
0.0478
0.0163
2.80
0.1799
0.0572
0.0165
3.11
0.2125
0.0562
0.0148
3.16
0.1814
0.0565
0.0236
3.00
0.2170
0.0566
0.0128
TABLE
32
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
8
SPQNSOR:
HAP
TASK
FORCE
INDIVIDUAL
ORGAN
WEIGHTS
AND
FINAL
BODY
WEIGHTS
[G]
WEEK
13
MALE
GROUP:
100
PPM
________­____­­__­­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
EPIDID
ADRENAL
THYROIDS
ANIMAL
SPLEEN
YMIDES
TESTES
THYMUS
GLANDS
/PARA
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69304
0.76
1.09
3.50
0.2438
0.0674
0.0140
69307
0.65
1.06
3.31
0.2473
0.0637
0.0197
69318
0.64
0.95
3.09
0.2204
0.0538
0.0228
69319
0.66
1.01
3.30
0
:1970
0
.
050.8
0.0152
69327
0.64
0.98
3.08
0.1762
0.0472
0.0166
69329
0.62
1.01
2.98
0.1926
0.0536
0.0224
69332
0.56
1.11
3.05
0.1944
0.0499
0.0150
69334
0.60
0.97
3.06
0.1969
0.0572
0.0225
69342
0.55
0.96
3.01
0.1683
0.0562
0.0168
69346
0.57
0.97
3.00
0.1742
0.0533
0.0159
MEAN
0.63
1.01
3.14
0.2011
0.0553
0.0181
S.
D.
0.062
0.057
0.172
0.02769
0.00620
0.00343
N
10
10
10
10
10
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
ANIMAL
FBW(
G)
­
­
­
­
_
­
­
_
_
_____­_____­
69354
196.
69366
179.
69367
196.
69378
180.
69384
168.
69398
197.
69404
199.
69416
192.
69419
193.
69432
179.
BRAIN
LIVER
____
1.90
5.34
1.71
4.41
1.79
4.64
1.81
4.86
1.72
4.70
1.86
4.72
1.81
4.81
1.84
5.16
1.76
4.90
1.81
4.93
MEAN
188.
1.80
S.
D.
10.5
0.059
N
10
10
w
t;
FBW
=
FINAL
BODY
WEIGHT
%
o\

5,
____
TABLE
32
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WEIGHTS
AND
FINAL
BODY
WEIGHTS
[Gl
FEMALE
GROUP:
0
PPM
HEART
SPLEEN
KIDNEYS
LUNGS
__­­______________­______

1.35
0.97
1.27
0.93
1.36
0.96
1.27
1.03
1.14
0.95
1.32
0.91
1.40
0.99
1.40
0.98
1.31
0.96
1.34
0.94
THYMUS
0.65
0.49
0.59
0.44
0.62
0.52
0.65
0.44
0.60
0.44
0.68
0.48
0.68
0.50
0.67
0.50
0.70
0.48
0.68
0.51
OVARIES
­
_
_
_
_
_
_
_
_
0.0923
0.0885
0.0744
0.0969
0.1006
0.1011
0.1018
0.1029
0.1059
0.0924
0.2110
0.1814
0.2682
0.2174
0.1931
0.2156
0.2587
0.2011
0.2328
0.1837
ADRENAL
GLANDS
.___
­­___
0.0645
0.0493
0.0457
0.0449
0.0491
0.0639
0.0567
0.0554
0.0506
0.0562
_­___­­­­____
THYROIDS
/PARA
__________­­_
0.0128
0.0131
0.0216
0.0109
0.0163
0.0155
0.0127
0.0181
0.0161
0.0132
4.85
1.32
0.96
0.65
0.48
0.0957
0.2163
0.0536
0.0150
0.263
0.077
0.034
0.037
0.030
0.00928
0.02952
0.00691
0.00316
10
10
10
10
10
10
10
10
10
PAGE
9
WEEK
13
TABLE
32
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
10
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
ORGAN
WEIGHTS
AND
FINAL
BODY
WEIGHTS
[G]
WEEK
13
FEMALE
GROUP:
15
PPM
__­___­_________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ANIMAL
FBW(
G)
­
_
­
_
_
­
­
­
_
­
­
_
_
_
_
_
­
­
_
­
_
69362
176.
69376
159.
69382
195.
69390
182.
69393
166.
63396
188.
69409
180.
69413
173.
69435
179.
BRAIN
_­_­­______
1.66
1.71
1.79
1.74
1.81
1.76
1.80
1.87
1.72
LIVER
_­_­
____
4.79
4.49
4.64
4.42
4.33
4.88
4.75
4.45
4.49
KIDNEYS
1.36
1.15
1.27
1.37
1.25
1.19
1.21
1.37
1.30
MEAN
178.
1.76
4.58
1.27
0.97
0.64
0.45
0.0989
0.1910
0.0589
0.0135
S.
D.
10.9
0.063
0.190
0.082
0.081
0.032
0.050
0.01719
0.02205
0.00529
0.00187
N
9
9
9
9
9
9
9
9
9
9
9
w
FBW
=
FINAL
BODY
WEIGHT
x
0
2
G
__
LUNGS
HEART
SPLEEN
OVARIES
_
_
_
_
_
_
_
_
_
_
_
_
­
­
­
_
­
.
_
_
­
­
_
­
.
_
_
_
­
­
_
_
­
_
1.10
0.66
0.53
0.1351
0.80
0.60
0.42
0.0985
0.93
0.65
0.46
0.0997
1.04
0.65
0.51
0.0858
0.97
0.59
0.41
0.0869
0.98
0.63
0.47
0.1049
0.96
0.64
0.43
0.0912
0.97
0.69
0.47
0.1115
0.97
0.61
0.37
0.0769
THYMUS
0.2288
0.1878
0.1678
0.2184
0.1759
0.1716
0.1997
0.1989
0.1705
ADRENAL
THYROIDS
GLANDS
/PARA
­
­
­
­
_
­
­
_
_
­­­­­­____­­___
0.0687
0.0103
0.0558
0.0128
0.0590
0.0129
0.0564
0.0126
0.0550
0.0164
0.0601
0.0147
0.0576
0.0152
0.0656
0.0120
0.0519
0.0146
PROJECT
NO.:
WlL­
417002
SPONSOR:
HAP
TASK
FORCE
ANIMAL
FBW(
G)
BRAIN
­____­­_­__­__­___­_________
69359
169.
1.74
69369
184.
1.82
69370
187.
1.69
69380
202.
1.81
69388
175.
1.82
69394
182.
1.73
69426
193.
1.79
69428
168.
1.75
69433
177.
1.79
69436
192.
1.78
MEAN
183.
1.77
S.
D.
11.0
0.043
N
10
10
w
t;
FBW
=
FINAL
BODY
WEIGHT
R
cn
G
____
TABLE
32
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WEIGHTS
AND
FINAL
BODY
WEIGHTS
[G]

FEMALE
GROUP:
40
PPM
­_­_
LIVER
_­____

4.26
4.41
4.95
4.77
4.93
4.56
4.98
4.41
4.91
5.02
LUNGS
HEART
KIDNEYS
­­­­­_­_­__­
1.21
1.31
1.20
1.34
1.30
1.30
1.40
1.20
1.38
1.39
0.83
0.61
1.00
0.62
0.97
0.64
0.97
0.66
0.96
0.70
1.00
0.64
0.93
0.67
0.94
0.63
1.06
0.66
0.95
0.62
SPLEEN
__­_­__

0.44
0.42
0.46
0.46
0.49
0.48
0.47
0.47
0.46
0.43
­_.
OVARIES
­_­­_­­_
0.0943
0.0831
0.0924
0.0870
0.1199
0.0891
0.0974
0.0808
0.1062
0.0750
____
THYMUS
_
­
_
_
_
_
_
_

0.2077
0.1986
0.1842
0.2330
0.1980
0.2163
0.1986
0.1873
0.2110
0.2076
ADRENAL
THYROIDS
GLANDS
/PARA
0.0557
0.0165
0.0579
0.0113
0.0578
0.0157
0.0545
0.0123
0.0637
0.0154
0.0488
0.0121
0.0553
0.0128
0.0495
0.0108
0.0488
0.0167
0.0517
0.0173
4.72
1.30
0.96
0.65
0.46
0.0925
0.2042
0.0544
0.0141
0.283
0.078
0.059
0.028
0.022
0.01308
0.01427
0.00479
0.00246
10
10
10
10
10
10
10
10
10
PAGE
11
WEEK
13
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
32
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WEIGHTS
AND
FINAL
BODY
WEIGHTS
[G]

FEMALE
GROUP:
100
PPM
PAGE
12
WEEK
13
ANIMAL
__­­­­__­­
69375
69379
69383
69385
69392
69402
69408
69415
69427
69431
FBW(
G)
­
_
_
_
­
_
_
_
_
­
­
171.
181.
178.
187.
165.
186.
181.
183.
178.
181.
BRAIN
1.74
1.79
1.79
1.73
1.74
1.72
1.80
1.80
1.75
1.78
MEAN
179.
1.76
S.
D.
6.7
0.031
N
10
10
w
s
FBW
=
FINAL
BODY
WEIGHT
%
a
5
LIVER
__­
__­___.
4.70
4.98
4.88
4.91
4.43
5.30
4.87
4.88
4.89
4.91
KIDNEYS
LUNGS
HEART
.__­___
0.60
0.65
0.67
0.73
0.60
0.66
0.67
0.76
0.66
0.72
SPLEEN
­­__
OVARIES
­
_
­
­
_
­
_
0.0816
0.1223
0.0952
0.0951
0.0763
0.0933
0.0958
0.1102
0.1062
0.1014
THYMUS
1.25
0.89
1.37
1.11
1.28
1.03
1.47
0.89
1.30
0.88
1.38
0.96
1.40
1.00
1.29
0.97
1.31
1.10
1.47
1.04
_
_
_
_
_
_
0.42
0.46
0.46
0.45
0.39
0.45
0.46
0.45
0.47
0.49
0.2034
0.2146
0.1797
0.2063
0.1873
0.2100
0.1681
0.2245
0.2529
0.2008
ADRENAL
THYROIDS
GLANDS
/PARA
_
_
_
_
­
­
­
_
________­­___

0.0505
0.0160
0.0633
0.0158
0.0572
0.0136
0.0547
0.0117
0.0508
0.0104
0.0541
0.0099
0.0548
0.0106
0.0537
0.0182
0.0619
0.0198
0.0645
0.0162
4.88
1.35
0.99
0.67
0.45
0.0977
0.2048
0.0566
0.0142
0.217
0.078
0.084
0.052
0.027
0.01334
0.02387
0.00503
0.00349
10
10
10
10
10
10
10
I.
0
10
POFBWv4.1
01/
18/
2002
R:
01/
18/
2002
TABLE
33
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
1
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
ORGAN
WTS.
RELATIVE
TO
FINAL
BODY
WTS.
[G/
100
G]
WEEK
13
MALE
GROUP:
0
PPM
________________­­__­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ANIMAL
FBW(
G)
BRAIN
LIVER
KIDNEYS
LUNGS
HEART
_____­______________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

69302
305.
0.600
2.810
0.620
0.410
0.325
69306
291.
0.622
2.835
0.718
0.395
0.309
69308
282.
0.667
2.979
0.699
0.390
0.348
69310
264.
0.655
2.784
0.708
0.436
0.360
69312
316.
0.595
2.677
0.684
0.396
0.320
69314
281.
0.619
2.665
0.665
0.423
0.302
69317
309.
0.595
2.709
0.654
0.392
0.288
69322
280.
0.661
2.657
0.714
0.450
0.311
69337
284.
0.648
2.827
0.676
0.415
0.359
69343
263.
0.696
2.966
0.684
0.449
0.338
MEAN
288.
0.636
2.791
0.682
0.416
0.326
S.
D.
17.9
0.0347
0.1170
0.0303
0.0231
0.0246
N
10
10
10
10
10
10
FBW
=
FINAL
BODY
WEIGHT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
33
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WTS.
RELATIVE
TO
FINAL
BODY
WTS.
[G/
100
Gl
MALE
GROUP:
15
PPM
PAGE
2
WEEK
13
ANIMAL
FBW(
G)
_
_
_
_
_
_
_
_
_
_­___­_______­____­_­­­­
69305
261.
69316
307.
69320
317.
69323
323.
69326
334.
69335
320.
69336
300.
69338
273.
69345
307.
69347
282.
BRAIN
_____­_­­­_____­_______
0.716
0.625
0.590
0.570
0.593
0.609
0.620
0.685
0.655
0.624
LIVER
KIDNEYS
2.728
0.716
3.186
0.733
2.760
0.694
2.740
0.653
2.692
0.656
2.769
0.700
2.903
0.693
2.645
0.663
2.821
0.746
2.844
0.706
MEAN
302.
0.629
2.809
S.
D.
23.5
0.0450
0.1521
N
10
10
10
FBW
=
FINAL
BODY
WEIGHT
LUNGS
­­­­__­­­­­__­_­­___­­­­
0.368
0.436
0.442
0.406
0.419
0.394
0.403
0.407
0.414
0.436
0.696
0.413
0.0315
0.0224
10
10
_­­­___­­___
HEART
0.310
0.326
0.315
0.307
0.293
0.338
0.330
0.322
0.319
0.309
0.317
0.0130
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
33
90­
DAY
INHAL.
STUDY
OF
l,
l.,
2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WTS.
RELATIVE
TO
FINAL
BODY
WTS.
[G/
100
G]
PAGE
3
WEEK
13
MALE
GROUP:
40
PPM
­­­­­­­­­­­­­­­­­­­­____________________­­­­­­­­­­~­­~­­­~­­­~­­­~~­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­~­­~­­­­~­­~­­­­­­

ANIMAL
­
­­­­__
­_
69303
69309
69313
69315
69324
69328
69339
69344
69348
69350
FBW(
G)
­­­­­­­­­­__­______­__
255.
308.
310.
253.
333.
322.
270.
316.
292.
280.
BRAIN
LIVER
­­­­­­­­­­­­­_­­__­­____________________­­­­­
0.631
2.510
0.614
2.604
0.616
2.906
0,731
2.625
0.586
2.691
0.590
2.668
0.656
2.756
0.582
2.848
0.658
2.863
0.671
2.600
KIDNEYS
­__­­_­­____­_­_________
0.690
0.792
0.729
0.688
0.673
0.683
0.719
0.734
0.743
0.696
LUNGS
_­__________
0.388
0.451
0.394
0.415
0.375
0.404
0.333
0.392
0.408
0.429
HEART
­­­..­­­­_­­­­____
0.349
0.315
0.332
0.344
0.303
0.329
0.337
0.320
0.325
0.329
MEAN
294.
0.634
S.
D.
28.3
2.707
0.0466
0.715
0.399
0.328
N
10
0.1315
10
0.0362
10
0.0318
10
0.0136
10
10
FEW
=
FINAL
BODY
WEIGHT
TABLE
33
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
4
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
ORGAN
WTS.
RELATIVE
TO
FINAL
BODY
WTS.
[G/
100
G]
WEEK
13
MALE
GROUP:
100
PPM
_____________­­__­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ANIMAL
FBW(
G)
___­
_____
.__­­__­­___­_____­
69304
323.
69307
327.
69318
308.
69319
305.
69327
303.
69329
293.
69332
293.
69334
288.
69342
306.
69346
303.

MEAN
305.
S.
D.
12.5
N
10
FBW
=
FINAL
BODY
WEIGHT
NA
=
NOT
APPLICABLE
BRAIN
0.591
0.596
0.594
0.613
0.607
0.638
0.648
0.632
0.585
0.587
LIVER
KIDNEYS
__­___­­­­­_­­­__­­__
._­­­­­­­­___­____­­­­­­­­­
2.780
0.731
2.902
0.679
2.825
0.698
2.774
0.718
2.564
0.663
2.846
0.754
2.580
0.662
2.944
0.753
2.765
0.725
2.934
0.739
LUNGS
HEART
0.402
0.416
0.393
0.416
0.403
0.413
0.379
0.413
0.373
0.393
._­­__
0.331
0.346
0.321
0.308
0.304
0.324
0.331
0.337
0.288
NA
0.609
2.791
0.712
0.400
0.321
0.0228
0.1323
0.0348
0.0154
0.0182
10
10
10
10
9
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
33
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WTS.
RELATIVE
TO
FINAL
BODY
WTS.
[G/
100
G]
PAGE
5
WEEK
13
GROUP:
0
PPM
­­­_______________

ANIMAL
­_­_­­__­____
69302
69306
69308
69310
69312
69314
69317
69322
69337
69343
MALE
_­_­__­_­_­___­_________________________­­­­
EBIDID
SPLEEN
YMIDES
___­__­_­__________­____________________­­­~

0.180
0.325
0.182
0.337
0.206
0.355
0.205
0.375
0.209
0.329
0.203
0.320
0.191
0.294
0.179
0.336
0.194
0.377
0.232
0.346
___­­­_­
TESTES
.­_­_­_­___________
0.941
1.086
1.074
1.057
1.085
1.060
1.013
1.068
1.092
1.076
­­_­­­­­­­­­­­­­­­­­____________________­­­­­­­­
ADRENAL
THYROIDS
___
THYMSJS_________­___
GLRNDS______________!
P~~_
0.059
0.015
0.006
0.056
0.020
0.007
0.065
0.022
0.007
0.070
0.021
0.004
0.066
0.020
0.005
0.062
0.017
0.005
0.067
0.013
0.003
0.060
0.022
0.005
0.066
0.021
0.008
0.057
0.020
0.007
MEAN
0.198
0.339
S.
D.
1.055
0.0164
0.063
0.0253
0.019
N
0.0459
0.006
10
0.0047
10
0.0031
10
0.0016
10
10
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
33
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WTS.
RELATIVE
TO
FINAL
BODY
WTS.
[G/
100
Gl
PAGE
6
WEEK
13
MALE
GROUP:
15
PPM
___­_______________­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
EPIDID
ADRENAL
THYROIDS
ANIMAL
SPLEEN
YMIDES
TESTES
THYMUS
GLANDS
/PARA
__­_______­__­______­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­

69305
0.188
0.368
1.165
0.060
0.023
0.008
69316
0.228
0.322
1.104
0.067
0.020
0.007
69320
0.196
0.300
0.972
0.065
0.017
0.005
69323
0.186
0.297
0.963
0.059
0.018
0.006
69326
0.201
0.326
1.015
0.067
0.016
0.007
69335
0.209
0.322
1.013
0.061
0.017
0.005
69336
0.200
0.313
0.967
0.067
0.021
0.005
69338
0.205
0.344
1.147
0.071
0.021
0.005
69345
0.212
0.352
1.042
0.073
0.019
0.005
69347
0.209
0.312
0.968
0.078
0.018
0.009
MEAN
0.203
0.326
1.036
0.067
0.019
0.006
S.
D.
0.0123
0.0228
0.0770
0.0060
0.0022
0.0015
N
10
10
10
10
10
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
33
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WTS.
RELATIVE
TO
FINAL
BODY
WTS.
[G/
100
G]
PAGE
7
WEEK
13
MALE
GROUP:
40
PPM
_______________­_­__­­­­­~­­­­­­~­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
EPIDID
ADRENAL
THYROIDS
ANIMAL
SPLEEN
YMIDES
TESTES
THYMUS
GLANDS
/FARA
69303
0.184
0.314
1.051
0.038
0.019
0.006
69309
0.192
0.328
1.055
0.068
0.021
0.005
69313
0.206
0.310
1.010
0.073
0.019
0.005
69315
0.166
0.372
1.111
0.071
0.019
0.007
69324
0.210
0.324
0.967
0.063
0.018
0.005
69328
0.196
0.335
1.227
0.064
0.015
0.005
69339
0.189
0.326
1.037
0.067
0.021
0.006
69344
0.215
0.313
0.984
0.067
0.018
0.005
69348
0.205
0.339
1.082
0.062
0.019
0.008
69350
0.218
0.311
1.071
0.078
0.020
0.005
MEAN
0.198
0.327
1.060
0.065
0.019
0.006
S.
D.
0.0159
0.0187
0.0735
0.0107
0.0017
0.0011
N
10
10
10
10
10
10
PROJECT
NO.:
WIL­
417002
TABLE
33
SPONSOR:
HAP
TASK
FORCE
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WTS.
RELATIVE
TO
FINAL
BODY
WTS.
[G/
100
G]
PAGE
8
WEEK
13
ANIMAL
SPLEEN
­____­­_­_____
­­­­_­­­­__­­­__­_________________
69304
0.235
69307
0.199
69318
0.208
69319
0.216
69327
0.211
69329
0.212
69332
0.191
69334
0.208
69342
0.180
69346
0.188
MALE
GROUP:
100
PPM
_____­­­­­_­_­______­­­­­­­­­­­­­­­­­­
EPIDID
YMIDES
TESTES
._­__­_­­­­__­­________________________

0.337
1.084
0.324
1.012
0.308
1.003
0.331
1.082
0.323
1.017
0.345
1.017
0.379
1.041
0.337
1.063
0.314
0.984
0.320
0.990
­­_­­­_­­­___­_____­____________________­­­­~
ADRENAL
THYROIDS
THYMUS
GLANDS
/PARA
­­_­­__­­­­­_­­­___­____________________­­­­­

0.075
0.021
0.004
0.076
0.019
0.006
0.072
0.017
0.007
0.065
0.017
0.005
0.058
0.016
0.005
0.066
0.018
0.008
0.066
0.017
0.005
0.068
0.020
0.008
0.055
0.018
0.005
0.057
0.018
0.005
MEAN
0.205
0.332
S.
D.
1.029
0.0159
0.066
0.0200
0.018
0.0364
0.006
N
0.0074
10
10
0.0015
10
0.0014
10
10
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
ANIMAL
69354
69366
69367
69378
69384
69398
69404
69416
69419
69432
FBW(
G)
______­__­__

196.
179.
196.
180.
168.
197.
199.
192.
193.
179.
BRAIN
0.969
0.955
0.913
1.006
1.024
0.944
0.910
0.958
0.912
1.011
TABLE
33
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WTS.
RELATIVE
TO
FINAL
BODY
WTS.
[G/
100
G]

LIVER
KIDNEYS
LUNGS
__­­___­___________­__
­­__­­­­­_­­­­__
2.724
0.689
0.495
2.464
0.709
0.520
2.367
0.694
0.490
2.700
0.706
0.572
2.798
0.679
0.565
2.396
0.670
0.462
2.417
0..
704
0.497
2.688
0.729
0.510
2.539
0.679
0.497
2.754
0.749
0.525
FEMALE
GROUP:
0
PPM
HEART
SPLEEN
OVARIES
­
­
­
_
_
­
_
_
_
0.332
0.330
0.316
0.361
0.357
0.345
0.342
0.349
0.363
0.380
0.250
0.047
0.246
0.049
0.265
0.038
0.244
0.054
0.262
0.060
0.244
0.051
0.251
0.051
0.260
0.054
0.249
0.055
0.285
0.052
THYMUS
­____
­__
0.108
0.101
0.137
0.121
0.115
0.109
0.130
0.105
0.121
0.103
___­__­____
­­_­­­__­­___­­
ADRENAL
THYROIDS
GLANDS
/PARA
___­__­__­­
___­­­__­­_____
0.033
0.007
0.028
0.007
0.023
0.011
0.025
0.006
0.029
0.010
0.032
0.008
0.028
0.006
0.029
0.009
0.026
0.008
0.031
0.007
PAGE
9
WEEK
13
MEAN
188.
0.960
2.585
0.701
0.513
0.348
0.256
0.051
0.115
0.028
0.008
S.
D.
10.5
0.0424
0.1651
0.0243
0.0339
0.0187
0.0128
0.0058
0.0120
0.0031
0.0017
N
10
10
10
10
10
10
10
10
10
10
10
FBW
=
FINAL
BODY
WEIGHT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
33
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WTS.
RELATIVE
TO
FINAL
BODY
WTS.
[G/
100
G]
PAGE
10
WEEK
13
FEMALE
GROUP:
15
PPM
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
1
ANIMAL
FBW(
G)
BRAIN
ADRENAL
THYROIDS
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
GLANDS
/PARA
__________­_
­
­
­
_
­
­
_
_
_
69362
176.
69376
159.
69382
195.
69390
182.
69393
166.
69396
188.
69409
180.
69413
3.73.
69435
179.
0.943
1.075
0.918
0.956
1.090
0.936
1.000
1.081
0.961
2
2
2
­
­
­
_
_
_
_
_
_
­
_
_
_
_
_
_
­
_
_
722
0.773
824
0.723
379
0.651
429
0.753
608
0.753
596
0.633
639
0.672
572
0.792
508
0.726
0.625
0.503
0.477
0.571
0.584
0.521
0.533
0.561
0.542
,­
0
0
0
0
0
0
0
0
0
375
377
333
357
355
335
356
399
341
_
­
_
_
_
­
­
_
_
.___
­
________
0.301
0.077
0.264
0.062
0.236
0.051
0.280
0.047
0.247
0.052
0.250
0.056
0.239
0.051
0.272
0.064
0.207
0.043
0.130
0.039
0.006
0.118
0.035
0.008
0.086
0.030
0.007
0.120
0.031
0.007
0.106
0.033
0.020
0.091
0.032
0.008
0.111
0.032
0.008
0.115
0.038
0.007
0.095
0.029
0.008
MEAN
178.
0.996
2.586
0.720
0.546
0.359
0.255
0.056
0.108
0.033
0.008
S.
D.
10.9
0.0686
0.1380
0.0557
0.0447
0.0217
0.0277
0.0103
0.0147
0.0035
0.0011
N
9
9
9
9
9
9
9
9
9
9
9
FBW
=
FINAL
BODY
WEIGHT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
ANIMAL
69359
69369
69370
69380
69388
69394
69426
69428
69433
69436
FBW(
G)
______­_____
169.
184.
187.
202.
175.
182.
193.
168.
177.
192.
BRAIN
1.030
0.989
0.904
0.896
1.040
0.951
0.927
1.042
1.011
0.927
MEAN
183.
0.972
S.
D.
11.0
0.0573
N
10
10
FBW
=
FINAL
BODY
WEIGHT
TABLE
33
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
11
INDIVIDUAL
ORGAN
WTS.
RELATIVE
TO
FINAL
BODY
WTS.
[G/
100
Gl
WEEK
13
FEMALE
GROUP:
40
PPM
_­­_________­­­__­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
_­.
____________­_____________________

LIVER
KIDNEYS
LUNGS
_­­_______­_____­­­_­.
­
_
_
_
_
_
_
2.521
0.716
0.491
2.397
0.712
0.543
2.647
0.642
0.519
2.361
0.663
0.480
2.817
0.743
0.549
2.505
0.714
0.549
2.580
0.725
0.482
2.625
0.714
0.560
2.774
0.780
0.599
2.615
0.724
0.495
HEART
SPLEEN
OVARIES
0.361
0.260
0.056
0.337
0.228
0.045
0.342
0.246
0.049
0.327
0.228
0.043
0.400
0.280
0.069
0.352
0.264
0.049
0.347
0.244
0.050
0.375
0.280
0.048
0.373
0.260
0.060
0.323
0.224
0.039
THYMUS
_
_
_
_
_
_
_
_
0.123
0.108
0.099
0.115
0.113
0.119
0.103
0.111
0.119
0.108
ADRENAL
THYROIDS
GLANDS
/FARA
­­________
­_____­_____­_
0.033
0.010
0.031
0.006
0.031
0.008
0.027
0.006
0.036
0.009
0.027
0.007
0.029
0.007
0.029
0.006
0.028
0.009
0.027
0.009
2.584
0.713
0.527
0.354
0.251
0.051
0.112
0.030
0.008
0.1460
0.0383
0.0396
0.0239
0.0207
0.0088
0.0075
0.0030
0.0015
10
10
10
10
10
10
10
10
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
ANIMAL
FBW(
G)
BRAIN
____­___­__­­______­________
69375
171.
1.018
69379
181.
0.989
69383
178.
1.006
69385
187.
0.925
69392
165.
1.055
69402
186.
0.925
69408
181.
0.994
69415
183.
0.984
69427
178.
0.983
69431
181.
0.983
MEAN
179.
0.986
S.
D.
6.7
0.0390
N
10
10
w
E
FEW
=
FINAL
BODY
WEIGHT
R
m
s
­.

­.
TABLE
33
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
12
INDIVIDUAL
ORGAN
WTS.
RELATIVE
TO
FINAL
BODY
WTS.
[G/
100
GI
WEEK
13
FEMALE
GROUP:
100
PPM
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

LIVER
LUNGS
HEART
__________
2.749
2.751
2.742
2.626
2.685
2.849
2.691
2.667
2.747
2.713
KIDNEYS
­­­­­_­­­__­
0.731
0.757
0.719
0.786
0.788
0.742
0.773
0.705
0.736
0.812
____
0.520
0.351
0.613
0.359
0.579
0.376
0.476
0.390
0.533
0.364
0.516
0.355
0.552
0.370
0.530
0.415
0.618
0.371
0.575
0.398
SPLEEN
_
_
­
_
_
_
_
0.246
0.254
0.258
0.241
0.236
0.242
0.254
0.246
0.264
0.271
OVARIES
­
_
_
_
_
_
_
0.048
0.068
0.053
0.051
0.046
0.050
0.053
0.060
0.060
0.056
ADRENAL
THYROIDS
THYMUS
GLANDS
/PARA
_____­____________________________
0.119
0.030
0.009
0.119
0.035
0.009
0.101
0.032
0.008
0.110
0.029
0.006
0.114
0.031
0.006
0.113
0.029
0.005
0.093
0.030
0.006
0.123
0.029
0.010
0.142
0.035
0.011
0.113.
0.036
0.009
2.722
0.755
0.551
0.375
0.251
0.055
0.115
0.032
0.008
0.0609
0.0342
0.0451
0.0204
0.0110
0.0066
0.0131
0.0028
0.0020
10
10
10
10
10
10
10
10
10
POFBWv4.1
01/
18/
2002
R:
01/
18/
2002
PROJECT
NO.:
WIL­
417002
TABLE
34
SPONSOR:
HAP
TASK
FORCE
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WEIGHTS
RELATIVE
TO
BRAIN
WEIGHTS
[G/
100
G]
PAGE
1
WEEK
13
______­___­_____________________________­~~
BRAIN
WT
ANIMAL
FBW(
G)
(GRAMS)
­­­­_­­­­­­­­_­__­­­____________________­­­
69302
305.
1.83
69306
291.
1.81
69308
282.
1.88
69310
264.
1.73
69312
316.
1.88
69314
281.
1.74
69317
309.
1.84
69322
280.
1.85
69337
284.
1.84
69343
263.
1.83
MALE
GROUP:
0
PPM
_______­_________­______________________

­
_
_
_
_
_
_
_
LIVER
­­­­_­­_____
468.306
455.801
446.809
424.855
450.000
430.460
454.893
402.162
436.413
426.230
KIDNEYS
­­____________­_­_­_
103.279
115.470
104.787
108.092
114.894
107.471
109.783
108.108
104.348
98.361
MEAN
288.
1.82
439.593
S.
D.
17.9
107.459
0.051
65.419
19.3561
51.290
N
10
5.1934
10
2.9922
10
3.1086
10
10
10
FBW
=
FINAL
BODY
WEIGHT
_________________

LUNGS
.­­­­
­­_­____.
68.306
63.536
58.511
66.474
66.489
68.391
65.761
68.108
64.130
64.481
HEART
.­_­______________
54.098
49.724
52.128
54.913
53.723
48.851
48.370
47.027
55.435
48.634
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
34
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WEIGHTS
RELATIVE
TO
BRAIN
WEIGHTS
[G/
100
Gl
ANIMAL
FBW(
G)
______­___­_­­
c__

69305
261.
69316
307.
69320
317.
69323
323.
69326
334.
69335
320.
69336
300.
69338
273.
69345
307.
69347
282.
MALE
GROUP:
15
PPM
__­­­­­­_­______­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

BRAIN
WT
(GRAMS)
LIVER
KIDNEYS
_­_______­­_______­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
1.87
380.749
100.000
1.92
509.375
117.188
1.87
467.914
117.647
1.84
480.978
114.674
1.98
454.040
110.606
1.95
454.359
114.872
1.86
468.280
111.828
1.87
386.096
96.791
2.01
430.846
113.930
1.76
455.682
113.068
MEAN
302.
1.89
448.832
111.060
S.
D.
23.5
0.073
40.0560
7.0516
N
30
10
10
10
FBW
=
FINAL
BODY
WEIGHT
PAGE
2
WEEK
13
LUNGS
HEART
_­­­­­_____________­____
.___­­_
51.337
43.316
69.792
52.083
74.866
53.476
71.196
53.804
70.707
49.495
64.615
55.385
65.054
53.226
59.358
47.059
63.184
48.756
69.886
49.432
66.000
6.8888
10
50.603
3.6834
10
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
ORGAN
WEIGHTS
RELATIVE
TO
BRAIN
WEIGHTS
[G/
100
G]
PAGE
3
WEEK
13
MALE
GROUP:
40
PPM
____________­_­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
TABLE
34
BRAIN
WT
ANIMAL
FBW(
G)
(GRAMS)
LIVER
KIDNEYS
LUNGS
HEART
­
_
­
­
­
_
_
_
­
69303
69309
69313
69315
69324
69328
69339
69344
69348
69350
_­­­__­­­__­___________

255.
308.

310.

253.
1
1
333.

322.
270.

316.

292,
280.
1
1
1
1
1
1
.­­­___­_^________

61
89
91
85
95
90
77
84
92
88
MEAN
294.
1.85
S.
D.
28.3
0.099
N
10
10
­­_­­­­___
397.516
424.339
471.728
358.919
459.487
452.105
420.339
489.130
435.417
387.234
__­_________­___________
109.317
129.101
118.325
94.054
114.872
115.789
109.605
126.087
113.021
103.723
__­

61
73
63
56
64
68
50
67
61
63
____________­___
491
545
874
757
103
421
847
391
979
830
­­____­___

55.280
51.323
53.927
47.027
51.795
55.789
51.412
54.891
49.479
48.936
429.621
113.389
63.224
51.986
40.3947
10.2130
6.2541
2.9534
10
10
10
10
w"
FBW
=
FINAL
BODY
WEIGHT
;;
'

2
5;
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
34
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WEIGHTS
RELATIVE
TO
BRAIN
WEIGHTS
[G/
100
G]
PAGE
4
WEEK
13
MALE
GROUP:
100
PPM
__________­­­____­__­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
BRAIN
WT
ANIMAL
FBW(
G)
(GRAMS)
LIVER
KIDNEYS
LUNGS
HEART
______­­­________­_­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69304
323.
1.91
470.157
123.560
68.063
56.021
69307
327.
1.95
486.667
113.846
69.744
57.949
69318
308.
1.83
475.410
117.486
66.120
54.098
69319
305.
1.87
452.406
117.112
67.914
50.267
69327
303.
1.84
422.283
109.239
66.304
50.000
69329
293.
1.87
445.989
118.182
64.706
50.802
69332
293.
1.90
397.895
102.105
58.421
51.053
69334
288.
1.82
465.934
119.231
65.385
53.297
69342
306.
1.79
472.626
124.022
63.687
49.162
69346
303.
1.78
499.438
125.843
66.854
NA
MEAN
305.
1.86
458.881
117.063
65.720
S.
D.
12.5
0.054
30.4098
7.2201
3.1061
N
10
10
10
10
10
FBW
=
FINAL
BODY
WEIGHT
NA
=
NOT
APPLICABLE
52.517
3.0131
9
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
34
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WEIGHTS
RELATIVE
TO
BRAIN
WEIGHTS
[G/
100
G]
PAGE
5
WEEK
13
MALE
GROUP:
0
PPM
­­­_­­­­­­­­­­­­­­­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~­­~~­~­­­~­­­­­­­­­­­­­­­­~­­­~­­­­­­­­­­­­~­~­­­~~­­­­­
EPIDID
ADRENAL
ANIMAL
THYROIDS
SPLEEN
YMIDES
TESTES
THYMUS
GLANDS
/PARA
­­­_­__­­­­­­­­­­­­­____________________­­­­~­­­­­­~­­­­­­­­­­~­­­­­­~­­­­­­­­­­~­­­­­~­­­­­~­­­­­­­­­­~­­­­­~­­­~­­­­­­­­­­~­­­­­­

69302
30.055
54.098
156.831
9.913
2.464
69306
1.077
29.282
54.144
174.586
8.945
3.287
69308
1.171
30.851
53.191
161.170
9.761
69310
3.335
1.106
31.214
57.225
161.272
10.607
3.156
69312
0.647
35.106
55.319
182.447
11.037
69314
3.394
0.787
32.759
51.724
171.264
10.000
69317
2.799
32.065
0.868
49.457
170.109
11.250
69322
2.136
0.571
27.027
50.811
161.622
9.027
3.254
69337
0.789
29.891
58.152
168.478
10.228
3.217
69343
33.333
1.239
49.727
154.645
8.158
2.831
1.049
MEAN
31.158
53.385
166.242
9.893
S.
D.
2.987
2.2902
0.930
2.9912
8.6425
0.9696
0.4199
N
0.2294
10
10
10
10
10
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
34
YO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WEIGHTS
RELATIVE
TO
BRAIN
WEIGHTS
[G/
100
G]

MALE
GROUP:
15
PPM
_____­__________­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
EPIDID
ANIMAL
SPLEEN
YMIDES
TESTES
THYMUS
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

69305
26.203
51.337
162.567
8.417
69316
36.458
51.563
176.563
10.703
69320
33.155
50.802
164.706
10.947
69323
32.609
52.174
169.022
10.315
69326
33.838
55.051
171.212
11.333
69335
34.359
52.821
166.154
10.087
69336
32.258
50.538
155.914
10.758
69338
29.947
50.267
167.380
10.364
69345
32.338
53.731
159.204
11.214
69347
33.523
50.000
155.114
12.557
MEAN
32.469
51.828
164.784
10.670
3.014
0.980
S.
D.
2.7617
1.6303
6.7896
1.0550
0.2286
0.2459
N
10
10
10
10
10
10
PAGE
6
WEEK
13
ADRENAL
THYROIDS
GLANDS
/PARA
_­_­_­___­__________________
3.246
1.139
3.276
1.083
2.872
0.909
3.136
0.967
2.631
1.258
2.774
0.744
3.323
0.785
3.016
0.781
2.920
0.692
2.949
1.438
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
34
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WEIGHTS
RELATIVE
TO
BRAIN
WEIGHTS
[G/
100
G]
PAGE
7
WEEK
13
MALE
GROUP:
40
PPM
____________­_____­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ANIMAL
SPLEEN
EPIDID
YMIDES
ADRENAL
THYROIDS
TESTES
THYMUS
GLANDS
/PARA
__­_­__­­____­______________
___­____­­_____­____
69303
29.193
69309
31.217
69313
33.508
69315
22.703
69324
35.897
69328
33.158
69339
28.814
69344
36.957
69348
31.250
69350
32.447
49.689
53.439
50.262
50.811
55.385
56.842
49.718
53.804
51.563
46.277
­___­__
­
­­­­­_­­­­­­­­___­­_­­­­
166.460
6.037
171.958
11.079
163.874
11.874
151.892
9.697
165.128
10.810
207.895
10.789
158.192
10.164
169.022
11.549
164.583
9.448
159.574
11.543
3.075
3.460
3.131
2.562
3,082
2.516
3.232
3.054
2.943
3.011
­­­_­
­
_
_
_
_
_
_

0.894
0.799
0.848
1.016
0.836
0.858
0.932
0.804
1.229
0.681
MEAN
31.514
51.779
167.858
10.299
3.007
0.890
S.
D.
4.0395
3.1210
15.1808
1.6987
0.2842
0.1482
N
10
10
10
10
10
10
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
34
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WEIGHTS
RELATIVE
TO
BRAIN
WEIGHTS
[G/
100
G]
PAGE
8
WEEK
13
MALE
GROUP:
100
PPM
__­__________­­___­__________________^__­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­
EPIDID
ADRENAL
THYROIDS
__""
r"""____­________________
s"""""________­____
'"
'""
s_____________
T""
T""______­______
'f"
'"
51s­___________­~~~~~~­­­­~­­­­~~­­!~~~­

69304
39.791
57.068
183.246
12.764
3.529
0.733
69307
33.333
54.359
169.744
12.682
3.267
1.010
69318
34.973
51.913
168.852
12.044
2.940
1.246
69319
35.294
54.011
176.471
10.535
2.717
0.813
69327
34.783
53.261
167.391
9.576
2.565
0.902
69329
33.155
54.011
159.358
10.299
2.866
1.198
69332
29.474
58.421
160.526
10.232
2.626
0.789
69334
32.967
53.297
168.132
10.819
3.143
1.236
69342
30.726
53.631
168.156
9.402
3.140
0.939
69346
32.022
54.494
168.539
9.787
2.994
0.893
MEAN
33.652
54.447
169.042
10.814
2.979
0.976
S.
D.
2.8460
1.9110
6.8990
1.2502
0.3014
0.1901
N
10
10
10
10
10
10
TABLE
34
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
9
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
ORGAN
WEIGHTS
RELATIVE
TO
BRAIN
WEIGHTS
[G/
100
Gl
WEEK
I.
3
FEMALE
GROUP:
0
PPM
_________­______________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­
BRAIN
WT
ADRENAL
THYROIDS
ANIMAL
FBW(
G)
(GRAMS)
LIVER
KIDNEYS
LUNGS
HEART
SPLEEN
OVARIES
THYMUS
GLANDS
/PARA
__­_____­___­__­________________________­­­­­
69354
196.
1.90
281.053
71
69366
179.
1.71
257.895
74
69367
196.
1.79
259.218
75
69378
180.
1.81
268.508
70
69384
168.
1.72
273.256
66
69398
197.
1.86
253.763
70
__­______­_­____________________
053
51.053
34.211
25
269
54.386
34.503
25
978
53.631
34.637
29
166
56.906
35.912
24
279
55.233
34.884
25
968
48.925
36.559
25
­­­­­­_­_­­­____­_­_­­­­­­­­­­­­
789
4.858
11.105
3
731
5.175
10.608
2
050
4.156
14.983
2
309
5.354
12.011
2
581
5.849
11.227
2
806
5.435
11.591
3
395
0.674
883
0.766
553
1.207
481
0.602
855
0.948
435
0.833
69404
199.
1.81
265.746
77.348
54.696
37.569
27.624
5.624
14.293
3.133
0.702
69416
192.
1.84
280.435
76.087
53.261
36.413
27.174
5.592
10.929
3.011
0.984
69419
193.
1.76
278.409
74.432
54.545
39.773
27.273
6.017
13.227
2.875
0.915
69432
179.
1.81
272.376
74.033
51.934
37.569
28.177
5.105
10.149
3.105
0.729
MEAN
188.
1.80
269.066
73.061
53.457
36.203
26.651
5.317
12.012
2.973
0.836
S.
D.
10.5
0.059
9.7528
3.3849
2.2934
1.7570
1.4385
0.5356
1.6240
0.3138
0.1806
N
10
10
10
10
10
10
10
10
10
10
10
FBW
=
FINAL
BODY
WEIGHT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
34
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WEIGHTS
RELATIVE
TO
BRAIN
WEIGHTS
[G/
100
G]
PAGE
10
WEEK
13
ANIMAL
69362
69376
69382
69390
69393
69396
69409
69413
69435
FBW(
G)
._­
_______
176.
159.
195.
182.
166.
188.
180.
173.
179,
­
­
­
_
­
_
­
­
­
BRAIN
WT
(GRAMS)
­
­
­
_
­
­
­
­
_
1.66
1.71
1.79
1.74
1.81
1.76
1.80
1.87
1.12
LIVER
KIDNEYS
LUNGS
HEART
­_­_­­_­_­_­­
_­___­­_­_
___­_­_­_­­­_
____­_______
288.554
81.928
66.265
39.759
262.573
67.251
46.784
35.088
259.218
70.950
51.955
36.313
254.023
78.736
59.770
37.356
239.227
69.061
53.591
32.597
277.273
61.614
55.682
35.795
263.889
67.222
53.333
35.556
237.968
73.262
51.872
36.898
261.046
75.581
56.395
35.465
FEMALE
GROUP:
15
PPM
­__­_­____­_­
____­____­_­_______

SPLEEN
.___
­___
31.928
24.561
25.698
29.310
22.652
26.705
23.889
25.134
21.512
_­_­____­_________­_____________________­­­­­­­­
ADRENAL
THYROIDS
OVARIES
THYMUS
GLANDS
/PAR?+
___­_______­_____­______________________­­­­­­­­

8.139
13.783
4.139
0.620
5.760
10.982
3.263
0.749
5.570
9.374
3.296
0.721
4.931
12.552
3.241
0.724
4.801
9.718
3.039
0.906
5.960
9.750
3.415
0.835
5.067
11.094
3.200
0.844
5.963
10.636
3.508
0.642
4.471
9.913
3.017
0.849
MEAN
178.
1.76
260.419
72.401
55.072
36.092
25.710
5.629
10.867
3.346
0.766
S.
D.
10.9
0.063
16.1563
5.3767
5.5152
1.9279
3.2511
1.0823
1.4649
0.3362
0.0988
N
9
9
9
9
9
9
9
9
9
9
9
2
FBW
=
FINAL
BODY
WEIGHT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
34
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WEIGHTS
RELATIVE
TO
BRAIN
WEIGHTS
[G/
100
Gl
PAGE
11
WEEK
13
ANIMAL
_
_
_
­
_
_
_
_
69359
69369
69370
69380
69388
69394
69426
69428
69433
69436
BRAIN
WT
FBW(
G)
(GRAMS)

169.
1.74
184.
1.82
187.
1.69
202.
1.81
175.
1.82
182.
1.73
193.
1.79
168.
1.75
177.
1.79
192.
1.78
LIVER
KIDNEYS
LUNGS
HEART
_­_________
_­­­_­­­­­­­
_­­­__­­­___
­
­
_
_
_
­
­
244.828
69.540
47.701
35.057
242.308
71.978
54.945
34.066
292.899
71.006
57.396
37.870
263.536
74.033
53.591
36.464
270.879
71.429
52.747
38.462
263.584
75.145
57.803
36.994
278.212
78.212
51.955
37.430
252.000
68.571
53.714
36.000
274.302
77.095
59.218
36.872
282.023
78.090
53.371
34.831
FEMALE
GROUP:
40
PPM
___­_­___­____­________________
_­­­__­­___­

SPLEEN
25.287
23.077
27.219
25.414
26.923
27.746
26.257
26.857
25.698
24.157
OVARIES
THYMUS
­_____
­__
___________^_
5.420
11.937
4.566
10.912
5.467
10.899
4.807
12.873
6.588
10.879
5.150
12.503
5.441
11.095
4.617
10.703
5.933
11.788
4.213
11.663
ADRENAL
THYROIDS
GLANDS
/PARA
3.201
0.948
3.181
0.621
3.420
0.929
3.011
0.680
3.500
0.846
2.821
0.699
3.089
0.715
2.829
0.617
2.726
0.933
2.904
0.972
MEAN
183.
1.77
266.457
73.510
54.244
36.405
25.864
5.220
11.525
3.068
0.796
S.
D.
11.0
0.043
16.4571
3.5274
3.3266
1.4113
1.4485
0.7079
0.7511
0.2596
0.1434
N
10
10
10
10
10
10
10
10
10
10
10
k?
FBW
=
FINAL
BODY
WEIGHT
\o
%
0­
l
s;
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
TABLE
34
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
ORGAN
WEIGHTS
RELATIVE
TO
BRAIN
WEIGHTS
[G/
100
Gl
PAGE
12
WEEK
13
ANIMAL
69375
69379
69383
69385
69392
69402
69408
69415
69427
69431
_________­_________

BRAIN
WT
FEW(
G)
(GRAMS)
_­­______­________­

171.
1.74
181.
1.79
178.
1.79
187.
1.73
lb5.
1.74
186.
1.72
181.
1.80
183.
1.80
178.
1.75
181.
1.78
LIVER
KIDNEYS
_____­___­­_
__________

270.115
71.839
278.212
76.536
272.626
71.508
283.815
84.971
254.598
74.713
308.140
80.233
270.556
77.778
271.111
11.667
279.429
74.857
275,843
82.584
FEMALE
GROUP:
100
PPM
___­­_­__­____
^__________­__­___________________

LUNGS
HEART
____­________­
­­__­­_­___­
51.149
34.483
62.011
36.313
57.542
37.430
51.445
42.197
50.575
34.483
55.814
38.372
55.556
37.222
53.889
42.222
62.857
37.714
58.427
40.449
SPLEEN
OVARIES
THYMUS
24.138
4.690
11.690
25.698
6.832
11.989
25.698
5.318
10.039
26.012
5.497
11.925
22.414
4.385
10.764
26.163
5.424
12.209
25.556
5.322
9.339
25.000
6.122
12.472
26.857
6.069
14.451
27.528
5.697
11.281
.­­­­­­­_­_­__­­________
ADRENAL
THYROIDS
GLANDS
/PARA
2.902
0.920
3.536
0.883
3.196
0.760
3.162
0.676
2.920
0.598
3.145
0.576
3.044
0.589
2.983
1.011
3.537
1.131
3.624
0.910
MEAN
179.
1.76
276.445
76.669
55.927
38.089
25.506
5.536
11.616
3.205
0.805
S.
D.
6.7
0.031
13.6070
4.7135
4.3431
2.7907
1.4285
0.7056
1.4092
0.2686
0.1943
N
10
10
10
10
10
10
10
10
10
10
10
FBW
=
FINAL
BODY
WEIGHT
POFBWv4.1
%
01/
18/
2002
o\
R:
01/
18/
2002
s
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
APPENDIX
A
Analysis
of
Test
Article
Samples
(Sponsor­
Provided)

341
of
619
Dow
USA
Texas
Operations
The
Dow
Chemi,
al
Company
2301
Brazospoti
Btvd
Freeport,
Texas
77541­
3257
July
27,
200
1
WIL
Research
Laboratoties,
Inc.
ATTN:
qeter
Voytek
1407
George
+d
Ashland,
OH
44805­
928
1
P&
z
Anaiysis
of
1,1,2­
Trichloroethane
samples
Dear
Mr.
Voytek
I
received
two
samples
of
l,
l,
Z­
trichloroethane
from
you
on
the
afternoon
of
7/
25/
01.
Reference
numbers
for
the
samples
are:
WE417001
and
WIL­
417002.
Tbe
samples
were
returned
for
assay
or
determination
of
the
purity
of
the
1,1,2­
Uichloroetha.
The
samples
were
analyzed
that
same
afternoon
in
our
Quality
Assurance
lab
which
dws
the
analytical
work
for
the
release
of
our
product.
The
results
are
as
foliows:

1,1,2­
trichloroetbane
1
,
1,1.2­
Tetrachloroethane
1,2­
ButyIene
Oxide
Secondary
Butanof
wIL­
417001
99.546
Wt
%
0.0600
Wt
%
Ct.
1893
WI
%
0.2047
Wt
%
`NIL417002
99.549
wt
%
0.0588
wt
%
normal
process
impurity
0.1895
wt
%
stabilizer
0.2023
Wt
%
stabilizer
This
material
is
Stabilized
1,1,2­
Trichloruethane.
The
1,2­
butytene
oxide
serves
as
an
acid
acceptor
and
provides
stability
against
metals.
The
secondary
butanol
sewes
to
provide
stability
against
metak.

The
analysis
was
done
by
gas
chromatography.
The
method
is
as
follows:

column
Temperature
program
DB
1701
I
p
film
thickness,
0.32
mm
X
60
meter
Initial
Temp
of
40°
C
for
3
min
10"
Chin
to
200°
C
stop
carrier
gas
Heiium
at
a
constant
flow
of
3
ccimin
Split
ratio
2OO:
l
As
you
know,
Dow
is
a
producer
of
I,
1
&richloroethane
and
producer
of
the
material
being
analyzed
I
believe.
We
routinely
analyze
this
materia1.
We
calibrate
the
gas
chromatographs
with
standards
containing
the
known
process
impurities
and
stabilizers
in
concentrations
in
the
range
that
these
impurities
and
srandards
are
normally
present.
We
prepare
the
standards
from
pure
components
using
an
analytical
balance.
We
determine
the
concentration
of
impurities
and
stabilizers
present
and
then
determine
assay
of
the
1
,I
,Z­
trichloroethane
by
subtracting
the
sum
of
the
impurities
and
stabilizers
from
100%.
II
is
probably
quite
obvious
that
this
method
gives
greater
precision
than
does
measuring
the
concentration
of
the
1.1,2­
bichloroethane
dir&
y.
The
foIlowing
simple
example
illustrates
this.
Let
us
assume
that
the
relative
standard
deviation
of
the
gas
chromatogmphic
analysis
is
~3%.
It
is
certainly
obvious
then
that
the
resuIts
of
direct
measuremcm
of
the
component
that
is
almosr
100%
of
the
total
will
have
a
standard
deviation
of
about
3%.

Now
let
us
assume
that
same
3%
RSD
applies
to
each
of
the
three
measured
components
then
the
combined
relative
standard
deviation
for
the
three
components
is:

342of619
RSD,
=
d­­=
5.2%

5.2%
of
a
total
of
about
0.45
wt
%
stabilizer
plus
impurity
is
about
i0.023%
compared
to
23%
for
direct
measurement.

I
am
enclosing
copies
of
the
GC
scans.
Note
the
following
internal
slang
terms
and
short
cuts
as
seen
on
the
GC
scam
and
computer
prints
outs.

BO
=
!
1.2­
Butylene
Oxide
SBA
SC
Secondary
Butanol
1112,
tetra
s
1,
I,
I
&tetrachloroethane
B­
Tri
(Beta­
Td
or
B­
Tri)
=
I,
1
,Z­
trichloroethane
Acetone
is
not
a
process
impurity
but
a
rinse
solvent
between
sample
vials
on
the
autoinjector.
Most
of
the
small
area
counts
seen
on
the
computer
printout
is
baseline
noise
as
can
bc
seen
by
comparing
it
to
the
scan.
The
product
can
also
contain
trace
amounts
(<
O.
O1
WI
%)
of
ethylene
dichloride,
trichloroethylene
and
bromochloroethane,

If
I
can
be
of
further
assistance
pkase
do
not
hesitate
to
contact
me.

a+#?

Douglas
L.
Teny
Chlorinated
Organic
Products
Technologies
Center
Building
A­
2422
Office:
979­
238­
4232
Pager
888437­
6791
FAX:
979­
238­
0136
E­
Mail
dougteny@
dow.
com
343
of
619
Sample
Worksheet
:
56260
Page
1
_­___­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
I
SOLVENTS
SAMPLE
WORKS4EETI
­­­__­­­­­­
I­­­­­­­­___
I________________­­­­­­­­

/
Worksheet
prepared
on
25­
JUL­
2001.

Sample
ID
:
56260
Text
ID
:
B­
VU
S­
JUL­
25­
52
Comments
:
#5015A
fl
­­­­­­­­­­­­­­­
L­­
C­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
PRODUCT
:
B­
TRI­
S
SPEC
LEVEL
:
PRODUCTION
SYIPMENT
LOT
NUMBER
:
CARRIER
ID
:
SAMPLE
TYlE
:
TEST
COMPARTMENT
:
LOGIN
DATE
:
25­
JUL­
2001
18:
36
LOGIN
BY
:
u137519
==­­­­­­­========================
s==
2==~==~==­­­­­­­­­­­­­========
­­­­­­­

The
foilowing
tests
have
been.
assigned
to
this
sample:
­­­
c­_~­_­­_­_~~­­~~~~~~~­~­­­­­­­­~­~~~~~~­~­~~­~~~~

­__­_
C­_______­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
I
Analysis
I
Component
Name
I
MIN
I
MAX
I
Result
1
Units
1
,­­­­
c­­
­­­­­+­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­+­­­­­­­+­­­­­­­­­­­­­­­­+­­­­­­­,
I
ASSAY­?
3TRI/
I
BO
jo.
100
10.200
IO.
1893
I
%wt
I
,
_­­­­­
­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­+­­­­­­­+­­­­­­­­­­­­­­­­~­­­­­­­,
I
I
saA
10.200
IO.
350
(0.2047
I
%wt
i
/­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­
f­­­­­­­­~­­­­­­­+­­­­­­­­­­­­­­­­~­­­­­­­,
I
1
1112,
Tetra
I
I
10.0600
%wt
I
­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­
+­­­­­­­­+­­­­­­­
i­­­­­­­­­­­­­­­­+­­­­­­­
I
I
j
B­
Tri
I
I
199.546
I
%wt
(­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­~­­­­­­­*
­­­­­­­­­­­­­­­­+­­­­­­­
I
The
Dow
Chemical
Company
Dow
Confidential
344of619
.
Sample
Worksheet
:
56260
Page
1
1
SOLVENTS
SAMPLE
WORKSHEET]
____­_­­___­­___­_­­___^________________­­­­­­­­

Worksheet
prepared
on
25­
JCJL­
2001.

Sample
ID
:
56260
Text
ID
:
B­
TRI­
S­
JUL­
25­
52
Comments
:
#5015A
lfl
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
PRODUCT
:
B
TRI
S
SPEC
LEVEL
:
PRODUTTION
SHIPMENT
:
LOT
NUMBER
:
SAMPLE
TYPE
:
TEST
LOGZN
DATE
:
25­
m­
2001
18:
36
CARRIER
ID
:
COMPARTMENT
:
LOGIN
BY
:
u137519
The
foll.
owing
tests
have
been
assigned
to
this
sample:
______­­­­­­­­­­­­­­_______
r____________­­­­­­­­­­­­­

___­_____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
_­_____­__­_
c­­_­­­­_____

Analysis
1
Component
Name
I
MIN
/
MAX
[
Result
[
Units
­­­­­­­­­­­­+­*­­­­­­­­­­_­_________
f___­­­­­
+­­­­­­­
i­­­­­­­­­­­­­­­­+­­­­­­­­­
ASSAY­
BTRI/
l/
BO
jo.
roo
~0.200
1
­­­­­­­­­­­­
f­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­~­­­­­­­~­­­­
Gf­
25
­___­­
!_"~
r~~~
(
SBA
10.200
lo.
350
\
;I
GV7
I
%Wt
­­­­­­­­­­*­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­~­­­­­­­
+­­­.­­­­­­­­­­­­­+­­­­­­­
[
1112,
Tetra
I
I
I
I
%wt
­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­
06
f­­­­­­­­+­­­­­­­+­­­­
'­­­­­­­­­­­+­­­­­­­
1
B­
Tri
I
I
1
$jT
jq6
I
%wt
­­­­­­­­,­­­­+­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­~­­­­­­­*­­­­­­­~­­­­­­­­~­­­­­­­

The
Dow
Chemical
Company
Dow
Confidential
345
of
619
.[
TERMIITAL]
191
BTR25jULO11845,1,1
Reported
on
25­
JUL­
2001
at
19:
06
Page
1
Injection
Report
Acquired
on
25­
JUL­
2001
at
18:
48
TX%
02
Texas
Division
Manufacturing
Labs
Analyst
Name
:
REED
Lims
Id
:
ASSAY
BTRI
Comment
:
#5015­#
1
Method
Title
:
B­
Tri
(1,1,2­
Trichloroethane)
Sample
Name
L
B­
Tri
(1,1,2­
Trichloroethane)
Sample
Id
:
56260
Sample
Type
:
Sample
Amount=
l.
OOOOO
Bottle
No
:
1
v­

PEAK
INFORMATION
346of619
TXVG02
Texas
Divis
f&
a
Lys
i
s
Name
:
CTERMINFILI
ELTrl
I1.1,2­
Trlchl.
oroethane)

Channel
191
B­
Tr
I
90
811
E
5
on
Mar­
w
fact
ur
i
ng
Labs
191
!3TR2S&
tL011845,1~
1.

Rmount
I
1
.cIcIO
1.

Ineti­
umant
II
HP5890­
13
Channe
I
Tit
le
a
Channel
~193
Llms
ID
8
56260
Acquired
on
25­
JUL­
2001
at
18~
48
Reported
on
25­
JUL­
2001
at
IPSO6
Met;
hod
s
B­
TRI
Callbrdtion
s
B­
TRI
Run
Sequence
s
B­
TRI
Sample
Worksheet
:
56261
Page
'1
­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
I
SOLVENTS
SAMPLE
WORKSHESTI
­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

Worksheet
prepared
on
25­.
TUL­
2001.

SamFle
ID
I
56261
Comments
:
#5015A
#2
Text
ID
:
B­
TRI­
S­
X?
L­
25­
53
­­­­­­­_­­­­­­L
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

PRODUCT
:
B­
TRI­
S
SPEC
LEVEL
:
PRODUCTION
SHIPMENT
LOT
NUMBER
.:
CARRIER
ID
:
SA???
LE
TYPE
:
TEST
COMPARTMENT
:
LOGIN
DATE
:
25­
JUL­
2001
18:
38
LOGIN
BY­
:
u137519
================
r=======­=========
n=================~=======~===========

The
following
tests
have
been
assigned
to
this
sample:
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­

1
Analysis
I
Component
Name
I
MIN
l
w4.
x
I
Result
I
Units
i
i­­
­­­­­­­­­­
f­­­­­­­­­­­­­­­­­­­­
­­­
s­­­­­­­­+­­­­­­­+­­­­­­­­­­­­­­+­­­­­­­
1
I
ASSAY­
BTRI/
I
BO
10.100
10.200
IO.
1895
%wt
,
­­­­
­­­­­­­­+­­­­­­­­­
­­­­­­­
r­­­­­­+­­­­­­­­+­­­­­­­+­­­+­­­­­­­­­­­­­­­­*­­­­­­­
I
1
I
SBA
10.200
10.350
10.2023
/
%wt
I
1­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­
f­­­­­­­­+­­­­­­­
+­­­­­­­­­­­­­­­­+­­­­­­­,
\
I
113.2,
Terra
I
I
10.3588
I
%wt
1
,
­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­+~~~­­­­­
i­­­­­­­+­­­­­­~­­­­­­­­­+­­­­­­­
I
j
B­
Tri
I­­­­­­­­­­­­,­­­­­­­­­­­­­­­­­­­­­­­
i­­­­­­­­
'
199.549
I
%wt
I
+­­­­­­­+­­­­­­­­­­­­­­­­+­­­­­­­
I
The
Dow
Chemical
Company
DOW
Confidential
348
of
619
Sample
Worksheet
:
55261
Page
I
­__­­_­­­­­­­­­­_­­­___
c_^______________­­­­­­­­

/
SOLVENTS
SAMPLE
WORKSHEET1
____­_­­­_­­­­_­__­­___
L________________­­­­­­­­

Worksheet
prepared
on
25­
J~
JL­
2001..

Sample
ID
:
56261
Text
ID
:
B­
TRI­
S­
m­
25­
53
Comments
:
#5015A
#2
­­­­­­­­­­­­­­­­­­­­__________
L_
r_______­­­­­­­­­­­­

PRODUCT
:
B
TRI
s
SPEC
LEVEL
:
PEODU?
TION
SHIPMENT
.
LOT
NUMBER
.
SAMPLE
TYPE
I
TEST
CARRIER
ID
1
COMPARTMENT
:
LOGIN
DATE
:
25­
JUL­
2001
l.
8:
38
LOGIN
BY
:
u13­
7519
The
following
tests
have
been
assigned
to
this
sample:
­­____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ti
1
halysis
j
Component
Name
1
MIN
I
­
I
Result
1
Units
­­­­­­­­­­­­*­­­­­­­­­­­­­­­­­­­­­­­
ASSAY­
BTRI/
l\
BO
c­­­­­­­­+­­­­­­­+­­­­­­­­­­­­­­­­*­­­­­­­
Jo.
100
jo.
200
1
%wt
­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­
i,
JPYs'
+­­­­­­­+­­
4­­
­­­­­­­­­­.
g.­­­­­­­

]
SBA
10.200
10.350
1
%wt
.­­­­­­­­­*­­­­­­­­­­­­­­­­­­­­­­­
~­­­­­­­­
c­­­­­­­+­­­
'­­­­­;­­­­­­+­­­­­~­­­­­­*
3c3'3
1
1112,
Tetra
­­­­­­­­­­­­+­­­­­­­­"­­­­­­­­­­­­
[
B­
Tri
­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­
f­­­­­­­­*­­­­­­­

The
Dow
Chemical
Company
Dow
Confidential
349of619
'[
TERMINAL!
191
BTR25JUL011919,1,1
Reported
on
25­
JUL­
2001
at
19:
41
Page
1
Injection
Report
Acquired
on
25­
J7UL­
2001
at
19:
22
TXVG02
Texas
Division
Manufacturing
Labs
Analyst
Name
:
ED
Lims
Id
:
ASSAY­
BTRI
Comment
:
#S015A
#2
Method
Title
:
B­
Tri
(1,1,2­
Trichloroethane)
Sample
Name
:
B­
Tri
(1,1,2­
Trichloroethane)
Sample
Id
:
56261
Sample
Type
:
Sample
Amount=
l.
00000
Bottle
No
:
1
350
of
619
TXVG02
Texas
Q
i
v
i
s
i
on
Maw
f&
t
ur
i
t­
g
Labs
Hna
1­
p
i
s
Name
:
[TERM
1
NRLI
19
1
BTR2SJULO
119
I9,1,1,

B­
Tr
I
(1.2.2­`
Tr
Ich
loroethanel
Rmount
I
1.000
Channel
191
B­
Tr
I
E
5
3
m
5
"r
70
`50
i
I­

50
­
50
­

40
­
40
­

30
­
30
­
t
t
a
a
w
w
20
­
20
­
ul
ul
2
2
10
10
A..
A..
I
I
t
I
I
I
L
I
I
t
I
I
I
L
0.0
0.0
2.0
2.0
Time
(mlnutesl
Hult
I&
ram
5­

.P
Instrument
g
HP5890­
A
Channel
Tit
te
g
Channel
tr.
lPl
Llms
ID
.a
56261
Acquired
on
25­
JUL­
2001
at
19~
22
Reported
on
25­
JUL­
2001
at
79g41
Het
hod
n
B­
TRl
Callhrat
Ion
P
R­
TRI
Run
Seqtience
s
B­
TRI
~TERMIw&
I
193.
BTR25SJLclli919,1,1
Reported
on
25­
JUi­
2001
at
19:
41
Page
2
­

ANALYSIS
SUMMARY
Method..........................
B­
TRI
Run
sequence....................
B­
TRI
Calibration.....................
B­
TRI
Normalised
%
calibration
using
area
Calibration
last
modified
on
25­~
PJL­
2001
at
19:
07
Method
last
modified
on
ll­
JAN­
2001
at
i5:
34
Uncalibrated
peaks
use
user
factor
(Q.
0000)
WIL­
4
17002
HAP
Task
Force
APPENDIX
B
1,
1,2­
Trichloroethane
Purity
Assessment
(WIL
Research
Laboratories,
Inc.)

353
of619
WIL­
4
17002
HAP
Task
Force
Page
1
A
90­
DAY
INHALATION
TOXICITY
STUDY
OF
1,1,2­
TRICHLOROETHANE
(l,
l,
ZTCE)
IN
RATS
(WITH
SATELLITE
GROUPS
FOR
PHARMACOlKENETIC
EVALUATIONS
IN
RATS
AND
MICE)

Purity
Assessments
Analytical
Chemistry
Department
WIL
Research
Laboratories,
Inc.

354
of
619
WIL­
417002
HAP
Task
Force
Page
2
A
90­
DAY
INHALATION
TOXICITY
STUDY
OF
1,1,2­
TRICHLOROETHANE
(1,1,2­
TCE)
IN
RATS
(WITH
SATELLITE
GROUPS
FOR
PHARMACOKENETIC
EVALUATIONS
IN
RATS
AND
MICE)

TABLE
OF
CONTENTS
m
I.
INTRODUCTION
4
II.
EXPERIMENTAL
4
A.
Gas
Chromatography
B.
Preparation
of
Samples
for
Purity
Analysis
5
C.
Purity
Assessment
5
III.
CONCLUSION
7
355
of
619
WIL­
417002
HAP
Task
Force
Page
3
A
90­
DAY
INHALATION
TOXICITY
STUDY
OF
1,1,2­
TRICHLOROETHANE
(l,
l,
ZTCE)
IN
RATS
(WITH
SATELLITE
GROUPS
FOR
PHARMACOKENETIC
EVALUATIONS
IN
RATS
AND
MICE)

INDEX
OF
FIGURES
m
Figure
1:
Representative
chromatogram
of
a
commercially
available
(Aldrich
Chemical
Co.)
1,1,2­
TCE
reference
standard
6
Figure
2:
Representative
chromatogram
of
a
test
article
container
sample
6
INDEX
OF
TABLES
m
I.
Purity
Assessments
8
356
of
619
WIL­
417002
HAP
Task
Force
Page
4
A
90­
DAY
INHALATION
TOXICITY
STUDY
OF
1,1,2­
TRICHLOROETHANE
(1,1,2­
TCE)
IN
RATS
(WITH
SATELLITE
GROUPS
FOR
PHARMACOKENETIC
EVALUATIONS
IN
RATS
AND
MICE)

Purity
Assessments
I.
INTRODUCTION
Bulk
samples
of
test
article
(1
,1,2­
TCE)
were
analyzed
to
determine
the
test
article
purity
by
gas
chromatography
with
flame
ionization
detection
(GUFID).

Retention
samples
(taken
from
the
test
article
container
prior
to
its
initial
use
on
the
study)
and
residual
samples
(taken
from
the
test
article
container
after
its
final
use
on
the
study)
were
analyzed
to
assess
purity
and
stability.

The
test
article
samples
that
were
analyzed
and
used
for
inhalation
exposures
were
greater
than
99.0%
pure.
Comparison
of
the
purity
of
samples
taken
at
the
beginning
and
end
of
use
of
the
container
demonstrated
that
the
test
article
was
stable
for
the
duration
of
use
on
this
study.

II.
EXPERIMENTAL
A.
Gas
Chromatography
Instrument:
Hewlett
Packard
6890A
(series
11)
gas
chromatograph
equipped
with
a
flame
ionization
detector
(FID),
an
HP7673
autosampler,
and
an
IIP
ChemStation
data
system,
or
equivalent
system
Column:
J
&
W
Scientific
DB­
wax
30
m
x
0.25
mm
ID,
.25
pm
film
thickness
Temperature
Program:
40°
C
for
4.0
minutes;
ramp
at
lO"
C/
minute
to
225°
C;
hold
0.0
minute
357
of
619
WIL­
4
17002
HAP
Task
Force
Page
5
Carrier
gas:
Helium
at
6.58
psi
at
40°
C
Injector
temperature:

Injection
volume:

Detector:

Retention
time:
250°
C
Purity
Check:
1
FL;
split
(67:
l)

FID
at
250°
C
Approximately
13.4
to
14.0
minutes
for
1,1,2­
TCE
B.
Preparation
of
Samples
for
Purity
Analysis
Bulk
samples
of
test
article
(1,1,2­
TCE)
were
analyzed
to
determine
the
test
article
purity
by
gas
chromatography
with
flame
ionization
detection
(GCFID).

Samples
were
analyzed
to
assess
purity
by
transferring
approximately
1
mL
of
test
article
into
amber
autosampler
vials.
The
vials
were
capped
and
an
aliquot
(1
pL)
injected
for
GC/
FID
analysis.

C.
Purity
Assessment
Samples
were
collected
at
the
beginning
and
end
of
use
from
the
test
article
container.
They
were
transferred
to
Analytical
Chemistry
for
GC/
FID
analysis.

At
least
duplicate
injections
were
made
from
each
sample.
The
purity
of
the
injected
test
article
was
calculated
based
on
the
area
percent
of
the
resulting
peaks.

Purity
assessment
results
are
presented
in
Table
I.
These
data
indicate
that
the
test
article
used
in
this
study
was
99.14%
pure
(mean
of
the
before
and
after
use
purity
assessments),
with
the
replicate
analytical
results
ranging
from
98.97%
to
99.39%.
Representative
chromatograms
of
a
commercially
available
(Aldrich
Chemical
Co.)
1,1,2­
TCE
reference
standard
(98.08%
pure)
and
a
test
article
container
sample
are
shown
in
Figures
1
and
2.

Comparison
of
the
beginning­
of­
use
purity
assessment
(99.0%
pure)
with
the
end­
of­
use
assessment
(99.3%
pure)
indicates
that
the
test
article
was
stable
during
room
temperature
storage
over
the
duration
of
the
study.

358
of
619
WIL­
417002
HAP
Task
Force
r
FIDI
B,
(417002A\
SIG20003.
D)
Page
6
P
4
14
oi
P
E
5
i5
i0
Figure
1:
Representative
chromatogram
of
a
commercially
available
(Aldrich
Chemical
Co.)
1,1,2­
TCE
reference
standard
FIDI
5,
(417002A\
SIG20006.
D)

Figure
2:
Representative
chromatogram
of
a
test
article
container
sample
359
of
619
WIL­
4
17002
HAP
Task
Force
Page
7
III.
CONCLUSION
The
test
article
(1,12­
TCE)
was
analyzed
to
assess
test
article
purity
and
storage
stability.
The
test
article
used
for
inhalation
exposures
was
greater
than
99.0%
pure.
Comparison
of
the
beginning­
of­
use
purity
assessment
(99.0%
pure)

with
the
end­
of­
use
assessment
(99.3%
pure)
indicates
that
the
test
article
was
stable
during
room
temperature
storage
over
the
duration
of
the
study.

Prepared
by:

e
SL.
/
Cathline
L.
Shayq
/,,`
I+@?
Leader
360of619
WIL­
417002
HAP
Task
Force
Page
8
A
90­
DAY
INHALATION
TOXICITY
STUDY
OF
1,1,2­
TRICHLOROETHANE
(l,
l,
ZTCE)
IN
RATS
(WITH
SATELLITE
GROUPS
FOR
PHARMACOKENETIC
EVALUATIONS
IN
RATS
AND
MICE)

TABLE
I
361
of
619
WIL­
417002
HAPTaskForce
A
90­
DAY
INHALATION
TOXICITY
STUDY
OF
1,1,2­
TRICHLOROETHANE
(1,1,2­
TCE)
IN
RATS
{WITH
SATELLITE
GROUPS
FOR
PHARMACOKINETIC
EVALUATIONS
IN
RATS
AND
MICE\

Table
I:
Purity
Assessments
Collected
Analyzed
ga&
pa&

5116/
01
6/
6/
01
Reference
#
Sample
j417002­
1
ID
l­
2
5015A#
2
Drum
­
beginning
of
use
Run
Number
5
Retention
Time
6.10
6.69
9.44
10.8
13.3
13.5
14.1
15.2
15.9
16.0
19.0
22.3
23.0
25.4
25.6
25.8
Area
Response
343
6.75
314
6.45
1.09
71388
0.755
0.956
1.68
1.80
26.7
3.10
4.09
8.10
2.81
3.44
total
area
72112.7
Area
@J
0.476
0.00937
0.436
0.00894
0.00151
99.00
0.00105
0.00133
0.00233
0.00249
0.0371
0.00430
0.00567
0.0112
0.00390
0.00477
Mean
Area
3
98.98
WIL­
417002
HAPTaskForce
Collected
pa&

5l16101
A
90­
DAY
INHALATION
TOXICITY
STUDY
OF
I,
I,
Z­
TRICHLOROETHANE
(l,
l,
P­
TCE)
IN
RATS
(WITH
SATELLITE
GROUPS
FOR
PHARMACOKINETIC
EVALUATIONS
IN
RATS
AND
MICE\

Table
I:
Purity
Assessments
Analyzed
Reference
#
Sample
Run
Retention
Area
Area
p&
(417002~\
E
Number
Time
Response
j%
J
6/
6/
01
1­
2
5015A#
2
6
6.10
343
0.483
Drum­
beginning
of
use
6.68
6.51
0.00915
9.44
313
0.441
10.8
6.28
0.00883
12.9
3.09
0.00435
13.3
0.989
0.00139
13.5
70357
98.97
14.1
0.845
0.00119
14.7
4.22
0.00594
15.2
0.822
0.00116
15.9
1.62
0.00280
16.0
1.69
0.00238
19.0
26.2
0.0369
20.3
1.24
0.00174
22.3
2.66
0.00375
23.0
3.79
0.00533
25.8
19.0
0.0268
total
area
71092.0
Mean
Area
x
WIL­
417002
HAPTask
Force
Collected
Date
9i21iOl
A
90­
DAY
INHALATION
TOXICITY
STUDY
OF
1
,l,
P­
TRICHLOROETHANE
(1,1,2­
TCE)
IN
RATS
{WITH
SATELLITE
GROUPS
FOR
PHARMACOKINETIC
EVALUATIONS
IN
RATS
AND
MICE)

Table
I:
Purity
Assessments
Analyzed
Reference
#
Sample
Run
Retention
&f&
J417002­
1
!!
2
Number
Time
9127101
8­
2
5015A#
2
13
6.54
Drum­
endofuse
6.87
9.52
10.1
Area
Area
Response
(%)
&

17.3
0.00652
99.30
1147
0.432
2.05
0.000770
881
0.332
11.6
23.2
0.00873
14.0
264630
99.22
15.2
1.08
0.000410
15.7
3.80
0.00143
15.9
1.93
0.000730
16.6
1.07
0.000400
16.9
1.66
0.000630
22.7
1.02
0.000380
total
area
266710.6
Mean
Area
WIL­
417002
HAPTaskForce
A
90­
DAY
INHALATION
TOXICITY
STUDY
OF
1,1,2­
TRICHLOROETHANE
(1,1,2­
TCE)
IN
RATS
JWITH
SATELLITE
GROUPS
FOR
PHARMACOKINETIC
EVALUATIONS
IN
RATS
AND
MICE)

Table
I:
Purity
Assessments
Collected
Analyzed
Reference
#
Sample
Run
Retention
Area
pa&
ga&
/417002­
1
i2
Number
Time
Response
9/
21101
9/
27/
01
8­
2
5015A#
2
14
6.58
7.950
Drum­
endofuse
6.92
1964
9.54
3.033
10.1
1482
11.8
52.01
14.0
580935
15.2
2.905
15.7
9.994
15.9
4.629
16.4
0.8537
16.5
0.9745
16.6
2.753
16.9
4.079
19.4
1.308
22.7
4.104
24.9
1.355
25.2
3.052
total
area
584480
Area
Mean
Area
fxJ
z
0.00136
0.336
0.000520
0.254
0.00890
99.39
0.000500
0.00171
0.000790
0.000150
0.000170
0.000470
0.000700
0.000220
0.000700
0.000230
0.000520
Overall
Mean
(%)
99.14
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
APPENDIX
C
Test
Atmosphere
Generation
and
Environmental
Conditions
During
Exposure
(WIL
Research
Laboratories,
Inc.)

366
of
619
WIL­
4
17002
HAP
Task
Force
Inhalation
Report
Page
1
A
90­
Day
Inhalation
Toxicity
Study
of
1,1,2­
Trichloroethane
(1,1,2­
TCE)
In
Rats
(with
Satellite
Groups
for
Pharmacokinetic
Evaluations
in
Rats
and
Mice)

Table
of
Contents
I.
Exposure
Methods
A.
Exposure
Regimen
B.
Inhalation
Exposure
Systems
Description
II.

III.
C.
Animal
Transport
and
Placement
D.
Exposure
Environmental
Conditions
Test
Atmosphere
Generation
Methods
Methods
of
Characterization
of
Exposure
Atmospheres
A.

B.

C.
Nominal
Exposure
Concentrations
Actual
Exposure
Concentrations
Determination
of
Homogeneity
and
Temporal
Stability
of
Exposure
Atmospheres
D.
Chemical
Purity
in
Vapor
Test
Atmosphere
IV.
E.
Aerosol
Monitoring
Results
of
Characterization
of
Exposure
Atmospheres
A.
Nominal
Exposure
Concentrations
B.
Actual
Exposure
Concentrations
367
of
619
­
WIL­
4
17002
HAP
Task
Force
Inhalation
Report
Page
2
A
90­
Day
Inhalation
Toxicity
Study
of
1,1,2­
Trichloroethane
(1,1,2­
TCE)
In
Rats
(with
Satellite
Grouns
for
Pharmacokinetic
Evaluations
in
Rats
and
Mice)

Index
of
Figures
1.
Schematic
Diagram
of
Generation
and
Exposure
System
(CH
2
&
3)

2.
Schematic
Diagram
of
Generation
and
Exposure
System
(CH
4)

Index
of
Tables
1.

2.

3.

4.

5.

6.

7.

8.
Daily
Mean
Chamber
Temperature
(Degrees
Celsius)

Daily
Mean
Chamber
Relative
Humidity
(%)

Daily
Mean
Chamber
Ventilation
Rate
(SLPM)

Test
Atmosphere
Homogeneity
Determination
Daily
Nominal
Concentrations
(ppm)

Daily
Mean
Test
Atmosphere
Concentrations
(PPM)

Daily
Environmental
Conditions
for
Secondary
Chamber
4
Daily
Concentrations
for
Secondary
Chamber
4
368
of
619
NIL­
4
17002
HAP
Task
Force
Inhalation
Report
Page
3
I.
EXPOSURE
METHODS
A.
Exposure
Repimen
The
test
article
was
administered
as
a
daily
six­
hour
exposure.

Exposures
were
conducted
five
days
per
week
at
approximately
the
same
time
each
day
for
90
days
(66
total
exposure
days).
Animals
in
the
control
group
were
subjected
to
the
identical
exposure
regimen.

B.
Inhalation
Exposure
Svstems
Description
Except
for
pharmacokinetic
group
rats
on
their
day
of
scheduled
blood
collection
(see
section
II),
exposures
were
conducted
in
four
2­
m3
stainless
steel
and
glass
whole­
body
inhalation
exposure
chambers
(Hazleton
H­
2000).
One
chamber
was
dedicated
for
each
group
for
the
duration
of
the
study.
Chamber
supply
air
was
provided
from
a
HEPA­

and
charcoal­
filtered,
temperature­
and
humidity­
controlled
source.

Exhaust
from
the
exposure
system
entered
the
main
exhaust
system,
and
was
treated
with
a
carbon
scrubber
prior
to
discharge
from
the
laboratory.

C.
Animal
Transport
and
Placement
Animals
were
individually
housed
in
stainless
steel
wire­
mesh
cage
batteries
suspended
over
cage
board
during
the
exposures.
Food
and
water
were
not
available
for
rats
and
food
was
not
available
for
pharmacokinetic
group
mice
during
exposure
period.

Animals
were
housed
in
a
normal
colony
room
during
the
non­
exposure
hours.
For
each
day's
exposure,
the
animals
were
transferred
to
the
appropriate
exposure
caging,
transported
to
the
exposure
chamber
room,
exposed
for
the
requisite
duration
and
returned
to
their
home
cages.

The
cage
batteries
were
rotated
on
a
daily
basis
through
six
battery
positions
in
the
chambers
to
help
ensure
a
similar
exposure
for
all
animals
within
each
group
over
the
duration
of
the
exposure
period.

369
of
619
WIL­
4
17002
HAP
Task
Force
Inhalation
Report
Page
4
D.
Exposure
Environmental
Conditions
Temperature,
relative
humidity,
chamber
ventilation
rate,
and
negative
pressure
within
the
chambers
were
monitored
continuously
and
recorded
manually
approximately
every
35
minutes.

Chamber
temperature
and
relative
humidity
were
monitored
by
100
ohm
platinum
resistance
temperature
detectors
and
thin
film
polymeric
sensors,
respectively
(Omega
Engineering,
Inc.,
Stamford,
CT).

Airflow
through
the
chamber
was
monitored
by
the
pressure­
drop
across
a
sharp­
edge
orifice
plate
as
measured
by
differential
pressure
gauges
(Dwyer
Magnehelic@
Indicating
Transmitter,
Michigan
City,
IN)
and
was
set
such
that
there
were
12­
15
air
changes
per
hour.
These
gauges
were
calibrated
under
the
conditions
of
exposure
for
conversion
from
pressure
to
airflow
in
liters
per
minute
(LPM)
through
the
use
of
a
FM
Series
Axial
Turbine
Flow
Transducer
(Flowmetrics,
Chatsworth,
CA).
Oxygen
content
was
measured
during
the
pre­
exposure
method
development
phase
with
a
MSA
Remote
Sampling
Sensor
(Pittsburgh,
PA).
Oxygen
content
was
approximately
20.5%.

Daily
means
for
chamber
temperature,
relative
humidity,
and
chamber
ventilation
rate
over
the
study
period
are
presented
in
Tables
1
through
3
of
this
appendix,
respectively.
The
following
table
summarizes
the
grand
mean
environmental
conditions
for
all
four
study
groups:

370
of
619
WIL­
4
17002
HAP
Task
Force
Inhalation
Report
Page
5
Temperature
Mean
("
C):
Standard
Deviation:
(days)
1
Grow
2
Grow
3
Group
4
Group
21
22
22
25
0.8
0.7
0.8
0.9
66
66
66
66
Relative
Humidity
Mean
(%):
49
46
44
42
Standard
Deviation:
2.3
2.1
3.6
4.0
(days)
66
66
66
66
Chamber
Ventilation
Rate
Mean
(SLPM):
Standard
Deviation:
(days)
434
440
4.4
12.2
66
66
421
433
11.3
4.9
66
66
II.
TEST
ATMOSPHERE
GENERATION
METHODS
Vapor
atmospheres
of
the
test
article
were
generated
using
a
system
similar
to
that
shown
in
Figure
1
(CH
2
&
3)
and
Figure
2
(CH
4).
The
system
operated
as
follows:
test
article
was
metered
using
a
Harvard
Compact
Infusion
pump
(Harvard
Apparatus,
Hollison,
MA)
for
CH
2
and
3,
and
a
positive
displacement
pump
(Fluid
Metering,
Inc.,
Oyster
Bay,
NY)
for
CH
4
at
a
known
and
constant
rate
to
glass
vaporization
columns.
The
vaporization
columns
for
test
article
exposure
groups
2,
3,
and
4
were
2.4
cm
inner
diameter
(I.
D.)
by
approximately
75
cm
and
were
filled
with
6­,
8­
and
12­
n­
m­
1
glass
beads.
The
vaporization
columns
were
wrapped
with
heating
tapes
that
were
controlled
by
temperature
controllers
(Model
CN370,
Omega
Engineering,
Stamford,
CT).

Compressed
air
was
metered
to
the
bottom
of
each
column
using
a
rotameter­

type
flowmeter
(Model
No.
FM­
1050,
Gilmont
Instruments,
Barrington,
IL).

The
liquid
test
article
was
delivered
onto
the
heated
glass
beads
and
vaporized
and
the
resulting
vapors
were
carried
out
of
the
generators
by
the
air
flowing
upward
through
the
columns.
The
concentrated
vapors
in
each
system
were
piped
to
the
chamber
inlet
where
the
concentration
was
diluted
to
the
target
concentration
by
the
chamber
ventilation
airflow.

371
of
619
WIL­
4
17002
HAP
Task
Force
Inhalation
Report
Page
6
The
following
table
defines
the
system
conditions
for
each
exposure
chamber:

Chamber
Number
1
2
3
4
Approximate
Test
Vaporization
Vaporization
Chamber
Article
Column
Flow
Rate
of
Ventilation
Metering
Pump
Flow
Rate
Temp.
Compressed
Air
Flow
Rate
Device
Setting
(m1imin.
j
li2.!
L2
a?
J3dJ
cLE!&
J
NA
NA
NA
75
17
430
Harvard
20
ind.
0.038
75
18
430
Harvard
20
ind.
0.080
75
19
430
FM1
30­
40%
0.186­
0.242
75
17
430
(till
scale)

A
500­
L
glass
and
stainless
steel
whole
body
inhalation
chamber
was
used
for
pharmacokinetic
study
rats
on
the
days
the
bloods
were
collected
for
Group
5
(100
ppm).
The
secondary
chamber
(CH4S)
for
Group
5
ran
under
the
same
conditions
as
Chambers
2
and
3
with
the
exception
of
the
test
article
delivery
on
6/
25/
01
and
ventilation
flow
rate
through
the
chamber.
A
Raze1
syringe
pump
(Raze1
Scientific
Instruments,
Inc.,
Stamford,
CT)
was
used
on
6/
25/
01
for
the
delivery
of
the
test
article
to
the
bead
column.
The
Raze1
syringe
pump
was
removed
following
exposures
on
6/
25/
01
and
a
Harvard
syringe
pump
was
used
for
test
article
delivery
for
the
remainder
of
exposures
conducted
in
this
chamber.

The
following
table
indicates
the
specific
conditions
for
CH
4­
S
each
day
it
was
used
for
exposure:

Target
Column
Test
Article
Compressed
Air
Ventilation
Exposure
Concentration
Temperature
Flow
Rate
Flow
Rate
Flow
Rate
&&
4iLlPdl
(Des
C]
&nl/
min.
J
4!?
ilba
(.
L&.
Q
0.1600­
612510
1
100
75
0.282
13
­400
6121101
100
75
0.092
13
­150
612910
1
100
75
0.092
13
­150
The
use
of
a
higher
than
normal
ventilation
rate
for
the
500­
L
chamber
on
6/
25/
01
would
not
be
expected
to
affect
the
exposure
of
the
pharmacokinetic
group
rats
on
that
day.

372
of
619
WIL­
4
17002
HAP
Task
Force
Inhalation
Report
Page
7
Oxygen
content
of
the
exposure
atmospheres
in
CH
4­
S
was
determined
during
the
6/
29/
01
animal
exposure
in
the
same
manner
as
Chambers
2­
4
with
a
calibrated
oxygen
sensor.
The
oxygen
content
was
greater
than
19%.
Daily
means
for
chamber
temperature,
relative
humidity,
and
chamber
ventilation
rate
for
CH
4­
S
are
presented
in
Table
7.

III.
METHODS
OF
CHARACTERIZATION
OF
EXPOSURE
ATMOSPHERES
A.
Nominal
Exposure
Concentrations
A
nominal
exposure
concentration
was
calculated
for
each
daily
exposure
for
each
chamber
from
the
total
amount
of
test
article
used
during
the
exposure
and
the
total
volume
of
air
passed
through
the
chamber
during
that
day's
exposure.
The
amount
of
test
article
used
was
obtained
by
weighing
the
reservoir
containing
the
test
article
for
each
chamber
prior
to
and
after
exposure
each
day.
The
total
volume
of
air
passed
through
each
chamber
was
calculated
from
the
daily
average
chamber
ventilation
flow
rate
in
liters
per
minute
(LPM)
and
the
exposure
duration.

The
nominal
concentration
was
calculated
as
follows:

ppm
Trichloroethane
=

Where:
Wt.
Trichloroethane
.
Mol.
Vol.
.
lo6
MW
.
Ch.
Flow
*
Exp.
Dur.

Wt.
Trichloroethane
=
Weight
of
test
article
in
grams
Mol.
Vol.
ZZ
Molar
volume
at
730
m.
mHg
and
2
1°
C
25.11
L/
mole
106
=
ppm
conversion
factor
=
Trichloroethane
molecular
weight,
133.41
Ch.
Flow
z
Daily
average
chamber
flowrate
for
a
given
day,
in
LPM.

Exp.
Dur.
=
Duration
of
a
given
day's
exposure,
in
minutes
373
of
619
WIL­
4
17002
HAP
Task
Force
Inhalation
Report
Page
8
B.
Actual
Exposure
Concentrations
Actual
exposure
concentrations
were
determined
using
a
Hewlett
Packard
5890
Series
II
gas
chromatograph
(GC).
Samples
of
the
exposure
atmospheres
from
each
chamber
were
manually
collected
at
approximate
35­
minute
intervals
using
a
sample
loop
and
multiposition
valve.

The
following
table
summarizes
the
GC
conditions:

Instrument:

Detector:

Column:

Gases:
Carrier
­
Helium
Fuel
­
Hydrogen
Air
Temperatures
("
C)
Injector
Column
Detector
Injection
volume
(ml)

Retention
time
(min.)
Approximately
0.825
Integrator
Run
Parameters
Chart
Zero
Offset
Chart
Attenuation
Chart
Speed
Peak
Area
Rejection
Value
Peak
Threshold
Peak
Width
0
1
1
.O
cm/
min
0
2
0.04
Hewlett
Packard
5890
Series
II
with
a
3396A
Series
II
integrator
Flame
ionization
J
&
W
DB­
Wax
Narrowbore
30
m
x
0.25
mm
I.
D.,
1.5­
micron
film
thickness
Pressure
(psinl
Flow
Rate
(mVmin.
1
80
10
25
30
25
300
250
160,
isothermal
250
0.25
The
chromatograph
was
standardized
using
40­
liter
Tedlar'
gas
bags
prepared
to
contain
known
concentrations
of
the
test
article.
The
standard
bags
were
prepared
by
injecting
known
volumes
of
test
article
into
a
374
of
619
WIL­
4
17002
HAP
Task
Force
Inhalation
Report
Page
9
500­
ml
glass
vaporization
bulb
heated
to
80°
C.
A
continuous
flow
of
air
carried
the
vaporized
test
article
to
a
40­
liter
bag.
The
total
volume
of
air
was
measured
by
a
dry
test
meter
(Model
DTM­
200A,
American
Meter
Co.,
Horsham,
PA).

Concentrations
of
the
gas­
phase
standards
were
calculated
as
follows:

Concentration
=

Where:
VOL.
R.
T
.
D
.
1O­
3
1
lo6
L.
GMW.
P
Concentration
is
in
ppm
VOL
=
volume
of
test
article
vaporized
into
bag
in
l.
tl
R
=
universal
gas
constant,
62.36
L
mmHg
mole
K
T
=
nominal
laboratory
temperature
in
K
(273
+
21°
C
=
294
IS)
D
=
10"
density
of
the
test
article,
1.4432
g/
ml
=
lo6
=
~1
to
ml
conversion
factor
conversion
factor
to
ppm
L
=
volume
of
air
used
to
prepare
bag,
30
liters
GMW
=
gram
molecular
weight,
133.4
1
g/
mole
P
=
nominal
laboratory
barometric
pressure,
730
mmHg
A
calibration
curve
was
prepared
for
concentration
analysis
during
the
study.
The
following
table
defines
the
standards
prepared
for
this
study:

Standard
Concentration
JrJ2?
aL
9
27
72
109
136
Volume
of
Test
Article
Used
4L
1
3
8
12
15
Total
Air
Volume
=e
30
30
30
30
Each
standard
was
prepared
in
triplicate
prior
to
the
exposure
period
and
analyzed
with
the
GC.
A
least­
squares
line
was
fitted
to
the
resulting
375
of
619
WIL­
4
17002
Page
10
HAP
Task
Force
Inhalation
Report
peak
areas.
Concentrations
were
then
calculated
using
the
slope
and
intercept
of
the
calibration
curves.

On
a
daily
basis,
the
integrity
of
the
prime
calibration
curves
was
checked
by
analyzing
one
freshly
prepared
standard.
On
a
rotational
basis,
a
different
one
of
the
five
standards
was
used
each
day.
If
the
analyzed
concentrations
were
within
110%
of
each
known
concentration,

C.
the
GC
was
considered
within
calibration
specifications.

Determination
of
HomoPeneitv
and
Temporal
Stab&
v
of
Exposure
Atmospheres
Evaluation
of
the
homogeneity
of
exposure
concentrations
was
accomplished
during
the
method
development
phase
of
the
study
prior
to
animal
exposures.
Four
test
locations
and
a
reference
location
were
used
for
these
determinations.
The
test
locations
were
Left
Upper
Front,
Left
Lower
Rear,
Right
Upper
Rear,
Right
Lower
Front,
identified
as
1,
2,
3
and
4,
respectively.
The
reference
position
was
located
in
the
approximate
center
of
the
chamber.
Samples
were
collected
as
rapidly
as
possible,
always
collecting
a
sample
from
the
reference
location
and
then
from
one
of
the
four
test
locations.
For
each
test
location,
the
measured
concentration
was
calculated
as
a
percent
difference
from
the
reference
location.
The
homogeneity
determination
was
performed
in
triplicate
for
each
test
article
exposure.
The
results
are
presented
in
Table
4
of
this
appendix.
The
following
table
summarizes
these
data
as
the
mean
of
the
replicates
for
each
chamber:

376of619
WIL­
417002
HAP
Task
Force
Inhalation
Report
Chamber
Number
2
Test
Mean
%
From
Location
Reference
1
­5.6
2
­1.7
3
3.0
4
­4.0
3
1
2
3
4
5
4
1
2
3
4
­0.8
0.1
­0.8
0.0
0.0
­0.7
0.0
0.3
4s
1
­1.0
2
­1.4
3
­2.4
4
­1.4
These
data
indicate
that
the
homogeneity
of
each
exposure
atmosphere
was
adequate
for
the
purpose
of
this
study.
To
insure
uniform
exposure
of
all
animals
to
the
test
article,
animal
cage
batteries
were
rotated
through
the
various
possible
chamber
locations
on
a
daily
basis.

During
the
method
development
phase
of
this
study
the
stability
of
the
test
article
vapor
concentrations
over
time
was
evaluated.
Vapor
chamber
generated
for
six
hours.
Samples
were
taken
approximately
every
35
minutes
and
were
found
to
be
within
the
*lOoh
range.

D.
Chemical
Puritv
of
the
Test
Atmosphere
On
5/
25/
01
and
5/
29/
01
of
method
development,
the
chemical
purity
of
the
test
atmosphere
was
analyzed
by
the
following
procedure.
A
sample
of
the
test
atmosphere
was
analyzed
by
the
gas
chromatograph.

The
GC
was
optimized
and
the
run
length
was
extended
to
allow
for
detection
of
all
test
article­
associated
peaks.
The
109
ppm
standard
was
377
of
619
WIL­
4
17002
HAP
Task
Force
Inhalation
Report
then
analyzed
in
the
same
manner.
The
percent
of
total
peak
area
counts
represented
by
the
area
counts
for
the
atmosphere
and
standard
peaks
were
calculated
and
compared.
The
1,1,2­
TCE
peak
represented
96.4%

and
96.3%
of
all
peaks
detected
for
the
test
atmosphere
and
109
ppm
standard,
respectively.
On
5/
29/
01
the
109
ppm
standard
and
both
chamber
4
test
atmosphere
samples
were
100%
of
the
1,1,2­
TCE
peak.

E.
Aerosol
Monitoring
Chamber
4
(100
ppm)
was
monitored
for
aerosol
formation
during
the
method
development
phase
of
the
study.
A
light
scattering
aerosol
photometer
(MIE
Industrial
Dust
Sensor,
Model
HPM­
1000,
MIE,
Inc.,

Billerica,
MA)
was
used
on
May
29,
2001
to
monitor
the
chamber
for
aerosol
formation.
The
monitor
was
connected
to
a
strip
chart
recorder
(Omega
Engineering,
Inc.,
Stamford,
CT)
such
that
a
display
of
the
dust
sensor
output
was
available
to
the
operator.
During
actual
determinations
of
aerosol
formation
in
the
chamber,
aerosols
were
not
detected
at
a
level
equal
to
or
above
the
room
and
it
was
concluded
that
no
aerosols
were
present.

IV.
RESULTS
OF
CHARACTERIZATION
OF
EXPOSURE
ATMOSPHERES
A.
Nominal
Exnosure
Concentrations
The
overall
mean
nominal
concentrations
were
24
ppm,
5
1
ppm
and
128
ppm
for
the
15,
40
and
100
ppm
groups,
respectively.
The
daily
nominal
concentrations
for
CH
l­
4
are
presented
in
Table
5
and
for
CH
4­
S
are
presented
in
Table
8
of
this
appendix.

378
of
619
WIL­
4
17002
HAP
Task
Force
Inhalation
Report
Page
B.
Actual
Exposure
Concentrations
The
overal
mean
analyzed
concentrations
were
I5
ppm,
40
ppm
a
100
ppm
for
the
15,
40
and
100
ppm
groups,
respectively.
Daily
mean
test
atmosphere
concentrations
for
CH
1­
4
are
presented
in
Table
6
and
for
CH
4­
S
97
ppm
overall
mean
concentration)
are
presented
in
Table
8
of
this
appendix.

prepar<
ez
Inhalation
Toxicology
Director,
Inhalation
Toxicology
379of619
WIL­
4
17002
HAP
Task
Force
Inhalation
Report
Page
14
Fim&
1.
Schematic
D&­
ram
of
Generation
and
Exposure
System
Chamber
2.
a.
nd
3
source
of
­
Chamber
Supply
Air
ZOOO­
Liter
Hazleton
Chamber
'
To
Compressed
Air
Source
Column
&
Temperature
Controller
Orifice
Meter
+

To
Chamber
Exhaust
380
of
619
WIL­
417002
HAP
Task
Force
Inhalation
Report
Page
15
Fipe
2.
Schematic
Diagram
of
Genertition
and
Exposure
System
Chamber
4
Source
of
j
,i_
f3m~
b~;
WP~
y
ZOO&
Liter
Hazleton
Chamber
­'

Orifice
Meter
i
/
/'
To
Compressed
Air
Source
Column
&
Temperature
/
\

Controlfer
Test
Material
To
Chamber
Exhaust
381
of
639
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
1
YO­
DAY
INHAL.
STUDY
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
DAILY
MEAN
CHAMBER
TEMPERATURE
(DEGREES
CELSIUS)

­­__­­­­­_____­_____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­
CHAMBER
1
CHAMBER
2
CHAMBER
3
CHAMBER
4
DATE
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
____­­­­­­­­­­­­­­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
05/
31/
01
19.
19.
20.
22.
06/
01/
01
20.
20.
20.
23.
06/
04/
01
22.
23.
22.
24.
06/
05/
01
21.
22.
22.
25.
06/
06/
01
21.
22.
23.
25.
06/
07/
01
21.
22.
23.
26.
06/
08/
01
20.
21.
22.
26.
06/
11/
01
22.
22.
22.
26.
06/
12/
01
22.
23.
22.
26.
06/
13/
01
21.
22.
22.
26.
06/
14/
01
21.
22.
23.
25.
06/
15/
01
22.
22.
24.
26.
06/
18/
01
21.
22.
22.
27.
06/
19/
01
22.
22.
22.
26.
06/
20/
01
22.
24.
23.
25.
06/
21/
01
21.
22.
22.
25.
%
06/
22/
01
21.
22.
23.
25.
06/
25/
01
21.
22.
23.
26.
cn
06/
26/
01
21.
22.
22.
25.
G
06/
27/
01
22.
22.
22.
26.
06/
28/
01
23.
23.
22.
25.
06/
29/
01
21.
22.
22.
24.
07/
02/
01
21.
22.
22.
24.
07/
03/
01
22.
22.
22.
24.
07/
04/
01
21.
21.
21.
24.
07/
05/
01
22.
22.
22.
24.
07/
06/
01
23.
23.
22.
24.
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
1
90­
DAY
INHAL.
STUDY
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
DAILY
MEAN
CHAMBER
TEMPERATURE
(DEGREES
CELSIUS)
PAGE
2
CHAMBER
1
CHAMBER
2
CHAMBER
3
CHAMBER
4
DATE
GROUP
:
0
PPM
15
PPM
40
PPM
100
PPM
­­_­__­­­­­­_____­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
07/
09/
01
21.
22.
22.
24.
07/
10/
01
21.
22.
22.
24.
07/
11/
01
22.
22.
24.
25.
07/
12/
01
21.
22.
22.
24.
07/
13/
01
22.
22.
22.
24.
07j16jOl
23
07/
17/
01
21
07/
18/
01
21
07/
19/
01
22
07/
20/
01
21
07/
23/
01
22
07/
24/
01
23
07/
25/
01
21
07/
26/
01
21
07/
27/
01
22
07/
30/
01
21
%
07/
31/
01
22
08/
01/
01
23
CT\
08/
02/
01
21
G
OEjO3jOl
21
08/
06/
01
21
08/
07/
01
22
08/
08/
01
22
08/
09/
01
23
08/
10/
01
21
08/
13/
01
21
08/
14/
01
21
23.
22
24.
22.
22
24.
22.
23
24.
22.
23
25.
23.
22.
23.
22.
22.
22.
22.
22.
23.
23
22.
22
22
22
22
22
23
24
22
22
22.
23
22.
24
22.
22
22.
22
24.
23
22.
22
22.
23
22.
24
24.
24.
25.
24.
24.
26.
25.
25.
26.
25.
25.
26.
25.
25.
26.
25.
25.
26.
.
.
.
mulm
NNN
.
.
.
NrnN
NNN
.
.
LnwLD
NNN
.
.
mmm
NCUCU
.
.
.
.
ln*
II)
uz
NNNN
384of619
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
2
PO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
DAILY
MEAN
CHAMBER
RELATIVE
HUMIDITY
(%)
PAGE
1
CHAMBER
1
CHAMBER
2
CHAMBER
3
CHAMBER
4
DATE
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
05/
31/
01
06/
01/
01
06jO4jOl
06/
05/
01
06/
06/
01
06/
07/
01
06/
08/
01
06/
11/
01
06/
12/
01
06/
13/
01
06/
14/
01
06/
15/
01
06/
18/
01
06/
19/
01
06/
20/
01
06/
21/
01
0,
06/
22/
01
06/
25/
01
o\

5
06/
26/
01
06/
27/
01
06/
28/
01
06j29;
Ol
07/
02/
01
07/
03/
01
07/
04/
01
07/
05/
01
07/
06/
01
__­­___­__­___­­___________
50.
57.
51.
50.
51.
53.
54.
51.
51.
53.
48.
44.
52.
46.
47.
48.
48.
51.
49.
46.
50.
49.
47.
48.
48.
47.
46.
48.
54.
50.
46.
47.
49.
48.
50.
46.
47.
45.
49.
48.
44.
46.
45.
45.
48.
46.
44
46
46.
43.
47.
45.
45.
44.
_______­­­­­___­­­­________
47.
57.
48.
48.
49.
49.
48.
51.
50.
50.
46.
46.
52.
49.
48.
48.
42.
44.
44.
43.
44.
43.
40.
41.
43.
43.
40.
40.
46.
54.
48.
52.
57.
47.
48.
45.
45.
41.
51.
47.
44.
44.
42.
43.
47.
43.
44.
44.
42.
39.
42.
41.
40.
39.
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
2
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
DAILY
MEAN
CHAMBER
RELATIVE
HUMIDITY
(%)
PAGE
2
_­__________­­___­______________________­­­­~~­­­­­­­­­­­­­~~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­
CHAMBER
1
CAHMBER
2
CHAMBER
3
CHAMBER
4
DATE
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
_________­­_________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

07/
09/
01
50.
47.
44.
42.
07/
10/
01
50.
45.
42.
40.
07/
11/
01
49.
46.
40.
42.
07/
12/
01
50.
47.
44.
42.
07;
13jo1
46.
44.
43.
40:
07/
16/
01
49.
47.
44.
44.
07/
17/
01
50.
07/
18/
01
50.
07/
19/
01
49.
07;
20;
01
07/
23/
01
07/
24/
01
07/
25/
01
w
07;
26jOl
%
07/
27/
01
07/
30/
01
%
07/
31/
01
08/
01/
01
CJY
G
08/
02/
01
08/
03/
01
08/
06/
01
08/
07/
01
48.
48.
55.
50.
47.
46.
52.
47.
49.
49.
50.
49.
52.
47.
46.
46.
44.
45.
52.
46.
42.
44.
47.
44.
44.
45.
45.
46.
47.
44.
42.
41.
41.
44.
49.
43.
39.
40.
44.
42.
42.
42.
40.
40.
45.
42
41
41
40
41
48
42
38
39
41
40
40
39
40
38
45
08;
08;
01
48.
45.
44.
41.
08/
09/
01
52.
49.
47.
44.
08/
10/
01
47.
43.
41.
38.
08/
13/
01
48.
44.
41.
38.
08/
14/
01
48.
44.
40.
37.
m
I
I
,
INHALATION
TABLE
3
PROJECT
NO.:
WIL­
4170021
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
DAILY
MEAN
CHAMBER
VENTILATION
RATE
(SLPM)
PAGE
1
CHAMBER
1
CHAMBER
2
CHAMBER
3
CHAMBER
4
DATE
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
__________­_­__­______________________
05/
31/
01
06/
01/
01
06/
04/
01
06jO5jOl
06/
06/
01
06/
07/
01
06/
08/
01
06;
ll;
Ol
06/
12/
01
06/
13/
01
06/
14/
01
06/
15/
01
06/
18/
01
E
06/
19/
01
06/
20/
01
00
06/
21/
01
0
06/
22/
01
r
06/
25/
01
cn
G
06/
26/
01
06/
27/
01
06/
28/
01
_­­­
433
433
433
433
433
429
429
434
434
437
437
438
433
433
434
445
437
441
421.
447.
432
446
426.
437.
433
451
416.
436.
433
437
424.
434.
436
441
422.
434.
429
424
438
440
424
437
425
421
461
451
457
450
431
454
450
451
._____­­­__________________
418.
418.
417.
415.
421.
419.
413.
412.
422.
418.
417.
426.
422.
430.
431.
427.
._­___­_____­­__
422.
431.
429.
433.
431.
431.
424.
431.
434.
439.
437.
436.
440.
434.
428.
437.

06j29jOl
435.
408.
419.
443.
07/
02/
01
439.
440.
425.
430.
07/
03/
01
441.
444.
426.
437.
07/
04/
01
430.
449.
424.
435.
07jO5jOl
437.
454.
419.
431.
07/
06/
01
438.
425.
429.
432.
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
3
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
RATS
&
MICE
DAILY
MEAN
CHAMBER
VENTILATION
RATE
(SLPM)
PAGE
2
__­__________­­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
CHAMBER
1
CHAMBER
2
CHAMBER
3
CHAMBER
4
DATE
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
_­_­___________­­­­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

07/
09/
01
433.
450.
423.

07/
10/
01
431.
433.
458.
429.
07/
11/
01
434.
433.
453.
419.
07/
12/
01
439.
427.
450.
426.

07/
13/
01
433.
433.
441.
420.
07/
16/
01
429.
436.
456.
422.
07/
17/
01
428.
434.
45%
421.
422.
07/
18/
01
07/
19/
01
07/
20/
01
07/
23/
01
07/
24/
01
07/
25/
01
433.
436.
433.
434.
426.
428.
429.
430.
430.

E
07j26jOl
07/
27/
01
a
07/
30/
01
435.
440.
422
426
421
430
423
440
432
%
07/
31/
01
08/
01/
01
m
z
08/
02/
01
08/
03/
01
08/
06/
01
08/
07/
01
432.
433.
430.
438.
433.
431
429
431.
430.
429.
430.
427.
436.
436.

08;
08;
01
08/
09/
01
08/
10/
01
08/
13/
01
08/
14/
01
432.
439.
434.
433.
431.
432.
431.
439.
444.
443.
454.
465.
436.
438.
433.
426.
437.
443.
438.
458.
440.
432.
448.
433.
421
409
428
431
421
421
430
420
415
430.
435.
432.
429.
432.
439.
431.
428.
433.
432.
432.
434.
449.
412
396
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
3
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
RATS
&
MICE
DAILY
MEAN
CHAMBER
VENTILATION
RATE
(SLPM)
PAGE
3
CHAMBER
1
CHAMBER
2
CHAMBER
3
CHAMBER
4
DATE
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
________­­___­_­­­­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
08/
15/
01
418.
460.
441.
08/
16/
01
436.
441.
436.
401.
08/
17/
01
427.
424.
441.
418.
441
08/
20/
01
425.
432.
413.
08/
21/
01
436.
441.
421.
402.
08/
22/
01
443.
438.
431.
409.
440.
08/
23/
01
437.
425.
410.
08/
24/
01
440.
437.
438.
422.
08/
27/
01
438.
434.
425.
404.
08/
28/
01
434.
441.
406.
388.
434.
08/
29/
01
441.
441.
408.
08/
30/
01
432.
433.
434.
386.
433.
_____­_________­­­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRAND
MEAN
434.
440.
421.
S.
D.
4.4
12.2
11.3
C.
V.
(%)
1.01
2.78
2.68
433.
4.9
1.14
%
N
66
66
66
66
6\
MANUALv1.00
F;
07/
09/
2001
R:
02/
14/
2002
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
4
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
RATS
&
MICE
TEST
ATMOSPHERE
HOMOGENEITY
DETERMINATION
PAGE
1
__­­­­_____­­­­­___­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­~­­­­~~~­­­­­~~
TARGET:
15
PPM
CHAMBER
#2
2.0
m3
_­_________­­­­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~­­­~~­­­­­­­­
DATE
SAMPLING
LOCATION
CONC.
(PPM)
%
FROM
REFERENCE
_________­_____­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­~~~~­~­­­­­­­~­­~~~­~~­­­­­­­
05/
27/
01
REFERENCE
PORT
16.1
LEFT
UPPER
FRONT
14.9
­7.5
REFERENCE
PORT
16.4
LEFT
LOWER
REAR
15.9
­3.0
REFERENCE
PORT
15.7
RIGHT
UPPER
REAR
17.4
10.8
REFERENCE
PORT
15.6
RIGHT
LOWER
FRONT
14.9
­4.5
05/
27/
01
REFERENCE
PORT
16.0
LEFT
UPPER
FRONT
15.3
­4.4
REFERENCE
PORT
15.4
%
LEFT
LOWER
REAR
REFERENCE
15.1
PORT
15.9
­1.9
E
RIGHT
UPPER
REAR
REFERENCE
14.9
PORT
16.6
­6.3
RIGHT
LOWER
FRONT
15.9
­4.2
o\
5;
05/
27/
01
REFERENCE
PORT
16.1
LEFT
UPPER
FRONT
15.3
­5.0
REFERENCE
PORT
15.7
LEFT
LOWER
REAR
15.7
0.0
REFERENCE
PORT
15.7
RIGHT
UPPER
REAR
16.4
4.5
REFERENCE
PORT
15.2
RIGHT
LOWER
FRONT
14.7
­3.3
MEAN
%
FOR
EACH
LOCATION:
LEFT
UPPER
FRONT
­5.6
LEFT
LOWER
REAR
­1.7
RIGHT
UPPER
REAR
3.0
RIGHT
LOWER
FRONT
­4.0
___­_­__________­_­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­~~­­­­­­­­~­­~~
CONC.
=
CONCENTRATION
PPM
=
PARTS
PER
MILLION
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
4
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
RATS
&
MICE
TEST
ATMOSPHERE
HOMOGENEITY
DETERMINATION
PAGE
2
TARGET:
40
PPM
CHAMBER
#3
2.0
m3
__­____­­____­­­­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­
DATE
SAMPLING
LOCATION
CONC.(
PPM)
%
FROM
REFERENCE
__­____­­__­____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­
05/
29/
01
REFERENCE
PORT
39
LEFT
UPPER
FRONT
39
0.0
REFERENCE
PORT
41
LEFT
LOWER
REAR
40
­2.4
REFERENCE
PORT
40
RIGHT
UPPER
REAR
39
­2.5
REFERENCE
RIGHT
LOWER
FRONT
38
0
05/
29/
01
REFERENCE
LEFT
UPPER
FRONT
39
REFERENCE
LEFT
LOWER
REAR
39
REFERENCE
RIGHT
UPPER
REAR
40
REFERENCE
RIGHT
LOWER
FRONT
40
PORT
39
PORT
39
0.0
PORT
40
PORT
40
0.0
PORT
39
2.6
05/
29/
01
REFERENCE
PORT
40
LEFT
UPPER
FRONT
39
­2.5
REFERENCE
PORT
38
LEFT
LOWER
REAR
40
REFERENCE
PORT
39
RIGHT
UPPER
REAR
39
0.0
REFERENCE
PORT
40
RIGHT
LOWER
FRONT
40
0.0
MEAN
%
FOR
EACH
LOCATION:
­2.6
­2.5
5.3
LEFT
UPPER
FRONT
­0.8
LEFT
LOWER
REAR
0.1
RIGHT
UPPER
REAR
­0.8
RIGHT
LOWER
FRONT
0.0
____­____­________­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
CONC.
=
CONCENTRATION
PPM
=
PARTS
PER
MILLION
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
4
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
RATS
&
MICE
TEST
ATMOSPHERE
HOMOGENEITY
DETERMINATION
PAGE
3
_____­­­­__­_­­­­­__­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­~­­­­­­­­­­­­
TARGET:
100
PPM
CHAMBER
#4
2.0
m3
______­­­­__­­­­____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~­­­­­­
DATE
SAMPLING
LOCATION
CONC.
(PPM)
%
FROM
REFERENCE
­_____­­­­­_­­­­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­~­­­­­­­~­­~­­­

05/
26/
01
REFERENCE
PORT
101
LEFT
UPPER
FRONT
101
0.0
REFERENCE
PORT
102
LEFT
LOWER
REAR
101
­1.0
REFERENCE
PORT
101
RIGHT
UPPER
REAR
102
1.0
REFERENCE
PORT
100
RIGHT
LOWER
FRONT
101
1.0
05/
26/
01
REFERENCE
PORT
101
LEFT
UPPER
FRONT
103
2.0
REFERENCE
PORT
102
LEFT
LOWER
REAR
101
REFERENCE
PORT
102
RIGHT
UPPER
REAR
101
­1.0
REFERENCE
PORT
101
%
RIGHT
LOWER
FRONT
101
0.0
a\

t;
05/
26/
01
REFERENCE
PORT
102
LEFT
UPPER
FRONT
100
­2.0
REFERENCE
PORT
101
LEFT
LOWER
REAR
101
REFERENCE
PORT
101
RIGHT
UPPER
REAR
101
0.0
REFERENCE
PORT
101
RIGHT
LOWER
FRONT
101
0.0
­1.0
0.0
MEAN
%
FOR
EACH
LOCATION:
LEFT
UPPER
FRONT
0.0
LEFT
LOWER
REAR
­0.7
RIGHT
UPPER
REAR
0.0
RIGHT
LOWER
FRONT
0.3
__­__________­­­­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­~­~­­­­~­­­­~~­­­­~­~­­
CONC.
=
CONCENTRATION
PPM
=
PARTS
PER
MILLION
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
4
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
RATS
&
MICE
TEST
ATMOSPHERE
HOMOGENEITY
DETERMINATION
PAGE
4
­­___­­____­­­­_­­­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~
TARGET:
100
PPM
CHAMBER
#4
S
0.5
m3
­­­___­____­­___­­­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
DATE
SAMPLING
LOCATION
CONC.
(PPM)
%
FROM
REFERENCE
___­____­_______­­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~­~­­­­­­­­­­­­­­­~­­~~­­­­­­­­­­~­­­­~~~­­­­­
06/
28/
01
REFERENCE
PORT
94
LEFT
UPPER
FRONT
94
0.0
REFERENCE
PORT
98
LEFT
LOWER
REAR
96
­2.0
REFERENCE
PORT
97
RIGHT
UPPER
REAR
96
­1.0
REFERENCE
PORT
96
RIGHT
LOWER
FRONT
95
­1.0
06/
28/
01
REFERENCE
PORT
97
LEFT
UPPER
FRONT
96
­1.0
REFERENCE
PORT
97
LEFT
LOWER
REAR
97
0.0
REFERENCE
PORT
98
RIGHT
UPPER
REAR
96
­2.0
REFERENCE
PORT
98
RIGHT
LOWER
FRONT
97
­1.0
06/
28/
01
REFERENCE
PORT
98
LEFT
UPPER
FRONT
96
­2.0
REFERENCE
PORT
98
LEFT
LOWER
REAR
96
­2.0
REFERENCE
PORT
98
RIGHT
UPPER
REAR
94
­4.1
REFERENCE
PORT
98
RIGHT
LOWER
FRONT
96
­2.0
MEAN
%
FOR
EACH
LOCATION:
LEFT
UPPER
FRONT
­1.0
LEFT
LOWER
REAR
­1.4
RIGHT
UPPER
REAR
­2.4
RIGHT
LOWER
FRONT
­1.4
___­­___­­______­­­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
CONC.
=
CONCENTRATION
PPM
=
PARTS
PER
MILLION
MANUAL
V1.00
07/
17/
2001
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
5
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
DAILY
NOMINAL
CONCENTRATION
(PMM)
PAGE
1
___­_­__­_______________________________­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
CHAMBER
1
CHAMBER
2
CHAMBER
3
CHAMBER
4
DATE
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
_______________­_­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
05/
31/
01
0.
25.
51.
123.
06/
01/
01
0.
24.
51.
130.
06/
04/
01
0.
24.
51.
127.
06/
05/
01
0.
24.
52.
128.
06/
06/
01
0.
25.
51.
126.
06/
07/
01
0.
24.
50.
127.
06;
08jol
0.
26
52.
125.
06/
11/
01
0.
25
52.
131.
06/
12/
01
06/
13/
01
06;
14;
01
06/
15/
01
06/
18/
01
06/
19/
01
06/
20/
01
06/
21/
01
0
06/
22/
01
2
06/
25/
01
z
06/
26/
01
06/
27/
01
06/
28/
01
06/
29/
01
07/
02/
01
07/
03/
01
07/
04/
01
07/
05/
01
07/
06/
01
0.
23
0.
23
0.
24
0.
23
0.
22
0.
23
0.
23
0.
25
0.
24
0.
24
0.
23
0.
25
0.
24
0.
26
0.
24
0.
24
0.
23
0.
24
0.
24
51.
51.
52.
49.
50.
49.
50.
50.
51.
50.
51.
50.
50.
51.
50.
50.
51.
51.
50.
129.
128.
130.
125.
129.
126.
128.
130.
128.
127.
128.
128.
128.
127.
128.
123.
128.
129.
128.
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
5
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
DAILY
NOMINAL
CONCENTRATION
(PPM)
PAGE
2
CHAMBER
1
CHAMBER
2
CHAMBER
3
CHAMBER
4
DATE
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
____­­­­_­________­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­~­­­­­­­­­­­­­­­­­­­­­­­~­­­­~­­­­­~~­­~~­~~­~­­­­­­­­­­
07/
09/
01
0.
23.
50.
129.
07/
10/
01
0.
23.
50.
129.
07/
11/
01
0.
23.
52.
127.
07/
12/
01
0.
23.
50.
129.
07/
13/
01
0.
24.
50.
127.
07/
16/
01
0.
23.
51.
127.
07/
17/
01
0.
23.
51.
129.
07/
18/
01
0.
24.
50.
128.
07/
19/
01
0.
24.
50.
123.
07/
20/
01
0.
23.
51.
128.
07/
23/
01
0.
23.
49.
127.
07/
24/
01
0.
22.
50.
127.
07/
25/
01
0.
24.
48.
127.
07/
26/
01
0.
24.
49.
127.
07/
27/
01
0.
24.
49.
125.
07/
30/
01
0.
24.
51.
125.
07/
31/
01
0.
24.
51.
127.
08/
01/
01
0.
24.
48.
128.
08/
02/
01
0.
24.
50.
128.
08/
03/
01
0.
24.
49.
129.
08/
06/
01
0.
24.
49.
127.
08/
07/
01
0.
24.
51.
128.
08/
08/
01
0.
23.
52.
128.
08/
09/
01
0.
25.
51.
127.
08/
10/
01
0.
25.
51.
126.
08/
13/
01
0.
24.
51.
128.
08/
14/
01
0.
24.
55.
128.
zooz/
PK/
zo:~
TOOZ/
6O/
LO
0
0
.
t*?
urlNuw
99
P'K
28.
K
.8ZK
__­­­­­­­­­­­­­___­_­­­­­­­­­­­­­­­
E'P
0
(2)
'A'3
­­­_­­­­­­­­­­­
'"
1I_..­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~~~­­­
z
'PZ
'0
mi3w
am3
m
__
'82­
i
'EZK
'8ZK
.
LZK
.
Of­
E
'8ZK
'EEK
'9ZK
"KEK
.9ZK
'TET:
`LZTm
_______­_­­__­­___­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
99
f'fi
OZ'Z
'KS
.__­­___

'SS
'ZS
.
f9
.
BS
'KS
'ZS
.
zs
.
ES
.
ES
.­
tS
'9s
.9s
.
PZ
'0
i­
O/
Of/
80
'PZ
'0
TO/
6Z/
80
'LZ
'0
10/
82/
80
'LZ
'0
­CO/
LZ/
80
'LZ
'0
TO/
tZ,`
EO
'SZ
'0
IO/
EZ/
80
'PZ
'0
TO/
ZZ/
80
'SZ
'0
TO/
TZ/
80
sz
'0
­CO/
OZ/
80
.
tiz
'0
IO/
LI/
80
'PZ
'0
KO/
9K/
80
'EZ
'0
TO/
ST/
80
lzldd
001
Wdd
OP
Wdd
5T
PJdd
0
:dClOtIE)
3ma
f/
tI38bwH3
f
?lIB'FlWVHS
Z
?338KVH3
5
tI38blUH3
__­___­____­____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

(Iddd)
NOIJkPLLN33N03
?IVNIblNON
XlIYcI
f
33Vd
3SIW
3
SLLtltI
NI
Xd
HLIM
SJiVtl
NI
3X­
Z'T'T:
d0
~aI­
LT.
S
"IVHNI
AVa­
06
S
B?
S.
'rld
NOI,
LV?
VHNI
33'dOJ
HSIL
dYH:
XOSNOdS
IZOOLIti­
TIM:
'ON
633POtId
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
6
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
DAILY
MEAN
TEST
ATMOSPHERE
CONCENTRATIONS
PAGE
1
GROUP
:
0
RPM
15
PPM
40
PPM
100
RPM
______­________­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

CH.
NO.
1
2.
OM3
CH.
NO.
2
2.
OM3
CH.
NO.
3
2.
OM3
CH.
NO.
4
2.
OM3
CONC
.
CONC
.
CONC
.
CONC
.
_______­___­____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

EXPOSURE
ON
31­
MAY­
01
MEAN
0.
15.
40.
96.
E(%,
0.00
0.0
4.16
0.6
2.71
1.1
2.45
2.4
N
10
10
10
10
EXPOSURE
ON
Ol­
JUN­
01
MEAN
0.
15.
SD
0.0
0.7
CV(%)
0.00
4.89
N
10
10
EXPOSURE
ON
04­
JUN­
01
MEAN
0.
15.
SD
0.0
0.7
CV(%)
0.00
4.41
N
10
10
EXPOSURE
ON
05­
JUN­
01
MEAN
0.
15.
SD
0.0
0.8
CV(%)
0.00
5.44
N
10
10
EXPOSURE
ON
06­
JUN­
01
MEAN
0.
15.
SD
0.0
1.3
CV(%)
0.00
8.52
N
10
10
40.
0.9
2.39
10
40.
0.7
1.77
10
40.
100.
0.7
3.9
1.77
3.96
10
10
40.
100.
1.4
2.5
3.61
2.55
10
10
102.
3.3
3.22
10
101.
3.3
3.23
10
CH.
=
CHAMBER,
NO.
=
NUMBER,
CONC.
=
CONCENTRATION
CONCENTRATION
IN:
PPM
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
6
PO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
DAILY
MEAN
TEST
ATMOSPHERE
CONCENTRATIONS
PAGE
2
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
CH.
NO.
1
2.
OM3
CH.
NO.
2
2.
OM3
CH.
NO.
3
2.
OM3
CH.
NO.
4
2.
OM3
CONC
.
CONC
.
CONC
.
CONC
.

EXPOSURE
ON
07­
JUNO1
MEAN
%%,
N
EXPOSURE
ON
08­
JUNO1
MEAN
SD
CV(%)
N
EXPOSURE
ON
ll­
JUN­
01
MEAN
SD
CV(%)
g
N
o\

5,
EXPOSURE
ON
12­
JUN­
01
MEAN
EXPOSURE
ON
MEAN
E(%,
N
0.
15.
39.
100.
0.0
0.4
1.1
1.3
0.00
2.77
2.13
1.31
10
10
10
10
0.
14.
39.
97.
0.0
0.8
0.9
7.5
0.00
5.76
2.42
7.74
10
10
10
10
0.
15.
40.
100.
0.0
1.0
0.9
4.5
0.00
6.98
2.39
4.54
10
10
10
10
0.
16.
40.
100.
0.0
0.5
1.1
2.8
0.00
3.40
2.76
2.84
10
10
10
10
13­
JUNO1
0.
16.
40.
100.
0.0
1.1
0.9
1.8
0.00
6.89
2.19
1.81
10
10
10
10
CH.
=
CHAMBER,
NO.
=
NUMBER,
CONC.
=
CONCENTRATION
CONCENTRATION
IN:
PPM
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
6
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
DAILY
MEAN
TEST
ATMOSPHERE
CONCENTRATIONS
PAGE
3
_____­__________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
__________­______­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
CH.
NO.
1
2.
OM3
CH.
NO.
2
2.
OM3
CH.
NO.
3
2.
OM3
CH.
NO.
4
2.
OM3
CONC
.
CONC
.
CONC
CONC
.
_____________­_­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

EXPOSURE
ON
14­
JUN­
01
MEAN
0.
15.
39.
100.
%(%)
0.00
0.0
3.14
0.5
4.96
2.0
4.31
4.3
N
10
10
10
10
EXPOSURE
ON
15­
JUN­
01
MEAN
SD
CV(%)
N
0.
15.
40.
99.
0.0
0.6
0.8
3.7
0.00
3.76
2.04
3.81
10
10
10
10
EXPOSURE
ON
18­
JUN­
01
MEAN
SD
CV(%)
N
0.
15.
40.
101.
0.0
1.2
1.0
2.1
0.00
8.09
2.48
2.05
10
10
10
10
EXPOSURE
ON
19­
JUN­
01
MEAN
0.
15.
SD
0.0
0.8
CV(%)
0.00
5.19
N
10
10
EXPOSURE
ON
20­
JUN­
01
MEAN
0.

E(%,
0.0
0.00
N
10
CH.
=
CHAMBER,
NO.
=
NUMBER,
CONC.
=
CONCENTRATION
CONCENTRATION
IN:
PPM
16.
0.5
3.40
10
40.
99.
1.1
3.0
2.85
3.00
10
10
40.
1.3
3.37
10
100.
5.0
5.01
10
IlVxw.
lH.
L.
L"
I"
IHBllI!
a
0
PROJECT
NO.:
WIL­
4170021
PO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
4
SPONSOR:
HAP
TASK
FORCE
DAILY
MEAN
TEST
ATMOSPHERE
CONCENTRATIONS
_­­­­­____­­_____­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­~­­­­­­­­­­­­­~­­­
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
________­_­­­­____­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~­­­­­­­­­­­­­
CH.
NO.
1
2.
OM3
CH.
NO.
2
2.
OM3
CH.
NO.
3
2.
OM3
CH.
NO.
4
2.
OM3
CONC
.
CONC
.
CONC
.
CONC
.
____­______­_­____­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

EXPOSURE
ON
21­
JUN­
01
MEAN
SD
cvt%)
N
0.
16.
40.
102.
0.0
1.8
1.0
2.7
0.00
11.39
2.48
2.63
10
10
10
10
EXPOSURE
ON
22­
JUN­
01
MEAN
0.
E(%,
0.00
0.0
N
10
EXPOSURE
ON
25­
JUN­
01
MEAN
SD
CV(%)
N
0.
0.0
0.00
10
EXPOSURE
ON
26­
JUN­
01
MEAN
0.
SD
0.0
CV(%)
0.00
N
10
EXPOSURE
ON
27­
JUN­
01
MEAN
0.
SD
0.0
CV(%)
0.00
N
10
CH.
=
CHAMBER,
NO.
=
NUMBER,
CONC.
=
CONCENTRATION
CONCENTRATION
IN:
PPM
16.
39.
101.
1.0
4.0
1.6
6.27
10.12
1.56
10
10
10
15.
39.
100.
0.8
0.8
5.7
5.19
2.14
5.71
10
10
10
15.
40.
100.
0.8
0.9
0.9
5.38
2.29
0.92
10
10
10
15.
40.
100.
0.7
0.7
0.7
4.95
1.67
0.67
10
10
10
INHALATION
TABLE
6
PROJECT
NO.:
WIL­
4170021
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
5
SPONSOR:
HAP
TASK
FORCE
DAILY
MEAN
TEST
ATMOSPHERE
CONCENTRATIONS
___­­­­__­­­________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
CH.
NO.
1
2.
OM3
CH.
NO.
2
2.
OM3
CH.
NO.
3
2.
OM3
CH.
NO.
4
2.
OM3
CONC
.
CONC
.
CONC
.
CONC
.

EXPOSURE
ON
28­
JUNO1
MEAN
0.
15.
40.
101.
SD
0.0
1.0
1.1
2.0
CV(%)
0.00
6.79
2.63
1.97
N
10
10
10
10
EXPOSURE
ON
29­
JUN­
01
MEAN
0.
SD
0.0
CV(%)
0.00
N
10
EXPOSURE
ON
OZ­
JUL­
01
'
SD
MEAN
td
0
CV(%)
`­+
a
N
o\

5;
EXPOSURE
ON
03­
JUL­
01
MEAN
0.
15.
39.
SD
0.0
1.7
0.8
CV(%)
0.00
11.02
2.14
N
10
10
10
EXPOSURE
ON
04­
JUL­
01
MEAN
0.
15.
40.
E(%,
0.00
0.0
8.04
1.2
1.59
0.6
N
10
10
10
0.
0.0
0.00
10
15.
40.
100.
3.4
1.1
1.4
23.14
2.85
1.42
10
10
10
16.
40.
100.
1.2
1.2
1.5
7.60
3.12
1.48
10
10
10
CH.
=
CHAMBER,
NO.
=
NUMBER,
CONC.
=
CONCENTRATION
CONCENTRATION
IN:
PPM
PP.
2.9
2.89
10
100.
1.2
1.23
10
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
6
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
DAILY
MEAN
TEST
ATMOSPHERE
CONCENTRATIONS
PAGE
6
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
_____­____­___­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­~­­­­­~­­­­­­­­­~­­­~­­
CH.
NO.
1
2.
OM3
CH.
NO.
2
2.
OM3
CH.
NO.
3
2.
OM3
CH.
NO.
4
2.
OM3
CONC
.
CONC
.
CONC
.
CONC
.
___­_______­__­_^_­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­~~­­­­­­­­­~~~~~­­­­­­~

EXPOSURE
ON
05­
JUL­
01
MEAN
0.
15.
40.
SD
0.0
0.7
1.2
CV(%)
0.00
4.41
3.09
N
10
10
10
EXPOSURE
ON
06­
JUL­
01
MEAN
0.
15.
40.
SD
0.0
2.0
1.3
CV(%)
0.00
13.33
3.31
N
10
10
10
EXPOSURE
ON
09­
JUL­
01
MEAN
0.
15.
%%)
0.00
0.0
3.16
0.5
N
10
10
EXPOSURE
ON
lo­
JUL­
01
MEAN
0.
15.
SD
0.0
0.6
CV(%)
0.00
4.16
N
10
10
EXPOSURE
ON
ll­
JUL­
01
MEAN
0.
15.
SD
0.0
0.8
CV(%)
0.00
5.19
N
10
10
CH.
=
CHAMBER,
NO.
=
NUMBER,
CONC.
=
CONCENTRATION
CONCENTRATION
IN:
PPM
40.
1.0
2.48
10
40.
1.0
2.49
10
40.
100.
0.7
0.3
1.70
0.32
10
10
100.
0.4
0.42
10
100.
0.9
0.92
10
100.
0.8
0.82
10
100.
0.9
0.87
10
PROJECT
NO.:
WTL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
6
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
DAILY
MEAN
TEST
ATMOSPHERE
CONCENTRATIONS
PAGE
I
___________­____­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GROUP:
0
PPM
15
PPM
40
RPM
100
PPM
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

CH.
NO.
1
2.
OM3
CH.
NO.
2
2.
OM3
CH.
NO.
3
2.
OM3
CH.
NO.
4
2.
OM3
CONC
.
CONC
CONC
.
CONC
__­______­_______­­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

EXPOSURE
ON
12­
JUL­
01
MEAN
0.
15.
40.
100.
SD
0.0
1.0
1.4
1.0
CV(%)
0.00
6.59
3.61
0.96
N
10
10
10
10
EXPOSURE
ON
13­
JUL­
01
MEAN
SD
CV(%)
N
EXPOSURE
ON
16­
JUL­
01
MEAN
E(%,
g
N
m
;s;
EXPOSURE
ON
17­
JUL­
01
MEAN
SD
CV(%)
N
EXPOSURE
ON
18­
JUL­
01
MEAN
SD
CV(%)
N
CH.
=
CHAMBER,
NO.
=
NUMBER,
CONCENTRATION
IN:
PPM
0.
0.0
0.00
10
0.
15.
40.
100.
0.0
0.8
0.7
0.5
0.00
5.44
1.70
0.48
10
10
10
10
0.
15.
40.
100.
0.0
0.9
0.9
0.6
0.00
5.88
2.39
0.57
10
10
10
10
0.
15.
40.
100.
0.0
1.1
1.0
1.9
0.00
7.61
2.48
1.95
10
10
10
10
CONC.
=
CONCENTRATION
16.
1.1
6.97
10
40.
100.
1.3
1.3
3.21
1.32
10
10
PROJECT
NO.:
WIL­
4170021
INHALATION
TABLE
6
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
8
SPONSOR:
HAP
TASK
FORCE
GROUP:
0
PPM
CH.
NO.
1
2.
OM3
DAILY
MEAN
TEST
ATMOSPHERE
CONCENTRATIONS
15
PPM
40
PPM
CH.
NO.
2
2.
OM3
CH.
NO.
3
2.
OM3
__­­­_
CONC
.
CONC
.
______________­___­­­­­­­­­­­~~­­­­­­~­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~­~­­­­­­­­­­­
100
PPM
CH.
NO.
4
2.
OM3
CONC
.
CONC
.

EXPOSURE
ON
19­
JUL­
01
MEAN
SD
CV(%)
N
EXPOSURE
ON
20­
JUL­
01
MEAN
SD
CV(%)
N
EXPOSURE
ON
23­
JUL­
01
$
SD
MEAN
CV(%)
g
N
m
G
EXPOSURE
ON
24­
JUL­
01
MEAN
SD
CV(%)
N
0.
0.0
0.00
10
0.
15.
40.
100.
0.0
0.9
0.7
0.9
0.00
5.80
1.67
0.92
10
10
10
10
0.
16.
40.
100.
0.0
2.3
1.4
1.5
0.00
14.36
3.54
1.49
10
10
10
10
0.
17.
40.
100.
0.0
4.2
1.1
0.9
0.00
25.11
2.82
0.87
10
10
10
10
15.
0.6
3.76
10
EXPOSURE
ON
25­
JUL­
01
MEAN
0.
14.
SD
0.0
1.4
CV(%)
0.00
9.92
N
10
10
CH.
=
CHAMBER,
NO.
=
NUMBER,
CONC.
=
CONCENTRATION
CONCENTRATION
IN:
PPM
40.
100.
1.0
1.0
2.59
1.00
10
10
40.
100.
2.5
1.1
6.32
1.06
10
10
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
6
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
DAILY
MEAN
TEST
ATMOSPHERE
CONCENTRATIONS
PAGE
9
_­_________­­­­­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
________­­­_____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
CH.
NO.
1
2.
OM3
CH.
NO.
2
2.
OM3
CH.
NO.
3
2.
OM3
CH.
NO.
4
2.
OM3
CONC
.
CONC
.
CONC
.
CONC
_____________­­­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~

EXPOSURE
ON
26­
JUL­
01
MEAN
0.
15.
40.
100.
SD
0.0
1.7
1.0
1.6
CV(%)
0.00
11.83
2.48
1.57
N
10
10
10
10
EXPOSURE
ON
27­
JUL­
01
MEAN
0.
15.
40.
99.
SD
0.0
1.0
1.4
2.1
CV(%)
0.00
6.79
3.48
2.16
N
8
10
10
10
EXPOSURE
ON
30­
JUL­
01
$i
SD
MEAN
on,
CV(%)
N
m
z
EXPOSURE
ON
31­
JUL­
01
MEAN
0.
16.
40.
100.
0.0
1.8
0.9
1.5
0.00
11.39
2.29
1.53
10
10
10
10
0.
15.
40.
100.
0.0
1.7
0.9
3.0
0.00
11.58
2.31
2.97
10
10
10
10
EXPOSURE
ON
Ol­
AUG­
01
MEAN
0.
15.
39.
SD
0.0
1.2
0.9
CV(%)
0.00
7.62
2.25
N
10
10
10
CH.
=
CHAMBER,
NO.
=
NUMBER,
CONC.
=
CONCENTRATION
CONCENTRATION
IN:
PPM
100.
1.3
1.29
10
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
6
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
DAILY
MEAN
TEST
ATMOSPHERE
CONCENTRATIONS
PAGE
10
___­___­­_______­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
_­_____­__­­____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

CH.
NO.
1
2.
OM3
CH.
NO.
2
2.
OM3
CH.
NO.
3
2.
OM3
CH.
NO.
4
2.
OM3
CONC
.
CONC
.
CONC
.
CONC
.
_­­____­________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

EXPOSURE
ON
02­
AUG­
01
MEAN
0.
16.
40.
100.
SD
0.0
3.5
1.3
1.9
CV(%)
0.00
22.28
3.34
1.91
N
10
10
10
10
EXPOSURE
ON
03­
AUG­
01
MEAN
0.
15.
40.
100.
Z(%)
0.00
0.0
20.45
3.1
2.36
0.9
3.20
3.2
N
10
10
10
10
EXPOSURE
ON
06­
AUG­
01
$
SD
MEAN
0.
0.0
%
CV(%)
N
0.00
10
cn
z
EXPOSURE
ON
07­
AUG­
01
MEAN
0.
SD
0.0
CV(%)
0.00
N
10
15.
39.
PP.
1.7
3.4
1.6
11.02
8.73
1.58
10
10
10
15.
40.
100.
1.2
1.5
1.4
7.58
3.85
1.45
10
10
10
EXPOSURE
ON
OE­
AUG­
01
MEAN
0.
15.
40.
SD
0.0
1.9
1.3
CV(%)
0.00
12.27
3.21
N
10
10
10
CH.
=
CHAMBER,
NO.
=
NUMBER,
CONC.
=
CONCENTRATION
CONCENTRATION
IN:
PPM
100.
1.8
1.76
10
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
6
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
DAILY
MEAN
TEST
ATMOSPHERE
CONCENTRATIONS
PAGE
11
________­____­__­_­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
_____­__­__________^____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
CH.
NO.
1
2.
OM3
CH.
NO.
2
2.
OM3
CH.
NO.
3
2.
OM3
CH.
NO.
4
2.
OM3
CONC
.
CONC
.
CONC
.
CONC
.

EXPOSURE
ON
09­
AUG­
01
MEAN
0.
15.
40.
100.
SD
0.0
1.9
1.1
1.5
CV(%)
0.00
12.66
2.71
1.55
N
10
10
10
10
EXPOSURE
ON
lo­
AUG­
01
MEAN
0.
16.
40.
SD
0.0
3.7
1.4
CV(%)
0.00
22.95
3.42
N
10
10
10
EXPOSURE
ON
13­
AUG­
01
MEAN
0.
16.
40.
SD
0.0
1.4
0.9
CV(%)
0.00
9.25
2.31
N
10
10
10
EXPOSURE
ON
15­
AUG­
01
MEAN
0.
15.
40.
SD
0.3
1.1
3.7
CV(%)
316.23
7.21
9.29
N
10
10
10
EXPOSURE
ON
17­
AUG­
01
MEAN
0.
16.
40.
SD
0.0
2.6
0.8
CV(%)
0.00
16.14
2.15
N
10
10
10
CH.
=
CHAMBER,
NO.
=
NUMBER,
CONC.
=
CONCENTRATION
CONCENTRATION
IN:
PPM
99.
1.4
1.44
10
100.
2.7
2.75
10
101.
2.7
2.70
10
99.
2.1
2.17
10
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
6
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
DAILY
MEAN
TEST
ATMOSPHERE
CONCENTRATIONS
PAGE
12
____­_____­­____­­_­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
___­___­____­___­__­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­~­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­
CH.
NO.
1
2.
OM3
CH.
NO.
2
2.
OM3
CH.
NO.
3
2.
OM3
CH.
NO.
4
2.
OM3
CONC
.
CONC
.
CONC
.
CONC
.

EXPOSURE
ON
20­
AUG­
01
MEAN
SD
CV(%)
N
EXPOSURE
ON
16­
AUG­
01
MEAN
SD
CV(%)
N
0.
15.
39.
101.
0.0
1.9
0.8
2.0
0.00
12.66
2.01
2.00
10
10
10
10
0.
16.
39.
100.
0.0
1.4
6.7
3.3
0.00
8.62
17.39
3.28
9
10
10
10
EXPOSURE
ON
14­
AUG­
01
MEAN
0.
16.
41.
101.
SD
0.0
3.0
2.3
3.2
CV(%)
0.00
19.09
5.71
3.19
N
10
10
10
10
EXPOSURE
ON
21­
AUG­
01
MEAN
SD
CV(%)
N
EXPOSURE
ON
22­
AUG­
01
MEAN
SD
CV(%)
N
0.
16.
40.
100.
0.0
2.1
0.5
0.9
0.00
13.18
1.30
0.95
10
10
I.
0
10
0.
17.
39.
100.
0.0
5.7
2.0
1.5
0.00
33.39
4.96
1.49
10
10
10
10
CH.
=
CHAMBER,
NO.
=
NUMBER,
CONC.
=
CONCENTRATION
CONCENTRATION
IN:
PPM
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
6
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
DAILY
MEAN
TEST
ATMOSPHERE
CONCENTRATIONS
PAGE
13
GROUP:
0
PPM
15
PPM
40
PPM
100
PPM
___­_______­_____­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

CH.
NO.
1
2.
OM3
CH.
NO.
2
2.
OM3
CH.
NO.
3
2.
OM3
CH.
NO.
4
2.
OM3
CONC
.
CONC
.
CONC
.
CONC
.
___­____________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

EXPOSURE
ON
23­
AUG­
01
MEAN
0.
SD
0.0
CV(%)
0.00
N
10
EXPOSURE
ON
24­
AUG­
01
MEAN
0.
EC%)
0.00
0.0
N
10
EXPOSURE
ON
27­
AUG­
01
MEAN
0.
SD
0.0
cv
(k)
0.00
N
10
EXPOSURE
ON
28­
AUG­
01
MEAN
0.
El%)
0.00
0.0
N
10
EXPOSURE
ON
29­
AUG­
01
MEAN
0.
SD
0.0
CV(%)
0.00
N
10
CH.
=
CHAMBER,
NO.
=
NUMBER,
CONC.
=
CONCENTRATION
CONCENTRATION
IN:
PPM
16.
39.
100.
2.8
1.1
1.9
17.68
2.83
1.85
10
10
10
16.
40.
100.
1.4
1.4
1.7
9.25
3.63
1.68
10
10
10
15.
39.
99.
1.4
1.3
2.0
9.07
3.43
2.04
10
10
10
16.
40.
100.
4.8
1.4
1.0
29.06
3.54
0.97
10
10
10
16.
39.
100.
1.6
0.8
1.9
9.98
2.18
1.93
10
10
10
411
of619
PROJECT
NO.:
WIL­
4170021
SPONSOR:
HAP
TASK
FORCE
INHALATION
TABLE
7
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
RATS
&
MICE
DAILY
ENVIRONMENTAL
CONDITIONS
FOR
SECONDARY
CHAMBER
4
(CH4­
S)
PAGE
1
DATE
MEAN
CHAMBER
TEMPERATURE
(DEGREES
CELSIUS)
MEAN
CHAMBER
RELATIVE
HUMIDITY
(%)
MEAN
CHAMBER
VENTILATION
RATE
(SLPM)
_­____­_________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

06/
25/
01
21.
48.
387.
06/
27/
01
21.
46.
15s.
06/
29/
01
21.
45.
153.
__­___­__________­­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GRAND
MEAN
21.
46.
232.
S.
D.
0.0
1.5
135.5
C.
V.
(%)
0.0
3.26
58.0
N
3
3
3
MANUALv1.00
07/
09/
2001
R:
02/
14/
2002
P
413
of
619
WIL­
417002
HAP
Task
Force
1,
1,2­
Trichloroethane
APPENDIX
D
Clinical
Pathology
Parameters
for
Control
Animals
(Study
Week
8)

414
of
619
,

415
of
619
I
.

416
of
619
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
1
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
SPECIAL
CHEMISTRY
VALUES
WEEK
8
LACTATE
ANIMAL
'GENASE
_­­______­­­________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
U/
L
GROUP:
0
PPM
MALES
69302
440.
69306
513.
69308
349.
69310
421.
69312
418.
69314
335.

MEAN
413.
S.
D.
64.8
N
6
____­­__________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
U/
L
=
INTERNATIONAL
UNIT/
LITER
.
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
2
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
SPECIAL
CHEMISTRY
VALUES
WEEK
8
_______^________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
LACTATE
­
ANIMAL
'GENASE
_________­_____­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

U/
L
________­­____­­­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GROUP:
0
PPM
FEMALES
69354
268.
69366
273.
69367
460.
69378
283.
69384
281.
69398
232.

MEAN
300.
S.
D.
80.8
N
6
_________­_______­__­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
U/
L
=
INTERNATIONAL
UNIT/
LITER
PCHEv4.01
11/
28/
2001
WIL­
417002
HAP
Task
Force
APPENDIX
E
Pretest
Clinical
Observations
1,
1,2­
Trichloroethane
PRETEST
CLINICAL
OBSERVATIONS
FOR
RATS
PROJECT
NO.:
WIL­
417002P
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
1
SPONSOR:
HAP
TASK
FORCE
SUMMARY
OF
CLINICAL
FINDINGS:
TOTAL
OCCURRENCE/
NO.
OF
ANIMALS
_____
MALE
­­­­_
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

TABLE
RANGE:
05­
15­
01
TO
05­
30­
01
GROUP:
1
______­_________­­­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­

NORMAL
­NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
142/
49
DISPOSITION
­SCHEDULED
SEROLOGY
NECROPSY
51
5
EYES/
EARS/
NOSE
­RIGHT
EYE
MISSING
31
1
­DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
21
1
_­­­_­­­________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

l­
PRETEST
421
of
619
422of619
WIL­
417002
HAP
Task
Force
1,
1,2­
Trichloroethane
APPENDIX
F
Serological
Screening
(BioReliance
Corporation)

423
of
619
BIORELIANCE=
Formerly
Microbiological
Associates
BtORELtANCE
CORPORATtON
14920
BROSCHART
ROAD
ROCKVtLLE,
MARYLAND
20850­
3349
USA
PHONE:
301.738.1000
l
FAX:
301.738.1036
TO:
Our
Code
MR
A079
Page
1
WIL
417002Q
Susan
Haley
WIL
Research
Laboratories,
Inc.
1407
George
Road
Ashland,
OH
44605
FROM:
Kathleen
M.
Vincent
$kX&,­
%(­&/
AC&
DATE:
May
30,
2001
SPECIMEN:
5
Mouse
Sera
RECEIVED:
May
25,
2001
RESULTS:
None
of
the
tests
were
positive.

Sample
ID
­­­­­­­­­­­­_­­­­_­
&ISA
­­­­­­­­­­­­­­­­___
EDIM
GDVII
MHV
MPul
PVM
Sendai
II
I
IFA
HA1
Sample
ID
Parvo
MVM
II
ELISA:
Positive
value
is
>=
0.17
OD
units
IFA:
+
=
positive;
­
=
negative
HAI:
Numerical
value
=
positive;
­
=
negative
424of619
BIORELIANCE
Formerly
Microbiological
Asociales
BIOREL~
ANCE
CORPoRAnON
4
Ec$
4920
BROXHART
ROAD
J.
3;:.
f&
nq$
u,
MAWLAND
20850­
3349
USA
Pi­
40
301.738.?
000
l
FAX:
301.738.1036
.

TO:

FROM:
DATE:
SPECIMHN:
RFX!
EIVED:
Kathleen
M.
Vincent
y~
cti~,
TX.
L,
L~
J&
May
30,
2001
10
Rat
Sera
May
25,
2001
RESULTS
:
None
of
the
tests
were
positive.
1/
LIL
/Q
'
:
:
:Ql
GT&+
Our
Code
MR
A078
Page
1
WIL417002P
Susan
Haley
WIL
Research
Laboratories,
Inc.
1407
George
Road
Ashland,
OH
44805
See
attached
tables
for
test
results
425
of
619
426of619
W­
IL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
APPENDIX
G
Clinical
Pathology
Methods,
Procedures
and
References
427of619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
CLINICAL
PATHOLOGY
METHODS,
PROCEDURES
AND
REFERENCES
Serum
Chemistry
­
Hitachi
911
Albumin
­
Bromcresol
Green
(BCG)
Method,
Modification
of
the
Doumas
reaction.
Hitachi
911
Application
Code
413.
Roche
Reagent,
catalog
number
1970593.

A/
G
Ratio
­
Calculated
from
Albumin
and
Globulin
Results.

Alkaline
Phosphatase
­
Kinetic
reaction
measuring
the
rate
of
p­
nitrophenol
liberation.
Hitachi
9
11
Application
Code
0
16.
Roche
Reagent,
catalog
number
4500
12.

Alanine
Aminotransferase
­
Modification
of
the
International
Federation
of
Clinical
Chemistry
(IFCC)
recommended
method.
Hitachi
9
11
Application
Code
033.
Roche
Reagent,
catalog
number
450065.

Aspartate
Aminotransferase
­
Kinetic
method
based
on
the
International
Federation
of
Clinical
Chemistry
(IFCC)
recommendations.
Hitachi
911
Application
Code
199.
Roche
Reagent,
catalog
number
450064.

Bilirubin
(Total)
­
Diazo
method
developed
by
Wahlefeld
et
al.
Stand
J
Clin
Lab
Invest
1972;
29:
Supplement
126.
Hitachi
911
Application
Code
018.
Roche
Reagent,
catalog
number
1039034.

Blood
Urea
Nitrogen
(BUN)
­
A
urease
triggered
methodology
based
upon
the
method
of
Talke
and
Schubert
Klin
Wschr,
1965;
43:
174.
Hitachi
911
Application
Code
427.
Roche
Reagent,
catalog
number
148932
1.

Calcium
­
Modified
method
using
a
gamma­
amino­
butyric
acid
(GABA)
buffer.
Hitachi
9
11
Application
Code
.
Roche
Reagent,
catalog
number
1125621.

Chloride
­
An
ion­
selective
electrode
that
measures
the
electrical
potential
of
the
ions
present
in
solution,
Hitachi
911
Application
Codes
097,
098,
and
099.
Roche
Reagent,
catalog
numbers
450041,450042,
and
450043.

Cholesterol
­
Enzymatic
reaction
as
described
by
Trinder.
Ann
Clin
Biochem
1974;
12:
266.
Hitachi
9
11
Application
Code
27
1.
Roche
Reagent,
catalog
number
45006
1.

Creatinine
­
Modified
Jaffe
reaction
based
on
the
work
of
Poper
et
al.
Biochem
2
1937;
291:
354
and
Seelig
and
Wuest,
Aerztl
Labor
1969;
15:
34.
Hitachi
911
Application
Code
077.
Roche
Reagent,
catalog
number
450019.

428
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
Serum
Chemistry
(continued)

Gamma­
Glutamyltransferase
(GGT)
­
Method
based
on
the
studies
of
Persijn
and
Van
der
Slik,
J
Clin
Chem
Clin
Biochem,
1976;
14:
42
1.
Hitachi
9
11
Application
Code
173.
Roche
Reagent,
catalog
number
450067.

Globulin
­
Calculation
obtained
by
subtracting
Albumin
from
Total
Protein.

Glucose
­
Glucose
hexokinase
method
based
on
the
work
of
Schmidt,
Peterson
and
Young.
Klin
Wschr
1961;
39:
1244.
Methods
of
Enzvrnatic
Analvsis,
Znd
Eng
ed.
New
York,
Academic
Press,
1974:
1196.
Anal
Biochemistrv
1958;
23:
301.
Hitachi
911
Application
Code
174.
Roche
Reagent,
catalog
number
450058.

Lactate
Dehydrogenase
(LD)
­
Modification
of
the
Gay
procedure
using
a
Tris
buffer.
Methods
of
Enzvmatic
Analysis,
ed.
3.
Weinheim,
Verlag
Chemie,
1983,
Vol
III,
pp
126
133.
Hitachi
911
Application
Code
115.
Roche
Reagent,
catalog
number
450022.

Phosphorus
­
Method
involves
the
formation
of
ammonium
phosphomolybdate.
Hitachi
911
Application
Code
161.
Roche
Reagent,
catalog
number
450024.

Potassium
­
An
ion­
selective
electrode
that
measures
the
electrical
potential
of
the
ions
present
in
solution.
Hitachi
911
Application
Codes
097,
098,
and
099.
Roche
Reagent,
catalog
numbers
450041,450042,
and
450043,

Sodium
­
An
ion­
selective
electrode
that
measures
the
electrical
potential
of
the
ions
present
in
solution.
Hitachi
911
Application
Codes
097,
098,
and
099.
Boehringer
Mannheim
Reagent,
catalog
number
450041,450042,
and
450043.

Total
Protein
­
Endpoint
biuret
method
that
utilizes
a
sample
blank.
Hitachi
911
Application
Code
166.
Roche
Reagent,
catalog
number
104090
1.

Triglycerides
­
Method
that
utilizes
lipase
from
a
microorganism
to
promote
rapid
and
complete
hydrolysis
of
triglycerides
to
glycerol.
Hitachi
911
Application
Code
006.
Roche
Reagent,
catalog
number
1488899.

Hematologv
­
CELL­
DYN'
3500
HCT
­
The
Hematocrit
is
the
ratio
of
red
blood
cells
to
plasma
and
is
expressed
as
a
percentage
of
the
whole
blood
volume.
The
HCT
is
calculated
from
the
red
blood
cell
429of619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
Hematology
­
CELL­
DYN'
3500(
continued)

count
and
the
mean
cell
volume
as
follows:
HCT
=
(RBC
x
MCV)/
lO
CELL­
DYN@
3500
Operator's
Manual.
Abbott
Diagnostics,

HGB
­
The
Hemoglobin
concentration
is
measured
using
a
modified
hemoglobincyanide
method.
A
filtered
LED
with
a
wavelength
of
540
m­
n
is
the
light
source.
A
photodetector
measures
the
light
that
is
transmitted.
The
Hemoglobin
is
directly
measured
and
expressed
in
grams
of
hemoglobin
per
deciliter
of
whole
blood.
CELL­
DYN@
3500
Operator's
Manual.
Abbott
Diagnostics.

MCV
­
The
Mean
Cell
Volume
is
the
average
volume
of
the
individual
red
blood
cells.
The
MCV
is
derived
from
the
RBC
size
distribution
data
and
is
expressed
in
femtoliters.
CELL­
DYN@
3500
Operator's
Manual.
Abbott
Diagnostics.

MCH
­
The
Mean
Corpuscular
Hemoglobin
is
the
average
amount
of
hemoglobin
contained
in
the
red
blood
cell
expressed
in
picograms.
The
MCH
is
calculated
from
the
RBC
and
HGB
as
follows:
MCH
=
(HGB/
RBC)
x
10
CELL­
DYN@
3
500
Operator's
Manual.
Abbott
Diagnostics.

MCHC
­
The
Mean
Corpuscular
Hemoglobin
Concentration
is
the
ratio
of
the
weight
of
hemoglobin
to
the
volume
of
the
average
red
blood
cell
expressed
in
percent.
It
is
calculated
from
the
HGB
and
the
HCT
as
follows:
MCHC
=
(HGB/
HCT)
x
100
CELL­
DYN'
3500
Operator's
Manual.
Abbott
Diagnostics.

PLT
­
Platelets
are
counted
and
sized
by
the
Aperture
Impedance
method.
The
Platelet
Count
is
derived
from
the
histogram
after
the
PLT
data
has
been
analyzed
by
the
platelet
algorithm.
The
Platelet
Count
is
expressed
as
#xlO'/~
l.
CELL­
DYN@
3500
Operator's
Manual.
Abbott
Diagnostics.

RBC
Count
­
The
Red
Blood
Cells
are
counted
and
sized
by
the
Aperture
Impedance
method.
The
Red
Blood
Cell
Count
is
directly
measured
and
given
the
number
of
RBC's.
The
RBC
Count
is
expressed
as
#x106/
yl.
CELL­
DYN'
3500
Operator's
Manual.
Abbott
Diagnostics.

430
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
Hematology
­
CELL­
DYN@
3500(
continued)

WBC
Count
­
The
White
Blood
Cell
Count
is
analyzed
in
two
separate
channels.
Both
an
optical
and
impedance
analysis
are
performed.
Combining
both
methodologies
minimizes
any
interference
caused
by
the
presence
of
fragile
WBCs,
NRBCs
or
lyse­
resistant
RBCs.
The
WBC
Count
is
expressed
as
#x103/
uL.
CELL­
DYN@
3500
Operator's
Manual.
Abbott
Diagnostics.

WBC
Differential
Count
­
The
light
scatter
information
is
graphically
presented
in
the
form
of
scatterplots.
Each
cell
analyzed
is
represented
by
a
dot
on
the
scatterplot.
The
dots
are
plotted
at
a
point
determined
by
the
intersection
of
the
channel
information
designated
on
the
X
and
Y
axes.
The
scatter
inforrnation
may
be
plotted
in
various
combinations
to
yield
different
information.
The
CELL­
DYN'
3500
uses
the
scatter­
plots
to
differentiate
the
WBCs
into
five
subpopulations:
Neutrophils,
Eosinophils,
Lymphocytes,
Basophils
and
Monocytes.
CELL­
DYN@
3500
Operator's
Manual.
Abbott
Diagnostics.

Hematology
­
Manual
Methods
White
Cell
Differential
­
Manual
method
of
counting
100
white
cells
stained
with
Wright
Giemsa
and
entered
on­
line
into
the
data
files.

Reticulocyte
Count
­
Manual
method
of
counting
the
reticulocytes
present
in
1000
red
blood
cells
stained
with
New
Methylene
Blue
and
entered
into
the
data
files.

Red
Blood
Cell
Morphology
­
Manual
method
of
evaluating
red
blood
cells
on
a
Wright
Giemsa
stained
slide
and
entered
into
the
data
files.

Coagulation
Prothrombin
Time
(Protime­
PT)
­
Photometric
clot
detection
is
used
to
measure
and
record
the
time
required
for
plasma
specimens
to
clot
by
adding
an
excess
of
thromboplastin
reagent
and
an
optional
amount
of
calcium
to
titrated
plasma.
Automated
Coagulation
Analyzer­
Electra
1400C.
Medical
Laboratory
Automation,
Inc.

Activated
Partial
Thromboplastin
Time
(APTT)
­
Photometric
clot
detection
is
used
to
measure
and
record
clotting
time
in
a
one­
stage
procedure
which
consists
of
recalcifying
plasma
in
the
presence
of
an
excess
of
platelet­
like
reagent
(cephalin)
containing
a
plasma
activator.
Automated
Coagulation
Analyzer­
Electra
14OOC.
Medical
Laboratory
Automation,
Inc.

431
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
APPENDIX
H
Individual
Clinical
Observations
432
of
619
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
ANIMAL
SEX
GROUP
CATEGORY
_­­__^­­__­­____________________________­­­
69302
M
0
PPM
NORMAL
DATE
TIME
GRADE
OBSERVATIONS
06­
06­
01
7~
27
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
6:
58
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
40
p
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
30
p
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
07
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
28
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
6:
56
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
6:
47
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
23
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
19
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
22
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
58
P
PRIMARY
NECROPSY
(WEEK
13)
07­
11­
01
6:
16
P
RED
DISCHARGE
LEFT
EYE
08­
30­
01
7:
38
P
OPACITY
LEFT
EYE
06­
06­
01
7:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
6:
58
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
41
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
30
P
~0
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
17
P
NO
SIGNIFICANT
CLINICAL
OBBERVATIONS
07­
18­
01
7:
28
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
6:
56
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
23
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
19
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
23
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
34
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
56
P
PRIMARY
NECROPSY
(WEEK
13)
08­
01­
01
6:
48
P
RED
DISCHARGE
RIGHT
EYE
06­
06­
01
7:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
PAGE
1
69302
M
0
PPM
DISPOSITION
69302
M
0
PPM
EYES/
EARS/
NOSE
69306
M
0
PPM
NORMAL
69306
M
0
PPM
DISPOSITION
69306
M
0
PPM
EYES/
EARS/
NOSE
69308
M
0
PPM
NORMAL
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
2
S??
ONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
ANIMAL
SEX
­____­­___­­_
69308
M
69308
M
69308
M
69310
M
%
ch
69310
M
G
69310
M
69310
M
69312
M
­­­­__­­__­­­
GRADE
CODE:
1
GROUP
0
PPM
0
PPM
0
PPM
0
PPM
0
PPM
0
PPM
0
PPM
0
PPM
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
CATEGORY
___­_­_­­­__­­_
NORMAL
­_­
­­­­
DATE
TIME
GRADE
OBSERVATIONS
_____­_____­___­__­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

06­
13­
01
6:
58
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
41
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
30
P
~0
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
18
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
29
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
6:
56
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
6:
48
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
23
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
19
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
23
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
55
p
PRIMARY
NECROPSY
(WEEK
13)
08­
30­
01
7:
32
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
06­
06­
01
7:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
30
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
29
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
6:
57
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
24
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
20
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
44
P
PRIMARY
NECROPSY
(WEEK
13)
07­
11­
01
6:
lP
P
SOFT
FECES
06­
13­
01
6:
59
P
TAIL
BROKEN
06­
20­
01
6:
42
P
TAIL
BROKEN
08­
01­
01
6:
48
P
TAIL
BROKEN
08­
22­
01
6:
24
P
TAIL
BROKEN
08­
31­
01
7:
07
P
TAIL
BROKEN
06­
06­
01
7:
32
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
DISPOSITION
EYES/
EARS/
NOSE
NORMAL
DISPOSITION
EXCRETA
SPECIAL
II
NORMAL
_­___­______­___­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
PAGE
3
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
____­­­________­___­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
__________­_­______­____________________­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­

69312
M
0
PPM
NORMAL
06­
13­
01
6:
59
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
42
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
30
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
20
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
29
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
6:
5­
l
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
6:
49
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
24
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
20
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
24
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7~
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69312
M
0
PPM
DISPOSITION
08­
31­
01
7:
44
69314
M
0
PPM
P
PRIMARY
NECROPSY
(WEEK
13)
NORMAL
06­
06­
01
7:
32
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
oo
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
42
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
30
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
%
07­
25­
01
6~
57
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
6:
49
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
o\
08­
08­
01
6:
24
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
E
08­
15­
01
7:
21
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
25
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69314
M
0
PPM
DISPOSITION
08­
31­
01
7:
45
P
PRIMARY
NECROPSY
(WEEK
13)
69314
M
0
PPM
EYES/
EARS/
NOSE
07­
11­
01
6:
21
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
07­
11­
01
6:
21
P
RED
DISCHARGE
LEFT
EYE
07­
18­
01
7:
30
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
69317
M
0
PPM
NORMAL
06­
06­
01
7:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
______­­­_______­­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
4
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
__­­­­__­­­________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
___­____­­­­____­___­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~­­­­­­­­­­­­­­­~~­­­­­­­­­­­~­­­~­­~­~­­­­­­­~­­­­­~­­­­­­­­­
69317
M
0
PPM
NORMAL
69317
M
0
PPM
DISPOSITION
69322
M
0
PPM
NORMAL
69322
M
0
PPM
DISPOSITION
69337
M
0
PPM
NORMAL
______­­___­­_______­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
06­
13­
01
7:
oo
P
06­
20­
01
6:
42
P
06­
27­
01
6:
31
P
07­
04­
01
6:
09
P
07­
11­
01
6:
22
P
07­
18­
01
7:
30
P
07­
25­
01
6:
58
P
08­
01­
01
6:
50
P
08­
08­
01
6:
24
P
08­
15­
01
7:
21
P
08­
22­
01
6:
25
P
08­
31­
01
7:
08
P
08­
31­
01
7:
45
P
06­
06­
01
7:
33
P
06­
13­
01
7:
00
P
06­
20­
01
6:
43
P
06­
27­
01
6:
31
P
07­
04­
01
6:
09
P
07­
11­
01
6:
23
P
07­
18­
01
7:
30
P
07­
25­
01
6:
58
P
08­
01­
01
6:
50
P
08­
08­
01
6:
25
P
08­
15­
01
7:
22
P
08­
22­
01
6:
25
P
08­
31­
01
7:
08
P
08­
31­
01
7:
45
P
06­
06­
01
7:
33
P
06­
13­
01
7:
00
P
___­­______________­­­.

SEVERE
P
­
PRESENT
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
PRIMARY
NECR~
PSY
(WEEK
13)
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
PRIMARY
NECROPSY
(WEEK
13)
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
__­
______
­­__­
DETAILED
FHYSICAL
EXAMINATIONS/
DISPOSITIONS
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
5
SFONSOR:
HAF
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
______­___­___­_____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
69337
M
0
PPM
NORMAL
06­
20­
01
6:
43
F
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
09
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
23
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
30
F
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
6:
58
F
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
6:
50
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
25
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
22
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69337
M
0
FFM
DISPOSITION
08­
30­
01
7:
56
P
PRIMARY
NECROPSY
(WEEK
13)
69337
M
0
FFM
EXCRETA
08­
22­
01
6:
26
F
DECREASED
DEFECATION
69337
M
0
PPM
SPECIAL
08­
22­
01
6:
26
F
WET
BROWN
MATERIAL
ANOGENITAL
AREA
69343
M
0
FPM
NORMAL
06­
06­
01
7:
34
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
Ol
F
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
pw
06­
20­
01
6:
43
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
4
07­
04­
01
6:
09
F
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
4
07­
11­
01
6:
24
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
cI\
07­
25­
01
6:
59
F
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
t;
08­
01­
01
6:
51
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
25
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
36
F
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69343
M
0
PFM
DISPOSITION
08­
30­
01
7:
57
P
PRIMARY
NECROPSY
(WEEK
13)
69343
M
0
PPM
EYES/
EARS/
NOSE
08­
15­
01
7:
23
P
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
08­
15­
01
7:
23
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
69343
M
0
PPM
SPECIAL
08­
15­
01
7:
23
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
22­
01
6:
27
F
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
_­­­_____________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
PAGE
6
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
_______­­_­___­____­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
___­_____­___­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­
69305
M
15
PPM
NORMAL
06­
06­
01
7:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
04
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
47
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
ll
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
30
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
04
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
6:
58
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
29
p
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
28
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69305
M
15
PPM
DISPOSITION
08­
30­
01
7:
56
P
69305
M
15
PPM
PRIMARY
NECROPSY
(WEEK
13)
EYES/
EARS/
NOSE
08­
30­
01
7:
34
P
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
69316
M
15
PPM
NORMAL
06­
06­
01
7:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
04
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
is
06­
20­
01
6:
48
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
co
06­
27­
01
6:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
0
07­
04­
01
6:
ll
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
2
07­
11­
01
6:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
z
07­
25­
01
7:
04
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
6:
58
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
30
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7~
28
p
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
32
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69316
M
15
PPM
DISPOSITION
08­
30­
01
7:
55
P
PRIMARY
NECR~
PSY
(WEEK
13)
69320
M
15
PPM
NORMAL
06­
06­
01
7:
39
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
______________­­___­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
p
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORcE
ANIMAL
SEX
____^_______
69320
M
_­­__________­­­­________

_____
GROUP
.____
­_­_

15
PPM
69320
M
15
PPM
69320
M
15
PPM
69323
M
15
PPM
69323
M
69323
M
15
PPM
15
PPM
DETAILED
PHYSICAL
EKAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
7
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
CATEGORY
­­­­_­____­­­__
NORMAL
DATE
TIME
GRADE
OBSERVATIONS
_
_
_
_
_
_
_
_
_
__­­­___________________________________­­­­­­­­­­­­­­­­­­­­
06­
13­
01
7:
05
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6~
48
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
ll
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
6:
58
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
30
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
29
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
08
p
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
45
p
PRIMARY
NECROPSY
(WEEK
13)
07­
25­
01
7:
05
P
SOFT
DISPOSITION
EXCRETA
DISPOSITION
EYES/
EARS/
NOSE
FECES
06­
06­
01
7:
39
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
05
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
48
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
34
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
12
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
32
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7~
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
05
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
30
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
29
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
34
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
45
P
PRIMARY
NECROPSY
(WEEK
13)
08­
01­
01
6:
59
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
08­
01­
01
6:
59
P
RED
DISCHARGE
LEFT
EYE
08­
31­
01
7:
08
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
________­­________­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­~~~­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SP~
NSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
8
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
ANIMAL
sEx
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
69326
M
15
PPM
NORMAL
06­
06­
01
7:
39
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
os
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
49
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
34
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
12
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
32
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
05
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
6:
59
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
30
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
30
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
34
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69326
M
15
PPM
DISPOSITION
08­
30­
01
7:
56
p
PRIMARY
NECROPSY
(WEEK
1.3)
69335
M
15
PPM
NORMAL
06­
06­
01
7:
40
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
05
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
49
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
34
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
0
07­
04­
01
6:
12
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
z
07­
11­
01
6:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
5
07­
18­
01
7:
36
P
NO
SIGNIFICANT
CLINICAL
07­
25­
01
7:
06
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
OBSERVATIONS
08­
01­
01
7:
00
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
30
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69335
M
15
PPM
DISPOSITION
08­
31­
01
7:
45
P
PRIMARY
NECROPSY
(WEEK
13)
69336
M
15
PPM
NORMAL
06­
06­
01
7:
40
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
____­_______­­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~­­­

GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
9
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
____­_____­­______­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­

ANIMAL
SEX
­____­­­­___

69336
M
69336
M
69338
M
69338
M
69338
M
69345
M
GROUP
CATEGORY
__­_______
_­­­____­___­­_______

15
PPM
NORMAL
15
PPM
15
PPM
15
PPM
15
PPM
15
PPM
DISPOSITION
NORMAL
DISPOSITION
EYES/
EARS/
NOSE
NORMAL
DATE
TIME
GRADE
OBSERVATIONS
­­­­___­____­____­__­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­~­­­

06­
13­
01
7:
06
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
50
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
13
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7
:
06
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
00
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
30
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
45
P
PRIMARY
NECROPSY
(WEEK
13)
06­
06­
01
7:
41
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
06
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
50
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
13
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
34
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
Ol
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
58
P
PRIMARY
NECROPSY
(WEEK
13)
07­
25­
01
7:
06
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
08­
30­
01
7:
38
P
RED
DISCHARGE
LEFT
EYE
06­
06­
01
7:
41
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
06
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
__________­­____­­______________^_______­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­~~­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
10
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
__­_______­­_______­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
___­­­_____­­___________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69345
M
15
PPM
NORMAL
06­
20­
01
6:
51
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
13
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
34
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
07
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
Ol
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69345
M
15
PPM
DISPOSITION
08­
31­
01
7~
45
P
PRIMARY
NECROPSY
(WEEK
13)
69347
M
15
PPM
NORMAL
06­
06­
01
7:
42
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
07
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
51
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
13
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
07
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
Ol
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
32
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69347
M
15
PPM
DISPOSITION
08­
30­
01
7:
56
P
PRIMARY
NECROPSY
(WEEK
13)
69347
M
15
PPM
EYES/
EARS/
NOSE
08­
30­
01
7:
35
P
RED
DISCHARGE
LEFT
EYE
69303
M
40
PPM
NORMAL
06­
06­
01
7:
48
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
ll
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
56
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
11
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
___­___­__­___­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
69303
M
40
PPM
69303
M
40
PPM
69309
M
40
PPM
69309
M
40
PPM
69313
M
40
PPM
___________­­____­_______
GRADE
CODE:
1
­
SLIGHT
2
NORMAL
06­
27­
01
6:
37
P
07­
04­
01
6:
16
P
07­
11­
01
6:
4l.
P
07­
18­
01
7:
39
P
07­
25­
01
7:
ll
P
08­
01­
01
7:
05
P
08­
08­
01
6:
35
P
08­
15­
01
7:
35
P
08­
22­
01
6:
38
P
08­
30­
01
7:
36
P
DISPOSITION
08­
30­
01
7:
57
P
NORMAL
06­
06­
01
7:
48
P
06­
13­
01
7:
ll
P
06­
20­
01
6:
56
P
06­
27­
01
6:
37
P
07­
04­
01
6:
16
P
07­
11­
01
6:
41
P
07­
18­
01
7:
39
P
07­
25­
01
7:
ll
P
08­
01­
01
7:
05
P
08­
08­
01
6:
36
P
08­
15­
01
7:
36
P
08­
22­
01
6:
38
P
08­
31­
01
7:
08
P
DISPOSITION
08­
31­
01
7:
45
P
NORMAL
06­
06­
01
7:
48
P
06­
13­
01
7:
ll
P
06­
20­
01
6:
57
P
06­
27­
01
6:
38
P
___­__­­___________­_
c_______________

MODERATE
3
­
SEVERE
P
­
PRESENT
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
PRIMARY
NECROPSY
(WEEK
13)
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
PRIMARY
NECROPSY
(WEEK
13)
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
___­_______­___­________________________­­­­­­­­­­­­­­­­­­~­~­~­~­­
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
12
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
_______­­­_________­____________________­­­­­­­­­­­­­­­­­­­­­­­~­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
69313
M
40
PPM
NORMAL
69313
M
40
PPM
DISPOSITION
69313
M
40
PPM
EYES/
EARS/
NOSE
69313
M
40
PPM
ORAL/
DENTAL
69315
M
40
PPM
NORMAL
69315
M
40
PPM
DISPOSITION
69324
M
40
PPM
NORMAL
07­
11­
01
6:
41
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
39
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6~
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
39
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
58
P
PRIMARY
NECROPSY
(WEEK
13)
07­
04­
01
6:
16
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
07­
25­
01
7:
12
P
UPPER
INCISORS
MALALIGNED
08­
01­
01
7:
07
P
UPPER
INCISORS
MALALIGNED
08­
01­
01
7:
08
P
LOWER
INCISOR(
S)
LONG,
TRIMMED
06­
06­
01
7:
49
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
12
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6157
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6~
17
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6~
42
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
39
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
I:
12
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7~
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
39
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
57
P
PRIMARY
NECROPSY
(WEEK
13)
06­
06­
01
7:
49
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
13
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6~
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
______­_________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
13
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
________­___­­___­______________________­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
­_

69324
M
40
PPM
NORMAL
69324
M
40
PPM
DISPOSITION
69324
M
40
PPM
EYES/
EARS/
NOSE
69324
M
40
PPM
BODY/
INTEG
II
69324
M
40
PPM
SPECIAL
II
ti
%
69328
M
40
PPM
cn
G
NORMAL
08­
15­
01
7:
37
P
08­
31­
01
7:
45
P
07­
11­
01
6:
43
P
07­
11­
01
6~
43
P
08­
01­
01
7:
09
P
08­
22­
01
6:
39
P
08­
31­
01
7:
OY
P
06­
13­
01
7:
12
P
06­
20­
01
6:
58
P
07­
11­
01
6:
43
P
06­
13­
01
7:
12
P
06­
20­
01
6:
58
P
07­
04­
01
6:
17
P
07­
11­
01
6:
43
P
07­
18­
01
7:
40
P
08­
01­
01
7:
09
P
08­
22­
01
6:
39
P
08­
31­
01
7:
09
P
06­
06­
01
7:
50
P
06­
13­
01
7:
12
P
06­
20­
01
6:
58
P
06­
27­
01
6:
38
P
07­
04­
01
6:
17
P
07­
11­
01
6~
43
P
07­
18­
01
7:
40
P
07­
25­
01
7:
13
P
08­
01­
01
7:
09
P
08­
08­
01
6~
37
P
08­
15­
01
7:
37
P
_____­_­­__­____­­­_____________________­­­­­­­­­­­­­~­­­­­­­­­­­­
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
PRIMARY
NECROPSY
(WEEK
13)
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
RED
DISCHARGE
LEFT
EYE
RED
DISCHARGE
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
SCABBING
END
OF
TAIL
SCABBING
END
OF
TAIL
SCABBING
END
OF
TAIL
END
OF
TAIL
MISSING
END
OF
TAIL
MISSING
END
OF
TAIL
MISSING
END
OF
TAIL
MISSING
END
OF
TAIL
MISSING
END
OF
TAIL
MISSING
END
OF
TAIL
MISSING
END
OF
TAIL
MISSING
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
________­_____­_­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
14
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
___________________­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

69328
M
40
PPM
NORMAL
08­
22­
01
6:
40
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
09
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69328
M
40
PPM
DISPOSITION
08­
31­
01
7:
45
P
PRIMARY
NE~
ROPS~
(WEEK
13)
69339
M
40
PPM
NORMAL
06­
06­
01
7:
50
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
13
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
58
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6~
17
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
44
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
40
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
13
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
lO
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
40
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
34
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
t
69339
M
40
PPM
DISPOSITION
08­
30­
01
8:
01
P
PRIMARY
NECROPSY
(WEEK
13)
cn
69344
M
40
PPM
NORMAL
06­
06­
01
7:
50
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
%
06­
13­
01
7:
13
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
cn
06­
20­
01
6:
59
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
5
07­
04­
01
6:
18
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
44
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
40
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
14
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
lO
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
40
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PAGE
15
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
_____­__­___­___________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
_____­_­­__­____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

69344
M
40
PPM
NORMAL
08­
31­
01
7:
09
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69344
M
40
PPM
DISPOSITION
08­
31­
01
7:
45
P
PRIMARY
NECROPSY
(WEEK
13)
69348
M
40
PPM
NORMAL
06­
06­
01
7:
51
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
13
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
59
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
39
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
18
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
45
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
14
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
lO
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
40
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69348
M
40
PPM
DISPOSITION
08­
30­
01
7:
55
P
PRIMARY
NECROPSY
(WEEK
13)
69348
M
40
PPM
SPECIAL
07­
18­
01
7~
41
P
WET
BROWN
MATERIAL
ANOGENITAL
AREA
69350
M
40
PPM
NORMAL
06­
06­
01
7:
51
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
14
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
%
06­
20­
01
6:
59
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
39
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
CR
07­
04­
01
6:
18
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
5,
07­
11­
01
6:
45
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
41
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
14
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
ll
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
40
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
09
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
16
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
____­­____­­­_____­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­~­­­­­­­­­­~­­­­­­­­­­­­­~­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
___­______­­__­__­­­__________^_________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

69350
M
40
PPM
DISPOSITION
08­
31­
01
7:
46
P
PRIMARY
NECROPSY
(WEEK
13)
69304
M
100
PPM
NORMAL
06­
06­
01
7~
56
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
17
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
05
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
41
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
20
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
52
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7~
46
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
18
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
15
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
41
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
43
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
43
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
09
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69304
M
100
PPM
DISPOSITION
08­
31­
01
7:
46
P
PRIMARY
NECROPSY
(WEEK
13)
69307
M
100
PPM
NORMAL
06­
06­
01
7:
56
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
17
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
05
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
42
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
21
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
52
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
46
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
18
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
41
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
43
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
44
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69307
M
100
PPM
DISPOSITION
08­
30­
01
7:
56
p
PRIMARY
NEcROPSY
(WEEK
13)
69307
M
100
PPM
EYES/
EARS/
NOSE
08­
01­
01
7:
16
P
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
_­­___­________­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­
GRADE
CODE;
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
17
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
___________________­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
­­­­­­­­_­­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69318
M
100
PPM
NORMAL
06­
06­
01
'7~
56
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
17
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
05
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6~
42
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
21
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
53
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
46
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
19
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
16
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
41
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
43
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69318
M
100
PPM
DISPOSITION
08­
30­
01
7:
57
P
PRIMARY
NECROPSY
(WEEK
13)
69318
M
100
PPM
SPECIAL
08­
22­
01
6:
44
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
69319
M
100
PPM
NORMAL
06­
06­
01
7:
57
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
18
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
06
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
42
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
21
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
53
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
47
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
19
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
17
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
42
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
44
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6~
44
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
09
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69319
M
100
PPM
DISPOSITION
08­
31­
01
7:
46
P
PRIMARY
NECROPSY
(WEEK
13)
69327
M
100
PPM
NORMAL
06­
06­
01
7:
57
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
___________­____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­~­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­~­­­­­­­­­­~~­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
18
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
_­­_­___________­­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
______­_________­­­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~~­­­­­­­­­­­­­­­­­­­­­­­­

69327
M
100
PPM
NORMAL
06­
13­
01
7:
18
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
06
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
42
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
22
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
54
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
47
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
19
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
17
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
42
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
44
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
44
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
09
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69327
M
100
PPM
DISPOSITION
08­
31­
01
7~
46
p
PRIMARY
NECROPSY
(WEEK
13)
69329
M
100
PPM
NORMAL
06­
06­
01
7~
58
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
18
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
06
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
43
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
23
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
54
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
48
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
20
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
18
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
42
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
44
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
44
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69329
M
100
PPM
DISPOSITION
08­
30­
01
7:
58
p
PRIMARY
NECROPSY
(WEEK
13)
69329
M
100
PPM
EYES/
EARS/
NOSE
08­
30­
01
7:
39
P
RED
DISCHARGE
RIGHT
EYE
69332
M
100
PPM
NORMAL
06­
06­
01
7:
58
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
18
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
19
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
_______­­­­­____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

69332
M
100
PPM
NORMAL
06­
20­
01
7:
07
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
43
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
24
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
55
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
48
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
20
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
18
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
42
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
44
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
45
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
09
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69332
M
100
PPM
DISPOSITION
08­
31­
01
7~
46
P
PRIMARY
NECROPSY
(WEEK
i3)
69334
M
100
PPM
NORMAL
06­
06­
01
I:
58
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
19
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
R
06­
27­
01
6:
43
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
24
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
B
07­
11­
01
6:
55
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
48
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
20
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
m
G
08­
01­
01
7:
18
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
42
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
45
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
45
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
34
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69334
M
100
PPM
DISPOSITION
08­
30­
01
7:
56
P
PRIMARY
NECROPSY
(WEEK
13)
69342
M
100
PPM
NORMAL
06­
06­
01
7:
59
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
19
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
20
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
_______________­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~­­­­~~­­­­­­­­­­­­­­­­­­~~~~­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
__.
________­­_
69342
M
69342
M
100
PPM
DISPOSITION
69346
M
100
PPM
NORMAL
0,
cn
ri
69346
M
69346
M
69354
F
100
PPM
NORMAL
100
PPM
DISPOSITION
100
PPM
EYES/
EARS/
NOSE
0
PPM
NORMAL
06­
27­
01
07­
04­
01
07­
11­
01
07­
18­
01
07­
25­
01
08­
01­
01
08­
08­
01
08­
15­
01
08­
22­
01
08­
31­
01
08­
31­
01
06­
06­
01
06­
13­
01
06­
20­
01
06­
27­
01
07­
04­
01
07­
11­
01
07­
18­
01
07­
25­
01
08­
08­
01
08­
15­
01
08­
30­
01
08­
01­
01
08­
22­
01
08­
30­
01
06­
06­
01
06­
13­
01
06­
20­
01
06­
27­
01
6:
43
6:
24
6:
56
7:
49
7:
20
7:
19
6:
43
7:
45
6:
45
7:
09
7~
46
7:
59
7:
20
7:
08
6:
43
6:
24
6:
56
7:
49
7:
21
6~
43
7:
45
7:
54
7:
lP
6:
45
7:
31
7:
34
7:
Ol
6:
44
6:
31
______
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
___
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
PRIMARY
NECROPSY
(WEEK
13)
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
PRIMARY
NECROPSY
(WEEK
13)
OPACITY
LEFT
EYE
OPACITY
LEFT
EYE
OPACITY
LEFT
EYE
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
21
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
69354
F
0
PPM
NORMAL
07­
04­
01
6:
09
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
24
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
6:
59
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
6:
51
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
25
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
23
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
28
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
09
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69354
F
0
PPM
DISPOSITION
08­
31­
01
7:
46
P
PRIMARY
NECROPSY
(WEEK
13)
69366
F
0
PPM
NORMAL
06­
06­
01
7:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
Ol
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
44
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
09
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
6:
59
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
6:
51
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
26
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
24
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
28
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
lO
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69366
F
0
PPM
DISPOSITION
08­
31­
01
7:
46
P
PRIMARY
NECROPSY
(WEEK
13)
69366
F
0
PPM
SPECIAL
07­
11­
01
6:
25
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
69367
F
0
PPM
NORMAL
06­
06­
01
7:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
09
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
25
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
6:
59
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
26
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
______­_­­_­______­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
22
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
______________­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
69367
F
0
PPM
69367
F
0
PPM
69367
F
0
PPM
69367
F
0
PPM
69378
F
0
PPM
CA
G
69378
F
0
PPM
69378
F
0
PPM
69378
F
0
PPM
69384
F
0
PPM
_______­__­______________
GRADE
CODE:
1
­
SLIGHT
2
NORMAL
DISPOSITION
EYES/
EARS/
NOSE
SPECIAL
NORMAL
DISPOSITION
EYES/
EARS/
NOSE
SPECIAL
NORMAL
08­
15­
01
7:
24
P
08­
30­
01
7:
55
P
08­
01­
01
6:
53
P
08­
22­
01
6:
29
P
08­
30­
01
7:
31
P
06­
13­
01
7:
02
P
06­
20­
01
6:
44
P
06­
27­
01
6:
32
P
07­
18­
01
7:
32
P
08­
01­
01
6:
53
P
08­
22­
01
6:
29
P
06­
06­
01
7:
35
P
06­
13­
01
7:
02
P
06­
20­
01
6:
45
P
06­
27­
01
6:
32
P
07­
04­
01
6:
lO
P
07­
11­
01
6:
26
P
07­
18­
01
7:
32
P
07­
25­
01
7:
00
P
08­
08­
01
6:
26
P
08­
15­
01
7~
25
P
08­
31­
01
7:
46
P
08­
01­
01
6:
53
P
08­
22­
01
6:
29
P
08­
31­
01
7:
lO
P
06­
06­
01
7:
36
P
06­
13­
01
7:
02
P
06­
20­
01
6:
45
P
06­
27­
01
6:
32
P
__­________________
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
PRIMARY
NECROPSY
(WEEK
13)
OPACITY
RIGHT
EYE
OPACITY
RIGHT
EYE
OPACITY
RIGHT
EYE
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
PRIMARY
NECROPSY
(WEEK
13)
RED
DISCHARGE
RIGHT
EYE
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
23
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
_____­­_________________________________­­~­­­­­­­­~­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
__­­____­_____­­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

69384
F
69384
F
69384
F
69384
F
69398
F
OH,
69398
F
69398
F
CT\

t;

69404
F
GRADE
CODE:
1
0
PPM
NORMAL
0
PPM
DISPOSITION
0
PPM
EYES/
EARS/
NOSE
0
PPM
SPECIAL
0
PPM
NORMAL
0
PPM
0
PPM
DISPOSITION
SPECIAL
0
PPM
NORMAL
07­
04­
01
6:
lO
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
26
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
32
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
oo
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6~
27
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
2S
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
57
P
PRIMARY
NEcROPSY
(WEEK
13)
08­
01­
01
6:
56
P
PUPIL
DILATED
RIGHT
EYE
08­
22­
01
6:
30
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
06­
06­
01
7:
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
03
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7~
32
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
oo
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
6:
56
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
27
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7~
26
P
No
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
57
P
PRIMARY
NECROPSY
(WEEK
13)
06­
20­
01
6~
45
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
06­
27­
01
6~
32
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
04­
01
6:
lO
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
07­
11­
01
6:
28
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
22­
01
6:
30
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
06­
06­
01
7:
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
03
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
46
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
32
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
lO
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
________­____­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
____­____________________
ANIMAL
SEX
GROUP
________­­_­­­­__________
69404
F
69404
F
69416
F
R
ch
69416
F
0,
69416
F
UY
6
0
PPM
0
PPM
69419
F
0
PPM
_____________
GRADE
CODE:
1
0
PPM
0
PPM
0
PPM
__­
_____
­
SLIGHT
2
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
PO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
24
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
NORMAL
07­
11­
01
6:
28
P
07­
18­
01
7:
33
P
07­
25­
01
7:
Ol
P
08­
01­
01
6~
57
P
08­
08­
01
6:
27
P
08­
15­
01
7:
26
P
08­
22­
01
6:
31
P
08­
31­
01
7:
lO
P
08­
31­
01
7:
46
P
06­
06­
01
7:
37
P
06­
13­
01
7:
03
P
06­
27­
01
6:
33
P
07­
04­
01
6:
lO
P
07­
11­
01
6:
29
P
07­
18­
01
7:
33
P
07­
25­
01
7:
Ol
P
08­
08­
01
6:
27
P
08­
30­
01
7:
55
P
06­
20­
01
6~
46
P
08­
01­
01
6:
57
P
08­
15­
01
7~
26
P
08­
22­
01
6:
31
P
08­
30­
01
7:
33
P
06­
06­
01
7:
37
P
06­
13­
01
7:
03
P
06­
20­
01
6:
47
P
06­
27­
01
6:
33
P
07­
04­
01
6:
ll
P
07­
11­
01
6:
29
P
_­____________________
SEVERE
P
­
PRESENT
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
PRIMARY
NECROPSY
(WEEK
13)
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
PRIMARY
NECROPSY
(WEEK
13)
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
DISPOSITION
NORMAL
DISPOSITION
SPECIAL
NORMAL
MODERATE
3
_________­­­­­­_­­­_________
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
PROJECT
NO.:
WIL­
417002
PO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
25
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
­­­­­___­­­____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
­­­­­­__­­­­_______­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69419
F
0
PPM
69419
F
0
PPM
69419
F
0
PPM
69419
F
0
PPM
69432
F
0
PPM
%
69432
F
0
PPM
o\
69432
F
0
PPM
t;
69432
F
0
PPM
69362
F
15
PPM
________­­_____­­­_______
GRADE
CODE:
1
­
SLIGHT
2
NORMAL
DISPOSITION
EYES/
EARS/
NOSE
SPECIAL
NORMAL
DISPOSITION
EYES/
EARS/
NOSE
SPECIAL
NORMAL
07­
18­
01
7:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
03
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
6:
57
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
56
P
PRIMARY
NECROPSY
(WEEK
13)
08­
08­
01
6:
28
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
08­
15­
01
7:
27
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
22­
01
6:
31
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
06­
06­
01
7:
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
04
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
ll
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
30
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
04
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
6:
58
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
28
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
32
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
lO
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7~
46
P
PRIMARY
NECR~
PSY
(WEEK
13)
.
08­
15­
01
7~
27
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
06­
20­
01
6~
47
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
15­
01
7~
27
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
06­
06­
01
7:
43
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
07
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
52
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
14
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
____­­­_­__­­­­­__­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
MODERATE
3
­
SEVERE
P
­
PRESENT
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
26
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
___­­______­____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
­­­­__­­___­­­­­­­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69362
F
15
PPM
NORMAL
69362
69362
69376
P
s
69376
69376
R
69376
o\

;;

69377
F
15
PPM
NORMAL
69377
F
15
PPM
DISPOSITION
69377
F
15
PPM
BEHAVIOR/
CNS
F
F
F
F
F
F
15
PPM
DISPOSITION
15
PPM
SPECIAL
15
PPM
NORMAL
15
PPM
DISPOSITION
15
PPM
EYES/
EARS/
NOSE
15
PPM
SPECIAL
07­
18­
01
7:
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
07
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
02
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
32
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
32
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
46
P
PRIMARY
NECROPSY
(WEEK
13)
08­
22­
01
6:
36
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
31­
01
7:
lO
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
06­
13­
01
7:
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
52
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
14
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7~
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
02
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
51
P
PRIMARY
NECROPSY
(WEEK
13)
08­
30­
01
7:
36
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
08­
30­
01
7:
36
P
RED
DISCHARGE
LEFT
EYE
06­
06­
01
7:
44
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
08­
01
6:
32
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
15­
01
7:
33
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
22­
01
6:
36
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
06­
06­
01
7:
44
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
52
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
30­
01
13:
57
P
EUTHANIZED
IN
EXTREMIS
DUE
PHYSICAL
CONDITION
06­
30­
01
13:
56
P
IMPAIRED
USE
OF
LEFT
HINDLIMB
___________­­____­__­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­~­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
PAGE
27
ANIMAL
SEX
GROUP
__­__­­­­­­__­_­­­_­­­­­­

69317
F
15
PPM
69377
F
15
PPM
69377
F
15
PPM
EXCRETA
69377
F
15
PPM
SPECIAL
69382
F
15
PPM
NORMAL
P
2
0
z
69382
F
15
PPM
5,
69382
F
15
PPM
69390
F
15
PPM
__­_________­­_____­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
CATEGORY
BEHAVIOR/
CNS
EYES/
EARS/
NOSE
DISPOSITION
SPECIAL
NORMAL
__
DATE
TIME
GRADE
OBSERVATIONS
__­­_­­_­­__­­__­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

06­
30­
01
13:
56
P
IMPAIRED
USE
OF
RIGHT
HINDLIMB
06­
30­
01
13:
52
P
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
06­
30­
01
13:
52
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
06­
30­
01
13:
53
P
RED
DISCHARGE
RIGHT
EYE
06­
30­
01
13:
54
P
RED
DISCHARGE
LEFT
EYE
06­
30­
01
13:
54
P
DECREASED
DEFECATION
06­
30­
01
13:
55
P
WET
YELLOW
MATERIAL
DORSAL
TRUNK
06­
30­
01
13:
55
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
06­
06­
01
7:
45
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
53
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
14
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6~
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7~
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
08
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
02
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
lO
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
46
p
PRIMARY
NECROPSY
(WEEK
13)
08­
22­
01
6:
37
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
06­
06­
01
7:
45
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
09
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
53
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
15
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
03
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
28
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
_______­_­_____­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
69390
F
15
PPM
DISPOSITION
69390
F
15
PPM
SPECIAL
08­
31­
01
06­
27­
01
07­
11­
01
07­
25­
01
08­
15­
01
08­
22­
01
08­
31­
01
08­
08­
01
08­
15­
01
08­
30­
01
06­
13­
01
07­
11­
01
07­
18­
01
07­
25­
01
07­
11­
01
07­
25­
01
08­
22­
01
06­
06­
01
06­
13­
01
06­
20­
01
06­
27­
01
07­
04­
01
07­
11­
01
07­
18­
01
08­
01­
01
08­
22­
01
08­
30­
01
06­
06­
01
06­
13­
01
7~
46
P
6:
36
P
6:
37
P
7:
09
P
7:
34
P
6:
37
P
7:
lO
P
6:
33
P
7:
34
P
7:
58
P
7:
lO
P
6:
38
P
7:
38
P
7:
09
P
6:
38
P
7:
09
P
6:
37
P
7~
46
P
7:
09
P
6:
53
P
6~
37
P
6:
15
P
6:
38
P
7:
38
P
7:
03
P
6:
37
P
7:
39
P
7~
46
P
7:
lO
P
­
­
_
_
_
_
.__
PRIMARY
NECROPSY
(WEEK
13)
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
PRIMARY
NECROPSY
(WEEK
13)
SCABBING
END
OF
TAIL
SCABBING
END
OF
TAIL
SCABBING
END
OF
TAIL
SCABBING
END
OF
TAIL
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
END
OF
TAIL
MISSING
END
OF
TAIL
MISSING
END
OF
TAIL
MISSING
END
OF
TAIL
MISSING
END
OF
TAIL
MISSING
END
OF
TAIL
MISSING
END
OF
TAIL
MISSING
END
OF
TAIL
MISSING
END
OF
TAIL
MISSING
END
OF
TAIL
MISSING
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69393
F
15
PPM
NORMAL
69393
F
15
PPM
DISPOSITION
69393
F
15
PPM
BODY/
INTEG
II
69393
F
15
PPM
SPECIAL
69393
F
15
PPM
SPECIAL
II
%
o\

G
69396
F
15
PPM
NORMAL
_____­­­­_________­­____________________­­,
__
.________­­_­___­_­­____________________­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
29
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
­­­­­­_­­­­­___­____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
________­­_____­_­­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

69396
F
15
PPM
NORMAL
06­
20­
01
6:
54
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
15
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
lO
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
04
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
34
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
34
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
36
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69396
F
15
PPM
DISPOSITION
08­
30­
01
7~
57
P
PRIMARY
NECROPSY
(WEEK
13)
69396
F
15
PPM
SPECIAL
08­
22­
01
6:
38
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
69409
F
15
PPM
NORMAL
06­
06­
01
7:
47
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
lO
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
54
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
16
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
39
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
lO
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
04
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
34
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
34
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69409
F
15
PPM
DISPOSITION
08­
30­
01
7:
56
P
PRIMARY
NECROPSY
(WEEK
13)
69409
F
15
PPM
SPECIAL
II
08­
22­
01
6:
38
P
TAIL
BROKEN
69413
F
15
PPM
NORMAL
06­
06­
01
7:
47
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
lO
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
54
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
30
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
69413
F
15
PPM
NORMAL
06­
27­
01
6:
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
16
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
39
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
lO
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
04
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
34
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7~
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
lO
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69413
F
15
PPM
DISPOSITION
08­
31­
01
7:
46
P
PRIMARY
NECROPSY
(WEEK
13)
69435
F
15
PPM
NORMAL
06­
06­
01
7:
47
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
ll
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
6:
55
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
37
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
16
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
04
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
34
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69435
F
15
PPM
DISPOSITION
08­
30­
01
7:
58
P
PRIMARY
NECROPSY
(WEEK
1.3)
69435
F
15
PPM
SPECIAL
07­
11­
01
6:
40
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
25­
01
7:
lO
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
69359
F
40
PPM
NORMAL
06­
06­
01
7~
52
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
14
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
00
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
39
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
_____­_______­__­­­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
31
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
_____­_____­____­­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
_______­______­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

69359
F
40
PPM
NORMAL
07­
04­
01
6:
18
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
46
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
41
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
15
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
ll
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69359
F
40
PPM
DISPOSITION
08­
30­
01
7~
55
P
PRIMARY
NECROPSY
(WEEK
13)
69359
F
40
PPM
SPECIAL
08­
22­
01
6:
41
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
69369
F
40
PPM
NORMAL
06­
06­
01
7:
52
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
14
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
00
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
l.
E
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
46
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
42
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
l.
5
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
L2
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
38
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
39
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
41
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
lO
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69369
F
40
PPM
DISPOSITION
08­
31­
01
7:
46
P
PRIMARY
NECROPSY
(WEEK
13)
69369
F
40
PPM
CARDIO­
PULMONARY
06­
27­
01
6:
39
P
RALES
69370
F
40
PPM
NORMAL
06­
06­
01
7:
52
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
lS
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
Ol
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
40
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
19
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
_______________­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
32
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
__________­­_­____­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
69370
F
40
PPM
NORMAL
07­
18­
01
7:
43
P
08­
08­
01
6:
38
P
08­
15­
01
7:
40
P
08­
22­
01
6:
41
P
08­
30­
01
7~
32
P
DISPOSITION
08­
30­
01
7:
55
P
CARDIO­
PULMONARY
07­
11­
01
6:
47
P
BODY/
INTEG
II
07­
25­
01
7:
15
P
08­
01­
01
7~
12
P
NORMAL
06­
06­
01
7:
53
P
06­
13­
01
7:
15
P
06­
27­
01
6:
40
P
07­
04­
01
6:
19
P
07­
18­
01
7:
43
P
07­
25­
01
7:
16
P
08­
01­
01
7:
13
P
08­
08­
01
6:
38
P
08­
22­
01
6:
41
P
DISPOSITION
08­
31­
01
7:
47
P
SPECIAL
06­
20­
01
7:
Ol
P
07­
11­
01
6:
47
P
08­
15­
01
7:
40
P
08­
31­
01
7:
lO
P
NORMAL
06­
06­
01
7:
53
P
06­
13­
01
7:
15
P
06­
27­
01
6:
40
P
07­
04­
01
6:
19
P
07­
11­
01
6:
48
P
07­
18­
01
7:
43
P
_________________­­­__________________
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
PRIMARY
NECROPSY
(WEEK
13)
RALES
SCABBING
END
OF
TAIL
SCABBING
END
OF
TAIL
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
PRIMARY
NECROPSY
(WEEK
13')
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69370
F
40
PPM
69370
F
40
PPM
69370
F
40
PPM
69380
F
%
69380
F
69380
F
cl­
l
6
69388
F
_________­­­­
GRADE
CODE:
1
40
PPM
40
PPM
40
PPM
40
PPM
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
PRESENT
­
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
PAGE
33
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
__­______________­­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
___________________­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69388
F
40
PPM
NORMAL
07­
25­
01
7:
16
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
13
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
39
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
40
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
35
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69388
F
40
PPM
DISPOSITION
08­
30­
01
7:
56
P
PRIMARY
NECROPSY
(WEEK
13)
69388
F
40
PPM
SPECIAL
06­
20­
01
7:
02
P
DRIED
YELLOW
MATERIAL
VENTRAL
TRUNK
08­
22­
01
6:
42
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
69394
F
40
PPM
NORMAL
06­
06­
01
7:
53
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
15
P
NO
SIGNLFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
02
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
40
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
19
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
48
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
43
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
16
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
13
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
39
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
41
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
42
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
ll
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69394
F
40
PPM
DISPOSITION
08­
31­
01
7~
47
P
PRIMARY
NECROPSY
(WEEK
13)
69426
F
40
PPM
NORMAL
06­
06­
01
7:
54
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
16
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
03
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
40
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
19
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
49
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
44
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
____________­______­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
PAGE
34
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
_________­­­____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~­­­
69426
F
40
PPM
NORMAL
07­
25­
01
7:
17
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
13
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
39
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
41
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
ll
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69426
F
40
PPM
DISPOSITION
08­
31­
01
7:
47
P
PRIMARY
NECROPSY
(WEEK
13)
69426
F
40
PPM
SPECIAL
08­
22­
01
6:
42
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
69428
F
40
PPM
NORMAL
06­
06­
01
7:
54
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
16
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
03
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
40
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
19
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
50
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
44
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
17
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
14
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
39
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
42
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69428
F
40
PPM
DISPOSITION
08­
31­
01
7:
47
P
PRIMARY
NECROPSY
(WEEK
13)
69428
F
40
PPM
EYES/
EARS/
NOSE
08­
22­
01
6:
42
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
08­
31­
01
7:
12
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
69428
F
40
PPM
SPECIAL
08­
22­
01
6:
43
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
69433
F
40
PPM
NORMAL
06­
06­
01
7:
55
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
16
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
03
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
41
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
20
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
50
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
17
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
_____­___­_______­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
35
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
ANIMAL
SEX
___­________­
69433
F
69433
F
69433
F
69436
F
69436
F
40
PPM
DISPOSITION
69436
F
40
PPM
SPECIAL
%
m
6
69375
F
100
PPM
NORMAL
__­_______­­_
GRADE
CODE:
1
­­_
GROUP
CATEGORY
_­____­__­__­­___­_______
40
PPM
NORMAL
40
PPM
DISPOSITION
40
PPM
SPECIAL
40
PPM
NORMAL
__­­­____­­_­___­________
SLIGHT
2
­
MODERATE
3
­
DATE
TIME
GRADE
OBSERVATIONS
08­
08­
01
6:
40
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
33
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
56
P
PRIMARY
NECROPSY
(WEEK
13)
07­
18­
01
7:
45
p
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
01­
01
7:
14
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
15­
01
7:
42
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
22­
01
6:
43
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
06­
06­
01
7~
55
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
16
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
20
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
40
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
43
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
54
P
PRIMARY
NECROPSY
(WEEK
13)
06­
20­
01
7:
04
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
06­
27­
01
6:
41
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
07­
11­
01
6:
51
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
07­
18­
01
7:
45
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
25­
01
7:
18
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
01­
01
7:
15
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
15­
01
7~
42
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
30­
01
7:
31
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
06­
06­
01
8:
00
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
20
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
09
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
43
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
24
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
6:
57
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
49
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
22
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
­______­________________________________­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­~~~­­~­­­­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
36
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
___________________­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
___________­_______­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69375
F
100
PPM
NORMAL
08­
01­
01
7:
20
08­
08­
01
6:
43
08­
15­
01
7:
46
08­
30­
01
7~
32
08­
30­
01
7:
55
08­
22­
01
6:
46
06­
06­
01
8:
00
06­
13­
01
7:
20
06­
20­
01
7:
09
06­
27­
01
6:
43
07­
04­
01
6:
24
07­
11­
01
6:
57
07­
18­
01
7:
49
08­
01­
01
7:
20
08­
08­
01
6:
43
08­
15­
01
7:
46
08­
22­
01
6:
46
08­
30­
01
7:
37
08­
30­
01
7:
57
07­
25­
01
7~
22
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
PRIMARY
NECROPSY
(WEEK
13)
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
PRIMARY
NECROPSY
(WEEK
13)
SOFT
FECES
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69375
F
100
PPM
DISPOSITION
69375
F
100
PPM
SPECIAL
69379
F
100
PPM
NORMAL
%
69379
F
69379
F
m
G
69383
F
100
PPM
NORMAL
GRADE
CODE:
1
100
PPM
DISPOSITION
100
PPM
EXCRETA
­­­_­­____­
­­____________
SLIGHT
2
­
MODERATE
3
­
06­
06­
01
8:
00
06­
13­
01
7:
20
06­
20­
01
7:
09
06­
27­
01
6:
44
07­
04­
01
6:
25
07­
11­
01
6:
57
07­
18­
01
7:
49
07­
25­
01
7~
22
______­­­____
C_­­___.
SEVERE
??
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
_­________­__­____­_____
ANIMAL
SEX
GROUP
_­_______­___­__________
69383
F
100
PPM
69383
F
100
PPM
69385
F
100
PPM
69385
F
100
PPM
69385
F
100
PPM
69392
F
100
PPM
___
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
37
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
__­___­_­____­_­­­­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
­_______­__­­__­­­­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­~­­­­­­~~­~
NORMAL
08­
01­
01
7:
20
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
43
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
46
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
22­
01
6:
46
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
31­
01
7:
12
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
DISPOSITION
08­
31­
01
7:
47
P
PRIMARY
NECROPSY
(WEEK
13)
NORMAL
06­
06­
01
8:
Ol
P
NO
SIGNIFICANT
CLINICAL
06­
13­
01
7:
21
P
NO
SIGNIFICANT
CLINICAL
06­
20­
01
7:
lO
P
NC)
SIGNIFICANT
CLINICAL
07­
04­
01
6:
25
p
NO
SIGNIFICANT
CLINICAL
07­
11­
01
6:
58
p
NO
SIGNIFICANT
CLINICAL
07­
18­
01
7:
50
P
NO
SIGNIFICANT
CLINICAL
07­
25­
01
7:
23
P
NO
SIGNIFICANT
CLINICAL
08­
01­
01
7:
20
P
NO
SIGNIFICANT
CLINICAL
08­
08­
01
6:
44
P
NO
SIGNIFICANT
CLINICAL
08­
15­
01
7:
46
P
NO
SIGNIFICANT
CLINICAL
08­
22­
01
6:
46
P
NO
SIGNIFICANT
CLINICAL
08­
31­
01
DISPOSITION
08­
31­
01
CARDIO­
PULMONARY
06­
27­
01
NORMAL
06­
06­
01
06­
13­
01
06­
20­
01
06­
27­
01
07­
04­
01
07­
11­
01
07­
18­
01
07­
25­
01
08­
01­
01
7:
12
7:
47
6:
44
8:
Ol
7:
21
7:
lO
6:
44
6:
25
6:
58
7:
50
7~
23
7:
21
P
P
P
P
P
P
P
P
P
P
P
P
OBSERVATIONS
OBSERVATIONS
OBSERVATIONS
OBSERVATIONS
OBSERVATIONS
OBSERVATIONS
OBSERVATIONS
OBSERVATIONS
OBSERVATIONS
OBSERVATIONS
OBSERVATIONS
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
PRIMARY
NECROPSY
(WEEK
13)
FALES
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
___­_____­__­_____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~­­­­­­~­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
PROJECT
NO.:
WIL­
417002
BO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
38
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
__­_____________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
69392
F
69392
F
69402
F
69402
F
%
69402
F
69408
F
a
5;

69408
F
­_.
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
_____­________.
NORMAL
DISPOSITION
NORMAL
DISPOSITION
SPECIAL
NORMAL
DISPOSITION
08­
08­
01
08­
15­
01
08­
22­
01
08­
31­
01
08­
31­
01
06­
06­
01
06­
13­
01
06­
20­
01
06­
27­
01
07­
04­
01
07­
18­
01
07­
25­
01
08­
01­
01
08­
08­
01
08­
15­
01
08­
22­
01
08­
31­
01
08­
31­
01
07­
11­
01
06­
06­
01
06­
13­
01
06­
27­
01
07­
04­
01
07­
18­
01
07­
25­
01
08­
01­
01
08­
08­
01
08­
15­
01
08­
31­
01
._______
­__
6~
44
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
7:
4­
l
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
6:
46
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
7~
12
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
7:
47
P
PRIMARY
NECROPSY
(WEEK
13)
8:
Ol
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
7:
21
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
7:
lO
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
6:
44
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
6:
25
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
7:
50
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
7~
23
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
7:
21
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
6:
44
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
7:
47
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
6~
47
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
7~
12
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
7:
47
P
PRIMARY
NECROPSY
(WEEK
13)
6:
59
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
8:
02
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
7:
22
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
6:
45
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
6:
26
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
7:
51
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
7~
24
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
7~
23
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
6~
45
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
7:
47
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
I:
47
P
PRIMARY
NECROPSY
(WEEK
1.3)

GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
39
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
69408
F
100
PPM
SPECIAL
06­
20­
01
7:
ll
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
11­
01
7:
00
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
22­
01
6:
47
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
31­
01
7~
12
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
69415
F
100
PPM
NORMAL
06­
06­
01
8:
02
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
22
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
45
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
26
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7:
24
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
45
P
NO
SIGNIFICANT
CLINICAL.
OBSERVATIONS
69415
F
100
PPM
DISPOSITION
08­
30­
01
7:
58
P
PRIMARY
NECROPSY
(WEEK
13)
69415
F
100
PPM
SPECIAL
06­
20­
01
7:
ll
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
07­
11­
01
7:
00
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
18­
01
7:
51
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
01­
01
7~
24
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
15­
01
7:
48
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
22­
01
6~
47
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
30­
01
7~
37
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
69427
F
100
PPM
06­
06­
01
8:
03
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
13­
01
7:
22
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
ll
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6:
45
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
26
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
7:
Ol
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
18­
01
7:
52
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
25­
01
7~
24
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
24
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
45
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
48
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
__­___­_____________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
DETAILED
PHYSICAL
EXAMINATIONS/
DISPOSITIONS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
40
TABLE
RANGE:
05­
31­
01
TO
08­
31­
01
_­_________________­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
69427
F
100
PPM
DISPOSITION
08­
30­
01
7:
55
P
PRIMARY
NECROPSY
(WEEK
13)
69427
F
100
PPM
SPECIAL
08­
22­
01
6:
47
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
30­
01
7:
33
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
69431
F
100
PPM
NORMAL
06­
06­
01
8:
03
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
06­
20­
01
7:
12
P
NO
SIGNlFICANT
CLINICAL
OBSERVATIONS
06­
27­
01
6~
45
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
04­
01
6:
26
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
07­
11­
01
7:
Ol
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
01­
01
7:
24
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
08­
01
6:
45
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
15­
01
7:
48
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
08­
30­
01
7:
31
P
NO
SIGNIFICANT
CLINICAL
OBSERVATIONS
69431
F
100
PPM
DISPOSITION
08­
30­
01
7:
55
P
PRIMARY
NECROPSY
(WEEK
13)
69431
F
100
PPM
SPECIAL
06­
13­
01
7:
23
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
18­
01
7~
52
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
25­
01
7~
25
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
22­
01
6:
48
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
__­_____________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­

GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PCRDv4.04
11/
28/
2001
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
PRIOR
TO
EXPOSURE
YO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
1
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
___________­___­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
69306
M
0
PPM
EYES/
EARS/
NOSE
69314
M
0
PPM
EYES/
EARS/
NOSE
69314
M
69317
M
69343
M
69343
M
69335
M
69335
M
69335
M
69338
M
%
o\

s
69338
M
69324
M
40
PPM
EYES/
EARS/
NOSE
0
PPM
0
PPM
0
PPM
0
PPM
15
PPM
15
PPM
15
PPM
15
PPM
15
PPM
07­
12­
01
08­
06­
01
08­
30­
01
08­
29­
01
06­
20­
01
69304
M
100
PPM
SPECIAL
69307
M
100
PPM
EXCRETA
7
38
P
55
P
56
P
21
P
35
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
SOFT
FECES
WET
BROWN
MATERIAL
ANOGENITAL
AREA
69318
M
100
PPM
SPECIAL
07­
19­
01
7
29
P
____­_____­________­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODEFATE
3
­
SEVERE
P
­
PRESENT
EXCRETA
EYES/
EARS/
NOSE
EYES/
EARS/
NOSE
SPECIAL
EYES/
EARS/
NOSE
EXCRETA
SPECIAL
EYES/
EARS/
NOSE
EXCRETA
07­
31­
01
07­
31­
01
07­
09­
01
07­
31­
01
07­
31­
01
07­
31­
01
o­
7­
09­
01
06­
21­
01
08­
17­
01
OS­
17­
Ol.
08­
13­
01
08­
17­
01
06­
14­
01
06­
15­
01
06­
15­
01
06­
15­
01
07­
24­
01
07­
31­
01
08­
03­
01
08­
24­
01
07­
09­
01
6
6
7
6
7
6
7
6
12
P
13
P
33
P
14
P
14
P
14
P
33
P
40
P
42
P
42
P
10
P
42
P
38
P
51
P
52
P
52
P
23
P
22
P
45
P
25
P
43
P
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
RED
DISCHARGE
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
RED
DISCHARGE
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
SOFT
FECES
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
RED
MATERIAL
AROUND
NOSE
DRIED
RED
MATERIAL
AROUND
NOSE
DECREASED
DEFECATION
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
SOFT
FECES
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
PRIOR
TO
EXPOSURE
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
2
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
­­_______~­____­­­­­____________________~~~~­­~~~~~~~~~~­~~~~~~~~~~~~~~~~~~~~~~~­~~~~~~~~~~~~~~~~~~~~~~~~~~~­~~~~~~~~~~~~~­~~~~­~­~
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
_________­­_­­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69318
M
69319
M
100
PPM
100
PPM
SPECIAL
SPECIAL
69329
M
69329
M
69346
M
100
PPM
EYES/
EARS/
NOSE
100
PPM
SPECIAL
100
PPM
EXCRETA
0
PPM
SPECIAL
0
PPM
EYES/
EARS/
NOSE
0
PPM
SPECIAL
0
PPM
SPECIAL
0
PPM
SPECIAL
0
PPM
SPECIAL
0
PPM
SPECIAL
08­
29­
01
08­
02­
01
08­
30­
01
07­
19­
01
08­
29­
01
08­
29­
01
08­
29­
01
7:
21
P
6:
23
P
7:
03
P
7:
30
P
7:
22
P
7:
22
P
7:
24
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
WET
YELLOW
MATERIAL
UROGENITAL
AREA
SOFT
FECES
69366
F
69367
F
69367
F
69378
F
69398
F
69404
F
69416
F
cn
G
69419
F
69419
F
69432
F
69432
F
0
PPM
0
PPM
EYES/
EARS/
NOSE
SPECIAL
0
PPM
0
PPM
BODY/
INTEGUMENT
EYES/
EARS/
NOSE
07­
31­
01
6~
15
P
08­
03­
01
6:
34
P
07­
31­
01
6:
16
P
07­
31­
01
6:
16
P
07­
31­
01
6:
17
P
07­
31­
01
6~
17
P
07­
26­
01
7~
24
P
07­
31­
01
6:
18
P
07­
31­
01
6:
18
P
08­
03­
01
6:
39
P
08­
07­
01
7:
19
P
08­
17­
01
6~
44
P
08­
28­
01
I:
33
P
07­
26­
01
7:
2s
P
07­
09­
01
7:
37
P
07­
31­
01
6:
19
P
08­
20­
01
7:
18
P
08­
29­
01
7~
27
P
08­
16­
01
7:
Ol
P
08­
16­
01
7:
05
P
08­
16­
01
7:
05
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DERMAL
ATONIA
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
____­___­____­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PRIOR
TO
EXPOSURE
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
3
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
__­_­_____­__­__________________________­­­­­­­­­­~­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
__­__­_____­____­__­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69432
F
0
PPM
EYES/
EARS/
NOSE
08­
17­
01
08­
17­
01
69432
F
0
PPM
EXCRETA
08­
16­
01
69432
F
0
PPM
SPECIAL
08­
14­
01
08­
16­
01
08­
16­
01
08­
16­
01
08­
17­
01
08­
17­
01
08­
20­
01
69362
F
15
PPM
SPECIAL
08­
03­
01
69376
F
15
PPM
EYES/
EARS/
NOSE
08­
03­
01
69376
F
15
PPM
SPECIAL
;D
69382
F
15
PPM
SPECIAL
69390
F
15
PPM
SPECIAL
______________­__­­­­­­­­­­­­­­­­­­­­­­
_­­­_­­__­­­_­­­_­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
08­
29­
01
08­
29­
01
06­
21­
01
07­
09­
01
07­
24­
01
08­
03­
01
08­
09­
01
08­
13­
01
08­
17­
01
08­
29­
01
08­
10­
01
07­
02­
01
07­
17­
01
07­
31­
01
08­
14­
01
08­
21­
01
08­
29­
01
6
6
7
6
45
P
45
P
07
P
22
P
06
P
06
P
06
P
45
P
45
P
18
P
46
P
47
P
32
P
32
P
46
P
45
P
24
P
47
P
24
P
11
P
50
P
32
P
16
P
45
P
45
P
24
P
26
P
04
P
33
P
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DECREASED
DEFECATION
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
HINDLIMB
WET
YELLOW
ANOGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
ANOGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRI.
ED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
ANIMAL
SEX
________­___
69393
F
69409
F
GROUP
._­
­_____
15
PPM
15
PPM
69359
F
69380
F
2
69426
F
cn
69428
F
0
69436
F
rh
cn
z
69375
F
69392
F
69408
F
CATEGORY
_­­____­­_­____
SPECIAL
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
__________­_­_____­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­~­­­­

DATE
TIME
GRADE
OBSERVATIONS
__
_­­_­­_­­___­­_­­­­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

SPECIAL
40
PPM
40
PPM
SPECIAL
SPECIAL
40
PPM
SPECIAL
40
PPM
EYES/
EARS/
NOSE
40
PPM
SPECIAL
100
PPM
100
PPM
100
PPM
SPECIAL
SPECIAL
SPECIAL
PRIOR
TO
EXPOSURE
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
4
07­
31­
01
08­
09­
01
08­
14­
01
07­
09­
01
07­
09­
01
07­
09­
01
07­
17­
01
08­
03­
01
08­
21­
01
08­
29­
01
06­
20­
01
06­
22­
01
07­
31­
01
08­
14­
01
08­
20­
01
08­
21­
01
08­
30­
01
08­
30­
01
06­
15­
01
06­
22­
01
07­
17­
01
08­
29­
01
08­
29­
01
08­
20­
01
08­
23­
01
08­
23­
01
08­
20­
01
08­
30­
01
07­
10­
01
6:
25
6:
25
I:
21
7:
47
7:
47
7:
47
6:
44
6:
49
6:
52
7:
33
7:
42
8:
03
6:
22
7~
27
7:
02
6:
52
6:
58
6:
59
8:
08
8:
03
6:
35
7:
36
7:
36
7:
08
7:
32
7~
32
7:
lO
7:
06
7:
40
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
VENTRAL
TRUNK
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
PRIOR
TO
EXPOSURE
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
5
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
­­­__­____­___­­­_______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
_____­__­____­____­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­~­­­­­­~­­­~­~­­­­­­­­­~­­­­­~­­­­­­~~­­~­­­­­­­­­­~­­~­­
69408
F
100
PPM
SPECIAL
07­
24­
01
6:
37
P
08­
09­
01
6:
31
P
08­
09­
01
6:
31
P
08­
09­
01
6:
32
P
08­
23­
01
7:
34
P
69415
F
100
PPM
SPECIAL
07­
24­
01
6:
38
P
08­
02­
01
6~
27
P
08­
07­
01
7:
29
P
08­
17­
01
6~
44
P
08­
21­
01
7:
oo
P
08­
23­
01
7:
34
P
69427
F
100
PPM
SPECIAL
07­
24­
01
6:
38
P
08­
02­
01
6:
28
P
08­
02­
01
6:
28
P
08­
07­
01
7:
29
P
08­
21­
01
7:
Ol
P
08­
23­
01
7:
35
P
08­
29­
01
7~
27
P
69431
F
100
PPM
SPECIAL
07­
24­
01
6:
38
P
07­
31­
01
6:
28
P
08­
02­
01
6:
28
P
08­
23­
01
7:
35
P
08­
29­
01
7:
27
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
BROWN
MATERIAL
ANOGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
__­_______­_______­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PCRDv4.04
11/
28/
2001
FOLLOWING
EXPOSURE
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
1
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
____________­___________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69306
69308
69314
69317
69317
69331
69343
69343
69320
69335
69335
%
69338
0,
69303
ch
69313
s
69324
69348
69348
69304
69307
69318
M
0
PPM
0
PPM
0
PPM
0
PPM
0
PPM
0
PPM
0
PPM
0
PPM
15
PPM
15
PPM
15
PPM
15
PPM
40
PPM
40
PPM
40
PPM
40
PPM
40
PPM
100
PPM
100
PPM
100
PPM
EYES/
EARS/
NOSE
SPECIAL
EYES/
EARS/
NOSE
EXCRETA
SPECIAL
SPECIAL
EYES/
EARS/
NOSE
SPECIAL
SPECIAL
EYES/
EARS/
NOSE
SPECIAL
EYES/
EARS/
NOSE
EXCRETA
SPECIAL
EYES/
EARS/
NOSE
EXCRETA
SPECIAL
SPECIAL
EYES/
EARS/
NOSE
SPECIAL
07­
28­
01
7:
35
P
07­
29­
01
7:
29
P
07­
21­
01
8:
08
P
07­
08­
01
6:
45
P
07­
29­
01
7:
29
P
08­
11­
01
7:
51
P
08­
11­
01
7:
51
P
08­
11­
01
7:
52
P
08­
12­
01
13:
13
P
08­
12­
01
13:
13
P
08­
11­
01
7:
56
P
06­
16­
01
7:
03
P
06­
17­
01
6:
54
P
06­
16­
01
7:
03
P
07­
21­
01
8:
13
P
07­
28­
01
7:
39
P
08­
25­
01
7:
44
P
08­
12­
01
13:
16
P
08­
05­
01
7:
45
P
07­
29­
01
7:
33
P
08­
12­
01
13:
16
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
WET
BROWN
MATERIAL
ANOGENITAL
AREA
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
RED
DISCHARGE
LEFT
EYE
SOFT
FECES
WET
BROWN
MATERIAL
ANOGENITAL
AREA
DRIED
BROWN
MATERIAL
ANOGENITAL
AREA
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
RED
MATERIAL
AROUND
NOSE
DRIED
RED
MATERIAL
AROUND
NOSE
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
SOFT
FECES
DRIED
BROWN
MATERIAL
ANOGENITAL
AREA
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
SOFT
FECES
07­
21­
01
a:
18
P
WET
BROWN
MATERIAL
ANOGENITAL
AREA
08­
12­
01
13:
16
P
WET
BROWN
MATERIAL
ANOGENITAL
AREA
08­
25­
01
7:
47
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
26­
01
7:
32
P
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
08­
25­
01
7:
48
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
____________­______­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
FOLLOWING
EXPOSURE
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
2
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
_________________­­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69318
M
69329
M
69366
F
69367
F
69367
F
69384
F
69384
F
69398
F
%
69404
F
ch
;;

69416
F
_­­­­_­­­_­­­.
GRADE
CODE:
1
100
PPM
100
PPM
0
PPM
0
PPM
0
PPM
SPECIAL
EYES/
EARS/
NOSE
SPECIAL
EYES/
EARS/
NOSE
SPECIAL
0
PPM
0
PPM
0
PPM
EXCRETA
SPECIAL
SPECIAL
0
PPM
SPECIAL
0
PPM
SPECIAL
08­
26­
01
7:
32
P
07­
21­
01
8:
21
P
08­
11­
01
7:
53
P
07­
28­
01
7:
36
P
07­
29­
01
7:
30
P
07­
01­
01
6:
49
P
07­
28­
01
7:
36
P
07­
29­
01
7:
30
P
08­
04­
01
6:
32
P
08­
26­
01
7:
27
P
07­
29­
01
7:
30
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
RED
DISCHARGE
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
SOFT
FECES
07­
28­
01
7:
37
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
04­
01
6:
31
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
06­
17­
01
6:
55
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
06­
23­
01
8:
Ol
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
01­
01
6:
49
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
07­
28­
01
7:
37
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
11­
01
7:
53
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
07­
21­
01
8:
lO
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
29­
01
7:
31
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
11­
01
7:
53
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
25­
01
7~
42
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
28­
01
7~
37
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
04­
01
6:
32
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
05­
01
7:
42
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
11­
01
7:
54
P
DRIED
YELLOW
MATERIAL
ANOGENITAL
AREA
08­
12­
01
13:
13
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
25­
01
7:
43
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
_____­_­­­_­­__­___­____________________­­­~­­­­­­~­­­~­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~~~~­­­­­­­~­­­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
FOLLOWING
EXPOSURE
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
3
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
__­__­_­­____­­__­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
___________­__­____­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69416
F
69419
F
69419
F
0
PPM
0
PPM
0
PPM
WET
YELLOW
MATERIAL
UROGENITAL
AREA
RALES
69419
F
0
PPM
69432
F
0
PPM
69376
F
15
PPM
69377
F
69377
F
69382
F
___­­_____­__
15
PPM
15
PPM
15
PPM
SPECIAL
08­
26­
01
7:
28
CARDIO­
PULMONARY
07­
22­
01
7:
08
EYES/
EARS/
NOSE
07­
21­
01
8:
ll
07­
22­
01
7:
oe
07­
22­
01
7:
08
SPECIAL
07­
28­
01
7:
38
07­
29­
01
7:
31
08­
04­
01
6:
31
08­
05­
01
7:
41
08­
25­
01
7:
43
SPECIAL
08­
04­
01
6:
31
08­
11­
01
7:
55
08­
11­
01
7:
55
08­
12­
01
13:
14
08­
12­
01
13:
14
SPECIAL
06­
10­
01
6:
54
06­
17­
01
6:
52
06­
23­
01
7:
59
06­
30­
01
7:
11
07­
01­
01
6:
49
07­
29­
01
7:
33
08­
04­
01
6:
30
08­
11­
01
7:
56
08­
12­
01
13:
15
EYES/
EARS/
NOSE
06­
30­
01
7:
16
06­
30­
01
7:
16
SPECIAL
06­
30­
01
7:
ll
06­
30­
01
7:
ll
SPECIAL
08­
11­
01
7:
57
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
RED
DISCHARGE
LEFT
EYE
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
HINDLIMB
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
YELLOW
MATERIAL
VENTRAL
TRUNK
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
FOLLOWING
EXPOSURE
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
4
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
__________­__­__________^_______________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­~­­­­­­­­­­­­­~­­­­­­~~­­­~­­­
69390
F
15
PPM
SPECIAL
69409
F
15
PPM
SPECIAL
69380
F
40
PPM
SPECIAL
69388
F
40
PPM
SPECIAL
69426
F
40
PPM
SPECIAL
69433
F
40
PPM
SPECIAL
69436
F
40
PPM
SPECIAL
69375
69385
69408
69415
F
100
PPM
SPECIAL
F
100
PPM
F
100
PPM
F
100
PPM
SPECIAL
SPECIAL
SPECIAL
07­
01­
01
07­
01­
01
07­
21­
01
07­
28­
01
08­
25­
01
08­
26­
01
07­
28­
01
06­
23­
01
08­
25­
01
08­
26­
01
07­
21­
01
07­
28­
01
06­
16­
01
06­
16­
01
06­
17­
01
06­
30­
01
07­
01­
01
08­
05­
01
08­
25­
01
08­
26­
01
07­
29­
01
08­
11­
01
07­
29­
01
07­
21­
01
08­
05­
01
08­
11­
01
08­
25­
01
06­
17­
01
06­
23­
01
6:
49
6:
49
8:
16
7:
39
7:
45
7:
29
7:
41
8:
00
7:
46
7:
31
8:
lY
7:
42
7:
04
7:
04
6:
51
7:
12
6:
51
7~
46
7:
47
7:
31
7:
35
7:
59
7136
8:
25
7~
48
7:
59
7:
48
6:
50
7:
58
P
DRIED
YELLOW
MATERIAL
VENTRAL
TRUNK
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
FOLLOWING
EXPOSURE
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
PAGE
5
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
___­______­________­__________^_________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
_________________­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69415
F
100
PPM
SPECIAL
06­
24­
01
6:
51
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
21­
01
8:
24
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
28­
01
7:
43
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
29­
01
7:
36
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
05­
01
7141
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
11­
01
8:
00
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
11­
01
8:
00
P
DRIED
YELLOW
MATERIAL
ANOGENITAL
AREA
08­
12­
01
13:
18
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
25­
01
7:
49
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
26­
01
69427
F
7:
33
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
100
PPM
SPECIAL
07­
28­
01
7:
44
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
11­
01
8:
00
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
25­
01
7:
49
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
26­
01
7:
33
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
69431
F
100
PPM
SPECIAL
07­
21­
01
8:
24
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
28­
01
7:
44
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
29­
01
I:
36
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
___________­__­____­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PCRDv4.04
11/
28/
2001
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
NON­
EXPOSURE
DAYS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
1
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
_­___­­___________­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
____­____­­­­­_­­­__­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

69306
M
0
PPM
EYES/
EARS/
NOSE
69310
M
0
PPM
SPECIAL
69314
M
0
PPM
EYES/
EARS/
NOSE
69314
M
0
PPM
EXCRETA
69317
M
0
PPM
EYES/
EARS/
NOSE
69343
M
0
PPM
EYES/
EARS/
NOSE
69343
M
0
PPM
SPECIAL
oy
69323
M
15
PPM
EYES/
EARS/
NOSE
ch
69335
M
15
PPM
5
EYES/
EARS/
NOSE
69338
M
15
PPM
EYES/
EARS/
NOSE
07­
31­
01
14:
42
P
07­
31­
01
14:
42
P
08­
01­
01
14:
35
P
07­
30­
01
14:
42
P
07­
09­
01
14:
36
P
07­
20­
01
14:
18
P
07­
30­
01
14:
48
P
07­
31­
01
14:
41
P
07­
31­
01
14:
41
P
08­
10­
01
15:
29
P
07­
09­
01
14:
36
P
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
RED
NASAL
DISCHARGE
RED
DISCHARGE
RIGHT
EYE
DRIED
BROWN
MATERIAL
ANOGENITAL
AREA
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
RED
DISCHARGE
LEFT
EYE
CLEAR
DISCHARGE
RIGHT
EYE
CLEAR
DISCHARGE
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
SOFT
FECES
06­
21­
01
15:
15
P
WET
RED
MATERIAL
AROUND
LEFT
EYE
08­
17­
01
14:
44
P
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
08­
17­
01
14:
44
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
08­
13­
01
14:
52
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
14­
01
14:
48
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
17­
01
14:
44
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
17­
01
14:
44
P
WET
YELLOW
ANOGENITAL
AREA
08­
01­
01
14:
39
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
06­
15­
01
15:
21
P
DRIED
RED
MATERIAL
AROUND
NOSE
06­
29­
01
13:
56
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
07­
04­
01
13:
56
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
07­
20­
01
14:
18
P
RED
DISCHARGE
LEFT
EYE
08­
06­
01
15:
08
P
CLEAR
DISCHARGE
LEFT
EYE
08­
06­
01
15:
08
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
08­
09­
01
14:
45
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
08­
09­
01
14:
45
P
RED
DISCHARGE
LEFT
EYE
08­
22­
01
14:
43
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
____­­­___­_____­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
NON­
EXPOSURE
DAYS
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
2
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
_______­­­­­_­­___­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
^­_____­­­­­_­­­____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69338
M
69313
M
69324
M
69304
M
69307
M
%
69318
M
CR
69329
M
15
PPM
40
PPM
40
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
0
PPM
EYES/
EARS/
NOSE
EYES/
EARS/
NOSE
EYES/
EARS/
NOSE
SPECIAL
EYES/
EARS/
NOSE
SPECIAL
EYES/
EARS/
NOSE
SPECIAL
SPECIAL
08­
24­
01
15:
41
08­
28­
01
14:
29
08­
03­
01
14:
06
07­
27­
01
14:
13
08­
06­
01
15:
15
08­
09­
01
14:
56
08­
28­
01
14:
42
08­
29­
01
14:
20
08­
30­
01
14:
16
07­
26­
01
14:
39
07­
27­
01
14:
ll
07­
30­
01
14:
44
07­
30­
01
14:
44
08­
03­
01
13:
57
08­
03­
01
13:
57
08­
10­
01
15:
25
08­
10­
01
15:
25
08­
28­
01
14:
41
08­
29­
01
14:
23
08­
22­
01
14:
55
08­
23­
01
14:
31
08­
23­
01
14:
31
08­
29­
01
14:
19
07­
20­
01
14:
25
08­
28­
01
14:
40
08­
29­
01
14:
25
08­
29­
01
14:
25
08­
03­
01
14:
00
07­
31­
01
14:
39
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
,p
P
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
RED
DISCHARGE
LEFT
EYE
RED
DISCHARGE
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
CLEAR
DISCHARGE
RIGHT
EYE
RED
DISCHARGE
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
RED
DISCHARGE
RIGHT
EYE
RED
DISCHARGE
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
RED
DISCHARGE
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
69332
M
69366
F
________­­______________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
NON­
EXPOSURE
DAYS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
3
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
_____________­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
__­____­___­____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69366
69367
69367
69378
69378
69384
69398
%
69416
m
69419
F
0
PPM
SPECIAL
F
F
F
F
0
PPM
SPECIAL
0
RPM
SPECIAL
0
PPM
EYES/
EARS/
NOSE
0
PPM
SPECIAL
0
PPM
0
PPM
0
PPM
EYES/
EARS/
NOSE
SPECIAL
SPECIAL
0
PPM
SPECIAL
08­
28­
01
14:
25
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
30­
01
14:
46
P
DRLED
RED
MATERIAL
AROUND
RIGHT
EYE
08­
29­
01
14:
20
P
RED
DISCHARGE
RIGHT
EYE
07­
13­
01
14:
42
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
07­
30­
01
14:
46
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
02­
01
15:
14
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
22­
01
14:
40
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
28­
01
14:
23
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
02­
01
15:
ll
P
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
08­
02­
01
15:
ll
P
RED
DISCHARGE
RIGHT
EYE
07­
31­
01
14:
39
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
09­
01
14:
34
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
28­
01
14:
21
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
07­
30­
01
14:
45
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
31­
01
14:
39
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
13­
01
14:
50
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
24­
01
15:
45
P
WET
YELLOW
MATERIAL
URO#
ENITAL
AREA
08­
28­
01
14:
26
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
07­
01
14:
45
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
13­
01
14:
50
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
17­
01
14:
48
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
22­
01
14:
40
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
28­
01
14:
24
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
29­
01
14:
20
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
07­
09­
01
14:
34
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
09­
01
14:
34
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
07­
30­
01
14:
50
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
02­
01
15:
lO
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
06­
01
15:
17
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
_________­____­_________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
NON­
EXPOSURE
DAYS
PO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
4
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
_______­__­__­­____­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­~­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
___­__­_____­__­_­­­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69419
F
69432
F
0
PPM
69432
F
0
PPM
69432
F
t­
z
69362
F
CR
69362
F
%
ch
s
69376
F
69376
F
________­­___
GRADE
CODE:
1
SLIGHT
2
_­­
­
0
PPM
0
PPM
15
PPM
15
PPM
15
PPM
15
PPM
SPECIAL
BODY/
INTEGUMENT
EYES/
EARS/
NOSE
SPECIAL
ORAL/
DENTAL
SPECIAL
EYES/
EARS/
NOSE
SPECIAL
08­
13­
01
14:
49
P
08­
22­
01
14:
40
P
08­
28­
01
14:
26
P
08­
16­
01
15:
oo
P
08­
16­
01
15:
oo
P
08­
16­
01
15:
OO
P
08­
17­
01
14:
46
P
08­
17­
01
14:
46
P
07­
30­
01
14:
44
P
08­
13­
01
14:
53
P
08­
16­
01
15:
oo
P
08­
16­
01
15:
oo
P
08­
16­
01
15:
oo
P
08­
17­
01
14:
46
P
08­
17­
01
14:
46
P
08­
22­
01
14:
40
P
08­
22­
01
14:
43
P
07­
20­
01
14:
19
P
08­
10­
01
15:
20
P
08­
23­
01
14:
31
P
08­
28­
01
14:
31
P
08­
22­
01
14:
44
P
08­
22­
01
14:
44
P
07­
13­
01
14:
49
P
07­
15­
01
14:
53
P
07­
30­
01
14:
53
P
08­
09­
01
14:
47
P
08­
10­
01
15:
20
P
08­
22­
01
14:
44
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DERMAL
ATONIA
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
HINDLIMB
WET
YELLOW
ANOGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
ANOGENITAL.
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
UPPER
INCISORS
MALALIGNED
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
RED
MATERIAL
AROUND
RIGHT
EYE
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
_______­_____­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
MODERATE
3
­
SEVERE
P
­
PRESENT
NON­
EXPOSURE
DAYS
PROJECT
NO.:
WIL­
417002
PO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
5
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
­­­___~___~__­­__­­_­­~~~­~­~~~­~­~­­­­­~~~­­~~~~­­~~~~­­­~~~­~~~~~~­­­~~~~~­~~~~~~~~~­~­~~~~­~~~~~~~~­­~~~~~­­­­~~~~­~~­­­­~~~~~~~
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
____________­______­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69376
F
15
PPM
SPECIAL
69382
F
15
PPM
SPECIAL
69390
F
15
PPM
SPECIAL
69393
F
15
PPM
SPECIAL
$
69396
F
4
%
69409
F
m
69413
F
s
69435
F
69359
F
.69359
F
____­________
GRADE
CODE:
1
15
PPM.

15
PPM
15
PPM
15
PPM
40
PPM
40
PPM
SPECIAL
SPECIAL
SPECIAL
SPECIAL
EXCRETA
SPECIAL
SLIGHT
2
­
MODERATE
08­
28­
01
14:
32
08­
02­
01
15:
lO
08­
24­
01
15:
41
08­
28­
01
14:
29
06­
15­
01
15:
15
07­
04­
01
13:
51
07­
05­
01
14:
22
07­
09­
01
14:
43
07­
20­
01
14:
20
08­
28­
01
14:
29
08­
29­
01
14:
32
08­
02­
01
15:
12
08­
09­
01
14:
44
OS­
14­
01
14:
44
08­
22­
01
14:
45
08­
29­
01
14:
27
08­
22­
01
14:
45
08­
28­
01
14:
31
07­
09­
01
14:
43
08­
09­
01
14:
43
08­
10­
01
15:
21
07­
04­
01
13:
57
07­
09­
01
14:
40
08­
13­
01
14:
43
08­
22­
01
14:
45
08­
28­
01
14:
30
07­
11­
01
14:
07
07­
11­
01
14:
07
.­_­­­­___­___­­____­­­­.

3
­
SEVERE
P
­
PRESENT
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
SOFT
FECES
WET
YELLOW
MATERIAL
UROGENITAL
AREA
__­___________­_­­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­
NON­
EXPOSURE
DAYS
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
6
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
________­____­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
_­__________­­­___­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­
69359
F
40
PPM
SPECIAL
07­
11­
01
14
07­
16­
01
14
07­
26­
01
14
07­
30­
01
14
08­
03­
01
14
08­
06­
01
15
08­
22­
01
14
08­
28­
01
14
08­
29­
01
14
08­
29­
01
14
08­
22­
01
14
08­
28­
01
14
06­
29­
01
13
07­
16­
01
14
07­
26­
01
14
07­
30­
01
14
07­
31­
01
14
08­
09­
01
14
08­
24­
01
15
08­
28­
01
14
08­
29­
01
14
08­
10­
01
15
08­
28­
01
14
08­
29­
01
14
06­
29­
01
13
07­
12­
01
13
08­
29­
01
14
07­
19­
01
14
07­
30­
01
14
08
P
34
P
49
P
56
P
08
P
17
P
51
P
34
P
30
P
30
P
50
P
34
P
50
P
29
P
45
P
53
P
33
P
50
P
50
P
36
P
29
P
21
P
34
P
31
P
47
P
40
P
32
P
19
P
51
P
WET
BROWN
MATERIAL
ANOGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
RED
DISCHARGE
RIGHT
EYE
RED
DISCHARGE
LEFT
EYE
69369
F
40
PPM
69380
F
40
PPM
a
s
69388
F
'
69394
F
40
PPM
40
PPM
69426
F
40
PPM
69428
F
40
PPM
SPECIAL
SPECIAL
SPECIAL
SPECIAL
SPECIAL
EYES/
EARS/
NOSE
_________­______________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
NON­
EXPOSURE
DAYS
PROJECT
NO.:
WIL­
417002
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
7
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
_____­___­___­__________________________­­­­­­­­~­­­­­­­­­­­­­­­~~­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­~~­­­~­­­­­­­­­~­~­­­­­­­­­~­­­~­~~

ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
__­_______­_________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­
69428
F
40
PPM
EYES/
EARS/
NOSE
07­
30­
01
14:
51
08­
03­
01
14:
04
08­
22­
01
14:
53
08­
29­
01
14:
30
69428
F
40
PPM
SPECIAL
07­
30­
01
14:
51
08­
22­
01
14:
53
08­
29­
01
14:
30
69433
F
40
PPM
SPECIAL
07­
11­
01
14:
08
07­
30­
01
14:
54
07­
30­
01
14:
54
07­
31­
01
14:
35
08­
03­
01
14:
06
08­
06­
01
15:
17
08­
22­
01
14:
53
08­
28­
01
14:
35
08­
29­
01
14:
28
69436
F
40
PPM
SPECIAL
06­
29­
01
13:
50
07­
LO­
01
14:
58
0,
07­
27­
01
07­
19­
01
14:
15
14:
14
(3
07­
30­
01
14:
53
G
07­
31­
01
14:
33
08­
02­
01
15:
19
08­
03­
01
14:
05
08­
03­
01
14:
05
08­
06­
01
15:
18
08­
07­
01
14:
48
08­
09­
01
14:
50
08­
13­
01
14:
43
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
RED
DISCHARGE
LEFT
EYE
RED
DISCHARGE
LEFT
EYE
RED
DISCHARGE
LEFT
EYE
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
_________­____­_____­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
NON­
EXPOSURE
DAYS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
8
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
­­­­­­­­­­­­­­­­­­__­­­­­_­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
69436
F
40
PPM
SPECIAL
08­
29­
01
14:
29
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
29­
01
14:
29
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
07­
16­
01
14:
26
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
30­
01
14:
49
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
24­
01
15:
49
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
28­
01
14:
43
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
29­
01
14:
22
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
16­
01
14:
25
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
27­
01
14:
09
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
16­
01
14:
21
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
28­
01
14:
39
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
06­
22­
01
15:
31
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
30­
01
14:
45
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
13­
01
15:
08
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
28­
01
14:
43
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
29­
01
14:
21
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
30­
01
14:
16
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
07­
30­
01
14:
48
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
02­
01
15:
22
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
29­
01
14:
20
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
29­
01
14:
20
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
30­
01
14:
16
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
23­
01
14:
26
P
DRIED
RED
MATERIAL
AROUND
LEFT
EYE
08­
09­
01
15:
06
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
23­
01
14:
26
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
08­
28­
01
14:
38
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
29­
01
14:
25
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
08­
30­
01
14:
17
P
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
06­
25­
01
14:
lP
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
69375
F
69379
F
69383
F
69385
F
69392
F
P
g
69402
F
%
a
G
69408
F
69408
F
69415
F
100
PPM
SPECIAL
100
PPM
100
PPM
100
PPM
100
PPM
SPECIAL
SPECIAL
SPECIAL
SPECIAL
100
PPM
SPECIAL
100
PPM
100
PPM
EYES/
EARS/
NOSE
SPECIAL
100
PPM
SPECIAL
­_______­_______________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
NON­
EXPOSURE
DAYS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
9
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
___­­____­­__­______­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
_­______­­­­_­­__­_­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­~­­­­­

69415
F
100
PPM
SPECIAL
06­
29­
01
07­
04­
01
07­
13­
01
07­
24­
01
07­
27­
01
07­
31­
01
08­
01­
01
08­
03­
01
08­
03­
01
08­
14­
01
08­
22­
01
08­
23­
01
08­
23­
01
08­
28­
01
08­
29­
01
08­
29­
01
69427
F
100
PPM
SPECIAL
07­
16­
01
07­
19­
01
rs,
07­
26­
01
07­
30­
01
a
08­
01­
01
G
08­
03­
01
08­
09­
01
08­
22­
01
08­
23­
01
08­
28­
01
08­
29­
01
69431
F
100
PPM
SPECIAL
07­
13­
01
07­
25­
01
13:
47
P
13:
50
P
15:
09
P
14:
20
P
14:
12
P
14:
32
P
14:
49
P
13:
59
P
13:
59
P
14:
40
P
14:
58
P
14:
28
P
14:
28
P
14:
42
P
14:
23
P
14:
23
P
14:
25
P
14:
23
P
14:
37
P
14:
47
P
14:
46
P
14:
Ol
P
15:
04
P
14:
58
P
14:
30
P
14:
40
P
14:
20
P
15:
lO
P
14:
48
P
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
VENTRAL
TRUNK
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002
SPONSOR:
HAP
TASK
FORCE
NON­
EXPOSURE
DAYS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
10
TABLE
RANGE:
05­
31­
01
TO
08­
30­
01
__­_­___________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­,­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

69431
F
100
RPM
SPECIAL
07­
30­
01
14:
43
P
08­
02­
01
15:
18
P
08­
03­
01
13:
56
P
08­
13­
01
14:
50
P
08­
22­
01
14:
58
P
08­
23­
01
14:
27
P
08­
28­
01
14:
40
P
08­
29­
01
14:
24
P
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
­_
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
DRIED
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
WET
YELLOW
MATERIAL
UROGENITAL
AREA
­____­_­____­­­____­____________________­­­­­­­­­­­­­­­
WIL­
4
17002
HAP
Task
Force
APPENDIX
I
1,
1,2­
Trichloroethane
Dispositions
and
Body
Weights
(Pharmacokinetic
Groups)

493
of
619
PROJECT
NO.:
WIL­
417002R
SPONSOR:
HAP
TASK
FORCE
DISPOSITIONS
FOR
RATS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
1
TABLE
RANGE:
06­
25­
01
TO
06­
29­
01
__________­______­______________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
__­_______­__­___­­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­~­­~­­­­­­­­­
69355
69357
69358
69360
69363
69364
69365
69368
69372
69373
69374
69386
69387
69389
69397
69399
69400
69401
0,
69403
69405
a
69406
s
69407
69410
69411
69412
69414
69418
69420
69421
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
100
PPM
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
DISPOSITION
06­
29­
01
06­
27­
01
06­
27­
02
06­
27­
01
06­
29­
01
06­
29­
01
06­
25­
01
06­
29­
01
06­
25­
01
06­
29­
01
06­
25­
01
06­
29­
01
06­
25­
01
06­
29­
01
06­
25­
01
06­
27­
01
06­
25­
01
06­
29­
01
06­
27­
01
06­
29­
01
06­
29­
01
06­
25­
01
06­
25­
01
06­
27­
01
06­
29­
01
06­
29­
01
06­
27­
01
06­
25­
01
06­
27­
01
16:
00
4:
oo
4:
oo
4:
oo
16:
OO
16:
OO
0:
oo
18:
OO
0:
oo
18:
OO
0:
oo
18:
00
0:
oo
18:
15
0:
oo
6:
00
0:
oo
18:
15
6:
00
18:
15
18:
17
0
:
00
0:
oo
6:
00
18:
17
18:
17
6:
15
0:
oo
6:
15
P
EUTHANIZED
FOR
BLOOD
COLLECTION
P
SCHEDULED
NECROPSY
INTERVAL
4
P
SCHEDULED
NECROPSY
INTERVAL
4
P
SCHEDULED
NECROPSY
INTERVAL
4
P
EUTHANIZED
FOR
BLOOD
COLLECTION
P
EUTHANIZED
FOR
BLOOD
COLLECTION
P
SCHEDULED
NECROPSY
INTERVAL
4
P
EUTHANIZED
FOR
BLOOD
COLLECTION
P
SCHEDULED
NECROPSY
INTERVAL
4
P
EUTHANIZED
FOR
BLOOD
COLLECTION
P
SCHEDULED
NECROPSY
INTERVAL
4
P
EUTHANIZED
FOR
BLOOD
COLLECTION
P
SCHEDULED
NECROPSY
INTERVAL
4
P
EUTHANIZED
FOR
BLOOD
COLLECTION
P
SCHEDULED
NECROPSY
INTERVAL
4
P
SCHEDULED
NECROPSY
INTERVAL
4
P
SCHEDULED
NECROPSY
INTERVAL
4
P
EUTHANIZED
FOR
BLOOD
COLLECTION
P
SCHEDULED
NECROPSY
INTERVAL
4
P
EUTHANIZED
FOR
BLOOD
COLLECTION
P
EUTHANIZED
FOR
BLOOD
COLLECTION
P
SCHEDULED
NECROPSY
INTERVAL
4
P
SCHEDULED
NECROPSY
INTERVAL
4
P
SCHEDULED
NECROPSY
INTERVAL
4
P
EUTHANIZED
FOR
BLOOD
COLLECTION
P
EUTHANIZED
FOR
BLOOD
COLLECTION
P
SCHEDULED
NECROPSY
INTERVAL
4
P
SCHEDULED
NECROPSY
INTERVAL
4
P
SCHEDULED
NECROPSY
INTERVAL
4
________________________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
DISPOSITIONS
FOR
RATS
PROJECT
NO.:
WIL­
417002R
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
PAGE
2
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
06­
25­
01
TO
06­
29­
01
__­__­_______­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
________­_­­_­__________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­~­­­­­­­~­­­~­­­

69422
F
100
PPM
DISPOSITION
06­
27­
01
6:
15
P
SCHEDULED
NECROPSY
INTERVAL
4
69423
F
100
PPM
DISPOSITION
06­
27­
01
6:
17
P
SCHEDULED
NECROPSY
INTERVAL
4
69424
F
100
PPM
DISPOSITION
06­
27­
01
6:
17
P
SCHEDULED
NECROPSY
INTERVAL
4
69425
F
100
PPM
DISPOSITION
06­
27­
01
6:
17
P
SCHEDULED
NECROPSY
INTERVAL
4
69429
F
100
PPM
DISPOSITION
06­
25­
01
0:
OO
P
SCHEDULED
NECROPSY
INTERVAL
4
69430
F
100
PPM
DISPOSITION
06­
25­
01
0:
OO
P
SCHEDULED
NECROPSY
INTERVAL
4
69434
F
100
PPM
DISPOSITION
06­
25­
01
0:
OO
P
SCHEDULED
NECROPSY
INTERVAL
4
____________­__­_­­_____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PCRDv4.04
01/
04/
2002
DISPOSITIONS
FOR
MICE
PROJECT
NO.:
WIL­
417002M
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
1
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
CLINICAL
OBSERVATIONS
TABLE
RANGE:
06­
25­
01
TO
06­
29­
01
______­____­____________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
_____­______­___________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
5204
5205
5206
5207
5209
5210
5212
5214
5215
5216
5217
5218
5219
5220
5221
%
5222
5224
OY
5225
%
5226
5221
m
5228
z
5229
5230
5231
5232
5234
5235
5236
5238
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
F
100
PPM
DISPOSITION
06­
29­
01
16:
00
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITION
06­
29­
01
16:
00
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITION
06­
29­
01
16:
00
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITION
06­
25­
01
16:
05
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITION
06­
25­
01
0:
OO
P
SCHEDULED
NECROPSY
INTERVAL
4
DISPOSITION
06­
29­
01
18:
Ol
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITION
06­
25­
01
16:
OS
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITLON
06­
25­
01
16:
05
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITION
06­
25­
01
0:
OO
P
SCHEDULED
NECROPSY
INTERVAL
4
DISPOSITION
06­
25­
01
0:
oo
P
SCHEDULED
NECROPSY
INTERVAL
4
DISPOSITION
06­
25­
01
0:
OO
P
SCHEDULED
NECROPSY
INTERVAL
4
DISPOSITION
06­
25­
01
0:
OO
P
SCHEDULED
NECROPSY
INTERVAL
4
DISPOSITION
06­
29­
01
18:
Ol
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITION
06­
25­
01
0:
OO
P
SCHEDULED
NECROPSY
INTERVAL
4
DISPOSITION
06­
25­
01
18:
Ol
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITION
06­
25­
01
0:
OO
P
SCHEDULED
NECROPSY
INTERVAL
4
DISPOSITION
06­
25­
01
18:
Ol
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITION
06­
25­
01
18:
Ol
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITION
06­
25­
01
0:
OO
P
SCHEDULED
NECROPSY
INTERVAL
4
DISPOSITION
06­
29­
01
18:
Ol
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITION
06­
29­
01
18:
15
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITION
06­
25­
01
0:
OO
P
SCHEDULED
NECROPSY
INTERVAL
4
DISPOSITION
06­
29­
01
18:
15
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITION
06­
29­
01
18:
15
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITION
06­
29­
01
18:
15
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITION
06­
25­
01
0:
OO
P
SCHEDULED
NECROPSY
INTERVAL
4
DISPOSITION
06­
29­
01
18:
20
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITION
06­
25­
01
18:
17
P
EUTHANIZED
FOR
BLOOD
COLLECTION
DISPOSITION
06­
25­
01
18:
17
P
EUTHANIZED
FOR
BLOOD
COLLECTION
___________________­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PROJECT
NO.:
WIL­
417002M
SPONSOR:
HAP
TASK
FORCE
DISPOSITIONS
FOR
MICE
90­
DAY
TNHAL.
STUDY
OF
l.,
1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
CLINICAL
OBSERVATIONS
PAGE
2
TABLE
RANGE:
06­
25­
01
TO
06­
29­
01
__­__________­_______________________^__­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
ANIMAL
SEX
GROUP
CATEGORY
DATE
TIME
GRADE
OBSERVATIONS
____________­___________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­
5239
F
100
PPM
DISPOSITION
06­
25­
01
18:
17
P
EUTHANIZED
FOR
BLOOD
COLLECTION
5240,
F
100
PPM
DISPOSITION
06­
29­
01
18:
20
P
EUTHANIZED
FOR
BLOOD
COLLECTION
5242
F
100
PPM
DISPOSITION
06­
29­
01
18:
20
P
EUTHANIZED
FOR
BLOOD
COLLECTION
5245
F
100
PPM
DISPOSITION
06­
25­
01
18:
17
P
EUTHANIZED
FOR
BLOOD
COLLECTION
5241
F
100
PPM
DISPOSITION
06­
25­
01
0:
OO
P
SCHEDULED
NECROPSY
INTERVAL
4
5248
F
100
PPM
DISPOSITION
06­
25­
01
0:
OO
P
SCHEDULED
NECROPSY
INTERVAL
4
5249
F
100
PPM
DISPOSITION
06­
25­
01
18:
17
P
EUTHANIZED
FOR
BLOOD
COLLECTION
______­_______­____­____________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
GRADE
CODE:
1
­
SLIGHT
2
­
MODERATE
3
­
SEVERE
P
­
PRESENT
PCRDv4.04
01/
04/
2002
PROJECT
NO.:
WIL­
417002R
SPONSOR:
HAP
TASK
FORCE
.­_
WEEK
___­
­­___
ANIMAL
69355
69357
69358
69360
69363
69364
69365
69368
69372
69373
69374
69386
69387
69389
69397
­1
0
_______­___­___­_­

125.
129.
152.
165.
174.
117.
124.
143.
149.
160.
115.
124.
140.
150.
155.
124.
126.
135.
139.
146.
130.
141.
157.
168.
178.
126.
135.
146.
168.
164.
117.
123.
140.
149.
156.
127.
133.
146.
154.
158.
120.
122.
144.
153.
159.
134.
134.
142.
149.
152.
126.
128.
147.
158.
166.
124.
124.
124.
150.
164.
128.
131.
141.
152.
156.
120.
123.
133.
136.
137.
119.
130.
145.
158.
169.
123.
127.
145.
154.
159.
115.
125.
147.
164.
171.
119.
127.
148.
162.
170.
129.
137.
148.
162.
169.
116.
122.
137.
145.
150.
130.
132.
147.
156.
161.
122.
127.
141.
148.
155.
117.
122.
140.
149.
156.
128.
135.
147.
154.
160.
124.
128.
135.
140.
145.
135.
142.
153.
159.
144.
69399
69400
69401
%
69403
69405
ch
69406
5,
69407
69410
69411
69412
69414
BODY
WEIGHTS
FOR
RATS
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
INDIVIDUAL
BODY
WEIGHTS
[Gl
PAGE
1
FEMALE
GROUP:
100
PPM
1
2
3
_____­_________­________________________­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
BODY
WEIGHTS
FOR
RATS
PROJECT
NO.:
WIL­
417002R
VO­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
BODY
WEIGHTS
[Gl
­1
.­­_____
­___
­___________
ANIMAL
69418
69420
69421
69422
69423
69424
69425
69429
69430
63434
115.
127.
123.
130.
137.
140.
121.
130.
141.
143.
129.
135.
136.
143.
128.
131.
119.
128.
126.
131.
FEMALE
GROUP:
100
PPM
1
2
3
._________­__­­­­­__­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­~­­­­­­­­­­~~­­

141.
141.
149.
150.
153.
154.
161.
140.
143.
153.
150.
143.
158.
160.
157.
167.
169.
147.
156.
161.
162
148
162
171
164
176
180
149
163
170
PAGE
2
MEAN
125.
130.
145.
154.
161.
S.
D.
6.7
6.2
7.2
8.4
10.2
N
36
36
36
36
36
PBFTSv4.23
02/
06/
2002
PROJECT
NO.:
WIL­
417002M
BODY
WEIGHTS
FOR
MICE
PO­
DAY
INHAL.
STUDY
OF
1.1.2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL'BGDY
WEIGHTS
(GRAMS)

WEEK
­­­__­­___
ANIMAL
5204
5205
5206
5207
5209
5210
5212
5214
5215
5216
5217
5218
5219
5220
5221
__
­2
_­_­­__
­1
_­____­____­
0
­­_­­­__­___­
FEMALE
GROUP:
1
2
___­___­__­________
100
PPM
3
­
_
­
­
­
_
_
­
­

NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
20.3
21.0
NA
21.2
22.5
NA
20.6
21.1
NA
20.8
22.3
NA
20.4
21.9
NA
20.7
22.2
NA
20.3
22.2
NA
20.9
22.5
NA
20.7
23.0
NA
19.5
21.2
NA
22.9
22.9
NA
20.8
23.1
NA
21.3
22.2
NA
21.0
22.8
NA
20.8
22.3
NA
21.7
22.6
NA
20.8
21.5
NA
20.3
21.7
NA
21.0
23.3
NA
21.0
22.6
NA
22.1
23.4
NA
20.4
21.8
NA
22.6
24.5
NA
21.0
21.9
NA
21.2
22.4
NA
22.1
23.4
NA
21.5
NA
23.1
NA
21.7
NA
22.5
NA
22.1
NA
22.6
NA
24.1
NA
22.2
NA
22.9
NA
21.7
NA
24.6
NA
23.2
NA
23.0
NA
23.2
NA
22.5
NA
23.2
NA
22.3
NA
21.7
NA
22.9
NA
22.5
NA
23.4
NA
21.9
NA
24.2
NA
21.9
NA
22.3
NA
23.8
5222
5224
5225
0
5226
ch
5227
ch
5228
5,
5229
5230
5231
5232
5234
NA
=
NOT
APPLICABLE
__­­__.
PAGE
1
4
__­­___­­­­­
c­­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
BODY
WEIGHTS
FOR
MICE
PROJECT
NO.:
WIL­
417002M
90­
DAY
INHAL.
STUDY
OF
1,1,2­
TCE
IN
RATS
WITH
PK
IN
RATS
&
MICE
PAGE
2
SPONSOR:
HAP
TASK
FORCE
INDIVIDUAL
BODY
WEIGHTS
(GRAMS)

WEEK
____________­
ANIMAL
5235
5236
5238
5239
5240
5242
5245
5247
5248
5243
2
_
­
­
­
_
­
­

NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
MEAN
21.1
22.4
22.8
S.
D.
0.71
0.73
0.75
N
36
36
36
3
NA
=
NOT
APPLICABLE
z
z
5,
­1
0
FEMALE
GROUP:
100
PPM
1
2
3
4
._­­_­­__­__­­­­­­­_­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

NA
NA
21.3
22
3
NA
NA
20.5
21
9
NA
NA
21.6
22
7
NA
NA
22.2
22
5
NA
NA
22.0
23
0
NA
NA
20.9
21
9
NA
NA
21.0
21
6
NA
NA
21.2
23
1
NA
NA
21.7
22
9
NA
NA
21.5
22
3
NA
22
7
NA
22
1
NA
23
3
NA
23
3
NA
22
7
NA
22
7
NA
22
9
NA
23
6
NA
22
2
NA
23
0
PBFTSv4.23
l.
1/
28/
2001
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
APPENDIX
J
Ophthalmic
Examination
Report
(David
A.
Wilkie,
D.
V.
M.,
M.
S.,
D.
A.
C.
V.
0.)

502
of
619
Concluding
Statement
Pertaining
to
Ophthalmic
Examinations
Performed
During
Conduct
of
Study
WIL­
417002
Al1
findings
observed
during
the
ophthalmic
examinations
for
the
above
mentioned
study
are
typical
in
prevalence
and
appearance
for
the
species
and
strain
or
breed
of
animals
examined.
There
were
no
significant
differences
within
or
among
dose
groups
or
compared
to
the
pretest
ophthalmic
examinations
to
suggest
a
test
article­
related
effect.

David
A.
Wilkie,
D.
V.
M.,
MS.
Diplomate
A.
C.
V.
O.
'
Da&

Tl­
230
503
of
619
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
APPENDIX
K
Histopathology
Report
(Experimental
Patholopy
Laboratories,
Inc).

504
of
619
EPL"
EXPERIMENTAL
PATHOLOGY
LABORATORIES,
INC.

WIL
RESEARCH
LABORATORIES,
INC.
STUDY
NUMBER
WIL­
417002
EPL
PROJECT
NUMBER
223­
057
A
BO­
DAY
INHALATION
TOXICITY
STUDY
OF
1,
I,
2­
TRICHLOROETHANE
(1,
1,
2­
TCE)
IN
RATS
(WITH
SATELLITE
GROUPS
FOR
PHARMACOKINETIC
EVALUATIONS
IN
RATS
AND
MICE)

PATHOLOGY
REPORT
Submitted
by:

Experimental
Pathology
Laboratories,
Inc.
P.
O.
Box
474
Herndon,
VA
20172­
0474
(703)
471­
7060
Submitted
to:

WIL
Research
Laboratories,
Inc.
Ashland,
OH
448059281
April
29,
2002
505
of
619
EPL"
EXPERIMENTAL
PATHOLOGY
LABORATORIES,
INC.

TABLE
OF
CONTENTS
PATHOLOGY
SUMMARY
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

QUALITY
ASSURANCE
FINAL
CERTIFICATION
_............................._..........

SUMMARY
INCIDENCE
TABLES
Males
.._.....
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
._
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
._
.
.
.

Females..
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
_.
.
.
.
.
.
.
.
.
_.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
_.
.
.
.
.
.
.

HISTOPATHOLOGY
INCIDENCE
TABLES
Males
.
.
.
.
.
.
.
.
.
.._
.
.
.
.
.
.
.._.....
_.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.._.....

Females
.._.....
.
.
.
.
.
.
.
.
.._...
.
.
.
.
.
.
.._.
.._.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
..,...
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

CORRELATION
OF
GROSS
AND
MICROSCOPIC
FINDINGS
m
1
11
l­
l
l­
7
II­
I
II­
21
Males..
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

Females..
.
.
.
.
.
.
.
.
.
.
._.
.
.
.
.
.
.
.
.
.
,
.
.
.
_.
.
.
.
.
.
.
.
.
.
_.
.
.
.
.
_.
.
.
.
.
.
.
.
.
_.
.
.
.
.
.
,
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
_.
.
.
.
.
.
.
.
.
.
.
Ill­
1
Ill­
5
506of619
PATHOLOGY
SUMMARY
507
of
619
EPL"
EXPERIMENTAL
PATHOLOGY
LABORATORIES,
INC.

Page
1
WIL
RESEARCH
LABORATORIES,
INC.
STUDY
NUMBER
WIL­
417002
EPL
PROJECT
NUMBER
223­
057
A
90­
DAY
INHALATION
TOXICITY
STUDY
OF
1,
1,2­
TRICHLOROETHANE
(1,
1,2­
TCE)
IN
RATS
(WITH
SATELLITE
GROUPS
FOR
PHARMACOKINETIC
EVALUATIONS
IN
RATS
AND
MICE)

PATHOLOGY
SUMMARY
The
purpose
of
this
study
was
to
evaluate
the
subchronic
toxicity
of
the
test
article,
1,
1,
2­
Trichloroethane
(1,
1,
2­
TCE),
when
administered
via
inhalation
to
rats
for
go­
days.
With
the
exception
of
one
Group
2
female
(69377),

all
toxicity
animals
exposed
to
the
test
article
at
concentrations
up
to
100
ppm
survived
to
the
end
of
the
study.

MATERIALS
AND
METHODS
Four
groups
of
male
and
female
Fisher
344
CDF@(
F­
344)
Crl:
BR
rats
were
studied
using
the
following
experimental
design.

No.
Group
Male
Female
Level
(ppm)

1.
Filtered
Air
10
10
0
2.
Low
1
,I
,2­
TCE
10
10
15
3.
Mid
1,1,2­
TCE
10
10
40
4.
High
1
,I
,2­
TCE
10
10
100
508
of
619
EPL"
EXPERIMENTAL
PATHOLOGY
LABORATORIES,
INC.

Page
2
WIL
Research
Laboratories,
Inc.
Study
Number
WIL­
417002
At
the
completion
of
the
study
interval,
all
surviving
adult
rats
were
euthanized,
and
necropsies
performed
by
WIL
Research
Laboratories,
Inc.

Tissues
were
collected
by
WIL
Research
Laboratories,
Inc.
and,
except
for
eyes,

testes
and
epididymides,
fixed
in
10%
neutral
buffered
formalin.
Eyes
were
placed
in
Davidson's
solution
and
testes
and
epididymides
were
fixed
in
Bouin's
solution.
After
fixation,
all
tissues
were
sent
to
Experimental
Pathology
Laboratories,
Inc
(EPLe),
where
they
were
embedded
in
paraffin
and
made
into
hematoxylin
and
eosin­
stained
sections
on
glass
microscope
slides.
The
following
tissues
were
examined
by
light
microscopy
as
available:

509
of
619
EPL"
EXPERIMENTAL
PATHOLOGY
LABORATORIES,
INC.

Page
3
WIL
Research
Laboratories,
Inc.
Study
Number
WIL­
417002
Adrenals
Aorta
Bone
with
marrow
(sternum)

Brain
(forebrain,
midbrain,
hindbrain)

Epididymides
Eyes
with
optic
nerves
Exorbital
lacrimal
glands
Gastrointestinal
tract
Esophagus
Stomach
Duodenum
Jejunum
Ileum
Cecum
Colon
Rectum
Harderian
glands
Heart
Kidneys
Larynx
(Levels
I­
III)

Liver
Lungs
(with
bronchi)
Lymph
node
(tracheobronchial
and
mediastinal)

Mammary
gland
(females
only)

Nasal
tissues
[nasal
turbinates
(Levels
I­
VI)]

Ovaries
with
oviducts
Pancreas
Parathyroids
Peripheral
nerve
(sciatic)

Pituitary
Prostate
Salivary
glands
(mandibular)

Seminal
vesicles
Skeletal
muscle
(rectus
femoris)

Skin
Spinal
cord
(cervical,
thoracic,
lumbar)

Spleen
Testes
Thymus
Thyroids
Trachea
Urinary
bladder
Uterus
with
vagina
All
gross
lesions
`=
Three
cross
sections
were
examined
in
accordance
with
the
method
described
by
Renne'.
b=
Six
cross
sections
of
the
nasal
passages
were
examined
in
`accordance
with
the
method
described
by
Morgan*.
Levels
I­
VI,
as
indicated
in
the
Histopathology
Incidence
Tables,
corresponds
to
levels
2,5,9,1
I,
23
and
28
as
described
by
Mery3.

All
tissues
required
by
protocol
are
presented
in
the
Histopathology
Incidence
Tables.
Microscopic
findings
for
each
tissue
examined
from
each
rat
are
listed
in
the
Histopathology
Incidence
Tables.
Microscopic
changes
were
graded
one
to
four
depending
on
severity.
Nongradable
findings
are
listed
as
510
of
619
EPLI
8
EXPERIMENTAL
PATHOLOGY
LABORATORIES,
INC.

Page
4
WlL
Research
Laboratories,
inc.
Study
Number
WIL­
417002
present
(P),
missing
tissues
are
listed
as
no
section
(N),
and
paired
organs
that
are
missing
one
of
the
pair
are
indicated
by
an
"m."
Incomplete
(I)
denotes
tissues
that
were
inadequately
collected
at
necropsy
and
had
an
insufficient
section
available
for
evaluation.
All
findings
for
all
animals
are
summarized
by
sex
and
treatment
group
in
the
Summary
Incidence
Tables,
together
with
the
total
number
of
animals
in
each
group
for
which
tissues
were
examined.
A
tabulation
of
gross
observations
noted
at
necropsy
with
the
corresponding
microscopic
change,
if
appropriate,
is
presented
in
the
Correlation
of
Gross
and
Microscopic
Findings
tables.
The
entries
in
these
tables
were
transcribed
from
the
gross
necropsy
records
provided
by
WIL
Research
Laboratories,
inc.

RESULTS
Except
for
one
Group
2
female
(69377)
sacrificed
in
a
moribund
condition,
all
rats
survived
to
the
end
of
the
study
interval.
Microscopic
changes
in
the
lumbar
spinal
cord
(hemorrhage,
myelomalacia)
of
this
Group
2
female
suggest
that
back
trauma
may
have
been
the
cause
of
the
early
sacrifice.

Except
for
the
liver
and
nasal
turbinates,
no
effects
considered
possibly
related
to
test
article
(1,
1,
Z­
ICE)
exposure
were
noted
in
any
tissues
examined.

In
the
liver,
hepatocellular
vacuolization
(minimal
severity)
interpreted
as
test
article
retated
was
observed
in
5/
l
0
males
and
1
O/
l
0
females
from
Group
4,

and
in
3/
l
0
females
each
from
Groups
2
and
3.
The
lesion
was
characterized
by
the
presence
of
small
vacuoles
within
the
cytoplasm
of
the
hepatocytes
in
a
focal
to
multifocal
distribution
within
the
sections
examined.
In
the
case
of
the
females,
there
was
no
apparent
dose­
related
increase
in
severity
between
the
three
exposure
groups,
nor
any
dose­
related
increase
in
incidence
between
511
of
619
EPL"
EXPERIMENTAL
PATHOLOGY
LABORATORIES,
INC.

I
Page
5
WIL
Research
Laboratories,
Inc.
Study
Number
WIL­
417002
Groups
2
and
3.
While
special
stains
were
not
employed
to
identify
the
material
in
the
vacuoles,
their
morphology
was
consistent
with
lipid
accumulation.

In
the
nasal
turbinates,
several
microscopic
lesions
interpreted
as
test
article
related
were
observed
in
males
from
Groups
3
and
4
and
females
from
all
dose
groups.
The
incidences
of
these
lesions
are
delineated
in
the
following
table:

Table
1
Incidence
of
Selected
Microscopic
Lesions
in
Nasal
Turbinates
Group/
Dose/
Sex
1
(Control)
2
(15
w­
N
3
(40
pw­
4
4
(100
w­
N
Lesion
MFMFMFMF
Atrophy,
Olfactory
Epithelium
O/
lOa
O/
IO
O/
IO
O/
IO
6110
7110
7110
IO/
IO
(0/
60)
b
(O/
60)
(O/
60)
(O/
60)
(8/
60)
(7160)
(15/
60)
(13/
60)

Vacuolization/
Cyst,
Olfactory
l/
IO
l/
IO
2110
4/
10
6/
10
4/
10
IO/
IO
8/
10
Epithelium
(l/
60)
(l/
60)
(2/
60)
(4/
60)
(1
I/
60)
(4/
60)
(15160)
(12/
60)

Respiratory
Epithelial
Metaplasia,
O/
IO
0110
1110
0110
l/
IO
l/
IO
3110
5/
10
Olfactory
Epithelium
(O/
60)
(O/
60)
(l/
60)
(O/
60)
(2/
60)
(l/
60)
(3/
60)
(960)
a
=
Number
of
animals
affected/
number
of
animals
examined
b
=
Total
number
of
individual
sections
affected/
total
number
individual
sections
examined
Atrophy
of
the
olfactory
epithelium
was
characterized
by
a
thinning
of
the
olfactory
epithelial
mucosa
primarily
due
to
a
reduction
in
the
thickness
of
the
nuclear
cell
layer.
The
lesions
were
generally
observed
in
sections
from
Levels
3,
4,
and
5,
of
minimal
to
mild
severity,
and
focal
in
distribution,
primarily
affecting
the
epithelium
of
the
nasal
septum
in
the
dorsal
medial
meatus.
Occasionally,

there
was
a
complete
absence
of
the
olfactory
mucosa
in
the
affected
area.
The
512
of
619
EPL"
EXPERIMENTAL
PATHOLOGY
LABORATORIES,
INC.

Page
6
WIL
Research
Laboratories,
Inc.
Study
Number
WIL­
417002
mechanism
for
the
cell
loss
was
not
microscopically
obvious;
however,
since
the
lesion
was
only
observed
in
animals
from
Groups
3
and
4,
it
was
interpreted
as
related
to
test
article
exposure.
The
focal
nature
of
the
lesion
could
not
be
explained.

Vacuolization
and/
or
microcyst
formation
in
the
olfactory
epithelium
was
characterized
by
the
presence
of
small
focal
to
multifocal
vacuoles/
microcysts
within
the
basilar
regions
of
the
olfactory
mucosa.
Again,
the
most
commonly
affected
area
was
the
olfactory
epithelium
lining
the
dorsal
medial
meatus
at
Levels
2
through
5.
Typically,
the
wall
of
these
vacuoles/
cysts
was
devoid
of
any
structure,
but
occasionally,
they
were
lined
by
a
cuboidal
epithelium,
which
most
resembled
the
epithelium
of
Bowman's
glands.
In
general,
the
vacuoles
were
devoid
of
any
content;
however,
occasionally
an
eosinophilic
globular
material
was
observed
within.
While
the
change
was
also
observed
in
one
control
male
and
female,
the
incidence
of
animals
affected
and
levels
per
animal
affected
generally
increased
with
exposure
to
increasing
concentrations
of
the
test
article.

Although
the
pathogenesis
of
the
lesion
was
not
apparent,
the
character
of
the
lesion
suggests
that
it
is
probably
degenerative
in
nature.
Whether
exposure
to
the
test
article
directly
induced
the
formation
of
these
vacuoles/
cysts
or
secondarily
accelerated
a
process
that
is
normally
present
within
the
nasal
olfactory
mucosa
could
not
be
determined.

Respiratory
epithelial
metaplasia
of
the
olfactory
epithelium
was
observed
in
males
from
Groups
2,
3,
and
4
and
females
from
Groups
3
and
4
and
characterized
by
the
presence
of
focal
areas
wherein
the
olfactory
epithelium
underwent
metaplastic
change
to
respiratory
epithelium.
Again,
these
changes
were
only
observed
in
the
olfactory
epithelium
lining
the
dorsal
medial
meatus
at
Levels
4
and
5.
Although
one
Group
2
male
(69335)
also
was
affected,
the
513
of
619
EPL"
EXPERIMENTAL
PATHOLOGY
LABORATORIES,
INC.

Page
7
WIL
Research
Laboratories,
Inc.
Study
Number
WIL­
417002
lesion
in
this
animal
was
considered
incidental
and
not
related
to
test
article
exposure
since
it
was
associated
with
inflammation
within
the
nasal
cavity
interpreted
as
spontaneous
in
origin.
Respiratory
epithelial
metaplasia
is
commonly
considered
to
be
a
sequela
to
atrophy
and
degeneration
of
the
olfactory
epithelium
with
replacement
by
ciliated
and
non­
ciliated
respiratory
epithelium.
It
may
be
seen
as
a
spontaneous
focal
lesion
in
aged
rats4.
Whether
test
article
exposure
directly
induced
this
change
or
accelerated
the
normal
aging
process
could
not
be
determined.

Additional
microscopic
findings
(described
below)
noted
in
rats
from
control
and
treated
groups
included
mononuclear
cell
infiltrates
in
various
tissues,
granulomatous
inflammation
in
the
larynx
and
trachea,
and
mineralization
or
mineral
deposition
in
the
kidney,
larynx,
nasal
turbinates,
and
cornea
of
the
eye.
In
general,
there
were
no
significant
differences
in
the
incidence
of
these
lesions
between
control
and
treated
groups.
Therefore,
they
were
considered
incidental
and
unrelated
to
test
article
(I,
1,
2­
TCE)

administration.

Mononuclear
cell
infiltrates,
observed
in
various
tissues,
typically
consisted
of
foci
of
lymphocytes
and
plasma
cells
generally
accompanied
by
a
few
neutrophils
as
a
minor
component.
This
morphology
is
consistent
with
subacute
inflammation.

Granulomatous
inflammation
was
observed
in
the
larynx
at
all
three
levels
examined.
The
lesion
was
characterized
by
the
presence
of
histiocytes
and
an
occasional
multinucleated
giant
cell
forming
discrete
focal
microgranulomas
surrounding
a
mineralized
center
located
just
below
the
mucosal
epithelial
layer.

Similar
lesions
were
also
occasionally
observed
in
the
trachea.
This
lesion
is
typically
observed
as
a
response
to
a
penetrating
foreign
body,
and
its
location
514
of
619
EPL"
EXPERIMENTAL
PATHOLOGY
LABORATORIES,
INC.

Page
8
WIL
Research
Laboratories,
Inc.
Study
Number
WIL­
417002
suggests
that
it
may
have
resulted
from
the
penetration
of
food
material
aspirated
into
the
larynx
and
trachea.
However,
any
such
material,
if
present
in
the
mineralized
core,
could
not
be
identified.

Mineralization
in
the
kidney
of
both
control
and
treated
male
and
female
rats
was
characterized
by
the
accumulation
of
lightly
to
intensely
staining
basophilic
material
within
the
lumina
of
the
renal
tubules.
The
mineral
deposition
observed
in
the
larynx
was
located
within
the
central
core
of
the
microgranulomas,
as
already
discussed.
These
changes
were
considered
incidental
and
not
related
to
treatment.

Mineral
deposition
in
the
nasal
turbinates
was
observed
in
sections
from
Levels
2
through
6
of
both
control
and
treated
male
and
female
rats.
This
lesion
was
characterized
by
the
deposition
of
basophilic
material
just
underlying
the
epithelium
of
the
transitional,
respiratory,
and
olfactory
mucosae.
In
some
cases,

the
mineral
could
be
localized
to
the
basement
membrane.
Similar
deposits
associated
with
the
basement
membrane
of
the
respiratory
and
olfactory
mucosae
have
been
reported
to
increase
in
frequency
with
age*.

Mineral
deposition
within
the
cornea
of
the
eye
was
characterized
by
the
presence
of
lightly
staining
basophilic
material
within
lamina
propria
of
the
cornea
just
underlying
the
cornea1
epithelium.
The
lesion
was
focal
in
distribution,

typically
located
in
the
central
region
of
the
cornea,
and
of
minimal
severity.
The
pathogenesis
of
this
lesion
was
not
determined.
However,
since
the
incidence
was
not
significantly
different
between
controls
and
treated
rats,
it
was
considered
incidental
and
not
related
to
treatment.

515
of
619
EPL"
EXPERIMENTAL
PATHOLOGY
LABORATORIES,
INC.

Page
9
WIL
Research
Laboratories,
Inc.
Study
Number
WIL­
417002
CONCLUSIONS
AND
SUMMARY
Except
for
the
liver
and
nasal
turbinates,
no
effects
considered
possibly
related
to
test
article
(1,
1,2­
TCE)
exposure
were
noted
in
any
tissues
examined.

In
the
liver,`
hepatocellular
vacuolization
interpreted
as
test
article
related
was
observed
in
5/
l
0
males
and
1
O/
l
0
females
from
Group
4,
and
in
3/
l
0
females
each
from
Groups
2
and
3.
In
the
nasal
turbinates,
several
microscopic
lesions
interpreted
as
test
article
related
were
observed
in
males
from
Groups
3
and
4
and
females
from
all
dose
groups.
These
lesions
included
atrophy
of
the
olfactory
epithelium,
vacuolization/
cyst
formation
within
the
olfactory
mucosa,

and
respiratory
epithelial
metaplasia
of
olfactory
epithelium.
The
few
other
changes
in
various
tissues
of
male
and
females
rats
from
control
and
treated
groups
were
considered
incidental
and
unrelated
to
test
article
(1,
1,
2­
TCE)

exposure.

FREDERICK
A.
RUECKER,
DVM,
MS,
Diplomate,
ACVP
Veterinary
Pathologist
FARfwk
I/

516of619
EPL"
EXPERIMENTAL
PATHOLOGY
LABORATORIES,
INC.

Page
10
WIL
Research
Laboratories,
Inc.
Study
Number
WIL­
417002
REFERENCES
1.
Renne,
R.
A..
Gideon,
K.
M.,
Miller,
R.
A.,
Mellick,
P.
W.,
and
Grumbein,
S.
L.
(1992).
Histologic
methods
and
interspecies
variations
in
the
laryngeal
histology
of
F344/
N
rats
and
B6C3Fl
mice.
Toxicol.
Pafhol.
20,
No.
1,44­
51.

2.
Morgan,
K.
(1991).
Approaches
to
the
identification
and
recording
of
nasal
lesions
in
toxicology
studies.
Toxicol.
Pafhol.
19,
No.
4
(Part
I),
337­
35
1.

3.
Mery,
S.,
Gross,
E.
A.,
Joyner,
D.
R.,
Godo,
M.,
and
Morgan,
K.
T.
(1994).
Nasal
diagrams:
A
tool
for
recording
the
distribution
of
nasal
lesions
in
rats
and
mice.
Toxicol.
Pafhol.
22,
No.
4,
353­
372.

4.
Greaves,
P.
Histopathology
of
Preclinical
Toxicity
Studies:
Interpretation
and
Relevance
in
Drug
Safety
Evaluation,
2"
d
ed.,
p
211.
Elsevier
Science,
Amsterdam,
The
Netherlands,
2000.

517
of
619
I
EXPERIMENTAL
PATHOLOGY
LABORATORIES,
INC.

Page
11
QUALITY
ASSURANCE
FINAL
CERTIFICATION
Study
Title:
A
QO­
Day
Inhalation
Toxicity
Study
of
1
,I
,BTrichloroethane
(1,1,2­
TCE)
in
Rats
(with
Satellite
Groups
for
Pharmacokinetic
Evaluations
in
Rats
and
Mice)

Client
Study:
WIL­
417002
EPL
Project
Coordinator:
Nelson
Wilson
EPL
Project
Number:
223­
057
EPL
Pathologist:
Dr.
Frederick
Ruecker
The
following
aspects
of
this
study
were
inspected
by
the
Quality
Assurance
Unit
of
Experimental
Pathology
Laboratories,
Inc.
Dates
inspections
were
performed
and
findings
reported
to
the
EPL
Project
Coordinator
and
Management
are
indicated
below.

Area
Inspected
inspection
Dates
Reporting
EPL
Project
Sheets
Project
Setup
Q/
4/
01;
Q/
19/
01;
12/
5/
01
914/
01;
Q/
19/
01;
12/
5/
01
9113/
01;
l/
2102
9/
l
3iOl;
l/
2/
02
Histology
Setup
9/
l
9101
9/
l
9101
Data
Review
Draft
Report
Final
Report
10/
12,18,25/
01
10/
12,18,25/
01
I/
2,
3102
I
f3lO2
4/
29/
02
4/
29/
02
Date
reported
to
Study
Director/
Management
4/
29/
02
Date
of
last
quarterly
facility
inspection
4/
02
/"
5%=
2&
/­­
kwLL;~~
EPL
Quality
Assurance
Unit
Y
­.
dq­
a2
Date
Form
No.
6­
2
(7/
2/
99)

518of619
SUMMARY
INCIDENCE
TABLES
519of619
SUMMARY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Male
Rat
EPL(
I­
1
Experimental
Pathology
Laboratories,
Inc.

520
of
619
SUMMARY
INCIDENCE
TABLE
WIL­
417002
go­
Day
Sacrifice
Male
Rat
Mineral
Deposition
I
4
9
)

EPL/
l­
2
Experimental
Pathology
Laboratories,
Inc.

521
of
619
SUMMARY
INCIDENCE
TABLE
WIL­
417002
BO­
Day
Sacrifice
Male
Rat
/
LIVER
(NO.
EXAMINED)

Degeneration/
Necrosis,

Hepatocytes
Hyperplasia,
Bile
Ducts
~
~
GROUP
GROUP
GROUP
GROUP
2
_~
(la,
3
4
(10)
(10)
(10)

1
infiltrate,
Mononuclear
Cell
Vacuolization,
Hepatocytes
(
)
10
LUNG
W/
BRONCHI
NO.
EXAMINED
(10)
(
)
(10)
(10)

Alveolitis/
lnterstital
Pneumonia
1
1
Hemorrhage
LYMPH
NODE,
MEDlASTlNAL
(NO.
EXAMINED)

Congestion/
Hemorrhage
(9)
(1)
(10)
2
1
LYMPH
NODE,
TRACHEOBRONCHIAL
(NO.
EXAMINED)

Congestion/
Hemorrhage
(9)
(7)
2
NASAL
TURBINATE,
LEVEL
I
(NO.
EXAMINED)

Hyperplasia,
Squamous
Epithelium
Hyperplasia,
Transitional
Epithelium
NASAL
TURBINATE,
LEVEL
II
(NO.
EXAMINED)
(10)
(10)
(10)
(10)
,$,
trate
b"
,.*^^..^
I^^
rP^
rI
1
Inflnmmnt
c
L
LJ"
LL
inflammatory
Cell
Exudate,

Medial
Meatus
Mineral
Deposition
VacuolizatioKyst,
Olfactory
Epithelium
L
.I
1
1
1
9
10
8
9
1
2
2
8
EPLl
l­
3
Experimental
Pathology
Laboratories,
Inc.

522of619
SUMMARY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Male
Rat
EPL\
l­
4
Experimental
Pathology
Laboratories,
Inc.

523
of
619
WIL­
417002
9C­
Day
Sacrifice
Male
Rat
SUMMARY
INCIDENCE
TABLE
j
GROUP
1
GROUP
j
GROUP
1
GROUP
(

NASAL
TURBINATE,
LEVEL
VI
(NO.

EXAMINED)

Atrophy,
Olfactory
Epithelium
Infiltrate,
Mononuclear
Cell
Mineral
Deposition
1
2
3
4
(10)
(10)
(10)
(10)

2
1
8
9
10
IO
I
I
I
I
I
PARATHYROID
(NO.
EXAMINED)
/
(10)
/
)
(10)
1
I
I
/

PERIPHERAL
NERVE
(SCIATIC)
(NO.

EXAMINED)
(10)
(10)

PITUITARY
(NO.
EXAMINED)
(10)
(10)
Hypertrophy,
Pars
Distalis
1
PROSTATE
(NO.
EXAMINED)

Atrophy,
Acinar
Epithelium
Hyperplasia,
Acinar
Epithelium
Infiltrate,
Mononuclear
Cell
(10)
(10)
1
1
2
SALIVARY
GLAND,
MANDIBULAR
(NO.

EXAMINED)
(10)
(10)

SKIN
(NO.
EXAMINED)
(10)
(10)

Inflammation,
1
SPINAL
CORD,
CERVICAL
(NO.

EXAMINED)
(10)
(10)

EPLl
l­
5
Experimental
Pathology
Laboratories,
Inc.

524
of
619
SUMMARY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Male
Rat
/
I
SPLEEN
(NO.
EXAMINED)
I
(10)
I
(1)
I
(1O)
L
I
Accessory
Tissue
1
1
Increased
Hematopoiesis
1
TRACHEA
(NO.
EXAMINED)
(10)
(10)
(10)
(10)

Infiltrate,
Mononuclear
Cell
2
1
3
3
Inflammation,
Granulomatous
1
2
1
Mineral
Deposition
1
2
1
EPLI
)
Experimental
Pathology
Laboratories,
Inc.
l­
6
525
of
619
SUMMARY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Female
Rat
1
GROUP
GROUP
j
GROUP
1
GROUP
/

Proteinaceous
Fluid,

Intraocular
1
d
1
Retinal
Dysplasia
I
I
I
I
,

HARDERIAN
GLAND
(NO.
EXAMINED)
1
(10)
I
(1)
I
1
(10)
/

EPLI
l­
7
Experimental
Pathology
Laboratories,
Inc.

526
of
619
SUMMARY
INCIDENCE
TABLE
WIL­
417002
SO­
Day
Sacrifice
Female
Rat
EPLl
1­
8
Experimental
Pathology
Laboratories,
Inc.

527of619
SUMMARY
INCIDENCE
WIL­
417002
OO­
Day
Sacrifice
Female
Rat
LIVER
(CONTINUED)

Infiltrate,
Mononuclear
Cell
Vacuolizetion,
Hepatocytes
GROUP
GROUP
GROUP
GROUP
1
2
3
4
6
8
9
9
3
3
10
TABLE
LUNG
W/
BRONCHI
(NO.
EXAMINED)

Alveolitis/
lnterstital
Pneumonia
Hemorrhage
(10)
(10)
(10)
(IO)

2
1
1
1
LYMPH
NODE,
MANDlBUViR
(NO.
EXAMINED)
(1)
(1)
Congestion/
Hemorrhage
1
1
1
(IO)
I
I
I
I
MAMMARY
GLAND
(NO.
EXAMINED)
,
I
(IO)
I
I
I
I
I
i
EPLl
l­
9
Experimental
Pathology
Laboratories,
Inc.

528
of
619
SUMMARY
INCIDENCE
TABLE
WlL­
417002
OO­
Day
Sacrifice
Female
Rat
/
GROUP
j
GROUP
)
GROUP
)
GROUP
)
1
1
1
1
2
/
3
j
4
1
..­..
­..­­
..­­
~.
NASAL
TUKBINATE,
LEVEL
Ill
(NO.
I
I
EXAMINED)
I
(10)
I
(10)
I
_(
lQ
I
(IO)
I
3
(
I
I
I
I
I
I
I
I
I
1
I
I
I
I
I
1
I
I
!
I
I
3
)

I
I
I
I
I
i
I
I
1
2
3
2
2
Epithelium
1
1
1
2
5
Atrophy,
Olfactory
Epithelium
Degeneration,
Respiratory
Epithelium
Infiltrate,
Mononuclear
Cell
inflammation
Inflammation,
Nasolacrimal
Duct
Inflammatory
Cell
Exudate,
Medial
Meatus
Mineral
Deposition
VacuolizationlCyst,
Olfar$
ory
NASAL
TURBINATE.
LEVEL
IV
(NO.
I
I
I
I
I
I
EXAMINED)

Atro[
,.&,+
r
I
I
I
I
(`
0)
!
(10)
I
(10)
I
(IO)
I
lhy,
Olfactory
Epithelium
II
111111
ate,
Mononuclear
Cell
Inflammation,
Nasolacrimal
Duct
3
3
1
Mineral
Deposition
Resniratorv
Enithelinl
Metaplasia,
Olfactory
Epithelium
Squamous
Metaplasia,

Respiratory
Epithelium
VacuolizationlCyst.
Olfactory
Epithelium
I
I
I
1
9
I
I
/

I
I
9
1
IO
(
10
1
I
I
I
I
1
3
1
1
NASAL
TURBINATE,
LEVEL
V
(NO.

EXAMINED)
(10)
(IOL
(10)
(10)

1
7
I
Atrophy,
Olfactory
Epfthelium
Infiltrate,
Mononuclear
Cell
Inflammatory
Cell
Exudate,

Medial
Meatus
Mineral
Deposition
Respiratory
Epithelial
Metaplasia,
Olfactory
Epithelium
I
I
!
!
I
­­
L
1
1
10
EPL]
I­
ICI
Experimental
Pathology
Laboratories,
Inc.

529
of
619
SUMMARY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Female
Rat
EPLI
l­
l
1
Experimental
Pathology
Laboratories,
Inc.

530
of
619
SUMMARY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Female
Rat
EPLl
l­
12
Experimental
Pathology
Laboratories,
inc.

531
of
619
HISTOPATHOLOGY
INCIDENCE
TABLES
532
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
­

6
9
3
1
L
I
h
­
­

h
h
c
c
I
­
­
­
­

I
­
­
­
­

c
­
­
­
­
­

7
I_

7
i
WIL­
417002
90­
Day
Sacrifice
Male
Rat
­

6
9
3
0
6
z
h
­
­

c
c
z
c
c
­
­
­
­

c
­
­
­
­
­
­
­
­
­
­

­I
;­
I­
1
6
3"
4
3
z
n
­
­

n
z
K
E
E
E
­
­
­
­
­
­
­
­

c
­
­

c
7
­

6
3"
2
2
x
­

x
­
­

4
z
h
E
z
­
­
­
­

z
­
­

?­

E
­
­
­

I
T
­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
I
I
n
ADRENAL
Vacuolization,
Cortex
L
1
J­

:

:

r
E
AORTA
X
Inflammatory
Cell
Infiltrate,
Adjacent
Brown
Fat
BONE
MARROW,
STERNUM
X
BONE.
STERNUM
X
BRAIN
X
EPIDIDYMIS
X
ESOPHAGUS
X
I
FVF
T­
*IL
Hyperplasia,
Cornea!
Epithelium
Inflammation,
Cornea
Mineralization,
Cornea
Proteinaceous
Fluid,
Intraocular
Retinal
Atrophy
Retinal
Dysplasia
HEART
Myocardial
Degeneration
1
INTESTINE­
LARGE,
CECUM
X
Inflammation
INTESTINE­
LARGE,
COLON
X
t
EPL/
II­
1
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
Hncomplete
A=
Autolysis
l=
minimal
P=
mild
Bcmoderate
4=
severe
P=
Present
B=
Benign
M=
Malignant
m=
missing
one
paired
organ
u=
unscheduled
sac./
deatn
533
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
WIL­
417002
go­
Day
Sacrifice
Male
Rat
A
N
I
M
A
L
2
INTESTINE­
LARGE,
RECTUM
X
Inflammation
Nematode
Parasite,
Lumen
INTESTINE­
SMALL,
DUODENUM
x
INTESTINE­
SMALL,
ILEUM
X
INTESTINE­
SMALL,
JEJUNUM
X
I
LACRIMAL
GLAND
(EXORBITAL)
IX
/

EPL(

Experimental
Pathology
Laboratories,
Inc.
6
6
9
9
;
i
68
pP
x
x
xx
xx
2
2
1_
1
x
x
1
1
11
I
3
1
1
­X
l­

:

II­
2
6
6
6
6
9
9
9
9
Key:
X­
Not
Remarkable
N=
No
Section
I=
lncomplete
A­
Autolysis
l=
minimal
P=
mild
3=
moderate
4=
severe
PEPresent
&Benign
M=
Malignant
m=
missing
one
paired
organ
u=
unscheduied
sac/
death
534
of
619
­­
HISTOPATHOLOGY
INCIDENCE
TABLE
WIL­
417002
QO­
Day
Sacrifice
Male
Rat
A
N
LIVER
Degeneration/
Necrosis,
Hepatocytes
Hyperplasia,
Bile
Ducts
Infiltrate,
Mononuclear
Cell
Vacuolization,
Hepatwytes
LUNG
W/
BRONCHI
Alveolitis/
lnterstitial
Pneumonia
Hemorrhage
LYMPH
NODE,
MEDlASTlNAL
_
Congestion/
Hemorrhage
NASAL
TURBINATE,
LEVEL
II
Infiltrate,
Mononuclear
Cell
Inflammation,
Nasolacrimal
Duct
Inflammatory
Cell
Exudate,
Medial
Meatus
Mineral
Deposition
VacuolizationKyst,
Olfactory
Epithelium
­

6
9
3
0
2
­

I
I
­

z
­
­
­

23
­

x
­

x
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

I
z
­
­
­­
I­
I
i
I
I
I
­

:
3
2
2
­
­
­

z
­

x
­
­
­

z
­

h
­
­
­
­
­
­

I
­
­
­
­
­
­
­
­
­
­

z
­
­
­
­
L
EPLI
II­
3
Experimental
Pathology
Laboratories,
Inc.
Key.
X=
Noi
Remarkable
N=
No
Section
l=
lncomplete
A=
Autolysis
l=
minimal2=
mtid
B=
modeiate
4=
severe
P=
Present
B­
Benign
M=
Malignant
m=
missing
one
paired
organ
u=
unscheduled
sac./
death
535
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
WIL­
417002
QO­
Day
Sacrifice
Male
Rat
A
N
::
L
Duct
Inflammatory
Cell
Exudate,
Medial
Meatus
Mineral
Deposition
Vacuolization/
Cyst,
Olfactory
Epithelium
NASAL
TURBINATE,
LEVEL
IV
Atrophy,
Olfactory
Epithelium
Infiltrate,
Mononuclear
Cell
Inflammation,
Nasolacrimal
Duct
Mineral
Deposition
Respiratory
Epithelial
Metaplasia,
Olfactory
Epithelium
Squamous
Metaplasia,
Respiratory
Epithelium
VacuolizationlCyst,
Olfactory
Epithelium
NASAL
TURBINATE,
LEVEL
V
Atrophy,
Olfactory
Epithelium
Infiltrate,
Mononuclear
Cell
Inflammatory
Cell
Exudate,
Medial
Meatus
Mineral
Deposition
Respiratory
Epithelial
Metaplasia,
Olfactory
Epithelium
VacuolizationlCyst.
Olfactory
Epithelium
6
9
3
0
2
­
­
­
­
­
­
­
­
­

1
­
­
­
­
­
­
­

I
­
­
­
­
­
­
­

^
­
­
­
­
­
­
­
­
­
­
­

EPLl
II­
4
­

i
Experimental
Pathology
Laboratories,
inc.
­L
i
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncomplete
A=
Autolysis
l=
minimal
2=
mild
J=
moderate
4=
severe
P=
Present
B=
Benign
M=
Malignant
m=
missing
one
paired
organ
u=
unscheduled
sacldeath
536
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
WIL­
417002
BO­
Day
Sacrifice
Male
Rat
GROUP
1
33333333j3
0001111234
2680247273
x
x
EPL(

Experimental
Pathology
Laboratories,
inc.
II­
5
Key,
X=
Not
Remarkable
N=
No
Section
I=
lncomplete
A=
Autotysis
l=
minimal
*­
mild
3=
moderate
4=
severe
P=
Present
B=
Benign
M=
Malignant
m=
misslng
one
paired
organ
u=
unscheduled
sac/
death
537
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Male
Rat
_STOMACH
Edema,
Nonglandular
Hyperplasia,
Squamous
Epithelium,
Nonglandular
Inflammation,
Nonglandular
TESTIS
THYMUS
Congestion
Necrosis,
Cortical
Lymphocytes
THYROID
URINARY
BLADDER
Infiltrate,
Mononuclear
Cell
EPLl
II­
6
Experimental
Pathology
Laboratories,
Inc.
GROUP
­

E
3
:

"
­
­

n
4
­
­

?I
­
­
­
­

h
2
­
­

3
­

z
­
­

n
­
­
­
­
­
­
­
­
­
­
6
9
3
1
4
x
­
­

h
h
­
­

h
­
­
­
­

xc
x
­
­

x
x
­
­
­

x
­
­
­
­
­
­
­
­
­
­

Key:
X=
Nol
Remarkable
N=
No
Section
t=
lncomptete
A=
Autolysis
t=
minimal
P=
mild
B=
moderate
4=
sevwe
P­
Present
B=
Benign
M=
Malagnant
mwwsing
one
paired
organ
u=
unscheduled
sac./
death
538
of
619
.
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
9
WIL­
417002
go­
Day
Sacrifice
Male
Rat
KIDNEY
Inflammation,
Pelvis
Mineralization
Nephropathy
5
6
1
1
1
infiltrate
Mononuclear
Cell
~

Infiltrate,
Mononuclear
Cell
~

LIVER
D%
eneration/
Necrosis,
Hepatocytes
Hyperplasia,
Bile
Ducts
Infiltrate,
Mononuclear
Cell
1
1
Vacuolization,
Hepatocytes
EPL]
II­
7
­

6
9
3
2
0
­

z
­
­
­

­i
3
­
­
­

3
­

I
­
­
­
­
­
­

I
i
I
­
­
­
­

1
­

xc
­
­
­
L
I
I
I
I
I
I
I
I
I
I
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncomplete
A=
Autoiysis
l=
minimal
2=
mild
B=
moderate
4=
severe
P=
Present
BsBenign
M=
Malignant
m=
missing
one
paired
organ
u=
Unscheduled
sacldeath
539
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
WIL­
417002
90­
Day
Sacrifice
Male
Rat
A
N
I
M
LYMPH
NODE,
MEDlASTlNAL
.
Congestion/
Hemorrhage
NASAL
TURBINATE.
LEVEL
II
Infiltrate,
Mononuclear
Cell
Inflammation,
Nasolacrimal
Duct
Inflammatory
Ceil
Exudate,
Medial
Meatus
Mineral
Deposition
Vacuolization/
Cyst.
Olfactory
Epithelium
NASAL
TURBINATE,
LEVEL
Ill
Atrophy,
Olfactory
Epithelium
Degeneration,
Respiratory
Epithelium
Infiltrate,
Mononuclear
Cell
Inflammation
inflammation,
Nasolacrimal
Duct
lnflammatow
Cell
Exudate,
Medial
Meatus
Mineral
Deposition
VacuolizationlCyst,
Olfactory
Epithelium
L
I
666666666
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
,
I
I
I
I
I
I
I
II)
(
)
I
I
I
I
I
I
I
I
I
Ill
II
I
I
I
I
I
I
I
I
I
I
I
II
I
I
I
I
I
I
I
I
I
I
EPL(
It­
8
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
l=
incomplete
A=
Autolysis
l=
minimal
2=
mild
3=
rnoderate
4=
severe
P=
Presenl
B=
Eenign
M=
Malignant
m=
missing
one
pared
organ
u=
unscheduled
sac.
ideath
540of619
HISTOPATHOLOGY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Male
Rat
A
N
I
M
A
L
NASAL
TURBINATE.
LEVEL
IV
Atrophy,
Olfactory
Epithelium
Infiltrate,
Mononuclear
Cell
Inflammation,
Nasolacrimal
Duct
Mineral
Deposition
Respiratory
Epithelial
Metaplasia,
Olfactory
Epithelium
Squamous
Metaplasia,
Respiratory
Epithelium
Vacuolization/
Cyst,
Olfactory
1
Epithelium
NASAL
TURBINATE,
LEVEL
V
Atrophy,
Olfactory
Epithelium
Infiltrate,
Mononuclear
Ceil
Inflammatory
Cell
Exudate,
Medial
Meatus
Mineral
Deposition
Respiratory
Epithetial
Metaplasia,
Olfactory
Epithelium
VacuolizationlCyst,
Olfactory
Epithelium
NASAL
TURBINATE,
LEVEL
VI
Atrophy,
Olfactory
Epithelium
Infiltrate.
Mononuclear
Cell
Mineral
Deposition
PANCREAS
Atrophy,
Acinar
Cell
Infiltrate,
Mononuclear
Cell
SEMINAL
VESICLE
Reduced
Secretion
­

I
­

EPLl
Experimental
Pathology
Laboratories,
Inc.
GROUP
1
2
s
1
2
I
1
2
T
­

6
:
4
1
­
­
­

?

I
­
­
­
­
­
­
­
­
­
­
­
­

I
­
­
­
­
­
­
­
­

I
­
­
­
­
­

3
­
­
­
T
II­
9
Key:
X=
Nol
Remarkable
N=
No
Section
I=
lncamplete
A=
Autolysis
1
=mnwnal
P=
mild
3=
moderate
d=
severe
P=
Present
B=
Benign
M­
Malignant
m=
misstng
one
paired
organ
u=
unscheduled
sxldeath
541
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Male
Rat
5
TRACHEA
X
Infiltrate,
Mononuclear
Cell
Inflammation,
Granulomatous
Mineral
Deposition
6
6
9
9
3
3
1
2
6
0
x
x
EPL\

Experimental
Pathology
Laboratories,
Inc.
GROUP
Key:
X=
Nol
Remarkable
N=
No
Section
Hncomplete
A=
Autolysis
l=
minimal
Z=
mild
B=
moderate
4:
severe
P=
Present
E=
Benign
M=
Malignant
rwmissing
one
paired
organ
u=
unscheduk?
d
sac.
ldeath
­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

542
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
WIL­
417002
90­
Day
Sacrifice
Male
Rat
LARYNX,
LEVEL
II
Hvperplasia,
Transitional
Epithelium
Infiltrate,
Mononuclear
Cell
1
Inflammation,
Granulomatous
Inflammatory
Cell
Exudate,
Lumen
Mineral
Deposition
Squamous
Metaplasia,
Transitional
Epithelium
Lumen
Mineral
Deposition
LIVER
Degeneration/
Necrosis,
Hepatocytes
Hyperplasia,
Bile
Ducts
Infiltrate,
Mononuclear
Cell
Vacuolization,
Hepatocytes
1
LUNG
W/
BRONCHI
Alveolitis/
lnterstitial
Pneumonia
Hemorrhage
X
­

6
9
3
0
s
­

1
I
­

z
­
­
­
­
­

T
I
­

I
­
­
­
­

1
z
­

c
­
­
­
­

z
­

s
­
­
­
L
6
6
9
9
3
3
1
1
3
5
1
1
1
1
N
I
1
1
11
1
1
1
1
1
1
XX
3
T
6
6
9
9
3
3
2
2
4
8
t
1
1
1
1
1
1
­

6
i
3
s
­

I
­

I
­
­
­
­
­

i=
i­
2­

z
­

I
­
­
­
­
­

z
­

z
­
­
­
­

z
­

K
­
­

I
­
­

6
9
3
4
4
­

T
x
­

T
­
­

n
­
­
­
­
­
­
­
­
­
­

?­

1
­

z
­
­
­
­

x
­

x
­
­
­

6
9
3
4
!­
­
t
I
­

K
­
­
­

x
­
­
­
­
­
­
­
­
­
­
­
­

I
­

z
­
­
­
­

I
­

E
­
­
­
­

6
9
3
5
0
­

T­

x
­
­

2
z
­
­
­
­

I
­

liI
­
­
­
­
­

I
­

x
­
­
­
­

I
­

x
­
­
­

EPL(
II­
11
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncompk?
te
A=
Autolysis
l=
minimal
P=
mild
3=
moderate
4=
severe
P=
Pre%?
nt
B=
Benign
M=
Malignant
m=
m!
ssing
one
paired
organ
u=
unscheduled
sac/
death
543
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
3
WIL­
417002
90­
Day
Sacrifice
Male
Rat
A
N
I
M
6666666666
A
9999999999
L
3333333333
0011223445
Inflammation
inflammation,
Granulomatous
Inflammatory
Cell
Exudate,
Medial
Meatus
I
I
I
I
I
I
,,,,,
I
,

NASAL
TURBINATE,
LEVEL
II
(XI
I
Infiltrate,
Monnnudear
Cell
I
lnflammatiol
Duct
lnflammator
Medial
MeL._­
Mineral
Deposition
Vacuolizatio
Epithelium
/
lllil
(1/
111/
111~
11
)
1
#n/
Cyst,
Oifactory
I
I
II
I
III
III
I
I
I
I
I
Ill
I
Ill
I
I
/
I
1
I
I
I
I
I
/
/
/

EPL/
II­
12
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncomplete
A:
Autolys~
s
l=
minimai
l=
mild
S=
moderate
4=
severe
P=
Present
B=
Benign
WMahgnant
m=
missfng
one
paired
organ
u=
unscheduled
%x./
death
544
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Male
Rat
A
N
I
M
.
A
L
Epitheiium
Squamous
Metaplasia,
Respiratory
Epithelium
VacuolizationlCyst,
Olfactory
Epithelium
NASAL
TURBINATE,
LEVEL
V
Atrophy,
Olfactory
Epithelium
Infiltrate,
Mononuclear
Cell
Inflammatory
Cell
Exudate,
Medial
Meatus
Mineral
Deposition
Respiratory
Epithelial
Metaplasia.
Olfactory
Epithelium
VacuolizatiorKyst.
Olfactory
Epithelium
NASAL
TURBINATE,
LEVEL
VI
Atrophy,
Olfactory
Epithelium
Infiltrate,
Mononuclear
Cell
Mineral
Deposition
SPLEEN
Accessory
Tissue
Increased
Hematopoiesis
STOMACH
Edema,
Nonglandular
Hyperplasia,
Squamous
Epithelium,
Nonglandular
­Nonglandular
­

6
9
3
0
3
­

I
­
­
­

­
­
­
­

I
­
­

1
­
­

­
­
­
­

1
­
­
­
­
­

­
­
­
­
­
­
GROUP
T
EPLj
Experimental
Pathology
Laboratories,
Inc.
3
6
9
3
2
8
­

2
L
­

I
­
­
­
­
­
­
­
­
­

z
­

3
3
­
­
­

1
­

2
­
­
­
­
­
­
­
­
­
­
­
­

­
­

­

­

­
­

­
­

­

II­
13
Key:
X=
Not
Remarkable
N=
No
Section
I~
tncomplete
A=
Autolysis
l=
mmimal
2=
mild
3=
moderate
4=
severe
PPresent
B=
Benign
M=
Malignant
m=
mkng
one
pared
organ
twmscheduled
sac./
death
­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

545
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
­

T
6
9
3
0
s
1
x
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

F
­
­
­
­
­
­
­
­
­
­
­
­
6
9
3
1
3
­

T
z
­
­

­
­
­
­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

t
­
­
­
­
­
­
­
­
­

f
­
­
­

6
9
3
2
4
h
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
6
9
3
i
4
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

6
:
3
s
I
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
i
­

6
9
3
0
3
1
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

:
3
1
5
x
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

6
9
3
4
4
Ix
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

­
­
­
­
­
­
­
­
­
­
­

­
­
­
­
­
­
­
­

6
9
3
4
$

­
­
­
­
­
­
­
­
­
­

­
­
­
­
­
­
­
­
­
­
­
­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
T
­

6
:
5
LL
x
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

­
­
WIL­
417002
go­
Day
Sacrifice
Male
Rat
A
N
TRACHEA
Infiltrate,
Mononuclear
Cell
inflammation,
Granulomatous
Mineral
Deposition
EPL]
II­
14
1
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncompkte
A=
Autolysis
l=
m1nimal2=
mild
3=
moderate
4=
severe
P=
Present
B=
Benign
M=
Matignant
m=
missing
one
paired
organ
u=
unscheduled
sac./
death
546of619
­
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
WIL­
417002
go­
Day
Sacrifice
Male
Rat
I
6
9
3
0
ADRENAL
Vacuolization,
Cortex
AORTA
Inflammatory
Cell
Infiltrate,
Adjacent
Brown
Fat
BONE
MARROW,
STERNUM
X
li__
li
BONE,
STERNUM
X
x
x
BRAIN
X
li_
x
EPIDIDYMIS
X
XX
ESOPHAGUS
X
x
x
6
6
9
9
3
3
0
1
7
8
1_
l
&X
INTESTINE­
LARGE,
COLON
Nematode
Parasite,
Lumen
.,

1
>

>
­

EPLj
II­
15
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncomplete
A=
Autolysis
I=
minimai
P=
mild
3=
moderale
4=
severe
P=
Present
B=
Benign
M=
Makgnant
m=
missing
one
paired
organ
u­
unscheduled
%x./
death
i
547of619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
WIL­
417002
go­
Day
Sacrifice
Male
Rat
A
N
M
A
L
r
INTESTINE­
LARGE,
RECTUM
Inflammation
Nematode
Parasite,
Lumen
INTESTINE­
SMALL,
DUODENUM
X
INTESTINE­
SMALL,
ILEUM
X
INTESTINE­
SMALL,
JEJUNUM
X
KIDNEY
Inflammation,
Pelvis
Mineralization
1
Nephropathy
1
I
LACRIMAL
GLAND
(EXORBITAL)
IX
LARYNX,
LEVEL
I
X
infiltrate,
Mononuclear
Cell
Inflammation,
Granulomatous
Mineral
Deposition
Lumen
I
Mineral
Deposition
I
1
EPLl
x
x
%
x
x
x
x
1
2
x
x
I
X
1
2
1
1
1
$
1
s
1
1
=t
1
Experimental
Pathology
Laboratories,
Inc.
II­
16
­

6
9
3
3
4
x
­
­

x
x
n
­
­

T
I
h
­

T
7­

z
­
­
­

1.
­
­
­
­
­
­
­
­

T
1
­

I
­

6
9
3
4
2
n
­
­

n
z
x
­
­

?

i
n
8
­
­
­
­
­
­

T
z
­

z
­
­
­
­

T
I
­

I
Key:
X=
Nol
Remarkable
N=
No
Section
I=
lncompleie
A­
Autolysis
l=
m!
nimal
Z=
mild
B=
moderate
4=
swere
P=
Present
B=
Benign
M=
Matfgnant
m=
missing
one
paired
organ
u=
unscheduled
sac/
death
548
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Male
Rat
A
N
M
A
L
LIVER
Degeneration/
Necrosis,
Hepatocytes
Hyperplasia,
Bile
Ducts
Infiltrate,
Mononuclear
Cell
Vacuolization,
Hepatocytes
LUNG
W/
BRONCHI
Alveolitisllnterstitial
Pneumonia
Hemorrhage
LYMPH
NODE,
MEDIASTINAL
Congestion/
Hemorrhage
Epithelium
Infiltrate.
Mononuclear
Cell
Inflammation
Inflammation,
Granulomatous
Inflammatory
Cell
Exudate,
Medial
Meatus
NASAL
TURBINATE,
LEVEL
II
infiltrate,
Mononuclear
Cell
inflammation,
Nasolacrimal
Duct
Inflammaton/
Cell
Exudate,
Medial
Meatus
Mineral
Deposition
Vacuolization/
Cyst.
Olfactory
Epithelium
EPL(
II­
17
­

6
9
3
0
5
­
­
­

T
z
n
­
­
­

x
­

E
­

n
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

z
1
­
­
­
GROUP
Experimental
Pathology
Laboratories,
Inc.
­

6
9
3
4
2
­
­
­

1
­

x
­
­
­

x
­

x
­

4
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

?

?
­
­

Key.
X­
Not
Remarkable
N=
No
Section
I=
lncomplete
A=
Autolysis
t=
minimal
P=
mild
3:
modeiate
4aevere
P=
Present
B=
Benign
M=
Malignant
m=
missing
one
paired
organ
u=
unscheduled
sac.
ldeath
549of619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
WIL­
417002
90­
Day
Sacrifice
Male
Rat
A
N
M
A
L
Duct
Inflammatory
Cell
Exudate,
Medial
Meatus
Mineral
Deposition
VacuolizatiorXyst.
Olfactory
Epithelium
i
­

6
9
3
0
4
h
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

z
­
­
­
­
­
­
­
­
­
­
­
­

I
­
­
­
­
­
­
2
1
1
1
1
*
1
1
1
1
_
2
2
1
EPLl
Experimental
Pathology
Laboratories,
Inc.
­

6
9
3
1
3
­
­
­
­
­
­
­
­
­

I
I
­
­
­
­
­

z
­
­
­
­
­
­
­
­
­
­
­
­

I
­

I
­
­
­
1
1
1
_
1
2
1
1
1
I
2
1
6
9
3
3
2
­
­
­

I
­
­
­
­
­
­

z
­
­
­
­
­

1
­
­
­
­
­
­
­
­
­
­
­
­

1
­
­
­
­
­
­
+

1
1
_
1
1
2
2
1
1
I
2
2
1
­

6
9
3
4
6
­
­
­
­
­
­
­
­
­
­
­

1
­

I
­
­

1
­
­
­
­
­
­
­
­

I
­
­

z
­
­
­
­
­
­
­
!
A..­
I
­

t
II­
18
Key:
X=
Not
Remarkable
N=
No
Section
I­
Incomplete
A=
Autolysts
l=
minimal2=
mdd
B=
moderate
4=
severe
P=
Present
B=
Semgn
M=
Malignant
m=
mlssing
one
paired
organ
u=
unscheduled
sac/
death
550
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
WIL­
417002
90­
Day
Sacrifice
Male
Rat
A
N
I
M
6
A
9
L
3
0
A
OPTIC
NERVE
Degeneration,
Vacuolar
PITUITARY
Hypertrophy,
Pars
Distalis
PROSTATE
X
Atrophy,
Acinar
Epithelium
Hyperplasia,
Acinar
Epithelium
Infiltrate,
Mononuclear
Cell
I
SALIVARY
GLAND,
MANDIBULAR
)
X
I
SEMINAL
VESICLE
Reduced
Secretion
X
SKELETAL
MUSCLE
(RECTUS
FEMORIS)
X
Degeneration
I
SKIN
IX
Inflammation,
Preputial
Gland
h
I
SPINAL
CORD,
CERVICAL
IX
I
EPL(
7
­

6
9
3
0
1.
­
­

1
x
6
6
9
9
3
3
1
2
Jai
r
II­
19
XX
XX
XX
li_
X
XX
XX
X
1
XX
li_
X
­

6
6
9
9
3
3
3
4
4
1.
­
­
­
­

z
1
x
x
­
­

x
E
­
­
­
­

x
21_

x
h
x
h
­
­

x
4
­
­
­
­
­
­

x
h
x
E
­
­
­
­

s
zc
­
­

s
x
­
­

x
x
­
­
­
­
­
­
­

I
/
I
I
1
I
/

I
I
,
I
/
I
I
I
I
I
I
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
I­
Incomplete
A­
Autolysis
t=
minimal
P=
mild
3=
moderate
4=
s.?~
ere
P­
Present
E=
Benign
M=
Malignant
m=
m&
ng
one
paired
organ
u=
unscheduled
sac./
death
551
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
­
T
:
3
2
7
K
­
­

x
h
­
­

f
E
­
­
­
­

h
E
­
­

c
­

z
­
­

n
­
­
­

I
­
­
­
­
­

t
­
­
WIL­
417002
90­
Day
Sacrifice
Male
Rat
I
SPINAL
CORD,
THORACIC
IX
I
SPLEEN
Accessory
Tissue
X
STOMACH
Edema,
Nonglandular
Hyperplasia,
Squamous
Epithelium,
Nonglandular
Inflammation,
Nonglandular
X
I
TESTIS
IX
I
THYMUS
Congestion
3
Necrosis,
Cortical
Lymphocytes
THYROID
X
TRACHEA
X
Infiltrate.
Mononuclear
Cell
Inflammation,
Granulomatous
Mineral
Deposition
URINARY
BLADDER
Infiltrate,
Mononuclear
Cell
x
I
­

E
3
0
7
n
­
­

n
n
­
­

x
­
­
­
­

n
­

z
­

x
­

I
­
­

II
­
­
­
­
­
­
­
­
­
­

EPLl
Experimental
Pathology
Laboratories,
Inc.
6
6
9
9
3
3
;:
XX
x
x
3
­
­

6
9
3
3
4
x
­
­

h
h
­
­

Tc
­
­
­
­

K
K
­

h
h
­
­
­

x
­
­

­
­
­
­
­
­
­
6
:

s
"
­
­

n
n
­
­

x
­
­
­
­

x
n
­
­

h
x
­
­
­

23
­
­
­
­
­
­
­
­
­
­
­

6
9
3
4
6
n
­
­

n
h
­
­

!I
­
­
­
­

h
E
­
­

h
h
­
­
­

x
­
­
­
­
­
­
­
­
­
­

II­
20
Key:
X=
Not
Remarkable
N=
No
Section
l=
lncomplete
A=
Autolysis
l=
mmimal
P=
mild
3=
moderate
4=
severe
P=
Present
B=
Benign
M=
Malignant
m=
missing
one
paired
organ
u=
unscheduled
sac/
death
552
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Female
Rat
A
N
6
9
3
I
BONE
MARROW,
STERNUM
IX
I
I
BONE,
STERNUM
IX
I
.BRAlN
X
ESOPHAGUS
X
eve
"

1
intraocular
Retinal
Atrophy
Retinal
Dysplasia
INTESTINE­
LARGE,
COLON
X
Nematode
Parasite,
Lumen
EPLl
II­
21
­

6
9
3
6
6
n
­

n
­
­

x
x
x
E
­
­
­
­

T
x­
2.
­

x
­
­
­

z
x
­

n
­
­
­
­
GROUP
1
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncompleie
A=
Autolysis
l=
minimal
Z=
mild
3=
moderate
4=
severe
P=
Present
B=
Benign
M=
Malignant
m=
missing
one
paired
organ
u=
unschedukd
%x./
death
553
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
1
WIL­
417002
90­
Day
Sacrifice
Female
Rat
II­
22
­

­

­

­

­

­

­
­

­

­

­

Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncompkte
A=
Autolysis
l=
minimal2=
mild
S=
moderate
4=
severe
P=
Present
B=
Benign
M=
Malignant
m=
missing
one
paired
organ
u=
unscheduled
%x./
death
554
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
­

6
:
5
4
­
­
­
r
­
x
­
­
­
­
­
"
­
c
­
L
WIL­
417002
go­
Day
Sacrifice
Female
Rat
A
N
ti
A
L
1
1
z
x
x
4
x
x
$I
Y
x
LYMPH
NODE,
MANDIBULAR
Congestion/
Hemorrhage
LYMPH
NODE,
MEDIASTINAL
Conqestionn­
lemorrhaqe
LYMPH
NODE,
TRACHEOBRONCHIAL
Congestion/
Hemorrhage
MAMMARY
GLAND
:

:

­

EPL]
II­
23
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Seciion
I=
lncompkte
A=
AutoIvsis
l=
minimal
P­
mild
3=
moderate
d=
severe
P=
Present
B=
Ben!
gn
M=
Malignant
m=
misSing
one
pared
organ
u=
unscheduled
sac.
ldeath
555
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Female
Rat
A
N
A
9
L
3
5
/
Medial
Meatus
/
1
/
Mineral
Deposition
T
GROUP
1
­

6
9
4
1
6
­
­
­
­
­

n
­
­
­
­
­
­
­
­
­
­
­
­

­
­
­
­

I
­
­
­
­
­
­
­
­
­
­
­
­

I
­

6
9
4
1
s
­

I?
I
­
­
­
­
­
­
­
­
­
­
­
­

1
­
­

­
­
­
­

1
­
­
­
­
­
­
­
­
­
­
­
­

I
EPLl
II­
24
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N­
No
Section
I=
lncamplete
A=
Autolysis
1
=minmai
l=
mild
3=
nwderate
4=
severe
P=
Present
B=
Benign
M=
Malignani
m=
missing
one
paired
organ
u=
un.
scheduled
sac/
death
556
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
­
­I­

6
9
3
8
4
­
­
­
­
­
­
­

x
­
­
­

K
­

x
h
­
­

h
­
­

x
>

x
h
­

h
­

E
­
­
1
6
9
3
9
s
­
­
­
­
­
­
­
­
­
­

I
n
­

n
n
­
­

n
­
­

5
­

x
x
­

n
­

n
­
­
­
­
­r
6
9
4
0
4
­
­
­
­
­
­
­
­
­
­

i
h
­

h
h
­
­

n
­
­

c
?I
h
­

"
­

h
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

6
9
3
5
4
­
­
­
­
­
­
­
­
­
­

z
n
­

x
n
­
­

n
­
­

Gi
­

n
n
­

n
­

x
­
­
­
­

6
9
3
6
6
­
­
­
­
­
­
­
­
­
­

z
h
­

x
h
­
­
­
­

r
E
z
E
­

E
­

h
­
­
­
­

6
9
3
6
I­
­
­
­
­
­
­
­
­
­
­

I
E
­

h
z
­
­

h
­
­

:rr
­

h
ix
­

h
­

h
­
­
­
­

6
:
7
8
­
­
­
­
­
­

­
­
­

I
?I
­

x
x
­

x
­

z
x
x
­

II.
­

n
­
­
­
­

6
9
4
1
6
­
­
­
­
­
­
­
­
­
­

T
x
­

x
?I
­
­

x
­
­

s
n
n
­

li
­

n
­
­
6
9
4
1
s
­
­
­
­
­
­
­
­
­
­

z
5
­

x
x
­
­

x
­
­

x
x
x
­

x
­

x
­
­
­
6
9
4
3
z
­
­
­
­
­
­

­
­
­

f
h
­

h
­
­

1
h
­

%

x
L(_
­

x
­

h
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

­
­

­

­

­

­
­

­

­

­
­I­
­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
WIL­
417002
90­
Day
Sacrifice
Female
Rat
A
N
I
M
A
L
L
OPTIC
NERVE
Degeneration,
Vacuolar
­)

OVARY
PITUITARY
Hypertrophy,
Pars
Distalis
SALIVARY
GLAND,
MANDIBULAR
SKELETAL
MUSCLE
(RECTUS
FEMORIS)
Degeneration
II­
25
EPLj
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncomplete
A=
Autolysis
l=
minimal
P=
mild
3=
rnoderate
4=
swere
P=
Prsseni
B=
Benign
M=
Malignant
m=
mssing
one
paired
organ
u=
unscheduled
sac/
death
557of619
HISTOPATHOLOGY
INCIDENCE
TABLE
WIL­
417002
So­
Day
Sacrifice
Female
Rat
SKIN
Inflammation,
Preputial
Gland
SPINAL
CORD,
THORACIC
SPLEEN
Accessory
Tissue
Increased
Hematopoiesis
STOMACH
Edema,
Nonglandular
Hyperplasia,
Squamous
Epithelium.
Nonglandular
Inflammation,
Nonglandular
THYMUS
Congestion
Necrosis,
Cortical
Lymphocytes
THYROID
TRACHEA
Infiltrate,
Mononuclear
Cell
Inflammation.
Granulomatous
Mineral
Deposition
URINARY
BLADDER
Infiltrate,
Mononuclear
Cell
UTERUS
Dilatation,
Lumen
EPL]
II­
26
6
6
9
9
3
3
f
5
6
4
6
x
x
x
x
x
x
x_
2i
XX
x
x
x
x
x
x
X
1
x
x
x
x
6
6
9
9
3
3
6
7
7
8
XX
&_
LL
x
x
x
x
x
x
&_
LL
x
x
x
x
x
x
i
x
x
x
x
GROUP
1
­

6
9
4
li
H
­

n
x
­
­

n
n
­
­

Ii
­
­
­
­

h
­
­

"

E
­
­
­

h
­

h
­
­
­
­
XX
x
x
x
x
x_
zL
X
3
2
xx
x
x
X
1
x_
li
X
3
­E
i
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Noi
Remarkable
N­
No
Section
I­
incomplete
A=
Autolysis
l=
minimal
P=
mild
?.=
moderate
4=
swere
P=
Present
B=
Benign
M=
Malignant
m=
mtssing
one
paired
organ
u=
unscheduled
sac/
death
558
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
­

6
:
8
4
E
­
­
­
­
­
­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

­
­
1
­

6
9
3
5
4
!I
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
6
6
J
i
;
6
6
6
7
x
x
t­
­

6
9
3
ii
^
­
­
­
­
­
­
­
­
­
­
i
4
­
­
­
­
­
­
­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

6
9
4
i
h
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
WIL­
417002
90­
Day
Sacrifice
Female
Rat
VAGINA
Inflammation
I
I
I
EPLj
II­
27
1
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncomplete
A=
Autolysts
l=
minimal
Z=
mild
3=
mcderate
4=
severe
P=
Present
B=
Benign
M=
Malignant
m=
missing
one
paired
organ
u=
unscheduled
sac./
death
559
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
WIL­
417002
90­
Day
Sacrifice
A
Female
Rat
N
I
M
A
L
ADRENAL
Vacuolization,
Cortex
AORTA
Inflammatory
Cell
Infiltrate,
Adjacent
Brown
Fat
BONE
MARROW,
STERNUM
BONE,
STERNUM
BRAIN
ESOPHAGUS
EYE
Hyperplasia,
Cornea1
Epithelium
Inflammation,
Cornea
Mineralization,
Cornea
Proteinaceous
Fluid,
Intraocular
Retinal
Atrophy
Retinal
Dysplasia
HEART
Myocardial
Degeneration
INTESTINE­
LARGE,
CECUM
Inflammation
INTESTINE­
LARGE.
COLON
Nematode
Parasite,
Lumen
­

6
9
3
6
P
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
I
I
I
I
I
I
I
I
­
I
I
I
I
I
I
I
I
I
I
1
I
I
I
1
XI
I
I
I
I
I
I
I
I
i
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
IX/
I
I
I
I
I
I
1
i
t
i
1
1
i
i
,
I
I
I
,
I
I
I
I
I
I
/
I
I
I
I
I
I
I
I
I
I
I
I
/
I
I
I
I
I
i
i
i
i
i
i
1
i
i
i
i
i
I
1
i
i
i.
i
i
I
I
/
I
/
I
\
,
(
I
I
I
,
I
I
I
I
I
I
I
­

I
/
I
I
I
I
I
L
EPLj
II­
28
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncomplete
A=
Autoiysis
l=
minimal
P=
mild
3=
rnoderale
4=
severe
P=
Present
B=
Bemgn
M=
Malignant
m=
missing
one
paired
organ
u=
unscheduled
sac./
deaih
560
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
2
w1L­
417002
90­
Day
Sacrifice
Female
Rat
EPLl
II­
29
Experimental
Pathology
Laboratories.
inc.
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncompleie
A=
Autolysis
l=
minimal
P=
mild
3=
moderate
4=
severe
P=
Present
E=&
nign
M=
Malignant
m=
missing
one
paired
organ
u=
unscheduted
sac./
death
561
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
2
­

6
9
3
6
z­
­
­
­

i­

z
c
­
­
­
­

c
­
­

1
T
­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

i
­
­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

i
­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

­
­
­
­
­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
7
II
WIL­
417002
90­
Day
Sacrifice
Female
Rat
i
LIVER
Degeneration/
Necrosis.
Hepatocytes
Hyperplasia,
Bile
Ducts
Infiltrate,
Mononuclear
Cell
Vacuolization,
Hepatocytes
LUNG
W/
BRONCHI
Alveolitisllnterstitial
Pneumonia
Hemorrhaqe
LYMPH
NODE,
MANDIBULAR
ConqestionlHemorrhaqe
t
t
MAMMARY
GLAND
EPLj
I
I­
30
Experimental
Pathology
Laboratories,
Inc.
Key:
X­
Not
Remarkable
N­
No
Section
I=
tncomplete
A=
AutolySis
l=
minimal
Z=
mild
3=
moderate
4=
swere
P=
Present
B=
Benign
M­
Malignant
m=
missing
one
paired
organ
u=
unscheduled
%x/
death
562
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
­

6
9
3
8
2
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

i
­
­
­
­
­
­
­

z
­
­
­
­
­
­
­
­
­
­
­
­
r­

z
6
9
3
9
0
­

I
I
4
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

I
­
­
­
­
­
­
­
­
­
­
­
­

I
6
9
3
9
2
­
­
­
­
­

h
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

I
­
­
­
­
­

I
­
­
­
­
­

!L
­

6
9
4
0
9
­

I
­
­

^
­
­
­
­
­
T
i
3
9
6
­

z
­
­
­
­
­
­
­
­
­
­
­
­
­
­

?
­
­
­
­
­

E
­
­
­
­
­
­
­
­

L­
­
­
­
­

z
­
­I­

6
9
4
3
5
­

z
­
­
­
­
­
­
­
­
­
­
­
­

I
­
­
­
­
­
­
­

z
­
­
­
­
­
­
­
­
­
­
­
­

f
­
T
6
9
3
6
2
­
­
­
­
­

n
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

I
­
­
­
­
­
­
­
­
­
­
­
­

r
7­

i
­

6
9
4
1
3
­

z
I
­

­
­
­
­
­
­
­
­

r
­
­
­
­
­
­
­

1
­
­
­
­
­
­
­
­
­
­
­
­

!I
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
WIL­
417002
90­
Day
Sacrifice
Female
Rat
A
N
M
A
L
6
6u
9
9
3
3
7
7
J37
1
1
2i__
L1_

t­­
­­­
T­­
NASAL
TURBINATE,
LEVEL
III
Atrophy,
Olfactory
Epithelium
Degeneration,
Respiraton,
Epithelium
Infiltrate.
Mononuclear
Cell
Inflammation
Inflammation,
Nasolacrimal
Duct
Inflammatory
Cell
Exudate,
Medial
Meatus
Mineral
Deposition
VacuolizatiorXyst,
Otfactory
Epithelium
NASAL
TURBINATE.
LEVEL
IV
Atrophy,
Olfactory
Epithelium
Infiltrate,
Mononuclear
Cell
Inflammation,
Nasolacrimal
Duct
Mineral
Deposition
Respiratory
Epithelial
Metaplasia,
Olfactory
Epithelium
Squamous
Metaplasia,
Respiratory
Epithelium
Vacuolization/
Cyst,
Olfactory
Epithelium
t­
1
1
Ii­
31
EPLl
Experimental
Pathology
Laboratories,
Inc.
Key:
X­
Not
Remarkable
N=
No
Section
I=
lncomplete
A=
Autolysis
l=
minimal
Z=
mild
3=
moderate
4=
swere
P=
Present
B=
Benign
M=
Malignant
m=
missing
one
paired
organ
u=
unscheduled
sac./
death
563
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
WIL­
417002
SO­
Day
Sacrifice
Female
Rat
A
N
il
A
L
EPL(
II­
32
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncomplete
A=
Autolysis
l=
minimal
P=
mild
3=
moderate
4=
severe
P=
Present
B=
Benign
M=
Malignant
m=
missing
one
paired
organ
u=
unschedukd
sac./
death
564
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Female
Rat
GROUP
2
EPLl
II­
33
Experimental
Pathdogy
Laboratories,
Inc.
Key:
X=
Nol
Remarkable
N=
No
Section
I=
lncomplete
A=
Autolysis
l=
minimal
?=
mild
a=
moderate
4=
severe
P=
Present
B=
Benign
M=
Malignant
m=
missing
one
paired
organ
u=
unscheduled
sac/
death
565
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Female
Rat
A
N
I
M
6
6
6u
A
9
99
L
3
33
6
77
2
67
UTERUS
X
Dilatation,
Lumen
VAGINA
Inflammation
1
/
I
I
I
I
,
I
I
I
I
I
I
I
I
I
I
1
I
I
I
I
I
I
I
I
EPLl
Experimental
Pathology
Laboratories,
Inc.
GROUP
+

II­
34
I
I
I
I
I
I
I
I
I
I
/
I
/
I
I
I
I
I
I
I
I
I
/
I
I
I
I
I
I
I
I
I
I
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncomplete
A=
Autolysis
l=
minimal
Z=
mIld
3=
moderate
4=
severe
P=
Present
B=
Benign
M­
Malignant
m=
mlssing
one
paired
organ
u=
unscheduled
sxideath
566
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
r
­5
I
'
­

E
4
2
3i
­

r
­

E
­
­
­
­
­
­

i
z
­

1
­

­
­

z
­
­
1­
­
­
­
­
­
­
­

I
z
­
­
­
WIL­
417002
go­
Day
Sacrifice
A
Female
Rat
N
I
M
6
A
9
L
3
:
KIDNEY
inflammation,
Pelvis
Mineralization
1
Nephropathy
1
­LARYNX,
LEVEL
I
Infiltrate,
Mononuclear
Cell
1
inflammation,
Granulomatous
Mineral
Deposition
6
6
9
9
3
3
8
9
a­
J
1
1
Cl
1
1
1_
J
­_
1
­1
1_
1
1
1
1
1
'tx
6
6
9
9
4
4
2
3
83
1
1
N
Ll
1
21
1
1
2
1
1
1
1
1
1
1
1
x
x
­.
L
LARYNX,
LEVEL
II
Hyperplasia,
Transitional
Epithelium
Infiltrate,
Mononuclear
Cell
Inflammation,
Granulomatous
1
inflammatory
Cell
Exudate,
Lumen
Mineral
Deposition
1
Squamous
Metaplasia,
Transitional
Epithelium
I
i
i
i
i
i
i
1
i
i
i
i
i
i
I
i
i
i
i
i
i
EPL(
II­
35
X=
Nol
Remarkable
N=
No
Section
klncompkte
A=
Autolysis
t=
minimal
Z=
mild
3=
moderate
4=
swew
P=
Present
B=
Eenign
M=
Mallgnant
m=
missing
one
paired
organ
u=
unscheduled
%x./
death
Experimental
Pathology
Laboratories,
Inc.
Key:

567
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
WIL­
417002
90­
Day
Sacrifice
Female
Rat
A
N
M
A
L
NASAL
TURBINATE,
LEVEL
I
Hyperplasia,
Squamous
Epithelium
Hyperplasia,
Transitional
Epithelium
Infiltrate,
Mononuclear
Cell
inflammation
Inflammation.
Granulomatous
Inflammatory
Cell
Exudate,
Medial
Meatus
NASAL
TURBINATE,
LEVEL
II
Infiltrate,
Mononuclear
Ceil
Inflammation,
Nasolacrimal
Duct
Inflammatory
Cell
Exudate,
Medial
Meatus
Mineral
Deposition
Vacuolization/
Cyst,
Olfactory
Epithelium
3
I
I
I
I
I
I
I
I
I
I
II
I
I
6666666666
9999999999
3333334444
5678892233
1
i
i
i
EPLI
II­
36
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncomplete
A=
Autolysis
l=
minimal
P=
mild
3=
moderate
4=
severe
P=
Present
B=
Benign
M­
MalIgnant
m=
missing
one
paired
organ
u­
unscheduled
sac/
death
568
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
WIL­
427002
go­
Day
Sacrifice
Female
Rat
A
N
M
A
L
NASAL
TURBINATE.
LEVEL
VI
X
Atrophy,
Olfactory
Epithelium
Infiltrate,
Mononuclear
Cell
Mineral
Deposition
TRACHEA
X
Infiltrate,
Mononuclear
Ceil
Inflammation,
Granulomatous
Mineral
Deposition
EPL(
II­
37
7
6
9
3
9
4
­

I
­
­
­
­
­
­
­
­
­
­
­
­

1
­
­
­
­
­
­
­
­

!I
h
­
­
­
­
­
­
­
­
­
­
­
­

6
9
4
2
s
­

2
­

3
­
­
­
­
­
­
­
­
­

I
­
­
­
­
­
­
­
­

f
H
­
­
­
­
­
­
­
­
­
­
­
­

6
9
4
2
s
­

z
­
­
­
­
­
­
­
­
­
­
­
­

1
­
­
­
­
­
­
­

z
zc
­
­
­
­
­
­
­
­
­
­
­
t
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncomplete
A=
Autolys~

l=
minimal
2=
mild
B=
moderate
4=
severe
P=
Present
B=
Benign
M=
Malignant
m=
mising
one
paired
organ
u=
unscheduk?
d
sac.
ldeath
569
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
WIL­
417002
90­
Day
Sacrifice
Female
Rat
ADRENAL
Vacuolization,
Cortex
AORTA
inflammatory
Cell
Infiltrate,
Adiacent
Brown
Fat
BONE
MARROW,
STERNUM
BONE,
STERNUM
BRAIN
,ESOPHAGUS
EYE
Hyperplasia,
Cornea1
Epithelium
Inflammation,
Cornea
Mineralization,
Cornea
Proteinaceous
Fluid,
Intraocular
Retinal
Atrophy
Retinal
Dysplasia
INTESTINE­
LARGE,
CECUM
Inflammation
INTESTINE­
LARGE,
COLON
Nematode
Parasite,
Lumen
EPLj
II­
38
6
6
9
9
3
3
7
7
5
9
x
x
f
4
i
:
4
4
0
0
18
XX
xx
x
x
x
x
x
x
XX
X
1_

X
1
1
1
XX
x
x
6
6
9
9
4
4
1
2
57
x
x
xx
x
x
x
x
xx
x
x
LL
x
x
1
1
x
x
x
x
­

6
9
4
3
1
H
­

x
­
­

x
z
x
x
E
­
­
­
­
­
­
­
­

h
­
­
­

1
x
­

4
­
­
­
­
I­­

Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncomplete
A=
Autolysis
l=
minimal
Z=
mild
3=
moderate
4=
severe
P=
Present
B=
Benign
M=
Malignant
m=
missmg
one
paired
organ
u=
unscheduk?
d
sacldeath
570
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Female
Rat
I
I
I
/
IPIPI
I
t
III
I
I
I
I
I
I
I
I
II
I
II
III/
LARYNX,
LEVEL
II
I
IX/
1
II
1)
/
/
/
1
j
/
11
)
/
/
4acia
Tmncitinnal
III
I
I
I
I
I
I
I
I
III
I
I
I
I
I
I
Hype&
.__._,
­.
._...­.
._.
Epithelium
t
I
I
I
I
11121
II
III
Ill
121
Infiltrate,
Mononuclear
Cell
I
inflammation,
Granulomatous
,2,:
,.
,
/.,
Inflammatory
Cell
Exudate,
1
Lumen
EPLl
II­
39
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
l=
lncomplete
A=
Autolysis
l=
minimal
Z=
mild
B=
moderate
4=
severe
P=
Present
8=
8enign
M=
Malignani
m=
missing
one
paired
organ
u=
unscheduled
sacldeath
571
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Female
Rat
A
N
I
M
6
6
6
A
9
9
9
L
3
3
3
7
7
8
LUNG
W/
BRONCHI
Alveolitis/
lnterstitial
Pneumonia
Hemorrhage
x
x
x
I
LYMPH
NODE,
MEDIASTINAL
ixjxlx
Congestion/
Hemorrhage
LYMPH
NODE,
TRACHEOBRONCHIAL
X
X
X
ConoestionlHemorrhage
MAMMARY
GLAND
x
x
x
NASAL
TURBINATE,
LEVEL
I
x
x
x
Medial
Meatus
I
I
I
NASAL
TURBINATE,
LEVEL
II
X
Infiltrate,
Mononuclear
Cell
inflammation,
Nasolacrimal
nt1ct
­­­.
Inflammatow
Cell
Exudate,
Medial
Meatus
Mineral
Deposition
1
1
VacuolizationKyst,
Olfactory
Epithelium
EPL(

Experimental
Pathology
Laboratories,
Inc.
GROUP
­­
r­+%
7
­

6
9
4
2
1
­
­
­

i­

1
x
­
­
­
­

1
h
­

L(_

x
­
­
­

­
­
­
­
­
­
­

­
­
­
­
­

I
II­
40
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncomplete
A=
Autolysis
l=
minimal
P=
mild
3=
moderate
4=
severe
P=
Present
B=
Benign
M=
Malfgnant
m=
missing
one
paired
organ
u=
unscheduled
sac./
death
572
of
619
­
HISTOPATHOLOGY
INCIDENCE
TABLE
WIL­
417002
GROUP
4
­
­
­

90­
Day
Sacrifice
Female
Rat
Epithelium
NASAL
TURBINATE,
LEVEL
V
Atrophy,
Olfactory
Epithelium
Infiltrate,
Mononuclear
Cell
Inflammatory
Cell
Exudate,
Medial
Meatus
Mineral
Deposition
Respiratory
Epithelial
Metaplasia,
Olfactory
Epithelium
VacuolizatiorXyst,
Olfactory
Epithelium
EPL/
II­
41
6
9
4
2
1
­
­
­
­
­
­
­
­
­
­
­

I
­
­
­
­
­

1
­
­
­
­

­
­
­

4
­
­

1
­
­
­
­
­
­
i
6
9
4
3
r
zc
­
­
­
­
­
­
­
­
­

I
­
­
­
­
­

r
­

z
­
­
­
­
­

z
­
­

x
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
T
1
Experimental
Pathology
Laboratories.
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
I=
tncomplete
A=
Autolysis
t=
miniinat
Psmitd
S=
moderate
rl=
severe
P=
PreseW
B=
Benign
M=
Mahgnant
m=
missing
one
paired
organ
wunscheduled
sac/
death
5'73
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
WIL­
417002
90­
Day
Sacrifice
Female
Rat
NASAL
TURBINATE,
LEVEL
VI
Atrophy,
Olfactory
Epithelium
Infiltrate,
Mononuclear
Cell
Mineral
Deposition
OPTIC
NERVE
Degeneration,
Vacuolar
OVARY
OVIDUCT
Inflammatory
Cell
Exudate,
Lumen
PANCREAS
Atrophy,
Acinar
Cell
infiltrate,
Mononuclear
Cell
PARATHYROID
PERIPHERAL
NERVE
(SCIATIC)

PITUITARY
Hypertrophy,
Pars
Distalis
SALIVARY
GLAND,
MANDIBULAR
SKELETAL
MUSCLE
(RECTUS
FEMORIS)
Degeneration
SKIN
Inflammation,
Preputial
Gland
SPINAL
CORD,
CERVICAL
SPINAL
CORD,
LUMBAR
Hemorrhage
Myelomalacia
EPL\
GROUP
T
II­
42
­

­
­
1
/

1
X
I
I
I
:m/
I
I
I
I
I
I
/
I
I
I
I
I
I
I
I
I
I
,
/
I
I
I
I
I
I
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Not
Remarkable
N=
No
Section
I=
lncomplete
A=
Autolysis
l=
minimai
*=
mild
3=
moderate
4=
severe
P=
Present
B=
Benign
M=
Malignant
m=
missing
one
pared
organ
u=
unscheduled
sac/
death
574
of
619
HISTOPATHOLOGY
INCIDENCE
TABLE
GROUP
4
­

­

­

­

­
­

­

­

­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
­
1
WIL­
417002
go­
Day
Sacrifice
Female
Rat
9"
:
4
4
1
2
5
7
li_
X
x
x
x
x
x
x
xx
x
1
K
x
I(
x
I(
x
SPINAL
CORD,
THORACIC
SPLEEN
Accesson/
Tissue
Increased
Hematopoiesis
x
x
x
x
1
x
x
x
x
+

THYROID
X
1
X
2
1
x
x
URINARY
BLADDER
Infiltrate,
Mononuclear
Cell
UTERUS
Dilatation,
Lumen
VAGINA
Inflammation
I
I
I
I
I
I
I
I
I
/
I
I
I
I
I
/
/
I
I
,

I
Experimental
Pathology
Laboratories,
Inc.
Key:
X=
Nol
Remarkable
N=
No
Section
I=
lncompkte
A=
Autolysis
l=
minimal
Z=
mild
3=
moderate
4severe
P=
Presenl
B=
Bemgn
M=
Malignant
m=
missing
one
pared
organ
u=
unscheduled
sac./
death
575
of
619
CORRELATION
OF
GROSS
AND
MICROSCOPIC
FINDINGS
576
of
619
WIL­
417002
90­
Day
Sacrifice
Species:
Rat
Animal
Number
3308
3314
CORRELATION
OF
GROSS
AND
MICROSCOPIC
FINDINGS
SW
Males
Group
Identification:
1
­
Sacrificed
Client
Topoarauhv
/
Site
Client
Gross
Observations
UNGS
Area(
s),
white,
few,
irregularly
shaped,
all
lobes
YMPH
NODE,
TRACHEOBRONCHIAL
Discoloration,
dark
red
YMPH
NODE,
MEDIASTINAL
Discoloration,
dark
red
KIN
Matting,
red,
ocular,
left
KIN
Matting,
red,
ocular,
left
­L
EPLl
Experimental
Pathology
Laboratories,
Inc.
111­
1
Microscopic
Observations
Jo
Correlatin
V/
BRONCHI
7
Lesion
(LUNG
ZongestionlHemorrhage
ZongestionlHemorrhage
Jo
Comment
Required
40
Comment
Required
CORRELATION
OF
GROSS
AND
MICROSCOPIC
FINDINGS
WIL­
417002
90­
Day
Sacrifice
Species:
Rat
Animal
Number
69305
69320
Client
l`
ouoeranhv
/
Site
­YMPH
NODE,
MEDIASTINAL
Sex:

.UNGS
Client
Gross
Observations
Discoloration,
dark
red
Males
Group
Identification:

Area(
s),
white,
few,
irregularly
I
shaped,
all
lobes
F
E
`ANCREAS
;KIN
;EMlNAL
VESICLES
Pale
Matting,
red,
ocular,
left
Small,
right
2
­
Sacrificed
I
;

69338
69347
I
No
Correlating
Lesion
No
Comment
Required
Reduced
Secretion
(SEMINAL
VESICLE)

Experimental
Pathology
Laboratories,
Inc.
III­
2
CORRELATION
OF
GROSS
AND
MlCROSCOPlk
FINDINGS
WIL­
417002
90­
Day
Sacrifice
Species:
Rat
S&
X:
Males
Group
Identification:
3
­
Sacrificed
Animal
Number
3328
­

3348
f
s
Client
Topoeraphy
/
Site
PLEEN
TOMACH
f
P
EPL(

Experimental
Pathology
Laboratories,
Inc.
Client
Gross
Observations
rccessoiy,
one,
3
mm
in
diameter
iontents,
dark
red
­

Ill­
3
Microscopic
Observations
iccessory
Tissue
Jo
Correlating
Lesion
WIL­
417002
QO­
Day
Sacrifice
Species:
Rat
Animal
Number
9304
9307
9329
i9346
EPLl
CORRELATION
OF
GROSS
AND
MICROSCOPIC
FINDINGS
Sex:
Males
Group
Identification:
4
­
Sacrificed
`HYMUS
Client
Toooeraphv
/
Site
UNGS
KIN
KIN
:YES/
OPTIC
NERVES
Client
Gross
Observations
discoloration,
dark
red
,rea(
s),
white,
few,
irregularly
haped,
all
lobes
latting,
red,
ocular,
right
,latting,
red,
ocular,
right
iye(
opacity,
left
longestion
longestion
MicroscoDic
Obsewations
MicroscoDic
Obsewations
$~$~$
tiicj
Lesion
(LUNG
$~$~$
tiicj
Lesion
(LUNG
Jo
Comment
Required
Jo
Comment
Required
Vo
Comment
Required
Vo
Comment
Required
:hE)
:hE)
i
perplasia,
Cornea1
Epithelium
i
perplasia,
Cornea1
Epithelium
Experimental
Pathology
Laboratories,
Inc.
CORRELATION
OF
GROSS
AND
MICROSCOPIC
FINDINGS
WIL­
417002
90­
Day
Sacrifice
Species:
Rat
Sex:
Females
Group
Identification:
Animal
Number
69367
Client
Touoeraphv
/
Site
EYES/
OPTIC
NERVES
Client
Gross
Observations
Eye(
s)
­
opacity,
right
LYMPH
NODE,
MANDIBULAR
Discoloration,
dark
red,
right
EPL
III­
5
Experimental
Pathology
Laboratories,
Inc.
1
­
Sacrificed
Microscopic
Observations
Inflammation,
Cornea
(EYE)

Congestion/
Hemorrhage
CORRELATION
OF
GROSS
AND
MICROSCOPIC
FINDINGS
WIL­
417002
SO­
Day
Sacrifice
Species:
Rat
Animal
Number
69362
69390
69396
Sex:
Females
Group
Identification:

Client
Touoarauhy
/
Site
­YMPH
NODE,
MANDIBULAR
JJNGS
SKIN
`ITUITARY
SKELETAL
MUSCLE
EPL]

Experimental
Pathology
Laboratories,
Inc.
Client
Gross
Observations
Discoloration,
dark
red,
bilateral
4rea(
s),
white,
few,
irregularly
shaped,
all
lobes
flatting,
yellow,
urogenital
small
liscoloration,
dark
red,
rurroundin
mechanical
trauma
frr;
ture
ofgtibia
and
ftbula,
­

Ill­
6
2
­
Sacrificed
Microscopic
Observations
Congestion/
Hemorrhage
g;;
rl$
tn{
Lesion
(LUNG
No
Comment
Required
No
Correlating
Lesion
Hemorrhage
(SKELETAL
MUSCLE,
OTHER)
CORRELATION
OF
GROSS
AND
MICROSCOPIC
FINDINGS
WIL­
417002
OO­
Day
Sacrifice
Species:
Rat
SW
Animal
Number
69377
Client
Topography/
Site
INTESTINE­
SMALL,
JEJUNUM
LIVER
LUNGS
SKIN
EPL(

Experimental
Pathology
Laboratories,
Inc.
/
Females
Group
Identification:

Client
Gross
Observations
Contents,
dark
red
Pale,
all
lobes
Area(
s),
dark
red,
few,
irregularly
shaped,
right
diaphragmatic
lobe
Matting,
red,
ocular,
bilateral
Contents,
dark
red
­I
2
­
Unscheduled
Sac/
Death
No
Correlating
Microscodc
Observations
Lesion
Vacuolization,
Hepatocytes
Hemorrhage
(LUNG
W/
BRONCHI)

No
Comment
Required
No
Correlating
Lesion
III­
7
CORRELATION
OF
GROSS
AND
MICROSCOPIC
FINDINGS
WIL­
417002
QO­
Day
Sacrifice
Species:
Rat
Animal
Number
69375
69379
69383
69415
69427
SKIN
Client
Touoaraphv
/
Site
Client
Gross
Observatiotk
Matting,
yellow,
urogenital
LIVER
Area(
s),
raised,
one,
3
x
3
x
1
mm,
white,
median
lobe
LUNGS
Area(
s),
white,
few,
irregularly
shaped,
all
lobes
OVARIES
Area(
s),
white,
multiple,
pinpoint,
bilateral
SKIN
Matting,
yellow,
urogenital
SKIN
Matting,
yellow,
urogenital;
anogenital
JTERUS
Contents,
clear
fluid,
both
horns
69431
I
S&
X:
Females
Grollp
Identification:
I
EPLl
Experimental
Pathology
Laboratories,
Inc.
ill­
8
4
­
Sacrificed
Microscopic
Observations
No
Comment
Required
No
Correlating
Lesion
No
Correlating
Lesion
(OVARY)

No
Comment
Required
No
Comment
Required
Dilatation,
Lumen
WIL­
4
17002
HAP
Task
Force
1,
1,2­
Trichloroethane
APPENDIX
L
Study
Protocol
585
of619
Sponsor:
HAP
Task
Force
A.
Title
of
Studv:

A
90­
Day
Inhalation
Toxicity
Study
of
1,
1,
Z­
Trichloroethane
(I,
I,
2­
TCE)
in
Rats
(With
Satellite
Groups
for
Pharmacokinetic
Evaluations
in
Rats
and
Mice)

B.
Protocol
Modification:

1)
VIII.
Experimenta
Observations:

The
following
information
modifies
that
currently
in
the
protocol.

H.
Anatomic
Pathology:

3.
Microscopic
Examination
(Toxicology
Groups):

All
tasks
for
histological
preparation
and
microscopic
examination
of
tissues
will
be
performed
by
Experimental
Pathology
Laboratories,
Inc.
(EPL).
The
study
pathologist
will
be
Frederick
A.
Ruecker,
D.
V.
M.,
M.
S.,
D.
A.
C.
V.
P.
EPL
will
provide
an
audited
pathology
report
for
inclusion
in
the
study
report.
EPL
will
be
responsible
for
all
Quality
Assurance
activities
for
these
tasks.

C.
Reason
for
Protocol
Modification:

To
modify
Anatomic
Pathology
section
to
state
that
histology
and
microscopic
examination
will
be
performed
by
Experimental
Pathology
Laboratories,
Inc.

Approved
By:

HAP
Task
Force
'
Peter
Vo$
tek<
Ph.
D.
Datk
Sponsor
Representative
Prepared
By:

WIL
Research
Laboratories,
Inc.
,

Study
Dir&
r
WIL
R!?
X.
EARCH
LABOR.%
TORIES.
JNC
1­
107
GEORGE
ROAD
ASHLAND.
OH
4­
18o59281
1419)
2848100
F.
A?(
(~
IQIZ~
Q­~

586
of
619
Study
Number:
WL­
417002
PROTOCOL
AMENDMENT
II
Sponsor:
HAP
Task
Force
A.
Title
of
Studv:

A
90­
Day
Inhalation
Toxicity
Study
of
1,
I
.
2­
Trichloroethane
(1,
1,
I­
TCE)
in
Rats
(With
Satellite
Groups
for
Pharmacokinetic
Evaluations)

B.
Protocol
Modifications:

1)
V.
Test
Svstem:

The
following
information
modifies
that
currently
in
the
protocol:

C.
Source:
Charles
River
Laboratories
G.
Identification
System:
Effective
May
21.
2001,
the
cage
label
will
not
include
the
date
of
animal
arrival
or
the
date
of
initiation
of
exposures.

VII.
Experimental
Desk:

3
A.
Animal
Receipt
and
Acchmation:

3)
E.
The
following
information
adds
to
that
currently
in
the
protocol:

To
allow
suitable
evaluation
of
animals
for
group
assignment.
the
animals
(rats
and
mice)
to
be
used
for
randomization
for
the
pharmacokinetic
evaluation
­groups
will
receive
a
detailed
physical
examination
within
3
days
of
the
day
of
group
assignment.

Exposure
Methods:

The
following
information
adds
to
that
currently
in
the
protocol
and
will
be
effective
May
3
1,200
1.

The
exposures
will
be
conducted
in
2
m'
stainless
steel
and
glass
whole­
body
exposure
chambers.
These
chambers
will
be
located
in
study
room
51.

587
of
619
WlL~
17002
Protocol
Amendment
II
Page
Two
Animal
cage
batteries
will
be
rotated
on
a
daily
basis
through
various
chamber
locations
in
order
to
reduce
the
potential
differences
in
exposure
due
to
any
residual
non­
homogeneity
in
chamber
concentrations.
The
rotation
procedure
to
be
used
will
be
described
in
the
data
records.

Drinking
water
will
be
avaitable
to
mice
during
exposures.

On
each
day
of
PK
blood
collection
(1':
3ti
and
5"
days
of
exposure
of
the
fourth
exposure
week),
the
female
rats
designated
for
blood
collection
on
the
specific
day
will,
be
exposed
to
the
target
concentration
of
100
ppm
in
a
500­
L
NYU­
type
whole­
body
chamber
(that
is,
separate
from
the
remaining
animals
in
the
group).
This
will
be
a
completeiy
separate
exposure
system
with
its
own
test
atmosphere
vapor
generator,
chamber
dilution
airflow
and
calibrated
exhaust
airflow.
The
methods
used
for
this
generation
and
exposure
system
will
be
similar
to
those
for
the
other
test
article
systems.
Specific
details,
settings
and
parameters
for
this
system,
which
wiIl
be
used
on
three
days
only,
will
be
documented
in
the
study
records.
The
exposure
chamber
will
be
monitored
using
the
same
methods
and
according
to
the
same
schedule
as
for
the
other
exposure
chambers.
The
12
animals
scheduled
for
blood
collection
on
the
specific
day
will
be
placed
in
a
Ii­
compartment
exposure
battery,
which
will
then
be
placed
in
the
exposure
chamber.
Only
one
exposure
battery
placement
level
will
be
used
for
the
three
days
this
chamber
is
used.
This
change
for
the
pharmacokinetic
(PK)
study
rats
will
facilitate
blood
collection
at
the
appropriate
time
points
relative
to
the
start
of
exposure
and
prompt
collection
of
blood
after
animals
are
removed
from
the
exposure
chamber
(4­
and
6­
hour
time
points).
The
use
of
different
exposure
systems
for
PK
study
rats
and
mice
will
permit
the
PK
rat
exposure
to
be
started
approximately
30
minutes
after
or
before
the
mouse
exposure.

4)
F.
Test
Atmosphere
Generation
Methods:

Should
be
modified
as
follows.
and
will
be
effective
on
May
31.
X01.

Vapors
of
the
test
article
will
be
generated
using
a
glass­
bead
vaporization
system
similar
to
that
shown
in
Figure
1
and
Figure
2.
The
vaporization
column
consists
of
a
glass
tube
filled
with
glass
beads.
For
Groups
2.3
and
4,
the
column
will
be
3.4
cm
in
diameter
(ID).
75
cm
long
filled
with
6­
and
12­
mm
beads.
Calibrated
Harvard
Syringe
Pumps
(model
97.5
with
a
20
cc
syringe
for
Group
2
and
model
975
with
a
50
cc
syringe
for
Group
3)
and
a
calibrated
FMT
pump
(model
QG­
6
with
a
l/
S­
inch
piston
for
Group
4)
will
be
used
to
meter
test
article
to
the
column.

j:,
r
.

1:
,.:.,_
.;:
..;::
.:.
i,
._::
_:,_
i::::::
.:
..:.
_
.;
`ipi
/
iv.;
­./.
j__
.

.._
;..::­.
:
..
i
f
_
:
5,
;
i.

!a?
a§
s
588
of
619
wlL­
41700~
Protocol
Amendment
II
Page
Three
Compressed
air
will
be
metered
to
the
bottom
of
the
column
using
calibrated
flowmeters.
Vaporization
occurs
as
the
test
article
flows
down
through
the
beads
and
the
compressed
air
flows
up
through
the
column.
The
concentrated
vapors
are
piped
to
the
chamber
inlet
where
the
concentration
is
reduced
to
the
desired
level
by
mixing
with
the
chamber
ventilation
air.
The
vaporization
columns
are
heated
by
heating
rapes
operated
from
Omega
CN370
temperature
controllers.

The
following
table
indicates
the
specific
generation
conditions
for
each
exposure
group.

Bead
Flow
Rate
of
Test
Article
Column
Compressed
Air
Chamber
Metering
Flow
Rate
Temperature
for
Vaporization
Number­
3ciairz
0
422
1
NA
NA
NA
75
17
2
Harvard
20
ind.
0.038
75
18
3
Harvard
20
ind.
0.080
75
19
4
l­
341
30­
4092
full
scale
0.186­
0.242
75
17
Nominal
Chamber
Ventilation
­
430
­
430
­
430
­
430
Chamber
ventilation
flow
rate
may
be
varied
within
400
to
500
LPM
to
maintain
the
desired
exposure
concentrations;
any
other
changes
to
these
operational
parameters
will
be
authorized
by
the
Inhalation
Department
Director,
Study
Director
or
appropriate
designee
and
recorded
in
the
study
records.

3
G.
Methods
for
Characterization
of
Exposure
Atmospheres:

Sections
G.
l­
2
should
be
modified
as
follows
and
will
be
effective
as
of
May
31,
ZOOl:

1.
Nominal
Concentrations:

Nominal
exposure
concentrations
will
be
determined
by
weighing
the
containers
of
test
article
prior
to
and
again
after
each
day's
exposure,
and
calculating
the
concentration
from
the
weight
difference
and
the
total
volume
of
air
passed
through
each
chamber
during
that
day's
exposure.

:..
.:_
.~,­
.::
i
,2,$
..
`i:
_:::
­:
_:.:
,~:.:;::,_;::
g:
i::.
:`
ilix:.
ie;
j~
ii;
i
ii"`;
/
.
.
.
.
.
.
­.,,:.
.­
:
_;
:_
:
:::
:
i
~/
.
.
.
.
`(
i
i
iz?
cmpy
`i
589
of
619
­.­­
w&
41700:!
Protocol
Amendment
II
Page
Four
2.
Actual
Exposure
Concentrations:

Actual
exposure
concentrations
will
be
determined
approximately
every
35
minutes
using
a
gas
chromatographic
method.

The
following
table
summarizes
the
operational
conditions
of
the
gas
chromatograph
and
signal
integrator:

GC
Manufacturer
Model
No.
Hewlett­
Packard
5890
Series
II
Detector
Type
Detector
Temperature
Column
Diameter
X
Length
Column
Type
Fuel
Gas
Fuel
Pressure
Fuel
Flowwte
Air
Pressure
Air
Flowrate
Carrier
Gas
Carrier
Gas
Pressure
Carrier
Gas
Flowrate
Injection
Volume
Retention
Time
Integrator
Manufacturer
Model
Number
Chart
Zero
Offset
Chart
Attenuation
Chart
Speed
Peak
Area
Rejection
Value
Peak
Threshold
Peak
Width
FID
250%

0.25
mm
x
30
m
DB­
WAX
Hydrogen
15
psig
30
mllmin.

25
psig
300
mVmin.

Helium
SO
psig
10
ml/
min
0.35
ml
Approx
0.825
min.

Hewlett­
Packard
5890
0
1
1
.O
cmimin.
0
2
.ii..
i:.
::
`7.
ii
::
J/
i,
pi:;:;
i;;
ijhG
::;.
:::...~:~
::.:..
y::.,
rYe"`
i;
j/:.:
i
.,_:,:
.
.:___
'
ii
L
i,
/j
;
::
::
E
:
::,
:,­

ki?
zmB'

590
of
619
wIL­
417002
Protocol
Amendment
II
Page
Five
Any
changes
to
these
operational
parameters
will
be
authorized
by
the
Inhalation
Department
Director,
Study
Director
or
appropriate
designee
and
recorded
in
the
study
records.

Using
the
GC
and
integrator,
samples
will
be
collected
manually
and
the
integrator
will
operate
a
gas­
sampling
valve
with
a
0.
X­
ml
sample
loop,
display
the
chromatogram
and
calculate
the
area
under
the
sample
peak.
The
operator
then
uses
a
slope
and
intercept,
from
the
GC
calibration
curve,
to
calculate
the
measured
concentration
in
patts
per
million
(ppm).

The
GC
will
be
calibrated
using
standards
prepared
in
Ted@
gas
bags.
The
gas
bag
standards
will
be
prepared
as
follows:
A
known
volume
of
test
atticle
will
be
injected
into
a
heated
(80°
C)
glass
vaporization
bulb.
Compressed
air
will
be
metered
into
the
bulb
to
vaporize
and
dilute
the
test
article.
The
total
volume
of
compressed
air
used
will
be
measured
with
a
dry
test
meter.
The
resulting
vapors
will
be
collected
in
40­
liter
gas
bags.

Prior
to
initiation
of
animal
exposures,
the
instrument
will
be
calibrated
with
sets
of
five
standards
prepared
in
triplicate.
The
calibration
curves
will
be
prepared
and
defined
by
9,27,72,
109
and
136
ppm
standards.
A
least­
squares
hne
will
be
fitted
to
the
data
set
for
each
set
of
standards
to
provide
a
prime
standard
curve.
Thereafter,
once
each
day
and
prior
to
initiation
of
exposures,
a
calibration
check
will
be
performed
using
a
single
freshiy
prepared
standard.
This
standard
will
be
one
of
the
five
vahtes
used
for
prime
calibration,
and
each
day
a
different
one
will
be
used.
If
the
daily
calibration
check
is
within
210%
of
the
prime
calibration
curve,
the
instrument
will
be
considered
to
be
within
normal
calibration
limits.
The
following
table
summarizes
the
standard
Standard
Volume
of
Concentration
Test
Article
0
fdJ
9
1.0
80
­
2.4
30
27
3.0
80
­
2.4
30
72
8.0
80
­
2.4
30
109
12.0
80
­
2.4
30
136
15.0
80
­
2.4
30
Nominal
Vaporization
Temperature
0
Nominal
Vaporization
Flow
Rate
ILPM)
Total
Dilution
Air
Volume
i&
J
_:::
.::
_
::_
:::.
::..
::
..:::.,
.::.
:;
_i,
i::::,;
.:..
::::::­,
.:I
;;:
iii;::
k<;
;(;?
z
%:­
,,
.:,.
i­
:.
::
:
1:.
:
j:
::
7.:
/::,
iz
rilmsma'

591
of
619
.
wiL417002
Protocol
Amendment
Il
Page
Six
VIII.
Exnerimental
Observations:

6)
B.
CIinical
Observations
(All
Animals):

7)
C.
The
following
information
modifies
and/
or
clarifies
that
currently
in
the
protocol.

For
toxicology
evaluation
animals:
On
exposure
days,
cIinica1
observations
will
be
performed
twice
per
day,
prior
to
exposure
and
following
exposure
(O­
2
hours
following
end
of
exposure).
On
non­
exposure
days,
clinical
observations
will
be
performed
once
in
the
morning.
For
pharmacokinetic
evaluation
animals:
On
exposure
days,
clinical
observations
will
be
performed
once,
prior
to
exposure.
On
non­
exposure
days,
clinical
observations
will
be
performed
once
in
the
morning.

Detailed
Physical
Examinations
(Toxicology
Groups):

The
following
information
clarifies
that
currently
in
the
protocol.

All
animals
will
receive
a
detailed
physical
examination
at
least
one
week
prior
to
and
on
the
day
of
group
assignment,
weekly
during
the
exposure
phase,
and
on
the
day
following
final
exposure
(prior
to
necropsy).

8)
The
foIlowing
information
clarifies
that
currently
in
the
protocol
(VIII.
D
and
E).

D.
Individual
Body
Weights
(All
Animals):

Individual
body
weights
will
be
recorded
weekly,
beginning
at
least
one
week
prior
to
test
material
administration.
For
the
toxicology
group
animals,
a
fasted
weight
will
be
determined
prior
to
blood
collection
and
necropsy.

E.
Individual
Food
Consumption
(Toxicology
Groups):

Individual
food
consumption
will
be
recorded
weekly
for
all
animals,
beginning
at
least
one
week
prior
to
test
material
administration.

592
of
619
wIL­
417002
Protocol
Amendment
II
Page
Seven
9)
H.
Anatomic
Pathology:

1.
Macroscopic
Examination
(Toxicology
Groups):

The
following
information
clarifies
that
currently
in
the
protocol.

Tissue
List:
Items
shouid
be
Exorbital
lacrimal
glands
(2)
and
Parathyroid.
d
Footnote
describes
requirements
for
microscopic
examination
of
parathyroids.

10)
1.
Blood
Collection
and
Processing
for
Pharmacokinetic
Groups:

The
following
information
adds
to
and/
or
clarifies
that
currently
in
the
protocol.

To
accommodate
the
Chour
time
point,
technicians
equipped
with
appropriate
protective
equipment.
including
Tyvek'
coveralls
and
supplied­
air
respirator.
will
quickly
open
the
high
concentration
chambers
(during
exposure),
remove
designated
animals
(3
rats
and
3
mice)
and
then
reseal
the
chambers.
The
same
procedure
wilt
be
used
for
the
&hour
time
point,
except
the
generator
will
be
turned
off
at
6
hours.

As
quickly
as
possible,
the
animals
scheduled
for
blood
collection
at
a
specific
time
point
(and
day)
wiIl
be
anesthetized
using
isoflurane
and
blood
will
be
collected
from
the
vena
cava
into
heparinized
syringes.
Blood
will
be
transferred
in
duplicate
directly
into
headspace
vials
for
analysis,
and
remaining'
bulk
blood
will
be
collected
and
saved
in
vacutainers
(with
dry
sodium
heparin).
For
the
headspace
vial
samples.
duplicate
blood
samples
of
100
1.11
from
each
animal
wilt
be
aliquoted
into
cold,
pre­
weighed
20­
ml
headspace
vials
with
crimp
tops
and
PTFE­
silicone
septa.
The
vials
will
be
sealed
as
quickly
as
possible.
The
headspace
vials
will
be
weighed
before
and
after
the
addition
of
blood
to
verify
volumes
added
gravimetrically.
Immediately
after
weighing,
the
vials
will
be
placed
on
dry
ice
to
freeze
the
biood
samples.
For
each
animal,
the
remaining
blood
will
be
placed
in
a
pre­
weighed,
pre­
cooled
vacutainer
tube,
which
will
be
sealed
and
re­
weighed.
Dry
ice
will
also
be
used
to
freeze
this
extra
blood.
At
the
time
of
sacrifice,
storage
stability
spike
standards
will
be
prepared
in
headspace
vials
using
control
blood
(from
untreated
rats)
spiked
with
known
quantities
of
1,1.2­
trichloroethane.
in
addition,
unspiked
control
bIood
(from
untreated
rats)
will
be
frozen
and
shipped
to
the
analytical
laboratory,
Battelle
Northwest
Laboratories,
for
preparation
of
standards
(for
calibration
curves)
and
samples
of
1,12­
trichloroethane
solution(
s)
used
to
prepare
the
storage
spike
samples
will
be
included
in
the
shipments.
:­:::
.::.
:::
.:._
_:_
::::
`7'
.*::.
li­
..::...
if:
y,:
jiiii:::
ii:
e;
y;;
;
`+$
;
.:
::
:i
+
:
"%

593
of
619
WL417002
Protocol
Amendment
Ii
Page
Eight
Samples
will
be
shipped
by
next
day
service
in
Styrofoam
containers
on
dry
ice
in
order
to
be
received
at
Battelle
on
a
Tuesday,
Wednesday
or
Thursday.
Samples
may
be
stored
at
­70°
C
until
shipment,
if
necessary.
The
blood
samples
and
other
samples
described
above
will
be
shipped
to
the
following
contact
person
and
address:

Attn:
Torka
Poet,
Ph.
D.
Bldg.
331,
Lab
313:
P7­
59
Battelle
Warehouse
790
6th
St.
Richland,
WA
99352
The
analytical
laboratory
and/
or
the
Sponsor
will
be
responsible
for
all
quality
assurance
activities
or
requirements
related
to
the
sample
analyses.
However,
copies
of
quality
assurance
inspection
repotts
will
be
supplied
to
the
study
director
at
WIL
for
review
and
evaluation
of
potential
effects
on
study
outcome,
quality
and
integrity.
The
analytical
Iaboratoty
and/
or
the
Sponsor
will
also
be
responsible
for
subsequent
data
analysis
and
reporting
for
the
PK
evaluations.

The
lungs,
liver,
kidneys,
spleen
and
whole
brain
will
be
collected
at
the
time
of
blood
collection
and
stored
at
­70°
C
by
WIL
Research
Laboratories,
Inc.
for
up
to
2
years.
To
minimize
chemical
loss,
all
sample
manipulations
will
be
conducted
on
ice
(to
maximum
extent
possible).
Each
organ
will
be
double­
wrapped
in
plastic
wrap,
placed
in
a
labeled
aluminum
foil
pouch,
frozen
in
liquid
nitrogen
and
then
sealed
in
a
plastic
storage
bag.

C.
Reasons
for
Protocol
Modifications:

1)
To
modify
information
regarding
the
study
animals.

2)
To
clarify
requirements
for
detailed
physicals
prior
to
group
assignment
for
the
PK
evaluation
animals.

3)
To
add
additional
information
on
exposure
methods.

4)
To
define
test
atmosphere
generation
methods.

5)
To
define
exposure
atmosphere
characterization
methods.

6)
To
clarify
daily
schedules
for
clinical
observations.

7)
To
clarify
the
schedule
for
detailed
physicals
of
toxicology
group
animals.
;:
h
.3:
;:
i:
,::
i;
i
:
::
i'
::
i
cc:::
xi':­;:
p:;:
iii
yz;.
.:::
i.::
­7:
g:­;
/
.,
J.
?
.:..
;.
y
:,
::
B
('
.:
i
LI
7
::
;;.
i.
`<
RiPc?
ak.

594
of
619
­­­­
WJ.
L­
417002
Protocol
Amendment
II.
Pap
Nine
8)
To
clarify
schedules
for
body
weights
and
food
consumption
measurements.

9)
To
correct
information
in
tissue
list.

10)
To
clarify
and
add
information
for
the
pharmacokinetic
evaluations.

Approved
By:

HAP
Task
Force
Peter
Voytec
Ph.
D.
Sponsor
Representative
Prepared
By:

WIL
Research
Laboratories,
Inc.

Study
Director
595
of
619
WIL­
417002
Protocol
Amendment
II
Page
Ten
Figure
1:
Schematic
Diagram
of
Exposure
and
Generation
System
Groups
2
&
3
source
of
Ii
c­
Chamber
Supply
_I_
Air
iI
20004W
H~
MCHI
Chamber
j
Havard
I
Pump
i
i
b
Glass
Bead
Column
8
iemperature
TO
controller
Compissed
Air
Source
*
Orifice
Meter
­

To
Chambw
Exhaust
596
of
619
wlL­
417002
Protocol
Amendment
II
Page
Eleven
Figure
2:
Schematic
Diagram
of
Exposure
and
Generation
System
Group
4
source
of
I
!
­
Chamber
Supply
ii­
Ait
2OtXWtar
Hazleton
Chamber
I
t
>
'
\i
Glass
Bead
i
:
i
Column&
Temwature
TO
Controller
Test
Material
Compressed
Air
Source
­

94%
­
v
Orifice
Meter
­

7
To
Chamber
Exhaust
=?`
I.
..
'
;::
_?:.
y
:I
:
Y­
::­
.A.,,
.c
,.:
i:­
..
i._
.::::::;._:I
::::.::.
:::I
­
.:::
1:
!
2,
::::::
/
.:
p,:­
ytr
;y
:
.i.~
.
U­.:­
Y
i
I
:!
7
+?
/
::
;j:
1:
i;

Em**

597
of
619
Study
Number:
WlL­
417002
PROTOCOL
AMENDMENT
I
Sponsor:
HAP
Task
Force
A.
Title
of
Studv:

A
go­
Day
inhalation
Toxicity
Study
of
1,
1,
2­
Trichloroethane
(I,
1,
2­
TCE)
in
Rats
(With
Satellite
Groups
for
Pharmacokinetic
Evaluations)

B.
Protocol
Modifications:

Title
of
Studv:

1)
The
following
modifies
the
study
title
as
required
by
WIL
JACUC.

A
90­
Day
Inhalation
Toxicity
Study
of
1,
1.
2­
Trichloroethane
(1,
1,
?,­
TCE)
in
Rats
(With
Satellite
Groups
for
Pharmacoknetic
Evaluations
in
Rats
and
Mice)

III.
Studv
Schedule:

The
following
information
replaces
that
currently
in
the
protocol.

Proposed
Experimental
Termination
Date:
To
be
added
when
dates
of
microscopic
examinations
are
known
Proposed
Audi
ted
Draft
Report
Date:

Proposed
Final
Report
Date:
December
15.200
1
February
1.5,
XK!

598
of
619
wL417002
Protocol
Amendment
I
Page
Two
VII.
Experimental
Design:

3)
D.
Organization
of
Test
Groups,
Exposure
Levels
and
Treatment
Regimen:

1.
Organization
of
Test
Groups:

The
following
table
presents
the
study
group
arrangement.

Groups
5
and
6
will
be
exposed
using
the
same
exposure
system
and
methods
used
for
Group
4.
Data
for
the
toxicokinetic
groups
will
be
collected
in
separate
WTDMS'
computer
protocols
(from
the
toxicology
groups).

C.
Reasons
for
Protocol
Modifications:

1)
To
modify
study
title
to
include
species
for
pharmacokinetic
evaluations
as
required
by
WrL
IACUC.
wIL­
417001
Protocol
Amendment
I
Page
Three
3
To
modify
information
for
study
schedule.

3)
To
clarify
target
exposure
concentrations.

Approved
By:

HAP
Task
Force
feL
d
hii
k
/w
Pete:
Voytek,
Ph.
D.
Sponsor
Representative
Date
Prepared
By:

WIL
Research
Laboratories,
Inc.

Study
Director
.~,
:+
c?
=:,
i.
:i.
..::
i..
2:.
A..
zi;
+;
zii;;;
i<.
2:::::
._
ix::.
i
­:::
::
s.::
"`
5
:i':
i
:
.&.
:`.
g'
:
L
$is.
Caiij
f,
/5
600
of
619
PagclDf19
PROTOCOL
WIL­
417002
May
15.2001
A
!&
DAY
INHALATION
TOXICITY
STUDY
OF
1,
1,
ZTRICHLOROETHANE
(1,
1,
Z­
TCE)
IN
RATS
(WITH
SATELLITE
GROUPS
FOR
PHARMACOKINETIC
EVALUATIONS)

(U.
S.
EPA­
TSCA
799.9346
Guideline)

Submitted
To:

HAP
Task
Force
do
Peter
Voytek,
Ph.
D.
P.
O.
Box
331
Millwood.
VA
23646
WIL
Research
Laboratories,
Inc.
1407
George
Road
Ashland,
OH
44805­
9181
601
of
619
w1L­
017002
Rp2of
19
May
IS.
2001
I.
Obiective:

II.
The
objective
of
this
study
is
to
evaluate
potential
subchronic
toxic
effects
of
the
test
article
when
administered
via
inhalation
to
rats
for
90­
days.
In
addition.
36
female
F­
344
rats
and
36
female
B6C3Fl
mice
will
be
exposed
by
inhalation
for
28
days
and
used
for
a
pharmacoklnetic
study.

This
protocol
has
been
designed
to
generally
conform
with
the
U.
S.
Environmental
Protection
Agency
(EPA)
TSCA
guideline
799.9346:
90­
Day
Inhalation
Toxicity
Study.

This
study
will
be
conducted
in
compliance
with
the
Good
Laboratory
Practices
Regulations
of
the
U.
S.
Environmental
Protection
Agency
­
TSCA:
40
CFR
Part
792.

Personnel
Involved
in
the
Studv:

A.
Sponsor
Representative:

Peter
Voytek,
Ph.
D.

B.
WIL
Study
Director:

Daniel
T.
Kirkpatrick,
Ph.
D.,
D.
A.
B.
T.
Assistant
Director,
Inhalation
Toxicology
C.
WIL
Deputy
Director:

Christopher
P.
Chengelis.
Ph.
D.,
D.
A.
B.
T.
Director,
Toxicology
D.
WIL
Departmental
Responsibilities:

Jozef
J.
W.
M.
Mertens,
Ph.
D..
D.
A.
B.
T.
Assistant
Director,
Toxicology
Gary
R.
Kiplinger,
B.
S.
Manager
II,
Inhalation
Ronald
E.
Wilson,
B.
S.
Director,
Informational
Systems
602
of
619
WIL­
417@
3?
Pdgc30fl9
May
15.2coI
Carol
A.
Kopp,
B.
S.
Group
Supervisor,
Gross
Pathology
and
Developmental
Toxicology
Laboratory
Jane
M.
Nagel,
M.
B.
A.,
B.
S.,
MT(
ASCP)
Manager,
Clinical
Pathology
Mike
Safron,
A.
S.,
HT(
ASCP)
Manager,
Histology
Sally
A.
Keets,
A.
S.
Manager
II,
Vivarium
Deborah
L.
Little,
B.
S.,
RQAP­
GLP
Manager
II,
Quality
Assurance
Daniel
W.
Sved,
Ph.
D.
Director,
Metabolism
and
Analytical
Chemistry
Charlene
A.
Weygandt.
B.
S.
Manager,
Technical
Report
Writing
PhiIip
L.
Stetson,
M.
D.,
Ph.
D.
Associate
Director,
Analytical
Chemistry
Karen
S.
Regan,
D.
V.
M.,
D.
A.
C.
V.
P.,
D.
A.
B.
T.
Director,
Pathology
and
Veterinary
Medicine
BarbaraL.
Smith,
D.
V.
M.,
M.
S.,
Ph.
D.,
D.
A.
C.
V.
S.
Director,
Laboratory
Animal
Resources
David
Wilke,
D.
V.
M.,
MS.
Diplomate
A.
C.
V.
O.
Consulting
Ophthalmologist
III.
Studv
Schedule:

Proposed
Animal
Receipt
Date:
May
15,2001
Proposed
Experimental
Stan
Date:
May
31,2001
Proposed
Necropsy
Date(
s):
August
30­
3
1,
200
1
Proposed
Experimental
Termination
Date:
To
be
added
by
protocol
amendment.

603
of
619
WIL­
417002
Page
4
of
19
May
15.2001
To
be
added
by
protocol
amendment.
Proposed
Draft
Report
Date:

IV.
Test
Article
Data:

A.
Identification:
1.
1,2­
Trichloroethane
(1,
1,
ZTCE).

NH06019301
B.
Lot
Number:

C.
Purity:
99.56%
by
weight
(from
Certificate
of
Analysis).
To
be
confirmed
by
WIL
Research
Laboratories,
inc.

D.
Stability:
To
be
demonstrated
by
WIL
Research
Laboratories,
Inc.

To
be
documented
by
WIL
Research
Laboratories,
Inc.
E.
Physical
Description:

F.
Storage
Conditions:

G.
Reserve
Samples:
Room
temperature
in
a
sealed
container.

Retention
samples
will
be
collected
and
stored
in
accordance
with
Standard
Operating
Procedures.

H.
Personnel
Safety
Data:
Provided
by
the
Sponsor,
preferably
in
the
fotm
of
a
Material
Safety
Data
Sheet.

At
a
minimum,
technical
staff
will
wear
safety
glasses.
appropriate
gloves,
and
facility
clothing
when
handling
or
working
with
the
test
article.
Additional
personal
protective
equipment,
such
as
a
respirator,
protective
coveralls
or
sleeve
covers,
may
be
required.
Specific
equipment
and
its
use
will
be
defined
by
study
management
and
communicated
to
technical
staff,
as
appropriate.

V.
Test
Svstem:

A.
Species:
Rat
and
mouse
Fischer
344
CDF@(
F­
344)
Crl:
BR
rat
B6C3Fl
mouse,
B6C3FlKrl:
BR.
B.
Strain:

604of
619
wlL­
417002
PageSOf
May
15.2ool
c.
source:
The
facihty
from
which
animals
were
received
wil1
be
documented
in
the
study
records.

D.
Number
on
Study:
Rats:
Forty
males
and
76
females
will
be
placed
on
study.
Approximately
50
males
and
86
females
will
be
purchased.
Mice:
Thirty­
six
females
will
be
placed
on
study.
Approximately
46
female
mice
will
be
purchased.

E.
Approximate
Age
and
Weight:
Animals
will
be
approximately
7
to
9
weeks
of
age
at
exposure
initiation.
Females
will
be
nulliparous
and
nonpregnant.

Rats:
The
males
will
weigh
approximately
150­
220
grams
and
the
females
will
weigh
approximately
100­
160
grams
at
exposure
initiation.
Individual
weights
will
be
within
k
20%
of
the
mean
for
each
sex.

Mice:
The
female
mice
will
weigh
approximately
18­
26
grams
at
exposure
initiation.
Individual
weights
will
be
within
50%
of
the
mean.

F.
Disease
Screen:
Approximately
seven
days
after
receipt
of
animais,
blood
will
be
collected
from
the
vena
cava
(under
isoflurane
anesthesia)
of
five
rats
per
sex
and
five
female
mice
for
serological
screening
for
pathogens.
These
animals
will
then
be
euthanized
(by
exsanguination)
and
discarded.
For
rats,
serum
samples
will
be
analyzed
for
antibodies
to
the
following
pathogens
(testing
laboratory
documented
in
study
records):
Sendai,
RCVKDA,
Reo,
KRV,
LCM,
H­
l,
PVM,
ROPV
viruses,
hf.
pulmonis
and
CARf3.
For
mice,
the
605of619
wIL417002
Page6of
19
May
15.2001
screening
profile
will
include:
Sendai,
EDIM.
GDVIl,
MHV.
PVM,
MPV,
MVM,
and
h4.
pulmonis.

G.
Identification
System:
Rats
will
be
uniquely
identified
by
a
Monele
metal
eartag
displaying
the
animal
number.
Mice
will
be
uniquely
identified
by
a
tail
tattoo.
Individual
cage
cards
will
be
affixed
to
each
cage
and
will
display
the
study
number,
group
number
exposure
level.
animal
number,
sex
and
the
dates
of
animal
arrival
and
initiation
of
exposure.

H.
Justification
for
Selection:
These
species
and
strains
are
generally
recognized
to
be
appropriate
for
subchronic
inhalation
toxicity
and
pharmacokinetic
studies
and
are
recommended
in
the
TSCA
guideline.

VI.
Specific
(Nonexposure
Period)
Maintenance
Schedule:

A.

B.
Animal
Housing:

The
rats
and
mice
will
be
housed
in
separate
environmentally
controlled
rooms.

Rats
will
be
housed
individually
in
clean
suspended
wire­
mesh
cages
in
an
environmentally
controlled
room.
Mice
will
be
housed
three
per
cage
in
clean
suspended
wire­
mesh
cages
in
an
environmentally
controlled
room
for
approximately
five
days
following
receipt.
Thereafter,
mice
will
be
housed
individually.
The
cages
will
be
elevated
above
cage­
board
or
other
suitable
material
which
will
be
changed
at
least
three
times
each
week.
The
facilities
at
WK
Research
Laboratories.
Inc.
are
fully
accredited
by
the
Association
for
Assessment
and
Accreditation
of
Laboratory
Animal
Care
International
(AALAC
International).

Environmental
Conditions:

Controls
will
be
set
to
maintain
room
temperature
at
72'
2
4°
F
(22
+
3°
C)
and
relative
humidity
at
approximately
30­
708.
Ruorescent
lighting
controhed
by
light
timers
will
provide
illumination
for
a
I2­
hour
IQ&/
dark
photoperiod.
The
light/
dark
cycle
may
be
interrupted
for
protocol
specified
activities.
Temperature
and
relative
humidity
will
be
recorded
once
daily.

::
Gk
HX:
iii:
,g.
PI
2:
.:::,
:­­::
;)
i;
/;
jcj/:
~:::­
pi
.:::::
:
::::::
i.__
.­..
_..::
i::.:
i
.
`­­::
"
::
._/:..
­..,
~
I:
c
::
:::
t
f
gg
i:,:
$
ii­:
i
/
:i
m.

606
of
619
WIL.
417002
Rgc7cf19
Ma?
15.
tool
C.
Drinking
Water:

Reverse
osmosis­
treated
tap
water
will
be
available
ad
libirum
(except
during
exposures
for
rats).
Water
will
be
available
to
exposure
cage
batteries
holding
mice
during
inhalation
exposures.
Filten
servicing
the
automatic
watering
system
will
be
changed
reguularly
according
to
WIL
Standard
Operating
Procedures.
Municipal
water
supplying
the
laboratory
will
be
analyzed
for
contaminants
according
to
Standard
Operating
Procedures
to
ascertain
that
none
are
present
in
concentrations
that
would
be
expected
to
affect
the
outcome
of
the
study.

D.
Basal
Diet:

PMI
Nutrition
International,
Inc.
Certified
Rodent
LabDiet'
5002
will
be
offered
ad
libirum
during
the
study
(except
during
exposures).
Each
lot
utilized
will
be
identified
and
recorded.
Analyses
of
the
certified
feed
for
the
presence
of
heavy
metals
and
pesticides
wili
be
provided
by
the
manufacturer
to
ensure
that
none
are
present
in
concentrations
that
would
be
expected
to
affect
the
outcome
of
the
study.
Feeders
will
be
changed
and
sanitized
once
per
week.

VII.
Experimental
Des&:

A.
Animal
Receipt
and
Acclimation:

Each
animal
will
be
inspected
by
a
qualified
technician
upon
receipt.
Animals
judged
to
be
in
good
health
and
suitable
as
test
subjects
will
be
acclimated
for
at
least
14
days.
All
animals
will
be
sexed,
weighed
and
assigned
a
permanent
animal
number.
During
acclimation,
each
animal
will
be
observed
twice
daily
for
changes
in
general
appearance
and
behavior.
All
animals
will
receive
a
detailed
physical
examination
approximately
one
week
prior
to
dosing
and
at
the
time
of
animal
selection
for
randomization.

B.
Randomization:

At
the
conclusion
of
the
acclimation
period.
animals
judged
to
be
suitable
for
testing
will
be
assigned
to
groups
using
stratified
randomization
based
on
body
weight
(toxicity
study
groups).
Female
rats
and
mice
will
be
assigned
to
the
pharmacokinetic
study
using
simple
randomization
by
weight.
Healthy
female
rats
not
assigned
to
the
toxicity
study
groups
will
make
up
the
group
assignment
pool
for
the
pharmacokinetic
group.
At
this
time,
the
animal
numbers
and
corresponding
body
weights
wiIi
be
entered
into
the
WIL
Toxicology
Data
Management
System
(WTDMSTM),
and
a
printout
containing
the
animal
numbers
and
individual
exposure
group
assignments
will
be
generated.
Animals
will
then
be
arranged
into
the
groups
according
fo
the
printout.
Three
607
of
619
WIL417cn2
Paec
8
of19
Mav
IS.
zcmt
WTDMS"
protocoIs
will
be
used,
including
one
for
the
toxicity
study
rats,
one
for
the
kinetic
study
rats
and
one
for
the
kinetic
study
mice.

.C.
Route
and
Rationale
of
Test
Material
Administration:

The
route
of
administration
will
be
whole­
body
inhalation
exposure
since
this
is
a
potential
route
of
human
exposure.

D.
Organization
of
Test
Groups,
Exposure
Levels
and
Treatment
Regimen:

1.
Organization
of
Test
Groups:

The
following
table
presents
the
study
group
arrangement.

a
Actual
target
exposure
levels
will
be
based
on
the
results
of
an
acute
inhalation
toxicity
study
(WIL­
4
17001)
and
will
be
defined
m
a
protocol
amendment.
b
Groups
5
and
6
will
be
exposed
using
the
same
exposure
system
and
methods
used
for
Group
4.
Data
for
the
toxicokinetic
groups
will
be
collected
in
separate
WTDMS*
computer
protocols
(from
the
toxicology
goups).

Filtered
air
or
test
article
vapor
will
be
administered
as
daily
six­
hour,
whole­
body
exposures
on
a
five
day
per
week
basis
for
thirteen
consecutive
weeks
(minimum
of
65
total
exposures).
On
the
day
following
the
final
exposure,
10
males
and
10
females
per
group
will
be
euthanized
and
evaluated
(clinical
and
anatomical
pathology).
The
first
day
of
exposure
is
defined
as
exposure
day
zero.

The
pharmacokinetic
component
of
this
study
consists
of
exposure
and
blood
collection
and
processing
for
36
female
F­
344
rats
and
36
female
B6C3Fl
mice
exposed
at
the
high
concentration.
Sample
analysis
methods,
analytical
records
and
data
and
interpretation
of
pharmacokinetic
data
are
part
of
a
separate
study
and
protocol
and
are
not
included
in
this
study.
The
608of619
wtL­
017002
Pape
9
of
19
Mav
IS.
2cnl
E.
Exposure
Methods:

F.
exposure
regimen
for
the
pharmacokinetic
groups
is
six
hours/
day,
five
days/
week
for
four
weeks.
On
the
Is*,
3",
and
5'
days
of
the
fourth
week
of
exposure
for
these
groups,
blood
will
be
collected
from
3
animals
per
specie
per
time
point
a
4,6,6.25
and
8
hours
after
the
start
of
exposure.

Exposures
will
be
conducted
in
stainless­
steel
and
glass
whole­
body
exposure
chambers.
One
chamber
will
be
dedicated
for
each
group
for
the
duration
of
the
study.
For
the
high
concentration
groups,
the
toxicology
and
kinetic
group
rats
and
the
kinetic
group
mice
will
be
exposed
in
the
same
inhalation
chamber.
This
is
considered
to
be
acceptable
for
6­
hour
exposures
and
for
the
shon
duration
of
the
kinetic
study
(28
days).
The
chambers
will
be
operated
under
dynamic
conditions
from
a
HEPA
and
charcoal
filtered
air
source.

Air
flow
rate
through
the
chamber
will
be
such
that
there
will
be
at
least
10
air
changes
per
hour.
Daily
average
chamber
temperature
and
relative
humidity
will
be
13t"
C
and
30­
70%,
respectively.
These
parameters
will
be
monitored
continuously
and
recorded
approximately
every
35
minutes
during
each
day's
exposure.
Oxygen
content
of
the
exposure
atmosphere
will
be
measured
during
the
methods
developmental
phase
of
the
study
and
will
be
at
least
19%.

All
animals
will
be
caged
individually
during
the
exposures.
Food
and
water
will
not
be
available
during
the
exposures.

All
animals
will
be
housed
in
normal
animal
colony
rooms
during
non­
exposure
hours.
For
each
days'
exposure,
the
animals
will
be
transferred
to
exposure
caging,
transported
to
the
exposure
chamber
room,
exposed
for
the
requisite
duration
and
returned
to
their
home
cages.

Test
Atmosphere
Generation
Methods:

If
appropriate
for
1,1.2­
trichloroethane,
vapors
will
be
generated
using
a
glass­
bead
column­
type
vaporization
system.
typically
operated
as
follows:
Test
article
and
air
carrier
gas
are
metered
to
the
column
with
air
entering
below
the
glass
beads
while
the
test
article
is
deposited
on
the
beads.
The
beads
may
be
heated
using
a
heating
tape
wrapped
around
the
coIumn.
An
electric
controller
and
thermocouple
(positioned
inside
the
bead
column)
are
used
to
provide
an
appropriate,
stable
temperature
and
avoid
overheating.
Vaporization
occurs
as
the
test
article
flows
over
the
surface
of
the
beads
and
air
moves
up
through
the
beads.
The
concentrated
vapors
are
piped
to
the
chamber
inlet
where
the
concentration
is
reduced
by
mixing
with
chamber
ventilation
air.
Tubing
and/
or
pipes
between
the
vaporization
column
and
the
chamber
inlet
may
also
be
heated
to
avoid
condensation
of
the
vapor.

609
of
619
t?
ane
toor
19
wrL.
417cQz
Mav
15.
tom
Additional
vaporization
approaches,
such
as
bubbling
air
through
minimally
heated
test
article
or
vaporization
of
a
fine
test
article
aerosol,
are
available
and
may
be
used,
if
required.
Details
of
generation
system
methodologies
will
be
defined
during
pre­
study
method
development.
Therefore,
this
information
will
be
added
as
a
protocol
amendment
after
preliminary
methods
evaluations
are
conducted.

G.
Methods
for
Characterization
of
Exposure
Atmospheres:

1.
NominaI
Concentrations:

Nominal
exposure
concentrations
wiIl
he
calculated
for
all
exposures.

2.
Actual
Exposure
Concentrations:

Actual
test
article
vapor
concentrations
in
the
exposure
atmospheres
wiI1
be
determined
at
least
at
hourly
intervals
for
each
chamber
using
an
appropriate
gas
chromatographic
method.
Details
concerning
specific
methods
to
be
used
and
the
frequency
of
determinations
will
be
defined
during
pre­
study
method
development.
Therefore,
this
information
will
be
added
as
a
protocol
amendment
after
preliminary
methods
evaluations
are
conducted.

3.
Temporal
Stability
and
Homogeneity
of
Vapor
Test
Atmospheres:

During
pre­
study
method
development
trials,
the
stability
of
the
test
article
vapor
concentrations
over
time
and
the
spatial
homogeneity
of
the
test
article
vapor
concentrations
will
be
evaluated
for
each
test
article
chamber.
Methods
and
results
of
these
evaluations
will
be
documented
in
the
study
records
and
described
in
the
study
report.

4.
Chemical
Purity
in
Vapor
Test
Atmosphere:

During
pre­
study
method
development
trials,
the
chemical
purity
of
the
vapor
in
the
high
concentration
chamber
will
be
evaluated.
In
general,
the
gas
chromatograph
will
be
optimized
in
an
attempt
to
allow
integration
and
peak
area
count
determination
for
all
peaks
resulting
from
the
test
article.
For
comparison
to
the
expected
1,1.2­
TCE
retention
time,
a
high
concentration
gas
bag
standard
wiI1
be
prepared
using
a
I.
l,
Z­
TCE
reference
material
or
the
test
article
and
analyzed
prior
to
chamber
sampling.
The
chamber
atmosphere
will
be
sampled
and
analyzed
and
the
?k
of
total
peak
area
counts
represented
by
the
area
counts
for
the
1,1,2­
TCE
peak
will
be
calculated.
High
concentration
chamber
sampling
and
analysis
will
be
610of
619
wIL­
417002
Page
11
of19
May
15.2001
performed
in
triplicate.
Additional
details
concerning
specific
methods
to
be
used
wiI1
be
added
by
protocol
amendment.

5.
Verification
of
Absence
of
Aerosols
in
Test
Atmosphere:

During
pre­
study
method
development,
the
high
concentration
chamber
will
be
evaluated
during
vapor
generation
for
the
presence
of
aerosols.
This
test
will
be
performed
using
a
light
scattering
type
real­
time
aerosol
monitor
that
has
been
optimized
for
detection
of
low
levels
of
aerosols.

H.
Test
Article
Characterization:

Purity
Analysis:

Samples
of
the
test
article
(5­
10
mL),
coltected
from
the
original
storage
container(
s)
prior
to
use
for
animal
exposures,
will
be
assessed
for
purity
using
GUFID
analysis
of
at
least
duplicate
injections
of
the
undiluted
sample.
The
test
article
purity
wiIl
be
expressed
as
`area
percent."

Stability
Analysis:

The
same
procedure
used
for
the
purity
analysis
will
be
followed
for
the
stability
analysis
of
sample(
s)
collected
after
completion
of
animal
exposures
or
after
completion
of
use
of
test
article
from
an
individual
container.
The
resulting
"area
percent"
values
will
be
compared
to
the
original
purity
values.

VIII.
Experimental
Observations:

A.
Viabiiity
Observations
(All
animals):

A11
animals
will
be
observed
for
mortality/
moribundity
twice
daily,
once
in
the
morning
and
once
in
the
afternoon.
Moribund
animals
will
be
euthanized
to
ensure
that
tissues
wiII
not
be
lost
due
to
autolysis.

B.
Clinical
Observations
(All
animals):

Chnical
observations
will
be
conducted
after
the
exposure
on
exposure
days.
Observations
will
include,
but
are
not
limited
to,
changes
in
the
skin,
fur,
eyes
and
mucous
membranes,
respiratory,
circulatory,
autonomic
and
central
nervous
system
functions,
somatomotor
activity
and
behavior
patterns.
Findings
noted
at
the
clinical
examination
will
be
recorded
for
individual
animals;
the
condition
of
animals
without
signs
will
be
documented
as
a
general
comment.

611
of
619
WlLJ1700?
Pa!
zc
12
of
19
Mav
15.2001
C.
Detailed
Physical
Examinations
(Toxicology
Groups):

All
animals
will
receive
a
detailed
physical
examination
approximately
one
week
prior
to
and
on
the
day
of
group
assignment,
weekiy
during
the
exposure
period,
and
on
the
day
following
the
final
exposure
(prior
to
necropsy).
The
animals
will
be
removed
from
their
home
cages
and
placed
in
a
standard
arena
for
observation.
Observations
wiIl
be
detailed
and
carefully
noted.
When
appropriate.
explicitly
defined
scoring
systems
will
be
used
if,
in
the
opinion
of
the
study
director,
doing
so
increases
the
utihty
of
the
data.
Signs
noted
shall
include,
but
are
not
limited
to,
changes
in
skin,
fur,
eyes,
mucous
membranes,
occurrence
of
secretions
and
excretions,
and
autonomic
activity
(e.
g.,
lacrimation,
piloerection,
pupil
size,
unusual
respiratory
pattern).
Changes
in
gait,
posture
and
response
to
handling,
as
well
as
the
presence
of
clonic
or
tonic
movements,
stereotypes
(e.
g.,
excessive
grooming,
repetitive
circling)
or
bizarre
behavior
(e.
g.,
self­
mutilation,
walking
backwards)
will
be
recorded.
The
absence
or
presence
of
findings
will
be
recorded
for
individual
animals.
Animals
to
be
euthanized
prior
to
scheduled
necropsy
will
undergo
an
additional
detailed
physical
examination
prior
to
euthanasia
to
assist
in
determination
of
the
cause
of
death.

D.
individual
Body
Weights
(AU
animals):

Individual
body
weights
will
be
recorded
weekly,
beginning
one
week
prior
to
test
material
administration.
For
the
toxicology
group
animals.
a
fasted
weight
wit1
be
determined
prior
to
blood
collection
and
necropsy.

E.
Individual
Food
Consumption
(Toxicology
Groups):

Individual
food
consumption
will
be
recorded
weekly
for
all
animals,
beginning
one
week
prior
to
test
material
administration.
Measurement
will
be
for
7­
day
interval.

F.
Ophthalmological
Examinations
(Toxicology
Groups):

Ocuiar
examinations
will
be
conducted
on
all
animals
by
a
board
certified
veterinary
ophthalmologist,
using
an
indirect
ophthalmoscope
and/
or
a
slit
lamp
or
other
equivaIent
suitable
equipment,
preceded
by
pupillary
dilation
with
an
appropriate
mydriatic
agent.
The
examinations
will
be
performed
before
exposure
initiation
and
near
exposure
termination.

612
of
619
G.
Clinical
Pathology
(Toxicology
Groups):

The
following
hematologic
and
biochemical
parameters
will
be
evaluated
on
all
surviving
animals
just
prior
to
the
scheduled
necropsy.
These
animals
wili
be
fasted
overnight
before
taking
blood
samples.
Blood
samples
will
be
collected
via
the
vena
cava
from
animals
under
deep
anesthesia
from
isoflurane
inhalation.

1.
Hematology:

Hemoglobin
Hematocrit
Etyhroc
yte
count
Total
Leukocyte
count
Differential
leukocyte
count
Activated
partial
thrombopfastin
time
2.
Blood
Chemistry:

Alanine
aminotransferase
Aspartate
aminotransferase
Alkaline
phosphatase
Phosphorus
Glucose
Urea
nitrogen
Creatinine
Total
cholesterol
Triglycerides
Gamma
glutamyl
transpeptidase
Platelet
count
Reticulocyte
counts
(if
signs
of
anemia
are
present)
MCH
.MCV
MCHC
Prothrombin
time
Total
bilirubin
Total
protein
Albumin
Globulin
A/
G
ratio
Calcium
Chloride
Potassium
Sodium
Additional
serum
chemistry
parameters
may
be
necessary
to
provide
an
adequate
toxicological
evaluation
of
1.
1
,
2­
TCE.
If
required,
specific
parameters
will
be
added
by
protocol
amendment
(may
result
in
additional
cost).

Ii.
Anatomic
Pathology:

1.
Macroscopic
Examination
(Toxicology
Groups):

A
complete
necropsy
will
be
conducted
on
all
animals
dying
spontaneously,
euthanized
in
e.
nrernis
or
at
the
scheduled
necropsy.
Necropsy
will
include
examination
of
the
external
surface,
all
orifices
and
the
cranial,
thoracic,
abdominat
and
pelvic
cavities
including
viscera.
At
the
time
of
necropsy
the
following
tissues
and
organs
will
be
coliected
and
placed
in
10%
neutral
buffered
formalin
(except
as
noted):

613
of
619
­
­
F@
e
I4Of
19
WILd17002
May
IS.
ZOO1
Adrenals
(2)
Aorta
Bone
with
marrow
(sternum)
Bone
marrow
smear
(taken
from
femur")
Brain
(forebrain,
midbrain.
hindbrain)
Epididytnides
(2)
'
Eyes
with
optic
nerve
(2)
b
Exorbital
lacrimal
gland
(2)
Gastrointestinal
tract
Esophagus
Stomach
Duodenum
Jejunum
IIeum
Cecum
Colon
Rectum
Harderian
glands
(2)
Heart
Kidneys
(2)
Larynx
Liver
(sections
of
two
lobes)
Lungs
(including
bronchi.
fixed
by
inflation
with
fixative
at
constant
pressure)
Lymph
node
(tracheobroichial
and
mediastinai)
Mammary
gland
(females
only)
Nasal
tissues'
Ovaries
with
oviducts
(2)
Pancreas
Parathyroids
(if
present)
Peripheral
nerve
(sciatic)
Pituitary
Prostate
Salivary
glands
[mandibular
(2)]
Seminal
vesicles
(2)
Skeletal
muscle
(rectus
femoris)
Skin
Spinal
cord
(3
sections
­
cervical.
thoracic,
lumbar)
Spleen
Testes
(2)
'
Thymus
Thyroids
Trachea
Urinary
bladder
Uterus
with
vagina
All
gross
lesions
'
=
b
Not
placed
in
formalin;
to
be
examined
only
if
scientifically
warranted.
=
The
eyes
will
be
placed
in
Davidson's
solution.
'
=
The
enure
head
will
be
removed
and
preserved.
Following
decalcification.
six
CTOSS­

sections
of
the
nasal
cavities
will
be
prepared
for
microscopic
exminatlon
in
accordance
with
the
method
described
by
Morgan'.
d
=
Parathyroid
glands
will
be
examined
rmcroscopicaily
if
in
the
plane
of
section
and
in
all
cases
when
a
gross
lesion
IS
noted.
'
=
The
testes
and
eptdidymides
will
be
placed
in
Bouin's
solution.

2.
Organs
Weights:

The
following
organs
weights
will
be
obtained
from
a11
animals
at
the
time
of
necropsy.
The
thyroids
will
be
weighed
following
fixation.
(Paired
organs
will
be
weighed
together):

614
of
619
WlLJ17002
paec
ISof
19
Ma\
IS.
1001
I.
Adrenals
BMI
Epididymides
Heart
Kidneys
Liver
Lungs
(prior
to
inflation
with
fixative)
Ovaries
Spleen
Testes
Thymus
Thyroids
(with
parathyroids)
a
Organ
to
body
weight
ratios
will
be
calculated.
a=
weighed
after
fixation
3.
Microscopic
Examination:

Microscopic
examination
of
hematoxylin­
eosin
stained
paraffin
sections
will
be
performed
on
the
tissues
listed
in
protocol
section
WII.
H.
1.
for
ah
animals
in
the
control
and
high
level
grouts
and
from
all
rats
that
die
or
are
euthanized
in
exrremis.
The
larynx.
lungs,
trachea,
nasal
tissues,
liver,
kidneys
and
all
gross
lesions
will
be
examined
from
all
animals
in
the
low
and
mid
level
groups.
If
a
potential
target
organ
is
noted
in
the
high
level
group,
that
tissue
will
be
examined
in
the
low
and
mid
level
groups.
Special
stains
may
be
used
at
the
discretion
of
the
pathologist
to
further
characterize
lesions
and
changes.
Any
special
stains
used
will
be
documented
in
the
individual
animal
data
and
interpretation
of
results
will
be
included
in
the
final
report.

Blood
Coliection
and
Processing
for
Pharmacokinetic
Groups:

On
days
I,
3
and
5
of
the
fourth
week
of
exposure
for
the
pharmacokinetic
group
rats
and
mice,
blood
will
be
collected
from
subgroups
of
12
animals
per
specie
on
each
day.
The
blood
collection
time
points
will
be
4.
6,
6.25
and
8
hours
following
the
exposure
start
and
three
animals
per
specie
will
be
used
for
each
time
point.

To
accommodate
the
Chour
time
point,
technicians
equipped
with
appropriate
protective
equipment,
including
Tyvek@
coveralls
and
supplied­
air
respirator,
will
quickly
open
the
high
concentration
chamber
(during
exposure),
remove
designated
animals
(3
rats
and
3
mice)
and
then
reseal
the
chamber.
The
same
procedure
will
be
used
for
the
6­
hour
time
point,
except
the
generator
will
be
turned
off
at
6
hours.
As
quickly
as
possible,
the
animals
scheduled
for
blood
collection
at
a
specific
time
point
(and
day)
will
be
anesthetized
using
isoflurane
and
blood
will
be
collected
from
the
heart
(open
chest
cardiac
stick)
or
vena
cava.
The
blood
will
be
mixed
with
an
anticoagulant
and
a
specific
volume
will
then
be
placed
in
a
head­
space
analysis
vial.
The
vials
will
be
placed
&.

615
of
619
WILJi700?

Papc
16619
May
15.301
Additional
information
regarding
storage
and
shipment
or
transfer
of
the
samples
will
be
added
by
protocol
amendment.

Following
blood
collection,
the
anesthetized
animals
will
be
exsanguinated
to
complete
euthanasia.
Organs/
tissues
required
by
the
Sponsor
will
be
collected
and
each
organ/
tissue
or
a
representative
sample
thereof
will
be
frozen
using
liquid
nitrogen.
The
organs/
tissues
to
be
collected
will
be
added
by
protocol
amendment.
Frozen
tissues
will
be
placed
in
an
appropriate
labeled
vial
or
other
container
and
stored
at
approximately
­70°
C.
The
Sponsor
will
determine
if
and
when
the
tissues
will
be
shipped,
analyzed
or
discarded
and
these
requirements
will
be
addressed
by
protocol
amendment.

IX.
Termination:

Animals
ordered
for
this
study
but
not
selected
for
use
on
this
study
will
be
transferred
for
use
on
other
studies
or
euthanited
with
CO*.

Animals
euthanized
in
exrremis
or
at
scheduled
necropsies
wiIl
be
anesthetized
with
Isoflurane@
and
exsanguinated.

X.
Statkticai
Methods:

All
analyses
will
be
two­
tailed
with
significance
levels
of
5%
and
1%.
Ali
means
will
be
presented
with
standard
deviations.
Analysis
of
weekly
body
weights,
body
weight
changes
and
food
consumption
as
well
as
clinica
pathology
values
(excluding
differential
white
cell
counts
other
than
segmented
neutrophils
and
lymphocytes),
and
absolute
and
relative
organ
weights
will
be
analyzed
by
a
one­
way
analysis
of
variance'
and
when
statistical
significance
is
noted,
comparison
of
the
control
group
to
each
treated
group
by
Dunnett's
test3.

XI.
Oualitv
Assurance:

The
study
will
be
audited
by
the
WIL
Quality
Assurance
Unit
while
in
progress
to
assure
comphance
with
Good
Laboratory
Practice
reguiations,
adherence
to
the
protocol
and
to
WlL
Standard
Operating
Procedures.
The
raw
data
and
draft
final
report
will
be
audited
by
the
WIL
Quality
Assurance
Unit
prior
to
submission
to
the
Sponsor
to
assure
that
the
final
report
accurately
describes
the
conduct
and
the
findings
of
the
study.

This
is
a
regulated
study
and
will
be
included
on
the
WI.
L
master
list
of
regulated
studies.

616
of
619
WIL.
41700?
Ree
17of
19
Mav
15.2CKIl
XII.
Records
to
be
Maintained:

All
original
raw
data,
as
defined
by
WIL
SOPS
and
the
applicable
GLPs,
will
be
stored
as
described
in
protocol
section
XIKL
in
the
Archives
at
WIL
Research
Laboratories,
Inc.

XIII.
Work
Product:

Sponsor
will
have
title
to
all
documentation
records,
raw
data,
slides,
specimens,
or
other
work
product
generated
during
the
performance
of
the
study.
All
work
product
including
raw
paper
data,
mapetically
encoded
records
and
specimens
will
be
retained
at
no
charge
for
a
period
of
ten
years
following
issuance
of
the
final
report
in
the
Archives
at
WT.
L
Research
Laboratories,
Inc.
Thereafter,
WIL
Research
Laboratories
will
charge
an
archiving
fee
for
retention
of
all
work
product
(at
the
yearly
fee
described
in
the
study
agreement).
All
work
product
will
he
stored
in
compliance
with
regulatory
requirements.

XIV.
Reports:

The
final
report
will
contain
a
summary,
test
material
data.
methods
and
procedures,
appropriate
individual
animal
and
summary
data
tabIes,
methods
and
results
of
test
atmosphere
generation
and
characterization.
a
copy
of
the
protocol
and
amendments
(if
any)
and
an
interpretation
and
discussion
of
the
study
results.
The
report
will
contain
al1
information
necessary
to
conform
with
current
EPA
TSCA
specifications
as
listed
in
the
799.9346
guideline.
The
report
will
be
comprehensive
and
shall
attempt
to
detine
toxicity
and
the
no­
observed­
effect
level(
s)
under
the
conditions
of
this
investigation.

WIL
Research
Laboratories
will
provide
one
(1)
copy
of
an
Audited
Draft
Report
(with
an
electronic
copy
of
the
text;
the
body
of
the
report
without
tables),
submitted
in
a
timely
manner
upon
completion
of
the
study
prior
to
issuance
of
the
final
report.
One
(1)
revision
will
be
permitted
as
part
of
the
cost
of
the
study,
from
which
Sponsor's
reasonable
revisions
and
suggestions
will
be
incorporated
into
the
Final
Report
as
appropriate.
Additional
changes
or
revisions
may
be
made.
at
extra
cost.
it
is
expected
that
the
Sponsor
will
review
the
draft
repon
and
provide
comments
to
WIL
within
a
one
(1)
month
time
frame
following
submission.
WIL
will
submit
the
Final
Report
within
one
(1)
month
following
receipt
of
comments.
One
(1)
unbound
original
and
eight
(8)
copies
of
the
Final
Report
will
be
provided;
requests
for
additional
copies
of
the
Final
Report
may
result
in
additional
charges.

XV,
Protocol
Modification:

Modification
of
the
protocol
may
be
accomplished
duting
the
course
of
this
investigation.
However,
no
changes
will
be
made
in
the
study
design
without
the
617
of
619
­
WILJl7002
Rpe
18
of
19
May
1s.
ICOI
verbal
or
written
permission
of
the
Sponsor.
In
the
event
that
the
Sponsor
verbally
requests
or
approves
changes
in
the
protocol,
such
changes
will
be
made
by
appropriate
documentation
in
the
form
of
protocol
amendments.
All
alterations
of
the
protocol
and
reasons
for
the
modification(
s)
will
be
signed
by
the
Study
Director
and
Sponsor
Representative.

XVI.
Animal
Welfare
Act
Compliance:

This
study
will
comply
with
all
applicable
sections
of
the
Final
Rules
of
the
Animal
Welfare
Act
regulations
(9
CFR).
The
Sponsor
should
make
particular
note
of
the
following:

l
The
Sponsor
signature
on
this
protocol
documents
for
the
Study
Director
the
Sponsors
assurance
that
the
study
described
in
this
protocol
does
not
unnecessarily
duplicate
previous
experiments.

l
Whenever
possible,
procedures
used
in
this
study
have
been
designed
to
avoid
or
minimize
discomfort,
distress
or
pain
to
animals.
AI1
methods
are
described
in
this
study
protocol
or
in
written
laboratory
standard
operating
procedures.

l
Animals
that
experience
severe
or
chronic
pain
or
distress
that
cannot
be
relieved
will
be
painlessly
euthanized
as
deemed
appropriate
by
the
veterinary
staff
and
Study
Director.

l
Methods
of
euthanasia
used
during
this
study
are
in
conformance
with
the
above
referenced
regulation.

XVII.
References:

1.
Approaches
to
the
Identification
and
Recording
of
Nasal
Lesions
in
Toxicology
Studies,
Morgan,
Kevin,
T.,
Toxicologic
Pathology,
Vol.
19,
No.
4
(Pait
I):
337­
351
(1991).

2.
Snedecor,
G.
W.
and
Cochran,
W.
G.
(1980)
One­
way
classification:
analysis
of
variance.
In:
Statistical
Methods,
Seventh
Edition.
Iowa
State
University
Press,
Ames,
IA,
pp.
215­
337.

618
of
619
WIL­
417002
Page
19of
19
May
IS.
2001
3.
Dunnett,
C.
W.
(1964)
New
tables
for
multiple
comparisons
with
a
control,
Biometrics,
20:
482491.

XVIII.
Protocol
Amroval:

HAP
Task
Force
Sponsor
approval
received
Sponsor
Representative
St;
dy
Director
619
of
619